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Chapter 1
General introduction
Over the past decades it has been demonstrated that the immune system has an 
indispensable critical role in tumor control. This has consequently driven the development 
of novel strategies that mediate tumor clearance by initiating new or boosting 
existing immune responses against the malignant cells. An example of one of the first 
successful immunotherapeutic strategies that has been developed is allogeneic stem cell 
transplantation (alloSCT). AlloSCT is a powerful cellular immunotherapy for patients 
with aggressive hematological malignancies, and to date, is the only possible curative 
option for many patients. The therapeutic effect is mediated by lymphocytes, mainly T 
cells and natural killer (NK) cells, originating from the donor graft that recognize the 
patient’s tumor cells as foreign and subsequently eradicate them; in brief called the graft-
versus-tumor (GVT) effect. However, in a significant number of patients the induction or 
reactivation of these immune responses is inadequate, contributing to disease progression 
or relapse. This illustrates the urgency to develop novel interventions to initiate and/or 
boost more potent GVT immunity and prevent tumor relapse post-alloSCT. This thesis 
describes the pre-clinical development of immunotherapeutic strategies that could 
potentially be applied as adjuvant therapy post-alloSCT to improve its therapeutic efficacy. 
Furthermore, these strategies could potentially also be applied in a non-transplant setting 
of hematological malignancies or solid cancers. We describe and characterize ex vivo-
generation of different dendritic cell (DC) subsets and NK cells from CD34+ hematopoietic 
stem and progenitor cells (HSPCs). These HSPC-derived cell products could be used for 
DC vaccination and adoptive NK cell transfer, respectively. Furthermore, we explore the 
potential of CLEC12A, an endocytic receptor expressed by DCs and other myeloid cells, as 
a receptor for in vivo-targeted vaccination strategies. This chapter provides an introduction 
to the studies presented in this thesis.
Normal hematopoiesis
Hematopoiesis represents the developmental process of hematopoietic stem cells 
(HSCs) into mature and functional blood cells, such as erythrocytes, thrombocytes and 
leukocytes. Each of these different cell lineages have their unique function: erythrocytes 
transport oxygen throughout the body, thrombocytes are important components of 
blood clotting, and leukocytes protect us against pathogens. Hematopoiesis in adults 
occurs mainly in the bone marrow, where HSCs reside, the cells that are the apex of the 
hematopoietic hierarchy. HSCs are capable of self-renewal to maintain a small pool of 
HSCs throughout our life-span. Furthermore, they give rise to multi-potent progenitor 
cells committed to more specific blood cell lineages (Figure 1).1,2 In the classical model 
of hematopoiesis, blood cells belong to either of two fundamental branches/lineages: the 
lymphoid branch or the myeloid branch. In this classical model, the lymphoid branch 
includes T, B and NK cells, while the myeloid branch gives rise to relatively short-lived cells 
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such as monocytes, granulocytes, DCs, megakaryocytes/thrombocytes and erythrocytes.1 
However, recent research shows that this segregation between lymphoid and myeloid is 
not black and white, and that the mature blood cells can originate from more than one 
type of progenitor cell.3,4 The choices in cell fate are tightly regulated by external cues from 
the environment, where cytokines play the most pivotal role. After interactions with cell-
surface cytokine receptors, subsequent downstream signaling regulates expression and 
activity of lineage-specific transcription factors, thereby determining the fate of the cell.5,6
Figure 1. Schematic overview of hematopoiesis. Diagram showing the classical representation of how HSCs 
develop into the different mature blood cells via intermediate hematopoietic progenitor cells. Dashed lines 
indicate alternative routes of differentiation of HSCs towards mature blood cells. HSC, hematopoietic stem 
cell; MPP, multi-potent progenitor; CMP, common myeloid progenitor; CLP, common lymphoid progenitor; 
MEP, megakaryocyte-erythrocyte progenitor; GMP, granulocyte-macrophage progenitor. Figure adapted 
from Kroeze and Koorenhof-Scheele.7
Hematological malignancies
Hematological malignancies are a group of neoplasms that affect the formation and 
function of the different blood cells. Due to malignant transformation of cells of the 
hematopoietic lineage, either in the bone marrow or in peripheral lymphatic systems, 
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the cells gain growth advantage and multiply uncontrollably, resulting in disturbance of 
normal hematopoiesis and function of normal blood cells. As a result, patients may suffer 
from fatigue and anemia, excessive bleeding and bruising, and recurrent infections. In 
total, new cases of hematological malignancies account for ~8% of all new cancer diagnoses 
in Europe, with an estimated 230.000 patients diagnosed per year.8,9 Hematological 
neoplasms are mainly a disease of the elderly, and since the general population is growing 
and aging, it is therefore expected that the incidence rates will rise exponentially in the 
forthcoming years.10
Diagnosis of hematological malignancies is based on morphology, histopathology, 
immunophenotype, clinical features and underlying genetic defects. According to the 
world health organization, malignancies are primarily stratified according to lineage as 
myeloid cancers, lymphoid cancers, cancers with myeloid and lymphoid lineage markers 
or histiocytic/dendritic cell cancers.11 Further classifications are based on whether the 
neoplasm rises from early progenitors (e.g. acute myeloid leukemia (AML), lymphoblastic 
lymphomas/leukemias) or more mature blood cells (e.g. (Non-)Hodgkin lymphoma, 
multiple myeloma), and whether the disease progression is fast (acute) or slow (chronic). 
The prognosis for patients with hematological malignancies depends not only on the type 
of disease and etiology, but also on the patient age and their morbidity. Older patients 
(>65 years) have a much poorer prognosis and lower survival rate.12,13 These factors 
also influence the choice of treatment. Standard treatments include chemotherapy and 
radiation therapy, which aims to reduce tumor burden and induce long-term remission. 
These therapies are often combined with hematopoietic stem cell transplantation (SCT) 
to reconstitute a new hematopoietic system. The HSCs can be obtained either from 
the patient itself (autologous) or from a relative or an unrelated donor (allogeneic). As 
allogeneic SCT (alloSCT) is the setting of this thesis, it is presented in more details below. 
Besides these standard treatments, several new and more tumor-specific drugs, associated 
with lower toxicity, have been developed in the past decades. For example, the first-line 
treatment currently used for chronic myeloid leukemia (CML) consists of tyrosine kinase 
blockers (e.g. Imatinib, Nilotinib and Dasatinib) that inhibit the BCR-ABL oncoprotein.14,15 
Since the introduction of those drugs, the 10-year overall survival for CML has increased 
from 10-20% to 80-90%.16,17 Another example is treatment of B cell lymphomas and other 
CD20-expressing malignancies which has been revolutionized with the development of 
anti-CD20 monoclonal antibodies, such as Rituximab.18,19 Furthermore, hypomethylating 
agents (HMA), such as decitabine and azacitidine, are increasingly being used as (additive) 
treatment for patients with myelodysplastic syndrome (MDS) and AML, not only because 
they are well tolerated and have direct pro-apoptotic effects on tumor cells, but also 
because of their immunomodulatory effects.20,21
Despite progresses with these new and more specific targeted drugs, alloSCT is the 
most effective therapy for patients with (very) poor risk hematological malignancies. Apart 
from reconstituting the patient with a new healthy immune system, the aim of alloSCT is 
13
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to induce specific immune responses against the tumor cells of the patient.22,23 Actually, 
alloSCT can be considered the most widely applied and, to date, the most successful 
cellular immunotherapy against cancer, with over 15.000 transplantations performed 
yearly in Europe.24
AlloSCT as therapy for hematological malignancies
Originally, the aim of SCT was to replenish the patient with a new healthy hematopoietic 
system, facilitating the delivery of higher dosages of chemo- and radiation therapy that 
would otherwise have been impossible. Without SCT, patients would have suffered from 
prolonged bone marrow aplasia. It soon became apparent though, that when patients 
were transplanted with allogeneic HSCs, an additional tumor eradication took place 
which was independent of the high-dose chemo/radiation therapy.25,26 This therapeutic 
effect was attributed to donor-derived allo-reactive immune cells, mainly T cells and NK 
cells, that recognized hematological tumor cells of the patient and eliminated them.23 
Unfortunately, development of this potent GVT effect is tightly linked to graft-versus-
host disease (GVHD), a life-threatening complication where the immune competent cells 
of the graft attack and damage healthy tissues of the patient. Development of GVHD is 
linked to the pre-transplant conditioning regimen, which induces tissue damage and pro-
inflammatory cytokine cascades that subsequently results in trafficking of allo-reactive T 
cells towards inflamed GVHD-prone organs.27 Therefore, to reduce GVHD, less intensive 
conditioning regimens (i.e. reduced-intensity and non-myeloablative conditioning 
regimens) and T cell depletion strategies have been developed and implemented in many 
alloSCT protocols. These protocols have also allowed older patients with high co-morbidity 
scores to be treated with alloSCT, patients that previously were unfit to receive alloSCT. 
Unfortunately, the GVHD prophylaxis regimens are associated with higher relapse rates, 
as the development and/or intensity of the GVT immunity is insufficient to eliminate the 
residual tumor cells.28 It is therefore important to continue working on improving this 
therapeutic strategy and to develop new adjuvant therapies that could be combined with 
alloSCT to selectively boost the potency of the GVT immune responses, while limiting 
the incidence and severity of GVHD. The overall aim is to thereby increase disease-free 
and overall survival of transplanted patients.
For alloSCT, the HSCs can be obtained from three different sources: bone marrow 
(BM), umbilical cord blood (UCB) or peripheral blood (PB) after mobilization of the HSCs 
to the PB using e.g. G-CSF (granulocyte colony-stimulating factor). Nowadays, mobilized 
PB collection is most common, as it can be obtained with minimal discomfort for the 
donor, has high numbers of HSCs and is associated with faster hematologic recovery.29 A 
very important aspect in alloSCT is to select a donor that has a similar human leukocyte 
antigen (HLA) genotype as the patient, to minimize the risk of graft rejection and GVHD. 
Preferable donors are relatives, e.g. a sibling, as the chances of HLA matching are higher. 
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However, many patients do not have a HLA-matched relative. Those patients then receive 
transplantation either from a HLA-matched unrelated donor, obtained from the stem 
cell registry, or from a related donor that is partially HLA-matched or haplo-identical. 
Notably, with the development of GVHD prophylaxis protocols mentioned above, the use 
of haplo-identical donors has increased in the past decade.30
GVT effector cells and targeted antigens
The principal task of the immune system is to distinguish self from non-self (foreign) 
antigens, and to recognize altered (mutated or damaged) self-antigens. In this regard, HLA 
molecules (major histocompatibility complex (MHC) class I and II) are very important, 
as they present the non-self/altered antigens on the cell surface for recognition by the 
appropriate T cells. All nucleated cells express MHC class I (HLA-A, HLA-B, HLA-C) 
molecules, which present cytoplasm-derived peptides and intracellular pathogens. On the 
other hand, MHC class II (HLA-DR, HLA-DQ, HLA-DP) expression is mainly restricted 
to hematopoietic cells such as macrophages, DCs and B cells. Extracellular antigens are 
presented in MHC class II. MHC class I and II molecules are recognized by CD8 and 
CD4 positive T cells, respectively. These HLA molecules and presented antigens play a 
major role in the pathogenesis and therapeutic effect of alloSCT. Donor-derived T cells 
recognize antigens, in the context of HLA, that differ between recipient and donor cells. 
This can result in their activation and subsequent attack of the recipient cells expressing 
the antigen, which can be healthy tissues and/or the malignant cells. This is the basis of 
the GVHD and GVT effect, respectively, and is primarily mediated by CD8+ cytotoxic T 
lymphocytes (CTLs).
The magnitude and specificity of the T cell activation depends on the extend of 
mismatching between donor and recipient. In a full HLA-matched setting, the primary 
immunological targets of allo-reactive T cells are minor histocompatibility antigens 
(MiHAs). These MiHAs are HLA-presented peptides derived from polymorphic genes that 
differ between donor and recipient.31,32 Patient-specific MiHAs may therefore be regarded 
as foreign to the donor immune T cells, and strong high-affinity T cell responses against 
MiHA-expressing cells can occur. If the MiHAs are exclusively expressed by hematopoietic 
cells, the MiHA-specific T cell responses specifically eliminate the hematopoietic cells of 
the patient, including the residual malignant cells (GVT effect). However, other MiHAs 
have a ubiquitous expression pattern and are hence also expressed by healthy tissues 
of the patient. When allo-reactive T cells are directed against these broadly expressed 
MiHAs, GVHD can occur. Therefore, strategies for separating GVHD from GVT aim at 
specifically targeting hematopoietic-restricted MiHAs, for example with DC vaccination 
or adoptive transfer of MiHA-specific T cells. Interesting target MiHAs in this respect 
include HA-1, HA-2, LRH-1, ARHGDIB and UTA2-1.33
Other important antigens in anti-tumor T cell immunity post-alloSCT are tumor 
antigens.34,35 Tumor antigens can be of different origin, but the general nominator is that 
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they are highly or specifically expressed by the tumor cells, while healthy cells have no or 
low expression of the particular antigen. Tumor-associated antigens (TAAs) are relatively 
restricted to tumor cells (e.g. overexpressed antigens, cancer-testis antigens and oncofetal 
antigens), whereas tumor-specific antigens (TSAs) are unique to tumor cells. TSAs are also 
called neoantigens, and arise for example due to somatic point mutation within the mutant 
clone. Overexpressed TAAs derived from self-proteins that have low expression on normal 
tissues are often considered to have lower immunogenicity than MiHAs or TSAs, due to 
potential immunotolerance.36,37 Despite this, studies have demonstrated that TAA-specific 
T cell responses can be induced with in vivo vaccination, without considerable toxicity.38 
Interesting therapeutic TAA-candidates in the context of hematological malignancies 
are WT1, PRAME, Proteinase 3, RHAMM, MAGE and NY-ESO1.34,39 Interesting TSA-
candidates are however more difficult to apply in current cancer vaccination strategies 
since they are often patient-specific and difficult to identify. Furthermore, studies indicate 
that hematological malignancies have a lower mutational load than many solid cancers, 
such as melanoma, resulting in fewer therapeutically-applicable TSAs.35
Besides CD8+ tumor-reactive T cells, the second key player in GVT immunity is the 
cytotoxic CD56+ NK cell.40 NK cells are innate immune cells that recognize and eliminate 
stressed and infected cells, but spare healthy cells. In contrast to T cells, NK cell activity 
does not require antigen-priming, so they can therefore rapidly kill targeted cells. The 
regulation of NK cell activation is dependent on the sum of signals they receive via a 
variety of activating and inhibitory receptors expressed on their surface.41,42 The most 
characterized inhibitory receptors are killer immunoglobulin-like receptors (KIRs) 
and the C-type lectin receptor NKG2A. The main ligands for these receptors are the 
ubiquitously expressed MHC class I molecules. In homeostasis, engagement of NK 
inhibitory receptors by MHC class I molecules prevents NK cells from becoming activated, 
thereby protecting healthy tissues from NK cell-mediated lysis. Tumor cells may lose 
or downregulate the expression of MHC class I molecules, thereby providing less or no 
inhibitory signal to NK cells. As a result, NK cells can become activated and mediate a 
response against the targeted cell. This is known as “missing-self”-mediated activation.42 
On the other hand, NK cells can become activated when the signals via their activating 
receptors are stronger than the signals via inhibitory receptors. NK cells express numerous 
activating receptors including natural cytotoxicity receptors (NCRs, including NKp30, 
NKp44, NKp46), the C-type lectin receptors NKG2D and NKG2C, Fc receptor CD16, 
activating KIRs and DNAM-1. While some healthy cells express the ligands for these 
receptors, their expression is primarily increased during cell stress, including infection 
or DNA damage, which can trigger the activation of NK cells. This is commonly referred 
to as “stress-induced self” recognition.42
NK cells are one of the first immune cells to repopulate after alloSCT.43-45 Early 
repopulation has been associated with reduced relapse rates, indicating that allo-reactive 
NK cells have a specific anti-tumor activity post-transplantation.46-50 Importantly, these 
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studies have shown that the allo-reactive NK cells do not cause GVHD. Furthermore, 
donor-derived NK cells may even suppress induction and/or severity of GVHD.51-53 The 
potential of NK cells to eliminate tumor cells has particularly been demonstrated in the 
alloSCT setting where patients are transplanted with a HSC-graft from a haplo-identical 
or other partially HLA-matched donor.53-55 In this setting, NK cell allo-reactivity was 
mainly dependent on reduced inhibitory signaling, as inhibitory KIRs on the donor NK 
cells did not match with their cognate HLA molecule on the recipient cells. The lack of 
KIR engagement allows the NK cells to kill the tumor cell. On the other hand, in the 
context of full HLA-matching, NK tumor-reactivity may depend on enhanced signaling 
via activating receptors, resulting in activation of the NK cells and subsequent cytotoxicity 
of target cells. In this regard, activating KIRs have been shown to play a role. The KIR 
gene family consists of many highly polymorphic genes, which are inherited as haplotype 
A or B from each parent.56 The main differences between those two haplotypes, is that B 
haplotypes have more genes encoding activating KIRs than A haplotypes. Recent studies 
into these KIR genetics have shown that alloSCTs from HLA-matched donors with KIR 
B/x genotype (containing one or two B haplotypes) are associated with lower relapse rate 
and improved progression-free survival of transplanted patients.57-59
Cytotoxic CD8+ T cells and NK cells kill their targeted malignant cells via several 
mechanisms. This includes release of cytotoxic granules containing perforin and 
granzymes, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-dependent 
cytotoxicity and Fas ligand-induced apoptosis.60,61 Moreover, the activated NK cells and 
T cells secrete cytokines, such as interferon (IFN)-γ, which further boosts the anti-tumor 
immune response by directly affecting the tumor cells and by promoting recruitment and 
activity of other immune effector cells.62 IFN-γ-secreting CD4+ T-helper (Th) T cells also 
contribute to GVT immunity.63,64 CD4+ T cells are generally thought to be less effective 
killers than CD8+ T cells, but they provide important help to the other immune effector 
cells.65 They stimulate antigen-presenting cells (APCs) for priming of CD8+ T cells, as well 
as secrete interleukin (IL)-2, which is an important cytokine for proliferation and cytotoxic 
functionality of CD8+ T cells and NK cells. Additional immune cells that participate in 
the GVT effect, but are not further discussed here, include NKT cells and γδ T cells.66-68
Boosting anti-tumor immunity with immunotherapy
To enhance the cure rate of patients with hematological malignancies both in the 
transplant and non-transplant setting, it is essential to improve current strategies and/
or develop new therapies to prime and boost anti-tumor immune responses and to 
create immunological memory for sustained remission. Currently, multiple different 
immunotherapeutic strategies are being investigated in this regard, either as standalone 
interventions or combined with other immunotherapeutic treatments or anti-cancer 
drugs. These include non-cellular interventions such as systemic treatment with tumor-
17
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targeting antibodies, immunomodulatory antibodies or immunostimulatory cytokines, 
and cellular-based approaches such as adoptive transfer of tumor-reactive T cells and NK 
cells. Furthermore, anti-cancer vaccination strategies, either non-cellular (using various 
antigen formulations) or cellular (using DCs), are being explored.69 Here below, DC-based 
vaccines and adoptive NK cell therapy is introduced in more detail, as these therapeutic 
approaches were the focus of this thesis.
DC-based vaccination
DC biology and therapeutic potential
DCs are the most potent APCs and play a pivotal role in determining the nature and 
magnitude of innate and adaptive immune responses. DCs are uniquely positioned in 
peripheral tissues, where they continuously sample the environment for non-self and 
altered antigens. The DCs subsequently process these antigens into smaller peptides 
as they mature and migrate towards secondary lymphoid organs. There, the DCs 
present the captured antigens to T cells in the context of MHC class I and II molecules, 
thereby inducing a cellular immune response. When compared to other APCs, such as 
macrophages, DCs are extremely efficient as they provide strong co-stimulatory signals 
needed for initial priming of naïve T cells. Furthermore, DCs excel at cross-presentation, 
where extracellular antigens (such as from dying infected cells) are presented in MHC class 
I molecules to CD8+ CTLs. DCs also orchestrate naïve and memory B cell responses, and 
can activate innate immune cells such as NK and NKT cells. Thus, DCs can orchestrate 
all the different aspects of the immune response, which makes them very attractive 
targets and tools for immunomodulatory strategies to improve tumor-reactive immune 
responses.70,71
The role of DCs is though more complicated than described above as they have a 
bilateral function, whereas on one hand they induce productive T cell responses under 
inflammatory conditions, they on the other hand maintain tolerance against self-antigens 
under steady state. When immature DCs present tissue antigens to T cells in the absence 
of appropriate co-stimulation, peripheral tolerance is induced resulting in T cell anergy 
and/or development of suppressive IL-10 secreting regulatory T cells.72-74 Moreover, 
presence of immature DCs within tumors has been associated with tumor progression 
and suppressed anti-tumor immune response development.75 Efficient maturation of the 
DCs is therefore of utmost importance to facilitate induction of productive anti-tumor 
immune responses. During DC maturation, tightly controlled series of events occur that 
are initiated by a spectrum of environmental and endogenous stimuli. In this respect, DCs 
express numerous receptors, that recognize different components of pathogens, such as 
proteins, lipids, carbohydrates, RNA (ribonucleic acid) and DNA (deoxyribonucleic acid). 
These receptors are collectively called pattern recognition receptors (PRRs), and include 
Toll-like receptors (TLRs), C-type lectin receptors, NOD-like receptors and RIG-I-like 
receptors.76 The TLRs are the most studied PRRs, where 10 different ones (TLR1-10), 
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have been characterized in human DCs.77 Upon stimulation/maturation via PRRs, DCs 
downregulate endocytic and phagocytic receptors, upregulate chemotactic receptors (that 
guide migration to lymph nodes) and co-stimulatory molecules such as CD80, CD86 and 
CD40, increase transport of peptide-MHC complexes to the surface, and synthesize and 
secrete a variety of cytokines. In the context of DC vaccination, synthetic TLR ligands can 
be used to mimic the “natural” pathogen-induced maturation pathways of DCs. Thereby 
immune responses can be skewed towards productive pro-inflammatory and cytotoxic 
T cell and NK cell responses.
DC subsets
DCs are a heterogenous population of cells, that comprise many different subsets which 
differ in ontogeny, phenotype, function and localization. Due to the low frequency of 
these cells, characterization and classification of different DC subsets has remained 
difficult. Furthermore, their phenotype is subject to changes dependent on location, 
environmental cues and maturation status, which further hampers the characterization 
and categorization. Despite these challenges, detailed insight has been gained about DCs 
since their discovery. The DC subsets found in human PB are broadly divided into two 
major categories: myeloid DCs (mDCs; also frequently referred to as conventional or 
classical DCs) and plasmacytoid DCs (pDCs) (Figure 2). mDCs can further be subdivided 
into two populations based on their differential expression of the surface molecules 
BDCA1 (CD1c) and BDCA3 (CD141).78 Although of low frequency, these three DC subsets 
(BDCA1+ mDCs, BDCA3+ mDCs, and pDCs) can also be identified in steady state in other 
lymphoid organs, such as lymph nodes and spleen, and also in some other peripheral 
tissues.79,80
Figure 2. Human dendritic cells (DCs). In peripheral blood and lymphoid tissue, three major populations 
of DCs can be identified, plasmacytoid DCs (pDCs), BDCA1+ myeloid DCs (mDCs) and BDCA3+ mDCs. 
These three DC subsets are considered the “bona fide” DC subsets. Other cells that can be classified as DCs 
include Langerhans cells, which are the most abundant DCs in the epidermis. Furthermore, monocytes can 
differentiate into DCs under certain circumstances, such as inflammation (inflammatory DC) or in vitro with 
GM-CSF and IL-4 (monocyte-derived DC (MoDC)).
19
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Recent reports have delineated the developmental pathway of these different DC subsets 
from CD34+ HSPCs in humans. These studies indicate that terminally differentiated DCs 
arise after series of lineage-restricted transitions from progenitor cells located in the BM 
(Figure 3). A study by Lee et al. described that these transitions go via a monocyte-DC 
progenitor (MDP) that has the capacity to develop into monocytes or the common DC 
progenitor (CDP). They further show that the CDP is restricted to generate the three 
major DC subsets mentioned above, by giving rise to pDCs and pre-mDCs that migrate 
through blood and replenish the pool of DCs in lymphoid organs and peripheral tissue.81 
Breton et al. further described that the pre-mDC is an immediate precursor of both 
BDCA1+ mDCs and BDCA3+ mDCs, but not of pDCs or monocytes, and can be found 
in BM, UCB, PB as well as tonsils.82 This pre-mDC is negative for CD34 and lineage 
markers (including BDCA1 and BDCA3), while positive for CD45RA, CD135 (FMS-like 
tyrosine kinase 3 (Flt3)), CD116 (granulocyte-macrophage colony-stimulating factor 
(GM-CSF) receptor) and CD117 (stem cell factor (SCF) receptor). Furthermore, the pre-
mDC expresses a high level of HLA-DR and intermediate level of CD123 (IL-3 receptor). 
Like for other immune cells, distinctive growth factors and transcription factors guide 
the development of DCs from hematopoietic progenitor cells.83,84 These growth factors 
include Flt3-ligand (Flt3L), SCF, GM-CSF and IL-3, which act via their respective surface 
receptor for modulating transcription and lineage commitment.85 In particular, Flt3L 
has been established as the key cytokine driving DC development and homeostasis. For 
example, studies both in humans and mice have shown that over-expression or injection 
of Flt3L markedly increases the numbers of circulating DC subsets and pre-mDCs.82,86,87 
Despite the recent advances in delineating human DC development, more understanding 
of the transcriptional network and dependency of different progenitors and DC subsets 
on distinctive cytokines is required, particularly in humans.
DCs that reside in lymphoid tissues are generally referred to as “resident” DCs. While, 
DCs that traffic from peripheral tissue into lymph nodes, carrying antigens that they 
have sampled in the periphery, are generally referred to as “migratory” DCs.83 These 
migratory DC subsets found in peripheral tissues are less characterized than DCs in 
lymphoid organs, with the exception of skin DCs. In skin, the different subsets listed 
above can be found, in addition to a special type of DC, called Langerhans cell (LC) 
(Figure 2). LCs were for many years considered to be the classical DCs, however, studies 
during the past decade showed that in steady-state this population can self-renew and is 
independent of adult hematopoiesis, and is therefore more similar to a macrophage than 
DC.88,89 Nevertheless, upon inflammatory stimuli or after SCT, LCs can also be generated 
from circulating bone marrow precursors.90-92 Whether these precursors are shared with 
the other DC subsets, BDCA1+ mDCs and BDCA3+ mDCs, remains to be elucidated. 
Interestingly, two recent studies indicate that BDCA1+ mDCs may have a potential LC-
precursor function, as BDCA1+ mDCs, when exposed to transforming growth factor 
(TGF)-β ex vivo, can differentiate into LCs.93,94
1
20
Chapter 1
In general, inflammatory conditions can induce major changes to the DC compartment. 
For example, upon inflammation, monocytes can adopt dendritic morphology and 
antigen-presentation functions.95 Transcriptome analysis showed that these DCs, referred 
to as monocyte-derived DCs (MoDCs) or inflammatory DCs (Figure 2), are distinct 
from steady-state lymphoid organ and blood DCs.96 Their functional contribution in 
vivo remains to be determined. In vitro however, MoDCs represent the best studied DC 
subset so far, as they can be readily generated from isolated monocytes by culturing 
them with the cytokines GM-CSF and IL-4.97 So far, most DC-based clinical trials have 
utilized MoDCs.
Besides ontogeny and location, other attributes differ between the DC subsets that 
influence their functional characteristics. Differential expression of PRRs is one such 
attribute, which conveys distinct maturation signals to the DC, and determines their 
activation status and the type of immune response generated. The two main PRRs 
expressed by pDCs are TLR7 and TLR9. TLR7 recognizes single-stranded RNA from RNA 
viruses, while TLR9 senses unmethylated DNA with CpG motifs derived from bacteria and 
viruses.98,99 In response to such ligands, pDCs secrete large amounts of type I interferons 
(IFN-α/β), which gives pDCs a critical role in induction of anti-viral immunity.100 The 
mDC subsets have a broader range of PRR expression than pDCs, which facilitates their 
response to a broader range of pathogens.77 Upon TLR-stimulation, BDCA1+ mDCs and 
BDCA3+ mDCs can produce IL-12, which is a key cytokine for induction of cytotoxic 
CD8+ T cells, IFN-γ-secreting CD4+ T cells and anti-tumor responses.101-104 For induction 
of anti-tumor immunity, cross-presentation of tumor-derived exogenous antigens to CD8+ 
T cells is another key feature of DCs in which PRRs are involved. BDCA3+ mDCs are 
considered the most efficient cross-presenting DC subset in humans, which is related to 
their selective expression of the C-type lectin CLEC9A (DNGR1), a receptor that mediates 
recognition and uptake of necrotic cells.105,106 However, cross-presentation capacity has also 
been demonstrated in vitro for both BDCA1+ mDCs and pDCs.107,108 Besides individual 
contribution of the DC subsets to induction of immune responses, studies show that pDCs 
and mDCs can interact and thereby synergistically enhance each other’s stimulatory 
capacity.109 This synergistic cross-talk has been shown to enhance the development of 
anti-tumor immune responses.110,111 Therefore, given the distinct functions of each subset 
and their potential to enhance each other’s stimulatory capacity via cross-talk, it is very 
interesting and promising to develop therapeutic strategies for cancer patients that involve 
these different DC subsets.
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Figure 3: Proposed model of dendritic cell (DC) development from hematopoietic progenitor cells. During 
DC development, first a granulocyte, monocyte and DC progenitor (GMDP) differentiates into a monocyte 
and DC progenitor (MDP), which then gives rise to a common DC progenitor (CDP). This CDP can develop 
into plasmacytoid DC (pDC) or pre-myeloid DC (mDC). Pre-mDCs migrate from the bone marrow into blood 
and peripheral tissue, where they produce the two major mDC subsets, BDCA1+ and BDCA3+ mDCs.81,82
Utilizing DCs for induction of anti-tumor immunity
Numerous different therapeutic vaccination strategies are under thorough investigation 
for evaluating their potential to induce productive anti-tumor immunity. All these 
strategies revolve around utilizing the exceptional capacity of DCs to present antigens 
and provide co-stimulation to T cells, in particular CD8+ T cells. The desired outcome 
elicited by the vaccines is priming and expansion of CD8+ CTLs that can eliminate the 
malignant cells, and formation of long-lived memory T cells that can rapidly generate new 
cytotoxic effector T cells in the case of relapse. These T cells responses can be directed 
against tumor antigens such as TAAs or TSAs.70 Furthermore, in the setting of MiHA-
mismatched alloSCT, DCs presenting hematopoietic-restricted MiHAs can be utilized to 
selectively boost GVT immunity.
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Anti-cancer vaccines can broadly be classified as ex vivo-loaded, non-targeted or 
in vivo-targeted vaccines.112 The first class involves infusing patients with DCs that are 
matured and loaded with antigens (TAAs, TSAs or MiHAs) ex vivo. As natural DC subsets 
in PB are scarce (less than 0.5% of white blood cells113), so far the majority of clinical 
trials has applied ex vivo-generated MoDC vaccines. Monocytes for DC generation can 
easily be isolated in high numbers from the patient, or from the stem cell donor in the 
case of alloSCT. After ex vivo differentiation of monocytes into MoDCs, maturation is 
induced by a combination of pro-inflammatory cytokines and/or synthetic TLR ligands. 
Thereafter, the mature DCs are loaded with the desired antigen (e.g. tumor antigen or 
MiHA) by 1) incubation with MHC class I- and/or class II-binding peptides, 2) incubation 
with tumor lysate, or 3) transfection with RNA encoding tumor antigens or MiHAs 
which will be synthesized into proteins and processed by the DCs themselves.114 Clinical 
studies in patients with solid tumors and hematological malignancies have concluded that 
vaccination with ex vivo-loaded DCs is feasible, safe and can induce expansion of tumor-
specific CD4+ and CD8+ T cells. Moreover, vaccination of alloSCT recipients has also been 
demonstrated to be safe without induction or aggravation of GVHD.38,115-119 However, 
despite induction of tumor-specific T cell responses, the number of vaccinated patients 
showing tumor regression and objective clinical responses is low. This illustrates that 
further optimizations of this strategy are warranted to improve the therapeutic potency. 
Multiple parameters could affect the clinical response/therapeutic efficacy, including DC 
maturation stimuli and duration, antigen loading strategy, route of administration, and 
dosing and frequency of the vaccine infusions. Furthermore, the subtype of DCs could 
also matter. We and others postulate that primary DC subsets, such as pDCs and mDCs, 
might be more potent stimulators of anti-cancer immune responses than MoDCs.120 In this 
regard, few clinical trials have recently explored the use of pDCs or BDCA1+ mDCs isolated 
from PB of melanoma and prostate cancer patients for therapeutic vaccination.121-123 An 
alternative approach, particularly for vaccination of alloSCT recipients, is the generation 
of different DC subsets from HSPCs obtained from SCT donors. We have established and 
investigated this strategy in chapters 2-4, where we describe novel ex vivo culture systems 
for generation of different subsets of DCs, including BDCA1+ mDCs, BDCA3+ mDCs, 
and pDCs, from CD34+ HSPCs. We demonstrate the potential of these DC subtypes 
to initiate and boost tumor-reactive T cell and NK cell responses ex vivo. It would be 
very interesting to explore vaccination with antigen-loaded DCs of different subtypes as 
post-transplantation therapy for alloSCT patients. It has the promise to selectively boost 
tumor-reactive T cell and NK cell responses, without evoking severe GVHD.
Besides studies that focus on ex vivo-loaded DC vaccines, multiple studies explore 
strategies that harness the DCs in vivo for induction of anti-tumor immunity. On one 
hand, these include non-targeted vaccination strategies, where for example formulations 
of tumor antigen (commonly long peptide) and adjuvant are infused. These formulations 
are captured randomly by DCs or other APCs at the injection site or in draining lymph 
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nodes, leading to in vivo antigen processing and presentation. On the other hand, multiple 
studies investigate efficacy of in vivo-targeted vaccines, that are delivered specifically to 
(a subset of) DCs by coupling or fusing antigens to antibodies directed against endocytic 
receptors expressed on the surface of DCs. In this regard, multiple DC-specific receptors 
are being characterized and evaluated for their effectiveness as DC targets, including 
DEC-205, DC-SIGN, mannose receptor, CLEC9A and Langerin.124 Many factors need to be 
considered when selecting the most appropriate receptor for targeting, dependent on the 
desired outcome. This includes for example the expression pattern of the targeting receptor 
on the different DC subsets, their ability to deliver antigens to intracellular compartments 
for processing and loading of peptides onto MHC, and the type of immune responses 
(e.g. Th1, Th2, cellular, humoral) that are initiated upon targeted delivery of antigens. In 
chapter 5, we describe such characterization for the C-type lectin receptor CLEC12A, 
an endocytic receptor expressed by all human DC subsets and monocytes. We show that 
CLEC12A is a promising targeting receptor, as targeted antigens were efficiently processed 
and presented in both MHC class I and II, leading to activation of antigen-specific CD4+ 
and CD8+ T cells.
Adoptive NK cell therapy
Immunotherapeutic strategies utilizing the potent cytolytic capacity of NK cells 
against tumor cells are being increasingly investigated both in the setting of solid and 
hematological cancers. The activation and cytolytic function of NK cells is regulated by 
signals they receive via inhibitory and activating receptors expressed on their surface. 
The principle of adoptive NK cell transfer is to infuse NK cells that get activated and 
target the tumor cells due to the absence of inhibitory signals (i.e. missing-self) and/or 
by infusing NK cells with high expression of activating ligands.42,125 The missing self-
mediated activation can be promoted by using allogeneic NK cells, and for that reason, the 
majority of clinical trials to date have utilized allogeneic NK cells for adoptive transfer. In 
this setting, NK cells are generally isolated or enriched from PB of a relative or unrelated 
donor. Subsequently, NK cells are infused into the patient right away, overnight stimulated 
with IL-2 and/or IL-15, or expanded ex vivo for up to three weeks in the presence of 
IL-2 to obtain higher numbers of cells for infusion. Clinical studies investigating these 
approaches have demonstrated that infusion of allogeneic NK cells is safe, but yet no firm 
conclusion on clinical efficacy has been drawn. Limited clinical efficacy of PB NK cells has 
been associated with low numbers and poor activation/maturation status.126 Furthermore, 
low purity and contamination with allogeneic T cells has hampered their use. Few trials 
have also investigated the use of autologous NK cells, though in that setting an inhibitory 
KIR-HLA engagement is likely still present, requiring powerful NK cell activation prior 
to infusion.127
An alternative approach for obtaining NK cells for adoptive transfer is to generate 
them ex vivo from HSPCs. In this regard, our group has developed a novel good 
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manufacturing practice (GMP)-compliant manufacturing procedure for generation of 
NK cells from CD34+ HSPCs isolated from UCB. Using this procedure, high numbers 
of NK cells can be generated.128,129 The feasibility and safety of using allogeneic UCB-
derived NK cells has recently been demonstrated in a phase I clinical trial in elderly 
AML patients who were ineligible for SCT.130 Before NK infusion, patients received 
cyclophosphamide and fludarabine (Cy/Flu) lympho-depleting chemotherapy which 
prevents immediate rejection of the allogeneic NK cells. Furthermore, Cy/Flu conditioning 
promotes cytokine availability for the transferred NK cells.131 Infusion of UCB-derived 
NK cells in combination with Cy/Flu conditioning was well tolerated, and did not induce 
GVHD nor other toxicity. Notably, 2 out of 4 patients with minimal residual disease 
(MRD) before treatment showed promising response as they became temporarily MRD 
negative.130 It would also be very interesting to explore the use of ex vivo-generated NK 
cells in the transplantation setting, since early repopulation and high NK cell numbers 
after transplantation have been associated with reduced relapse rates.46-50 Furthermore, NK 
cells also provide protection against viral, bacterial and fungal infections in transplanted 
patients.132-134 In the alloSCT setting, it would be most ideal to inject NK cells of stem cell 
donor origin, to avoid rejection and allow longer persistence. Thereby, multiple infusions 
of NK cells would be feasible. Furthermore, pre-conditioning with lympho-depleting 
chemotherapy might not be required when donor-derived NK cells are used. For this, the 
NK cells would need to be generated from CD34+ HSPCs isolated from G-CSF-mobilized 
PB or BM, as these stem cell sources are more commonly used for transplantation of 
patients than UCB. In chapter 6, we describe the optimization of the before-mentioned 
culture system for generation of NK cells from G-CSF-mobilized PB and BM HSPCs. 
Infusion of these HSPC-derived NK cells post-transplantation has the potential to induce 
long-term GVT efficacy and protection against infectious complications post-alloSCT.
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Outline of this thesis
AlloSCT has the potential to cure patients with hematological malignancies by clearing 
residual disease. However, alloSCT is still associated with significant morbidities, such 
as development of the detrimental GVHD and opportunistic infections, that affect the 
patient’s quality of life and outcome. Furthermore, a significant portion of patients 
experiences relapse of the malignancy. For these reasons, development of new (adjuvant) 
therapeutic strategies are needed to improve the outcome and long-term relapse-free 
survival of transplanted patients. In this respect, new strategies aim to boost GVT 
immunity, while preventing adverse events such as GVHD and infections. In this thesis, 
we describe the pre-clinical development of such immunotherapeutic strategies, including 
DC vaccination and NK cell adoptive transfer.
In chapter 2, we aimed to develop a culture protocol for generating immunostimulatory 
DCs from CD34+ UCB HSPCs to use as a vaccine for patients with hematological 
malignancies. We describe a step-wise ex vivo culture protocol using specific combinations 
of different cytokines and growth factors, that facilitates the generation of high numbers of 
phenotypically mature DCs. Within this culture system, primarily CD1a+ mDCs and LC-
like DC subsets were generated, that could efficiently induce allogeneic and MiHA-specific 
T cell responses in vitro. Furthermore, cytomegalovirus (CMV)-loaded UCB-derived DCs 
induced proliferation of CMV-specific CD8+ cytotoxic T cells, both in vitro and in vivo. 
However, this culture system did not support the generation of other DC subsets, such as 
pDCs and BDCA3+ mDCs. As we believe these subsets may be superior for induction of 
anti-tumor immunity, we explored alternative culture protocols. In chapter 3, we describe 
our discovery that inhibition of the aryl hydrocarbon receptor (AhR), using the antagonist 
StemRegenin 1 (SR1), was essential for differentiation of pDC, BDCA1+ mDC and BDCA3+ 
mDC subsets from CD34+ HSPCs ex vivo. We demonstrated how these subsets could be 
generated in high numbers from both UCB and G-CSF mobilized PB CD34+ HSPCs. 
Furthermore, we assessed their phenotype and function, which was comparable to their 
naturally occurring counterparts in blood. In chapter 4, we describe further optimization 
of this novel SR1-based culture protocol for generation of higher amounts of the different 
DC subsets and adaptations to GMP-culture conditions. Importantly, we demonstrated 
the superior capacity of SR1-generated HSPC-derived pDCs and BDCA1+ mDCs in 
stimulating tumor-reactive T cell and NK cell responses.
In addition to the ex vivo-generated DC approach, we pursued the idea to move 
towards an off-the-shelf vaccine for stimulating anti-tumor immunity in chapter 5. In 
this regard, we investigated the potential of targeting DCs in vivo via endocytic receptors. 
We show that CLEC12A, a C-type lectin receptor expressed by all the different DC subsets, 
is an attractive target. We demonstrate that CLEC12A targeting does not negatively affect 
DC maturation nor function, and that antigens delivered via CLEC12A were efficiently 
presented to CD4+ and CD8+ T cells. Importantly, we observed that CLEC12A-targeted 
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delivery of MiHAs resulted in efficient antigen cross-presentation and activation of MiHA-
specific CD8+ T cells.
Our group has previously established a GMP-compliant cytokine-based ex vivo 
culture protocol for generation of high numbers of NK cells from UCB CD34+ HSPCs. 
As recent advances have shown that AhR does not only play a role in DC development, 
but also regulates homeostasis and differentiation of various other immune cells,135 we 
examined the effect of SR1 addition during ex vivo generation of NK cells. In chapter 6, we 
demonstrate that SR1 not only enhances expansion of CD34+ HSPCs, but also potentiates 
the differentiation of these cells into NK cells. As a result, high numbers of NK cells 
could be generated from BM and G-CSF mobilized PB CD34+ HSPCs. Furthermore, we 
demonstrated that these NK cells were highly active and efficiently targeted and lysed 
malignant hematopoietic cells. Finally, as these NK cells have the potential to be used 
for adoptive transfer post-transplant, we showed that NK cell proliferation and function 
was not inhibited by cyclosporine A (CsA), an immunosuppressive drug often used after 
alloSCT.
In chapter 7 the findings described in this thesis are summarized and in chapter 8 
they are discussed in the context of potential future implications.
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Abstract
Autologous, patient-specific, monocyte-derived dendritic dell (MoDC) vaccines 
have been successfully applied in the clinical studies so far. However, the routine 
application of this strategy has been hampered by the difficulties in generating 
sufficient numbers of DCs and the poor DC vaccine quality due to pathology or 
prior treatment received by the patients. The immunotherapeutic potential of other 
subsets of DCs has not been thoroughly investigated due to their rarity in tissues 
and difficulties associated with their ex vivo generation. The high expansion and 
differentiation potential of CD34+ hematopoietic stem and progenitor cells (HSPC), 
isolated from umbilical cord blood (UCB), into different DC subsets make them 
an attractive alternative DC source for cancer immunotherapy. Therefore, the 
aim of this study was to generate a large number of different DC subsets from 
CD34+ HSPCs and evaluate their functionality in comparison with MoDCs. Our 
culture protocol generated a clinically relevant number of mature CD1a+ myeloid 
DCs and CD207+ Langerhans cell (LC)-like DC subsets from CD34+ HSPCs with 
>95% purity. Both DC subsets exhibited a cytokine profile that favor cytotoxic 
T cell responses. Furthermore, UCB-DCs and UCB-LCs demonstrated superior 
induction of proliferation of both allogeneic as well as viral antigen-specific CD8+ 
T cells, both in vitro and in vivo. Additional studies revealed that UCB-DCs and 
UCB-LCs can efficiently expand minor histocompatibility antigen (MiHA) HA-
1-specific cytotoxic T cells in the peripheral blood of leukemia patients and prime 
MiHA HA-1-specific and HA-2-specific cytotoxic T cells in vitro. These pre-clinical 
findings support the pharmaceutical development of the described culture protocol 
for clinical evaluation.
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Introduction
Acute myeloid leukemia (AML) is the most common type of acute leukemia occurring in 
adults.1 Despite improvements in chemotherapy and supportive care, AML has still a very 
poor prognosis resulting in a 5-year overall survival rate of only 24%.2 One of the main 
causes for this bad prognosis is relapse of the disease after reaching complete remission 
with classical polychemotherapy due to persistence of chemo-resistant malignant cells 
during remission.3,4 Although, allogeneic hematopoietic stem cell transplantation together 
with donor lymphocyte infusion (DLI) after polychemotherapy is a curative option, the 
treatment-related mortality and morbidity issues, and lack of suitable donors limit its 
routine use in elderly AML patients.5,6 Therefore, alternative treatment options are urgently 
needed to improve the prognosis of AML patients.
Evidence for immunosurveillance of AML and susceptibility of leukemia cells to both 
T and NK cell attack has paved way for the development of new immunotherapeutic 
strategies.7 Currently, interleukin (IL)-2 administration8, monoclonal antibody therapy9 
vaccination with peptides derived from leukemia-associated antigens (LAA)10,11 and 
cellular therapies12 are being explored as adjuvant therapies to eradicate minimal residual 
disease (MRD) or to induce anti-leukemic immunity to control relapse of malignant 
disease. Among these cellular therapies, dendritic cell (DC)-based immunotherapy holds 
a great potential as an adjuvant cancer therapy in the setting of MRD to boost the patient’s 
own immune system to eradicate AML cells and induce immunological memory that 
protects against disease recurrence.
DCs are the most potent antigen presenting cells identified to date. The unique 
capability of DCs to activate naïve T cells and orchestrate primary immune responses 
make them an ideal candidate for cellular immunotherapy.13 The invention of the protocol 
to generate considerable numbers of DCs from monocytes in vitro boosted the enthusiasm 
for the clinical application of DC-based vaccines.14,15 Since then, numerous clinical 
trials have evaluated the safety, feasibility and clinical efficacy of DC-based vaccines 
derived from patient’s own monocytes or G-SCF mobilized CD34+ hematopoietic stem 
and progenitor cells (HSPCs) in cancer patients.14,16-22 Although, the published results 
of clinical trials have clearly demonstrated that monocyte-derived DC (MoDC)-based 
cancer vaccination strategy is feasible, safe and can induce potent anti-cancer immune 
responses, the clinical responses observed so far are limited.23,24 In addition, the routine 
application of this strategy has been hampered mainly by a) the difficulties associated 
with the generation of sufficient numbers of DCs for vaccination purposes and b) poor 
DC vaccine quality due to pathology or prior treatment received by the patients.12
Although DCs are composed of multiple subsets with specialized functions, the vast 
majority of clinical studies conducted so far have used MoDCs. The physiological standing 
of this subset and whether it is an ideal subset for cancer immunotherapy is currently 
unclear. Alternatively, CD34+ HSPCs can be expanded and differentiated ex vivo into 
various types of myeloid DCs that resemble CD14+ dermal DCs, CD1a+ interstitial or blood 
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DCs, BDCA3+ blood DCs and CD207+ Langerhans cells (LCs).25-31 So far, granulocyte 
colony-stimulating factor (G-CSF)-mobilized peripheral blood HSPC from cancer patients 
have been used for generation of autologous DC vaccines.32,33
Tumor-associated antigens (TAAs) usually trigger weak immune responses in contrast 
to potent allogeneic responses directed against non-self major histocompatibility complex 
(MHC). These allogeneic immune responses are mediated by MHC class II-restricted 
CD4+ T cells that can promote bystander antigen-specific cytotoxic T lymphocyte (CTL) 
responses.34 In DC vaccination strategy, allogeneicity could therefore be exploited to 
promote immunogenicity towards tumor antigens by vaccinating cancer patients with 
TAA-loaded DCs generated from partial HLA-matched donors.
In this study, we explored umbilical cord blood (UCB) as an alternative source of 
HSPCs for generation of allogeneic DC-based vaccines for AML. By combining the 
established approaches that either induced enormous expansion of DC precursors30,31 or 
proper DC differentiation27,29, we have developed a robust cytokine-based culture protocol 
that generates clinically relevant numbers of mature CD1a+ myeloid DCs and CD207+ 
LC-like DCs from CD34+ HSPCs. Furthermore, we compared the phenotype, cytokine 
secretary profile and allogeneic, as well as, viral antigen-specific T cell stimulatory capacity 
of generated UCB-DCs and UCB-LCs with MoDCs. Most importantly, model minor 
histocompatibility antigen (MiHA) HA-1-specific CTL expansion and HA-1 and HA-2 
antigen-specific CTL priming capability of UCB-DCs and UCB-LCs was studied using 
the peripheral blood of leukemia patients or healthy donors, respectively.
Materials and Methods
Isolation of CD34+ cells from UCB
UCB samples from full-term deliveries were obtained via the cord blood bank of the 
Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands, after written 
informed consent. Mononuclear cells were isolated from UCB by density gradient 
centrifugation using Ficoll-hypaque gradient (Healthcare, WI, USA). CD34+ cells 
were purified from mononuclear cells, using the human CD34+ magnetic cell sorter 
(MACS) MicroBead Kit (Miltenyi Biotec, Bergisch Gladbach, Germany), according to 
manufacturer’s recommendations.
Generation of MoDCs from buffy coats and UCB
MoDCs were generated in 7-8 days from plastic adherent monocytes isolated from healthy 
donor buffy coats (Sanquin blood foundation, Nijmegen, the Netherlands) or UCB using 
800 IU/mL GM-CSF (granulocyte-macrophage colony-stimulating factor) and 500 IU/
mL interleukin (IL)-4 (both Immunotools, Friesoythe, Germany) in X-VIVO-15 medium 
(Lonza, Verviers, Belgium) supplemented with 2% human serum (HS, PAA laboratories, 
Pasching, Austria) (Figure 1). Maturation was induced by adding IL-6 (20 ng/mL), IL-1β 
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(5 ng/mL), tumor necrosis factor (TNF)-α (20 ng/mL; all from Immunotools) and PGE2 
(prostaglandin E2, 1 µg/mL, Pharmacia & Upjohn, Puurs, Belgium) and culturing for 
two additional days (Figure 1).
Figure 1. Culture scheme for generation of UCB-DCs and UCB-LCs from UCB-CD34+ cells and MoDCs 
from peripheral blood or UCB-derived monocytes. UCB-CD34+ cells were first expanded for 7 days in 
medium (IMDM or X-VIVO) supplemented with 10% FCS or HS and Flt3L, SCF, IL-3 and IL-6 (FS36) 
cytokines. At day 7, IL-3 and IL-6 in the expansion medium were replaced with TPO (FST). At day 11, DC 
precursors were differentiated in medium supplemented with GM-CSF and IL-4. During the last four days 
of differentiation TNF-α was also added. LC medium was additionally supplemented with TGF-β1. At day 
18, both UCB-DCs/UCB-LCs were matured with IL-1β, IL-6, TNF-α and PGE2. Alternatively, MoDCs were 
differentiated from plastic adherent monocytes in medium supplemented with GM-CSF and IL-4, and were 
matured with IL-1β, IL-6, TNF-α and PGE2.
Generation of UCB-DCs and UCB-LCs
Isolated CD34+ cells from UCB were expanded for 7 days by seeding them at 0.2 x 
106cells/mL in Iscove-modified Dulbecco medium (IMDM, GIBCO Invitrogen, CA, 
USA) supplemented with 10% fetal calf serum (FCS; PAA Laboratories, Colbe, Germany), 
Flt3L (FMS-like tyrosine kinase 3 ligand, 100 ng/mL), SCF (stem cell factor, 100 ng/
mL), IL-3 (20 ng/mL) (all R&D Systems, Abingdon, UK) and IL-6 (20 ng/mL) (Figure 
1). During the additional 4 days of expansion, IL-3 and IL-6 in expansion medium was 
replaced with TPO (thrombopoietin, 20 ng/mL). During the expansion period, medium 
was refreshed every other day. Expanded cells were differentiated into either UCB-DCs 
with medium supplemented with GM-CSF (800 IU/mL) and IL-4 (500 IU/mL) or UCB-
LCs with medium supplemented with TGF-β1 (transforming growth factor β1, 10 ng/
mL, ImmunoTools) in addition to GM-CSF and IL-4 (Figure 1). During the last 3 days of 
UCB-DC or UCB-LC differentiation, TNF-α (20 ng/mL) was also added to the media. The 
cell density was maintained at 0.25 x 106cells/mL and 0.5 x 106cells/mL during expansion 
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and differentiation, respectively. Immature UCB-DCs and UCB-LCs were matured using 
the cytokine combination listed above for MoDCs.
Flow cytometric analysis of mature DCs
Mature MoDC, UCB-DC and UCB-LC cultures were analyzed by flow cytometry (FC500, 
Beckman Coulter, Fullerton, CA, USA) after staining with monoclonal antibodies 
conjugated with f luorescein Isothiocyanate (FITC): CD1a (clone: HI149, Becton 
Dickinson), CD40 (clone: HB-7, Becton Dickinson), CD80 (clone: MAB104), CD86 (clone: 
BU63, DAKO), hCCR7 (clone: 150503, R&D Systems) and HLA-DR (clone: Immu357); 
phycoerythrin (PE): CD83 (clone: HB15a), CD40 (clone: MAB89), CD207 (clone: DCGM4), 
CD11c (clone: BU15); electron coupled dye (ECD): HLA-DR (clone: Immu358); cyanine-5 
(Cy5)-conjugated: CD11c (clone: BU15); and cyanine-7 (Cy7)-conjugated: CD14 (clone: 
RMO52) and CD11b (clone: Bear1). All monoclonal antibodies were from Beckman 
Coulter, unless stated otherwise. The data was analyzed using Kaluza analysis software 
(Beckman Coulter).
Cytokine release and quantification
Immature UCB-DCs and UCB-LCs were plated at 5 x 104 cells/mL/well in a 24-well 
plate (Corning Costar, Amsterdam, the Netherlands) and stimulated with or without 
Resiquimod (R848) (5 µg/mL, Alexis biochemicals, Lausen, Switzerland) and Poly I:C 
(Polyinosinic:polycytidylic acid, 20 µg/mL, Sigma-Aldrich, St. Louis, USA) in IMDM with 
10% FCS. After 24 hours, supernatant was collected for quantification of pro-inflammatory, 
T-helper 1 (Th1) and Th2 cytokine production by UCB-DCs/UCB-LCs and stored at -20°C 
until evaluation by Luminex assay or enzyme-linked immunosorbent assay (ELISA). The 
concentration of IL-1β, IL-4, IL-6, IL-10, TNF-α, GM-CSF and interferon (IFN)-γ was 
quantified using the Human Cytokine Ten-Plex panel kit (Invitrogen, Carlsbad, CA, 
USA) and IL-12 was quantified using the Human IL-12p70 ELISA Ready-SET-Go! Kit 
(eBioscience, San Diego, CA, USA) following the methods provided by the manufacturer.
Allogeneic mixed leukocyte reaction (MLR)
Allogeneic T cell stimulatory capacity of mature MoDCs, UCB-DCs and UCB-LCs 
was tested in a carboxyfluorescein diacetate succinimidyl ester (CFSE)-based MLR 
assay. Allogeneic peripheral blood mononuclear cells (PBMCs) labeled with 5 µM CFSE 
(Molecular Probes Europe, Leiden, the Netherlands) were used as responder cells. 
Responder cells (0.5 x 106) were co-cultured in triplicate for a week with 5 x 104, 1 x 104 or 
5 x 103 stimulator cells (MoDCs, UCB-DCs or UCB-LCs) to get responder to stimulator 
cell ratios of 1:10, 1:50 and 1:100. On days 4 and 7, culture samples were subjected to 
flow cytometric analysis after staining with anti-CD4 (PE-Cy5, Clone: 13B8.2, Beckman 
Coulter) and anti-CD8 (PE-Cy7, clone: SFCI21Thy2D3, Beckman Coulter) antibodies to 
evaluate allogeneic CD4+ and CD8+ T cell proliferation.
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Expansion of cytomegalovirus (CMV)-specific CD8+ effector T cells
In vitro: CD8+ T cell were isolated from CMV-positive donor buffy coats by positive 
selection with a magnetic cell sorting device (Miltenyi Biotec) and were stimulated with 
CMV pp65 peptide-loaded (5 µM, TPRVTGGGAM, RPHERNGFTVL) MoDCs, UCB-
DCs or UCB-LCs at a ratio of 10:1 (T cell:DC) in 1 mL IMDM with 10% FCS in a 24-
well plate (Corning Costar). On day 4, IL-2 (50 IU/mL, Immunotools) and IL-15 (5 ng/
mL, Immunotools) were added to the cultures. On day 0, 4 and 7 post-stimulation, the 
frequency of CMV-specific CD8+ T cells was quantified after staining the samples with PE-
labeled HLA-B7 tetramers presenting the corresponding CMV pp65 peptide. Tetramers 
were kindly provided by Prof. F. Falkenburg (Dept. of Hematology, Leiden University 
Medical Center, Leiden, the Netherlands).
In vivo: Twenty-four, 6-week-old female NOD-SCID-IL-2Rγ-/- mice were 
intraperitoneally (IP) injected with 3.5 x 106 peripheral blood lymphocytes (PBLs) isolated 
from a CMV-specific CD8+ T cell-positive healthy donor buffy coat. Four hours after PBL 
injection, 4 groups of 6 mice were injected with PBS or CMV peptide-loaded MoDCs, 
UCB-DCs or UCB-LCs (0.2 x 106 cells, IP). Additional PBS or CMV peptide-loaded 
MoDCs, UCB-DCs or UCB-LCs (0.1 x 106 cells, IP) injections were given to the respective 
groups on days 7 and 14 post-PBL injection. On day 21, mice were sacrificed, peripheral 
blood and spleen samples were collected, cell numbers were counted and the frequency of 
CMV-specific CD8+ T cells was quantified by flow cytometry. This animal experimental 
protocol was reviewed and approved by the institutional animal ethics committee of 
Radboud university medical center Nijmegen (Permit Number: 2011-178).
Expansion of MiHA-specific T cells ex vivo
PBMC samples of HA-1-specific CD8+ T cell-positive AML patients were stimulated with 
HLA-matched, HA-1 negative, MoDCs, UCB-DCs or UCB-LCs loaded with HA-1 peptide 
(5 μM, VLHDDLLEA) at a ratio of 10:1 in 2 mL IMDM supplemented with 10% HS in 
24-well plates (Costar Corning). Non-peptide-loaded MoDCs, UCB-DCs or UCB-LCs 
were included as negative controls. At day 4, culture medium was supplemented with 50 
IU/mL IL-2 and 5 ng/mL IL-15 (Immunotools). At day 7, cells were harvested, counted 
and the percentage of HA-1-specific CD8+ T cells was determined by flow cytometry after 
HA-1-specific tetramer and CD8 staining.
Induction of MiHA-specific T cells ex vivo
CD8+ T cell were isolated from HLA-A2+ healthy donor PBMCs and were stimulated 
with HLA-A2-matched, HA-1-negative or HA-2-negative MoDCs, UCB-DCs or UCB-LCs 
loaded with HA-1 peptide (5 μM, VLHDDLLEA) or HA-2 peptide (5 µg/mL, YIGEVLVSV) 
at a ratio of 10:1 in 2 mL IMDM supplemented with 10% HS in 24-well plates (Costar; 
Corning). Non-peptide-loaded MoDCs, UCB-DCs or UCB-LCs were included as negative 
controls. At day 4, culture medium was supplemented with 50 IU/mL IL-2 and 5 ng/
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mL IL-15 (Immunotools). At day 7, cells were harvested, counted and the percentage 
of MiHA-specific CD8+ T cells was determined by flow cytometry after MiHA-specific 
tetramer and CD8 staining.
Statistical analysis
The data were analyzed by one-way or two-way ANOVA with Bonferroni post-hoc 
correction using GraphPad Prism software.
Results
High numbers of DCs and LCs can be generated from UCB CD34+ cells
UCB-DC and UCB-LC precursors were expanded for seven days in the medium 
supplemented with Flt3L, SCF, IL-3 and IL-6. On day 7, IL-3 and IL-6 in expansion 
medium were replaced with TPO and cells were further expanded for 4 additional days 
(Figure 1). During the total expansion period of 11 days, UCB-CD34+ cells expanded on 
average 467-fold (Figure 2A). Expanded precursor cells were washed and resuspended 
in medium containing GM-CSF and IL-4 without or with TGF-β1 to differentiate them 
into either UCB-DCs or UCB-LCs, respectively. Addition of TNF-α during the last four 
days of differentiation accelerated the process of differentiation of both immature UCB-
DCs and UCB-LCs. Subsequently, immature UCB-DCs and UCB-LCs were matured by 
culturing them in medium containing IL-1β, IL-6, TNF-α and PGE2. During the total 
culture period of 20 days, the mean increase in total cell number was 648-fold and 338-
fold for mature UCB-DCs and UCB-LCs, respectively (Figure 2A).
Mature UCB-DCs and UCB-LCs show phenotypic resemblance to MoDCs
UCB-derived CD34+ cells gradually lost the expression of stem cell markers CD34 and 
CD133, and expressed myeloid lineage marker CD33 upon expansion (Figure 2B and 
Supplementary Figure 1A). A part of the expanded cells also expressed CD14 and CD11c, 
the markers expressed on monocytes and DCs (Figure 2B and Supplementary Figure 
1A). More than 60% of the expanded cells expressed MHC class II cell surface receptor 
HLA-DR on their surface (Figure 2B and Supplementary Figure 1A).
Both immature UCB-DCs and UCB-LCs expressed comparable levels of the myeloid 
DC differentiation marker CD1a and other markers expressed on DCs such as CD11c, 
HLA-DR, CD40, CD80, CD86 and CD83 (Figure 2C and Supplementary Figure 1B). 
However, UCB-LCs expressed higher levels of the LC-specific marker CD207 when 
compared to UCB-DCs (Figure 2C and Supplementary Figure 1B). Only a very low 
percentage of UCB-DCs and UCB-LCs expressed the monocyte marker CD14, indicating 
a proper DC/LC differentiation (Figure 2C, Supplementary Figure 1B and Supplementary 
Table 1).
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Figure 2. High numbers of phenotypically mature UCB-DCs and UCB-LCs can be generated from UCB-
CD34+ cells. (A) The fold increase of UCB-DCs and UCB-LCs during expansion, differentiation and maturation 
is shown. (B-D) The phenotypic characteristics of precursor UCB-DCs/UCB-LCs (B), immature UCB-DCs/
UCB-LCs (C) and mature UCB-DCs/UCB-LCs (D) analyzed by flow cytometry at day 11, 18 and 21, respectively 
are shown. Additionally, the phenotypic characteristics of the mature MoDCs are also shown (D). The data 
shown are the mean ± SE of three independent donors tested.
Mature UCB-DCs and UCB-LCs generated from CD34+ cells phenotypically resembled 
the MoDCs (Figure 2D and Supplementary Figure 1C) and expressed DC maturation 
marker CD83 and co-stimulatory markers CD80 and CD86 to the same extent as that of 
MoDCs. UCB-DCs and UCB-LCs expressed no or low levels of the monocyte marker CD14 
and high levels of CD11b, CD11c, HLA-DR and CD40 (Figure 2D and Supplementary 
Figure 1C). The expression levels of lymph node homing chemokine receptor CCR7 were 
comparable between all three DC subsets evaluated (Figure 2D and Supplementary Figure 
1C). The purity of mature UCB-DCs and UCB-LCs, quantified based on CD11c+CD83+ 
expression, reached greater 95% and it was slightly higher compared to mature MoDCs 
(Figure 2D and Supplementary Figure 1C)
UCB-DCs and UCB-LCs produce low levels of pro-inflammatory, but high levels of 
Th1 cytokines and induce strong allogeneic MLR
The cytokine profile expressed by DCs upon activation gives an indication on the 
magnitude and the type of the immune response initiated. The DC subset/s producing 
cytokines that favor the differentiation of Th0 cells into Th1 cells are preferred for cancer 
immunotherapy. Therefore, the cytokine profile expressed by UCB-DCs and UCB-LCs was 
compared to that of MoDCs. The data revealed that UCB-DCs and UCB-LCs produced 
2
46
Chapter 2
relatively lower levels of pro-inflammatory cytokines IL-1β, IL-6 and TNF-α, but higher 
levels of the Th1 cytokine IL-12β when compared to MoDCs (Figure 3A). Among the other 
cytokines measured, UCB-DCs and UCB-LCs produced slightly lower levels of IL-4 when 
compared to the levels produced by MoDCs (Figure 3A).
Next, mature UCB-DCs, UCB-LCs or MoDCs were used as stimulator cells and 
PBMCs isolated from healthy donor blood were used as responder cells in allogeneic 
MLR. Both mature UCB-DCs and UCB-LCs induced equal (at E:T ratios 1:10 and 1:50) 
or significantly higher (at E:T ratio 1:100, P<0.001) proliferation of both CD4+ and CD8+ 
T cells in an allogeneic MLR when compared to mature MoDCs (Figure 3B).
Figure 3. UCB-DCs and UCB-LCs exhibit cytokine profiles that favor Th1 immune responses. (A) Pro-
inflammatory (IL-1β, IL-6 and TNF-α), Th2 (IL-4 and IL-10) and Th1 (IL-12β) cytokine production by UCB-
DCs and UCB-LCs in comparison with MoDCs upon stimulation with Resiquimod (R848) (5 µg/mL) and Poly 
I:C (20 µg/mL, Sigma-Aldrich, St. Louis, USA) was quantified using Luminex and ELISA. The data shown are 
the mean ± SE of three independent donors tested. The data was analyzed by one-way ANOVA with bonferroni 
correction. *, P<0.05. (B) Allogeneic T cell stimulatory capacities of UCB-DCs and UCB-LCs in comparison 
with MoDCs were tested in a MLR. In vitro generated UCB-DCs, UCB-LCs or MoDCs were used as stimulators 
for CFSE-labeled PBMCs that were isolated from healthy donor buffy coats at a ratio of 1:100, 1:50 or 1:10 ratio 
(DC:PBMC). Five days later, the proliferation of CD8+ and CD4+ T cells was analyzed by flow cytometry. This 
is a representative result (mean ± SE) of three experiments. The data was analyzed by two-way ANOVA with 
bonferroni correction. ***, P<0.001.
UCB-DCs and UCB-LCs efficiently activate memory CTLs both in vitro and in vivo
The antigen-specific memory CTL activation capacity of UCB-DCs and UCB-LCs was 
evaluated in vitro by co-culturing HLA-A2-matched PBMCs containing either CMV-
specific CD8+ T cells or HA-1-specific CD8+ T cells with CMV or HA-1 peptide-loaded 
UCB-DCs or UCB-LCs. In these assays autologous MoDCs loaded with the respective 
peptide were included as a control. The absolute number of antigen-specific T cells was 
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determined at day 7 post co-culture. UCB-DCs induced proliferation of both CMV 
and HA-1 specific CD8+ T cells as efficiently as MoDCs (Figure 4A,B). Although, there 
were no marked phenotypic differences in expression pattern of either maturation or 
co-stimulatory markers between UCB-DCs, UCB-LCs and MoDCs, notably UCB-LCs 
induced the highest level of HA-1-specific T cells proliferation in comparison to UCB-
DCs and MoDCs (Figure 4B).
Figure 4. UCB-DCs and UCB-LCs effectively activate and induce proliferation of both viral antigen-specific 
and MiHA HA-1-specific CD8+ T cells. (A) The absolute numbers of CMV-specific CD8+ T cells in the cultures 
restimulated in vitro with CMV pp65 peptide-loaded MoDCs, UCB-DCs or UCB-LCs. CD8+ T cells were 
isolated from CMV-positive HLA-B7+ donor buffy coats and were stimulated with DC subsets loaded with or 
without CMV pp65 peptide for 4 days. (B) The absolute numbers of HA-1-specific CD8+ T cells in the cultures 
restimulated with HA-1 peptide-loaded MoDCs, UCB-DCs or UCB-LCs. PBMC samples of HA-1-positive 
HLA-A2+ AML patients were stimulated with DC subsets loaded with or without HA-1 peptide for 7 days. 
The absolute numbers of CMV-specific or HA-1-specific CD8+ T cells were quantified by flow cytometry after 
staining with respective tetramers and CD8 antibody. The data shown are the mean ± SE that are corrected for 
background proliferation induced by the respective non-pulsed DC control from two independent experiments 
(CMV-specific T cell restimulation) or four AML patient PBMCs tested (HA-1-specific T cell restimulation). (C) 
The percentage of CMV-specific CD8+ T cells in the peripheral blood and spleen of CMV+ donor PBL-engrafted 
NOD-SCID-IL2Rγ-/- vaccinated with CMV peptide-loaded DC subsets. NOD-SCID-IL2Rγ-/- mice were injected 
IP with 3.5 x 106 PBL isolated from a HLA-B7+ CMV+ donor buffy coat. Four hours after PBL injection, four 
groups of 6 mice received either PBS or CMV pp65 peptide-loaded MoDCs, UCB-DCs or UCB-LCs (2 x 105, IP). 
Additional booster injections of PBS or CMV pp65 peptide-loaded DC subsets (1 x 105, IP) were given on day 
7 and 14. At day 21, mice were sacrificed, blood and spleen samples were collected to evaluated the frequency 
of CMV-specific CD8+ T cells by flow cytometric technique after staining the samples with mouse CD45, 
human CD45, human CD8 and CMV tetramer. The data shown are mean ± SE of six mice tested per group.
In order to evaluate the antigen-specific memory CTL activation capacity of UCB-
DCs and UCB-LCs in vivo, NOD-SCID-IL-2Rγ-/- mice were engrafted with PBLs isolated 
from a HLA-matched CMV antigen-specific T cell-positive healthy donor blood and were 
injected with CMV peptide-pulsed UCB-DCs, UCB-LCs or MoDCs. After three rounds 
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of vaccination with CMV peptide-pulsed DCs/LCs, the frequency of CMV-specific T 
cells in peripheral blood and spleen of NOD-SCID mice was evaluated by flow cytometry 
(Supplementary Figure 2). These data demonstrated that the efficiency of induction of 
CMV-specific T cell proliferation of both UCB-DCs and UCB-LCs was equivalent to that 
of MoDCs (Figure 4C).
UCB-DCs and UCB-LCs efficiently prime MiHA specific CD8+ T cells ex vivo
Tumor antigen-specific T cell priming capacity of UCB-DCs and UCB-LCs was evaluated 
using the MiHAs HA-1 and HA-2. For this, MoDCs, UCB-DCs and UCB-LCs were 
generated from HLA-A*0201-positive, HA-1-negative or HA-2-negative UCB units. 
The DCs/LCs were pulsed with the corresponding peptide and were used to stimulate 
unprimed CD8+ T cells isolated from HLA-matched MiHA- healthy donor PBMCs. In 
these experiments, MiHA peptide-pulsed autologous MoDCs and MoDCs generated from 
plastic adherent monocytes of UCB were included as a controls. The data showed that 
both peptide pulsed UCB-DCs and UCB-LCs can efficiently prime HA-1-specific and 
HA-2-specific CD8+ T cells in vitro (Figure 5A,B).
Figure 5. UCB-DCs and UCB-LCs efficiently prime HA-1-specific and HA-2-specific T cells. (A-B) The 
bar diagrams show the absolute numbers of HA-1-specific (A) and HA-2-specific (B) CD8+ T cells primed by 
MoDCs, UCB-DCs or UCB-LCs pulsed with respective peptide. CD8+ T cells were isolated from HLA-A2+ 
healthy donor PBMCs and were primed with HA-1-negative or HA-2-negative, HLA-A2+ peptide-pulsed DC 
subsets. After 7 days of priming, the frequency of HA-1-specific or HA-2-specific CD8+ T cells in the cultures 
was quantified by flow cytometry after staining the samples with respective tetramer and CD8 antibody. 
Representative data of four experiments are shown.
Animal serum-free culture conditions also generates DCs from UCB CD34+ cells
In order to make the UCB-DC culture protocol suitable for clinical application, subsequent 
attempts were made to generate UCB-DCs in the presence of pooled HS instead of FCS 
using the cytokine mixtures listed in Figure 1. The replacement of FCS with HS resulted 
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in higher expansion rates (Figure 6A). The phenotype of the expanded pre-DCs was only 
marginally affected by the replacement of FCS with HS in the expansion medium (Figure 
6B). However, the percentage of UCB-DCs expressing the MHC class II marker (HLA-
DR), co-stimulatory marker (CD86) and DC maturation (CD83) was moderately reduced 
by the replacement of FCS with HS (Figure 6C). Most importantly, although UCB-DCs 
generated in the medium supplemented with HS were less mature, they met the accepted 
release criteria of >70% purity for therapeutic DC products and they did not greatly differ 
in their allogeneic T cell stimulatory capacity when compared to UCB-DCs generated 
in the medium supplemented with FCS (Figure 6D). These data demonstrate that the 
UCB-DC vaccines can be efficiently generated in animal serum-free culture conditions.
Figure 6. High numbers of functional UCB-DCs can be generated in animal serum-free culture conditions. 
(A) The fold increase of UCB-DCs cultured in medium supplemented with either FCS or pooled HS during 
expansion, differentiation and maturation is shown. (B-C) The phenotypic characteristics of precursor UCB-
DCs (B), and mature UCB-DCs (C) analyzed by FACS at day 8 and 17, respectively, are shown. (D) Allogeneic 
T cell stimulatory capacity of FCS-UCB-DCs and HS-UCB-DCs was tested in a MLR. In vitro generated UCB-
DCs were used as stimulators for CFSE-labeled PBMCs that were isolated from healthy donor buffy coats at a 
ratio of 1:1000, 1:100 or 1:10 ratio (DC:PBMC). Five days later the proliferation of CD8+ and CD4+ T cells was 
analyzed by flow cytometry. The data shown are the mean ± SE of two independent donors tested.
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Discussion
Despite of the progress made in the field of modern treatment for leukemia, the outlook 
for the majority of patients with AML has remained dismal with poor long term survival.12 
Therefore, need for alternative therapies remains high to improve the prognosis for 
patients with AML. A broad array of immunotherapeutic strategies are under active 
investigation as adjuvant therapy to improve the overall survival of AML patients by 
eliminating residual leukemic cells following standard therapy.12 DC-based vaccination 
is an attractive immunotherapeutic strategy, due to its ability to induce leukemia-specific 
T cell responses, that offers the desired anti-tumor effects with minimal toxicity. In AML, 
DC vaccines are generated either by differentiating myeloid leukemia cells into AML-
derived DCs or differentiating monocytes isolated from AML patients in remission to 
MoDCs. Phase I clinical trials conducted so far have demonstrated that DC vaccines are 
safe and can induce immunological responses in AML patients. However, the feasibility 
in terms of obtaining sufficient AML-DC vaccines and the clinical responses induced by 
AML-DC vaccines have been limited.35-38 The aim of this study was therefore to evaluate 
the possibility to generate clinically relevant doses of potent AML-reactive T cell inducing 
DC and LC vaccines from UCB-CD34+ cells. Here we report that clinically relevant doses 
of mature CD1a+ myeloid DC and CD207+ LC-like DCs can be generated from CD34+ 
HSPC. Most importantly, the generated UCB-DCs and UCB-LCs efficiently expanded 
MiHA HA-1-specific cytotoxic T cells in the peripheral blood of leukemia patients and 
also primed MiHA HA-1-specific and HA-2-specific cytotoxic T cells. In the final part 
of this study, an attempt was made to generate UCB-DCs in animal serum free culture 
conditions. The replacement of FCS with clinically acceptable pooled HS in UCB-DC 
expansion medium enhanced the expansion rate of DC precursors and did not affect the 
phenotype of the DC precursors. However, the use of HS in the DC differentiation and 
maturation medium had a marginal negative effect on the purity of mature UCB-DCs.
The key role played by DCs in inducing immunity has been the rationale for the 
application of DC-based vaccines in cancer immunotherapy. DCs, comprised of 
heterogeneous populations of HSPC-derived cells, have the unique ability to activate 
naïve T cells and direct the subsequent immune response towards a Th1, Th2, Th17 or T 
regulatory (Treg) profile. The distinct capacity of DCs to induce immune responses or 
tolerance depends not only on their activation or maturation state, but also on the DC 
subset involved.39 Human DCs can be categorized into two major types depending on 
their lineage: 1. The myeloid DCs (mDCs, also called classical or conventional DCs) and 
2. Plasmacytoid DCs (pDCs). The DC subsets reside in the tissue where they are poised 
to capture antigen, or circulate in the blood. So far, human DC subsets in skin and blood 
are the best characterized, although DCs also can be found in other tissues.40 Skin DCs 
comprise of three types of mDCs, the epidermal LCs, the dermal interstitial CD1a+ DCs 
and CD14+ DCs.41 Blood DCs comprise of two subsets of BDCA2+ pDCs, (CD2high pDCs 
and CD2low pDCs) and three subsets of CD11c+ mDCs (CD1c+ mDCs, CD141+ mDCs and 
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CD16+ mDCs). Among mDCs, LCs21 and CD141+ mDCs31 posses the most robust CD8+ 
T cell stimulatory capacity, followed by the CD1a+ interstitial DCs, making them the 
most preferred subsets of DCs for cancer immunotherapy.27,39 Due to rarity of LCs and 
CD141+ mDCs in the tissues and difficulties with their generation ex vivo, the majority of 
the studies have used autologous ex vivo-generated MoDCs (that is, interstitial DC and 
CD1c+ blood DC equivalent), while only few trials have used mDCs derived from CD34+ 
precursors. Nevertheless, it has been suggested that DCs generated from CD34+ cells 
are more potent inducers of anti-tumor T cell responses than MoDCs.15,42 The favorable 
effect of DCs generated from CD34+ cells was attributed to contaminating LCs in the DC 
vaccines prepared from CD34+ cells. In light of the above findings, we aimed at generating 
LCs, dermal DC equivalent, CD141+ mDCs and pDCs from CD34+ cells isolated from 
UCB. Notably, we succeeded in generation of higher numbers of mature LC (UCB-LC)-
like and dermal DC equivalent (UCB-DC) with high purity and high levels of expression 
of co-stimulatory molecules in contrast to the previously used protocol for generation 
of DCs from CD34+ cells.42 Phenotypically both UCB-LCs and UCB-DCs expressed 
typical myeloid DC markers (CD1a, CD11c, HLA-DR, CD40, CD80, CD83, CD86) with 
the exception that UCB-LCs expressed higher levels of Langerin (i.e. CD207). Unlike 
previous report, UCB-LCs did not express e-cadherin or lacked expression of CD11b and 
CD52.27 These phenotypic differences may in part be attributed to the discrepancies in the 
source of CD34+ cells (UCB in the current study vs. G-CSF mobilized) and the addition 
of IL-4 to the current UCB-LC differentiation medium. We observed the expression of 
LC marker Langerin in a small fraction of UCB-DCs cultured with GM-CSF, IL-4 and 
TNF-α without TGF-β1. The presence of TNF-α in UCB-DC differentiation medium 
may explain this finding, as exposure of DC precursors to proinflammatory cytokines 
such as TNF-α during their differentiation is known to induce Langerin expression.28 In 
line with previous reports, UCB-DCs and UCB-LCs were slightly better than MoDCs in 
stimulating allogeneic, as well as tumor-reactive T cells in vitro27 and all the three studied 
subsets of DCs pulsed with MiHA peptide exhibited comparable HA-2-specific T cell 
priming capacity. So far, the ability of LCs to cross-present exogenous antigens to CD8+ 
T cells via MHC class I pathway and induce very potent CTL responses makes them an 
attractive vaccine target for cancer immunotherapy43, whether that also holds true for 
UCB-LCs still needs to be investigated.
Despite of the ample success achieved so far with DC-based cancer vaccines; one of 
the main problems remains the limited number of DCs available for immunotherapy.44 
As DCs play a pivotal role not only in the initiation of CTL responses but also in the 
maintenance of CTLs, it may be crucial to repeatedly vaccinate cancer patients with DC 
vaccines.45 So far the general maximum dose of DC vaccines applied has been 30 x 106 DC 
per injection46, whether this is the maximum optimal dose for DC vaccines has yet to be 
investigated. Therefore, we aimed at generating a high number of DCs for multiple DC 
vaccination rounds. The mature UCB-LC/UCB-DC yields obtained in the current protocol 
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ranged between 34 x 106 and 65 x 106 from 1 x 105 UCB-CD34+ cells. According to our 
previous report, on average 2 x 106 CD34+ cells can be isolated from an UCB unit.47 Thus, 
the current protocol will generate on average 6.8 x 108 and 1.3 x 109 mature UCB-LCs and 
UCB-DCs, respectively, from one UCB unit. Those achieved numbers should be sufficient 
for multiple vaccinations of one or even multiple patients. The possibility to freeze aliquots 
of expanded precursors or fully mature DCs provide an additional advantage for the 
preparation of our off-the-shelf DC vaccine batches that could be applied to a group of 
patients at multiple time-points.
Routinely applied DC vaccines in cancer immunotherapy have been generated from 
autologous monocytes, but reports indicate that wide scale application of such DC 
vaccines suffers from a very high inter-patient variability38 and sometimes also the poor 
vaccine quality.14,48 Alternatively, DCs can be generated from G-CSF-mobilized peripheral 
blood CD34+ cells.14 However, these DCs are not preferred for cancer immunotherapy 
due to their polarization towards the Th2 response. Furthermore, G-CSF treatment for 
mobilization of CD34+ cells poses an extra burden on the patients. In order to overcome 
these limitations associated with autologus DC vaccines, allogeneic DCs have been 
considered as an attractive alternative. The major advantage of using allogeneic DCs 
is the feasibility of large scale production of more standardized DC vaccines in terms 
of phenotype and maturation status, that can be applied to all patients.38 In addition, 
HLA-matched allogeneic DC vaccines are reported to induce strong anti-tumor immune 
responses and clinical responses in cancer patients.49,50 In the current study, we explored 
UCB as a source of CD34+ cells for generation of allogeneic DCs.
UCB is an extremely attractive source of HSPCs not only for clinical transplantation, 
but also for the generation of a multitude of cell therapy products due to their strong multi-
lineage expansion and differentiation potential. Unlike other allogeneic HSPC sources, 
UCB do not pose any risk to the donor and are readily available from the cord blood banks 
worldwide. As cord blood banks have large numbers of HLA-typed HSPCs available, 
there is a higher probability of finding a partially HLA-matched donor for generation of 
DC vaccines for immunotherapeutic purposes. A combination of UCB-derived HSPCs 
for transplantation and DCs generated from the same donor may provide an appealing 
new treatment option for patients suffering from hematological malignancies. There 
are few reports on the DC generation from UCB-derived CD34+ cells.51-55 However, the 
current study supersedes the number, purity and maturation status of the generated UCB-
DCs. Most importantly, this study is the first to describe the preclinical evidence for 
the suitability of UCB-DCs for either induction or reactivation of MiHA-specific T cells 
that are of clinical significance in transplanted patients suffering from hematological 
malignancies.
The type and the concentration of the serum present in the DC culture medium is 
known to affect the expression pattern of key DC and LC identification markers such as 
CD1a and CD207.56-58 Therefore, we initially generated UCB-DCs and UCB-LCs in medium 
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containing FCS. Although, some clinical trials have used FCS for DC generation59,60, 
in order to prevent immune responses against xenoserum constituents and transfer of 
xenoinfections, DCs generated in serum-free or HS-supplemented medium are preferred. 
Hence, we subsequently replaced FCS by pooled HS in UCB-DC/UCB-LC generation 
medium and demonstrated the feasibility of the current UCB-DC culture protocol for 
clinical application. However, the feasibility of UCB-LC culture protocol could not be 
demonstrated because of lack of expression of the LC-specific marker Langerin on the 
cells cultured in the absence of FCS. The identification of key components in FCS that 
induce Langerin expression is crucial for further development of UCB-LCs for the clinical 
application.
In conclusion, a very high number of mature DCs can be generated from CD34+ 
HSPCs for clinical evaluation using the current protocol. Both allogeneic, as well as 
tumor-reactive T cell stimulatory capacity exhibited by the mature UCB-DC make them 
a good vaccine candidate for leukemia. These pre-clinical findings support the further 
pharmaceutical development of the described culture protocol for clinical evaluation.
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Supplementary Figure 1. (A-D) The phenotypic characteristics of precursor, immature and mature UCB-
DCs/UCB-LCs next to the mature MoDCs analyzed in terms of percentages by flow cytometry are shown. A 
representative donor data is shown.
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Supplementary Figure 2. CMV-antigen specific T cell stimulatory capacity of UCB-DCs and UCB-LCs in 
comparison with MoDCs in vivo. (A) The experimental scheme. (B) Engraftment of human CD3+ T cells in 
peripheral blood of NOD-SCID-IL2Rγ-/- mice. The data shown are mean ± SE of six mice tested per group. 
NOD-SCID-IL2Rγ-/- mice were injected IP with 3.5 x 106 PBLs isolated from HLA-B7+ CMV+ donor buffy coat. 
Four hours after PBL injection, four groups of 6 mice were treated with either PBS or CMV pp65 peptide-loaded 
MoDCs, UCB-DCs or UCB-LCs (2 x 105, IP). Additional booster injections of PBS or CMV pp65 peptide-loaded 
DC subsets (1 x 105, IP) were given at day 7 and 14. At day 21, mice were sacrificed, blood and spleen samples 
were collected to evaluated the frequency of CMV-specific T cells by flow cytometric technique after staining 
the samples with mouse CD45, human CD45, human CD8 and CMV tetramer.
Supplementary Table 1. The percentages of CD1a and CD14-positive cells in immature and mature UCB-DC 
and UCB-LC cultures analyzed by flow cytometry at day 18 and 21, respectively are presented.
Culture #
CD1a (immature) CD14 (immature) CD14 (mature)
UCB-DC UCB-LC UCB-DC UCB-LC MoDC UCB-DC UCB-LC
1 12 42.9 15.0 6.2 17.0 1.4 0.2
2 34.5 39.5 5.8 4.1 1.0 3.0 1.0
3 46.2 52.5 4.7 3.5 8.3 7.2 2.6
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Abstract
The superiority of dendritic cells (DCs) as antigen-presenting cells has been 
exploited in numerous clinical trials, where generally monocyte-derived DCs 
(MoDCs) are injected to induce immunity in patients with cancer or infectious 
diseases. Despite promising expansion of antigen-specific T cells, the clinical 
responses following vaccination have been limited, indicating that further 
improvements of DC vaccine potency are necessary. Pre-clinical studies suggest 
that vaccination with combination of primary DC subsets, such as myeloid and 
plasmacytoid blood DCs (mDCs and pDCs, respectively), may result in stronger 
clinical responses. However, it is a challenge to obtain high enough numbers of 
primary DCs for immunotherapy, since their frequency in blood is very low. We 
therefore explored the possibility to generate them from hematopoietic stem and 
progenitor cells (HSPCs). Here, we show that by inhibiting the aryl hydrocarbon 
receptor with its antagonist StemRegenin 1 (SR1), clinical-scale numbers of 
functional BDCA2+BDCA4+ pDCs, BDCA1+ mDCs and BDCA3+DNGR1+ mDCs 
can be efficiently generated from human CD34+ HSPCs. The ex vivo-generated DCs 
were phenotypically and functionally comparable to peripheral blood DCs. They 
secreted high levels of pro-inflammatory cytokines such as IFN-α, IL-12 and TNF-α 
and upregulated co-stimulatory molecules and maturation markers following 
stimulation with TLR ligands. Furthermore, they induced potent allogeneic T cell 
responses and activated antigen-experienced T cells. These findings demonstrate 
that SR1 can be exploited to generate high numbers of functional pDCs and mDCs 
from CD34+ HSPCs, providing an alternative option to MoDCs for immunotherapy 
of patients with cancer or infections.
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Introduction
Dendritic cells (DCs) are specialized in capturing, processing and presenting antigens to 
T cells, and thereby play a crucial role in initiating and shaping immune responses.1 The 
prominent role of DCs in T cell activation is the rationale for DC-based immunotherapy 
of cancer and infectious diseases, while their tolerogenic potential is being exploited 
in the recently developing field of DC-based therapy for auto-immune diseases.1-3 In 
cancer, DC vaccination therapy aims to induce tumor-specific T cell responses, and to 
develop immunological memory to control tumor relapse. So far, the vast majority of DC 
vaccination studies have been performed with DCs differentiated ex vivo from monocytes 
(MoDCs).4,5 This strategy has been reported to induce the expansion of tumor-specific T 
cells in the majority of patients, however only a fraction of the patients develop clinical 
responses.2,6 Various strategies to improve the potency of DC-based vaccines are being 
investigated, such as using natural occurring DCs from peripheral blood or combining 
multiple DC subsets in one vaccine to provide cross-talk.4,7,8
DCs form a heterogeneous population of cells, comprising several subsets with 
different phenotypes and functional properties. In human blood two main DC subsets 
can be defined; CD11c+ myeloid DCs (mDCs) and CD11c-CD123hiBDCA2+BDCA4+ 
plasmacytoid DCs (pDCs). The mDCs can be further divided into BDCA1(CD1c)+ and 
BDCA3(CD141)+DNGR1+ cells.2 These pDC and mDC subsets express a diverse set of 
pattern recognition receptors, including Toll-like receptors (TLRs), and secrete different 
cytokines and induce diverse T cell responses following activation by pathogens.9 mDCs 
are for example broadly responsive to microbial stimulation, where they upregulate 
co-stimulatory molecules and secrete cytokines such as interleukin (IL)-12 and tumor 
necrosis factor (TNF)-α following activation.10 On the contrary, pDCs play a crucial role 
in initiating anti-viral immunity by secreting high levels of type I interferons (IFN-α/β) 
in response to TLR7 and TLR9 ligation by viruses.11 Additional studies indicate that pDCs 
and mDCs interact during the development of immune responses.12-14 For example, it 
has been shown that activated pDCs strongly enhance the ability of mDCs to stimulate 
potent anti-tumor cytotoxic T lymphocyte (CTL) responses.8,15,16 Therefore, combining 
these naturally occurring DCs appears to be attractive strategy to exploit for DC-based 
therapy. However, since the frequency of pDCs and mDCs in the blood is very low, it 
is a challenge to obtain high enough numbers for immunotherapy. It would therefore 
be advantageous if high numbers of DCs, which are phenotypically and functionally 
similar to blood pDCs and mDCs, could be generated from CD34+ hematopoietic stem 
and progenitor cells (HSPCs).
Recent findings indicate that the aryl hydrocarbon receptor (AhR) not only regulates 
toxic effects of environmental contaminants, but also plays a role in modulating 
hematopoiesis and the immune system.17 For instance, Boitano et al. reported that 
StemRegenin 1 (SR1), a small molecule inhibitor of AhR, promotes the ex vivo expansion 
of human CD34+ HSPCs that are able to effectively engraft immunodeficient mice.18 
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Furthermore, differentiation of Langerhans cells and monocytes in vitro from HSPCs 
was inhibited by the addition of the AhR agonist VAF347.19 In light of these data, we 
investigated whether it was possible to generate DC subsets from CD34+ HSPCs by 
supplementing SR1. We observed that SR1 explicitly and simultaneously induced the ex 
vivo differentiation of pDCs, BDCA1+ and BDCA3+ mDCs. Importantly, SR1 induced the 
generation of high numbers of all these DC subsets, high enough to be included in clinical 
vaccination studies. Furthermore, these different DC subsets were phenotypically and 
functionally comparable to their blood counterparts and potently stimulated antigen-
specific T cell. Therefore, our SR1 culture system not only allows detailed study of DC 
differentiation and molecular regulations in vitro, but it also offers the opportunity to 
evaluate the in vivo efficacy of a combined pDC and mDC vaccine in patients with cancer, 
viral infections or auto-immune conditions.
Materials and Methods
Ex vivo generation of DCs from CD34+ hematopoietic progenitor cells
Umbilical cord blood (UCB) was obtained at birth after normal full-term delivery with 
written informed consent from the cord blood bank of the Radboud university medical 
center (Nijmegen, The Netherlands). Mononuclear cells from UCB were isolated by Ficoll-
Hypaque (1,077 g/mL; GE Healthcare, Uppsala, Sweden) density gradient centrifugation. 
Next, CD34+ cells were isolated from mononuclear cells using anti-CD34 immunomagnetic 
beads (Miltenyi Biotech, Bergisch Gladbach, Germany). A small aliquot of CD34+ cells 
was obtained from stem cell donors after the CliniMACS (Miltenyi Biotech) selection 
procedure of granulocyte colony-stimulating factor (G-CSF)-mobilized blood after written 
informed consent. The purity of the isolated CD34+ cells from UCB and G-CSF-mobilized 
blood was 71±12% (n=9) and 90±5% (n=3), respectively. CD34+ cells were either used 
freshly or cryopreserved until use.
CD34+ cells were plated at 104-105 cells/mL in 24-well tissue culture plates (Corning 
Costar, NY, USA) in Glycostem Basal Growth Medium (GBGM, Glycostem Therapeutics, 
s’Hertogenbosch, The Netherlands) with 100 ng/mL of the following cytokines: 
thrombopoietin (TPO), stem cell factor (SCF), FMS-like tyrosine kinase 3 ligand (Flt3L: all 
three from Cellgenix, Freiburg, Germany) and IL-6 (ImmunoTools, Friesoythe, Germany). 
Additionally, CD34+ cells were cultured in the presence of 1 μM SR1 (Cellagen Technology, 
CA, USA), which was identified as the optimal dose in dose titration experiments (see 
Supplementary Figure 1). The AhR agonist VAF347 (Exclusive Chemistry, Obninsk, 
Russia) was used in the concentrations 0.05-50 nM. Corresponding concentrations of 
DMSO (dimethyl sulfoxide, Merck, Darmstadt, Germany) were used as control. Fresh 
medium containing cytokines and compounds was added every 2-4 days, and the cells 
were split upon confluence and transferred to 6-well plates (Corning Costar) if needed. 
Cells were cultured at 37˚C, 95% humidity and 5% CO2. The total number of viable cells 
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was determined by trypan blue exclusion counting on day 7, 14 and 21. At each time-
point a sample was taken for flow cytometry analysis, and absolute numbers of DCs were 
calculated by multiplying the frequency of DCs with the absolute number of total cells 
generated from 105 CD34+ cells.
Isolation of peripheral blood (PB)- and HSPC-DCs
PB-DCs were isolated from buffy coats (Sanquin blood bank, Nijmegen, The Netherlands) 
of healthy individuals after written informed consent. First, PBMCs were purified using 
Ficoll-Hypaque density centrifugation. Subsequently, non-DCs were depleted from PBMCs 
by negative selection with anti-CD3/CD14/CD19 magnetic beads (Becton Dickinson, 
Franklin Lakes, NJ, USA) or with Pan-DC enrichment kit (Miltenyi Biotech). Next the 
negative fraction was labeled with anti-BDCA1, anti-BDCA3, anti-BDCA4 (all from 
Miltenyi Biotech), anti-CD14, anti-CD20 (both from Biolegend, CA, USA) and anti-CD19 
(Dako, Glostrup, Denmark). Finally, pDCs, BDCA1+ mDCs and BDCA3+ mDCs were 
sorted on an EPICS Elite cell sorter (Beckman Coulter, Fullerton, CA, USA) or FACS 
Aria (Becton Dickinson) as BDCA4+BDCA1-CD14-CD19-, BDCA1+BDCA3-CD14-CD19-
CD20- and BDCA3+BDCA1-CD14-CD19-CD20- cells, respectively.
HSPC-DCs were sorted from the whole bulk of cultured cells at day 21 of culture. First, 
the cultured cells were incubated with 10-20% human serum (HS; PAA Laboratories, 
Austria) at 4˚C to block Fc receptors. Next, the cultured cells were stained with anti-
CD123 (Biolegend), anti-CD14 (Beckman Coulter), anti-BDCA2 (Miltenyi Biotech), 
anti-BDCA1 and anti-BDCA3 antibodies and sorted with the FACS Aria for pDCs 
(CD14-CD123hiBDCA2+ cells), BDCA1+ mDCs (CD14-CD123lowBDCA1+BDCA3- cells) 
and BDCA3+ mDCs (CD14-CD123low BDCA3+BDCA1- cells). Purity of isolated PB- and 
HSPC-DCs was >90%.
Flow cytometry
Immunophenotypical analysis was performed by flow cytometry, where cells were 
first washed with PBS/0.5% BSA and subsequently stained with appropriate antibody 
concentrations for 30 min at 4˚C. To determine the phenotype and maturation state of 
DCs, following antibodies and isotype controls were used: anti-BDCA1, anti-BDCA2, 
anti-BDCA3 (all from Miltenyi Biotech), anti-CD83, anti-CD123, anti-lineage cocktail 
(CD3, CD14, CD16, CD19, CD20, CD56) (all from Becton Dickinson), anti-CD11c, 
anti-CD14, anti-CD80, anti-CD86, anti-HLA-DR, mouse IgG1, mouse IgG2b (all from 
Beckman Coulter), anti-DNGR1, anti-CCR7, mouse IgG2a (all from Biolegend,) and 
anti-CD86 (Dako). To evaluate T cell proliferation in mixed lymphocyte reaction (MLR), 
cells were stained with anti-CD3, anti-CD8 (both from Beckman coulter) and anti-CD4 
(Biolegend). For all analysis, live cells were gated based on forward scatter and side scatter 
characteristics. Additionally, in some experiments, SYTOX blue stain (Invitrogen, CA, 
USA) was used to further exclude dead cells from analysis. Furthermore, cell doublets 
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were excluded based on signal pulse height and width. Acquisition was performed with the 
Coulter FC500 flow cytometer or CyAn ADP analyzer and data analysis was performed 
with Kaluza or CXP analysis software (all from Beckman Coulter).
DC stimulation with TLR ligands
Sorted HSPC-derived pDCs, BDCA1+ mDCs and BDCA3+ mDCs were resuspended in 
IMDM (Iscove-modified Dulbecco medium, Invitrogen) supplemented with 10% fetal 
calf serum (FCS, Integro, Zaandam, The Netherlands), 1% penicillin and streptomycin 
(PS; MP Biomedicals, Ohio, USA) and seeded in a 96-well round bottom plate (Corning 
Costar). 10 ng/mL IL-3 or 800 IU/mL granulocyte-macrophage colony-stimulating factor 
(GM-CSF; both from ImmunoTools) was additionally added to the medium for survival 
of the pDCs and mDCs, respectively. Next, pDCs were stimulated with 3.4 μg/mL CpG 
ODN 2216 (CpG-A) or CpG ODN 2006 (CpG-B, both from Enzo Life Sciences, NY, USA) 
whereas mDCs were stimulated with 20 μg/mL Poly I:C (Polyinosinic:polycytidylic acid, 
Sigma-Aldrich, St. Louis, USA) and 5 μg/mL R848 (Resiquimod, Enzo Life Sciences). After 
overnight stimulation, IFN-α, IL-6, TNF-α and IL-12 concentrations were measured in the 
supernatant by ELISA according to manufacturer’s instructions (Human IFN-α Module 
set ELISA (Bender MedSystems GmbH, Vienna, Austria); Human IL-6 ELISA Ready-
Set-Go (eBioscience); PeliPair human TNF-α ELISA reagent set (Sanquin, Amsterdam, 
The Netherlands); IL-12 ELISA (Pierce Endogen, Rockford, IL, USA)) and phenotypical 
maturation was evaluated by flow cytometry.
Allogeneic MLR
HSPC-pDCs and mDCs were harvested and washed after overnight stimulation with 3.4 
μg/mL CpG-B or 10 μg/mL Poly I:C, respectively. Subsequently, they were co-cultured with 
allogeneic PBMCs from healthy donors that were labeled with 1.25 μM carboxyfluorescein 
diacetate succinimidyl ester (CFSE, Molecular Probes Europe, Leiden, The Netherlands) as 
described previously.20 Co-cultures were performed at a 1:10 ratio (DC:PBMCs) in IMDM 
supplemented with 10% FCS and 1% PS in 96-well round bottom plates in triplicate. After 
4-5 days of co-culture, supernatant was collected for cytokine analysis (Th1/Th2/Th17 
cytometric bead array, Becton Dickinson) and T cell proliferation was quantified by flow 
cytometry by evaluating the CFSE dilution within the CD3+CD4+ and CD3+CD8+ T cell 
populations.
Antigen-specific T cell activation
CD8+ T cells specific for the minor histocompatibility antigen LRH-1 or HA-1 were 
isolated from PBMCs obtained from patients that had chronic myeloid leukemia and 
were treated with allogeneic stem cell transplantation and pre-emptive donor lymphocyte 
infusion as previously described.21,22 Sorted HSPC-DCs from HLA-B7+ or HLA-A2+ donors 
were loaded with 1 μM LRH-1 peptide (TPNQRQNVC, IHB-LUMC peptide synthesis 
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facility, Leiden, The Netherlands) or HA-1 peptide (VLHDDLLEA, IHB-LUMC peptide 
synthesis facility), respectively. After 1 hour incubation at 37˚C, LRH-1-specific CD8+ CTL 
culture RP1 or CD8+ HA-1-specific T cell bulk containing 38% HA-1 tetramer positive T 
cells were added. At the same time, 5 μg/mL R848 was added for the maturation of pDCs 
or 5 μg/mL R848 and 10 ug/mL Poly I:C for the maturation of mDCs. Co-cultures were 
performed at 1:1 ratio (104 DCs with 104 T cells/well) in replicates of three or six in 96-well 
round bottom plates in 200 μl IMDM supplemented with 10% HS, 1% PS and 10 ng/mL 
IL-3 or 800 IU/mL GM-CSF for pDCs and mDCs, respectively. After 24 hour incubation, 
IFN-γ production was measured by ELISA (Pierce Endogen).
RNA isolation and real-time quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from PB-DCs, HSPC-DCs and total PBMCs with the Quick-RNA 
MinPrep isolation kit (Zymo Research, CA, USA) according to the manufacturer’s protocol. 
cDNA synthesis and PCR amplification were performed as previously described.20 qRT-PCR 
reactions were run on an ABI 7900-HT real time PCR system (Applied Biosystems, Bleiswijk, 
The Netherlands) with 2 μl of cDNA, 1xSYBR green PCR master mix (Invitrogen) and 300 
nM of following primers: TLR3-Fw: AGTTGTCATCGAATCAAATTAAAGAG TLR3-Rv: 
CATTGTTCAGAAAGAGGCCAAAT TLR4-Fw: 5’-GGCATGCCTGTGCTGAGTT-3’, 
TLR4-Rv: 5’-CTGCTACAACAGATACTACAAGCACACT-3’, TLR7-Fw: 5’-TGCC 
ATCAAGAAAGTTGATGCT-3’, TLR7-Rv: 5’-GGAATGTAGAGGTCTGGTTGAAGAG-3’, 
TLR8-Fw: CGGAATGAAAAATTAGAACAACAGAA TLR8-Rv: GAACCAGAT 
ATTAGCAGGAAAATGC TLR9-Fw: 5’-TGAAGACTTCAGGCCCAACTG-3’, TLR9-
Rv: 5’-TGCACGGTCACCAGGTTGT-3’, phorphobilinogen deaminase (PBGD)-Fw: 
5’-GGCAATGCGGCTGCAA-3’, PBGD-Rv: 5’-GGGTACCCACGCGAATCAC-‘3. 
PBGD primers were purchased from Eurogentec (Maastricht, The Netherlands). mRNA 
expression of TLRs in DCs is depicted as ΔΔCt values and was quantified relative to 
mRNA expression in total PBMCs, which was set at 1. ΔΔCt was calculated as follows: 
2^-(ΔCtpDCs – ΔCtPBMCs) in which ΔCt was normalized for PBGD by calculating ΔCt = 
Cttarget gene – CtPBGD per sample.
Statistics
Statistical analysis was performed using GraphPad Prism 5.0. One-tailed paired Student’s 
t-test or one-way or two-way ANOVA with repeated measures (RM), followed by 
Bonferroni post-hoc test, was used, as indicated in figure legends. P-values <0.05 were 
considered significant.
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Results
The AhR antagonist SR1 induces ex vivo differentiation of pDCs and mDCs from 
human CD34+ HSPCs
To simultaneously generate sufficient numbers of pDCs and mDCs for use in DC 
vaccination therapy, we studied the effect of inhibiting AhR during ex vivo DC 
differentiation. Therefore, UCB CD34+ HSPCs were cultured for three weeks with the early 
acting cytokines TPO, SCF, Flt3L and IL-6 23-25. Additionally, we cultured the cells with 
1 μM SR1 or DMSO as control. Interestingly, addition of SR1 promoted the emergence of 
pDCs (CD11c-CD123hi BDCA2+ cells), BDCA1+ mDCs (Lin1-HLA-DR+BDCA1+BDCA3- 
cells) and BDCA3+ mDCs (Lin1-HLA-DR+BDCA1-BDCA3+ cells) (Figure 1A). After three 
weeks of culture, the frequency of these DC subsets was significantly higher in cultures 
with SR1 compared to control conditions; 2.9% vs. 0.04% for pDCs, 4.6% vs. 0.5% for 
BDCA1+ mDCs and 1.1% vs. 0.1% for BDCA3+ mDCs (Figure 1B). The average yield after 
three weeks of culture with SR1 starting from 105 CD34+ HSPCs was 3.8 x 106 pDCs, 5.3 x 
106 BDCA1+ mDCs and 1.2 x 106 BDCA3+ mDCs (Figure 1C and Supplementary Table 1). 
Figure 1. Effect of AhR antagonist SR1 on differentiation of pDCs, BDCA1+ mDCs and BDCA3+ mDCs 
from HSPCs. (A-C) UCB or (D-F) G-CSF-mobilized CD34+ cells were cultured for three weeks with 1 μM 
SR1 or 0.01% DMSO (control) after which the occurrence of pDCs and mDCs was evaluated by flow cytometry. 
(A,D) Dot plots show the percentage of pDCs (CD123hi), BDCA1+ mDCs and BDCA3+ mDCs within the total 
population of live cells. pDCs are gated as CD11c- cells and mDCs as lineage marker-, HLA-DR+ cells. mDCs 
are further defined as single positive for either BDCA1 or BDCA3. (B,E) Frequency within total cultured 
cells, and (C,F) total yield from 105 UCB CD34+ cells of pDCs, BDCA1+ mDCs and BDCA3+ mDCs. Data are 
depicted as mean ± SEM of 3-5 independent donors tested. Statistical analysis was performed with one-tailed 
paired Student’s t-test. *P<0.05, **P<0.01.
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Furthermore, SR1 promoted the differentiation of DC subsets from CD34+ cells obtained 
from peripheral blood of G-CSF-mobilized donors (Figure 1D). The average frequency 
of DCs in these SR1-cultures was 4.7%, 3.8% and 0.9% for pDCs, BDCA1+ and BDCA3+ 
mDCs, respectively (Figure 1E), which is comparable to the frequency obtained from UCB 
CD34+ cells. The expansion potential of G-CSF-mobilized blood CD34+ HSPCs was lower 
than that of UCB CD34+ cells, resulting in average DC yields of 0.6 x 106, 0.5 x 106 and 0.1 
x 106 from 105 CD34+ cells (Figure 1F and Supplementary Table 2).
Figure 2. Time kinetics and AhR involvement in pDC differentiation. For panels A-C, CD34+ UCB cells 
were cultured for three weeks with 1 μM SR1 or 0.01% DMSO (control). Total cell number was determined 
at day 7, 14 and 21 and the frequency of pDCs was evaluated at each time point by flow cytometry. (A) Fold 
increase of total nucleated cells in the cultures. (B) Frequency of pDCs (CD123hi cells) at each time point and 
(C) total number of pDCs generated from 105 CD34+ HSPCs. For panels D-E, CD34+ UCB cells were cultured 
for three weeks with 1 μM SR1 and titrated concentrations of VAF347. At day 21, (D) the frequency of pDCs 
within the total cultured cells was evaluated by flow cytometry and (E) the fold increase of total nucleated cells 
in the culture was determined on day 7, 14 and 21. Data are expressed as mean ± SEM of results from 5 (A-C) 
or 2 (D-E) UCB donors. Statistical analysis was performed using two-way RM ANOVA (A-C) or one-way RM 
ANOVA (D) followed by a Bonferroni post-hoc test. *P<0.05, **P<0.01, ***P<0.001. 
During the three weeks culture period the total nucleated cells continuously expanded 
(Figure 2A). Analysis of pDC differentiation in time revealed that the maximum frequency 
of pDCs was already reached at day 14 (Figure 2B). However, the absolute number of 
pDCs was highest on day 21 (Figure 2C). The antagonizing effect of SR1 on AhR signaling 
is mediated through direct binding and inhibition of AhR.18 To proof a similar effect 
of SR1 in our experiments, we evaluated if the SR1-induced DC differentiation was 
indeed AhR-dependent by adding the AhR agonist VAF347. The frequency of pDCs 
was partially decreased by addition of 5 nM VAF347 to the SR1-cultures, but 50 nM of 
VAF347 completely blocked the differentiation of HSPCs into pDCs (Figure 2D). Addition 
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of VAF347 to the SR1-cultures did not inhibit the proliferation of total cells (Figure 2E). 
Collectively, these data demonstrate that the AhR pathway is a negative regulator of DC 
differentiation, and that by using SR1 together with early acting cytokines, high numbers 
of pDCs, BDCA1+ and BDCA3+ mDCs can be generated from UCB and G-CSF-mobilized 
HSPCs ex vivo.
SR1-generated HSPC-DCs have phenotypical and functional characteristics of PB-DCs
Next, we assessed the phenotype and function of DCs generated in the presence of SR1 
(Figure 3A). Similar to their naturally occurring counterparts in blood, we observed 
that the three different HSPC-DC subsets were negative for the monocyte marker CD14, 
while they all expressed HLA-DR. On the other hand, their expression of CD11c was 
diverse; HSPC-pDCs were negative for CD11c, while DNGR1+BDCA3+ mDCs expressed 
CD11c. In contrast, only a fraction of the HSPC-BDCA1+mDCs expressed CD11c. Similar 
to their in vivo counterparts, the HSPC-pDCs selectively expressed BDCA2, while the 
HSPC-BDCA3+ mDCs uniquely expressed DNGR1. HSPC-pDCs additionally expressed 
BDCA4, CD4, CD45RA and CD62L (supplementary Table 3) similarly as PB-pDCs.11,26
To further characterize the HSPC-DCs, we isolated pDCs, BDCA1+ mDCs and 
BDCA3+ mDCs by cell-sorting on day 21 of culture and evaluated their TLR expression. 
PB-DCs were sorted from healthy individuals for comparison. In line with published 
results9,27, we observed that both HSPC-pDCs and PB-pDCs had the highest expression 
of TLR7 and TLR9 (Figure 3B). In addition we observed that BDCA3+ mDCs, derived 
from HSPCs or PB, had the highest expression of TLR3 of all the different DC subsets. 
However, the expression of TLR3 was in general lower in HSPC-DCs than PB-DCs. 
TLR8 expression was highest in BDCA1+ mDCs, followed by BDCA3+ mDCs and lowest 
in pDCs. Similarly, the TLR4 expression was highest in BDCA1+ mDCs, however the 
expression was in generally low as it is depicted relative to total PMBCs, which contain 
high proportion of TLR4-expressing monocytes.
Subsequently, phenotypical maturation and cytokine secretion by sorted HSPC-DCs 
in response to TLR stimulation was analyzed. For that reason, HSPC-pDCs were cultured 
overnight with two different CpG oligonucleotide ligands, CpG-A or CpG-B, while HSPC-
mDCs were stimulated with a combination of Poly I:C and R848. In addition, IL-3 and 
GM-CSF was added to all conditions for pDCs and mDCs respectively, as we observed 
that it enhanced their survival and activation (data not shown). Directly following sorting 
and before overnight culture, the DCs did not express CD80, CD86, CD83 or CCR7 (data 
not shown) and had intermediate levels of HLA-DR (Figure 3A). However, as seen in 
Figure 4A, the majority of HSPC-DC subsets upregulated co-stimulatory molecules and 
maturation markers upon TLR stimulation, and all of them highly expressed HLA-DR. 
We additionally observed that in the presence of IL-3 or GM-CSF alone (medium), the 
DCs expressed low levels of CD80, CD86, CD83 and CCR7 (Figure 4B and Supplementary 
Figure 2), but highly upregulated them upon TLR-ligation. The only exception was CD80 
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on BDCA1+ mDCs, which was expressed to the same level with or without TLR stimulation 
(Figure 4B and Supplementary Figure 2).
Figure 3. Phenotype of DCs derived from HSPCs in SR1 cultures. (A) CD34+ UCB cells were cultured 
for three weeks with 1 μM SR1 after which the expression of HLA-DR, CD11c, CD14 and the DC specific 
markers, BDCA1, BDCA2, BDCA3 and DNGR1 on HSPC-DCs was evaluated by flow cytometry. Dot plots 
are representative of cultures from at least 5 different UCB donors and gated on live cells or live cells and 
CD14- cells as indicated in the figure. (B) pDCs, BDCA1+ and BDCA3+ mDCs were sorted by flow cytometry 
from SR1 cultures at day 21 (HSPC-DCs n=4) or peripheral blood (PB-DCs, n=3). mRNA was extracted and 
expression of TLR3, TLR4, TLR7, TLR8 and TLR9 was determined by qRT-PCR. Expression was normalized 
to the housekeeping gene phorphobilinogen deaminase (PBGD), and is shown relative to that of PBMCs, 
which was set at 1.
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Figure 4. Phenotypical maturation of HSPC-DCs with TLR agonists. pDCs, BDCA1+ and BDCA3+ mDCs 
were sorted by flow cytometry from SR1-cultured CD34+ cells at day 21 of culture and stimulated overnight 
with TLR agonists. Expression of maturation and co-stimulatory molecules was evaluated by flow cytometry. 
(A) Histograms show expression of CD80, CD86, CD83, CCR7 and HLA-DR (black line) versus isotype control 
(grey line) for pDCs stimulated with CpG-B and BDCA1+ and BDCA3+ mDCs stimulated with R848 and 
Poly I:C. (B) The mean fluorescent intensity (MFI) of CD80, CD86, CD83, CCR7 and HLA-DR for non-TLR 
stimulated and TLR-stimulated pDCs, BDCA1+ and BDCA3+ mDCs. All conditions were supplemented with 
IL-3 or GM-CSF for survival of pDCs and mDCs, respectively. Data depict mean ± SEM of results from four 
(pDCs), two (BDCA1+ mDCS) or one (BDCA3+ mDCs) UCB donor.
Finally, we assessed the cytokine secretion by TLR-stimulated HSPC-DCs. HSPC-
pDCs activated with CpG-A secreted high levels of IFN-α and moderate amounts of 
TNF-α and IL-6, while CpG-B-activated HSPC-pDCs secreted both IL-6 and TNF-α, 
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but no IFN-α (Figure 5A). This is in line with previous reports on responses of PB-pDCs 
to different classes of CpG.28,29 Furthermore, HSPC-pDCs also responded to R848 by 
secreting IFN-α and upregulating co-stimulatory molecules (data not shown). HSPC-
BDCA1+ mDCs secreted TNF-α in response to TLR stimulation (Figure 5B) but no IL-12, 
while HSPC-BDCA3+ mDCs secreted both TNF-α and IL-12 (Figure 5C). Collectively, 
these data demonstrate that pDCs, BDCA1+ mDCs and BDCA3+ mDCs generated ex vivo 
by culturing CD34+ HSPCs with SR1 display similar phenotype and functional properties 
as PB-DCs.
Figure 5. Cytokine secretion by HSPC-DCs in response to TLR agonists. pDCs, BDCA1+ and BDCA3+ mDCs 
were sorted by flow cytometry from SR1-cultured CD34+ cells at day 21 of culture and stimulated overnight 
with TLR ligands. Concentrations of cytokines in the supernatant was measured by ELISA. (A) Concentrations 
of IFN-α, IL-6 and TNF-α secreted by pDCs seeded at 105 cells/mL. Data depict mean ± SEM of 4 independent 
UBC donors. Statistical analysis was performed using one-way RM ANOVA followed by a Bonferroni post-hoc 
test, comparing stimulated cells (CpG-A/CpG-B) with non-stimulated cells (medium). **P<0.01, ***P<0.001. 
(B) Concentration of TNF-α secreted by BDCA1+ mDCs seeded at 5 x 105 cells/mL. Data show mean ± SEM of 
2 independent donors. (C) Concentration of TNF-α and IL-12 secreted by BDCA3+ mDCs seeded at 1.8 x 105 
cells/mL. Data of 1 out of 3 independent experiments is shown and bars are depicted as mean ± SD.
HSPC-DCs are potent inducers of allogeneic T cell responses
To determine the T cell stimulatory capacity of HSPC-derived DCs, we performed 
allogeneic MLR assays where HSPC-pDCs, BDCA1+ mDCs and BDCA3+ mDCs were 
matured overnight and subsequently co-cultured with CFSE-labeled PBMCs from 
allogeneic donors for 4-5 days. All the different HSPC-DC subsets induced robust 
proliferation of both CD4+ and CD8+ T cells (Figure 6A,B). In addition, allogeneic T cells 
stimulated with HSPC-DCs secreted both IFN-γ and IL-2 (Figure 6C,D), while IL-4, 
TNF-α and IL-17 were non-detectable and the concentrations of IL-10 were low in the 
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supernatant (data not shown). These data show that the SR1-induced HSPC-DCs are potent 
inducers of allogeneic T cell responses.
Peptide-loaded HSPC-DCs induce activation of antigen-experienced T cells
In order to extend our observations of potent antigen-specific T cell activation by HSPC-
DCs, we determined the level of IFN-γ produced by CD8+ T cells recognizing the minor 
histocompatibility antigen LRH-1 or HA-1. Upon stimulation by HLA-B7+ HSPC-DCs 
loaded with LRH-1 peptide, LRH-1-specific CD8+ CTLs secreted significantly higher 
levels of IFN-γ than in response to non-peptide-loaded DCs (Figure 7A). Furthermore, 
concurrent maturation of the DCs with TLR ligands significantly enhanced the ability 
of the HSPC-DCs to activate IFN-γ secreting CD8+ T cells. Similarly, HA-1+ HLA-A2+ 
HSPC-DCs loaded with extra HA-1 peptide were used as stimulators of HA-1-specific 
T cells. Activation of HA-1-specific T cells was higher in response to HSPC-DCs loaded 
with the HA-1 peptide than to HSPC-DCs without exogenous peptide (Figure 7B), and 
the T cell activation was additionally potentiated by TLR-induced maturation of DCs. 
These data demonstrate that peptide-loaded HSPC-DCs can effectively activate antigen-
experienced T cells.
Discussion
DC-based vaccination is an attractive strategy to boost T cell immunity in patients 
with cancer and infectious diseases. So far, the vast majority of clinical trials have 
been performed with MoDCs. However, due to sub-optimal clinical effects, further 
improvements of DC vaccine potency are essential. One strategy is to use primary DC 
subsets isolated from blood, such as pDCs, BDCA1+ mDCs and BDCA3+ mDCs. Recently, 
it has been shown that pDCs can recognize, process and cross-present foreign antigens 
to CD8+ T cells, a quality important for generation of effective anti-tumor responses.30-32 
A seminal study by Tel et al. showed that some metastatic melanoma patients that were 
vaccinated with antigen-loaded pDCs, could induce antigen-specific CD4+ and CD8+ T cell 
responses and anti-tumor immunity.7 Pre-clinical studies have shown that pDCs induce 
anti-tumor immunity not only by direct priming and activation of tumor-specific T cells, 
but also by the high amounts of type I interferons they secrete, which enhances cross-
priming capacity of other DC subsets, and induces activation of NK cells.33-35 In addition, 
pDCs also interact with mDCs through cell-cell contact, such as by the CD40-CD40L axis, 
further enhancing the T cell stimulation capacity of mDCs.16 The therapeutic potential 
of this cross-talk between DC subsets has been investigated in murine tumor models. 
For instance, Nierkens et al. published that immunization of mice with mDCs activated 
in the presence of pDCs facilitated tumor clearance due to enhanced cross-priming 
capacity of the mDCs.8 Furthermore, Lou et al. reported that immunization of mice 
with a combination of activated pDCs and mDCs resulted in increased levels of antigen-
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Figure 6. T cell stimulation capacity of HSPC-DCs in allogeneic mixed lymphocyte reactions. HSPC-DCs 
from SR1-cultured UCB CD34+ cells were sorted by flow cytometry at day 21 and stimulated overnight with 
TLR ligands (CpG-B for pDCs and Poly I:C for BDCA1+ and BDCA3+ mDCs). Subsequently the DCs were 
used as stimulators of CFSE-labeled PBMCs from healthy donors at a ratio of 1:10 (DC:PBMCs). Five days later 
the proliferation of T cells was analyzed by flow cytometry and IL-2 and IFN-γ measured in the supernatant 
by cytometric bead array. (A) Dot plots depict the proliferation of CD3+CD4+ and CD3+CD8+ T cells of one 
representative PBMC donor out of four tested. (B) Average CD3+CD4+ and CD3+CD8+ T cell proliferation of 
four different PBMC donors. (C-D) Average concentration of IL-2 (C) and IFN-γ (D) in the supernatant of 
co-cultures with four different PBMC donors. Data are expressed as mean ± SEM and show the results of one 
representative experiment out of two experiments conducted with different HSPC donors. Statistical analysis 
was performed with one-tailed paired Student’s t-test. *P<0.05, **P<0.01.
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specific CD8+ T cells and enhanced anti-tumor response compared with immunization 
with either DC subset alone.15 These studies indicate that combination of pDCs and mDCs 
for DC-based immunotherapy would result in more favorable responses.
Our novel SR1-based culture method demonstrates simultaneous generation of 
high amounts of pDCs, BDCA1+ and BDCA3+ mDCs from UCB and G-CSF-mobilized 
CD34+ HSPCs. We demonstrated that the HSPC-derived DCs were phenotypically 
and functionally similar to their naturally occurring counterparts found in blood. The 
HSPC-pDCs expressed both BDCA2 and BDCA4 which are surface-antigens specifically 
found on pDCs.26 Furthermore, they highly expressed TLR7 and TLR9 and responded to 
stimulation with corresponding TLR-ligands by secreting high amounts of IFN-α, IL-6 
and TNF-α and upregulating co-stimulatory molecules and maturation markers. The 
HSPC-derived BDCA3+ mDCs exclusively expressed DNGR1, a C-type lectin receptor 
which mediates antigen uptake and cross-presentation by BDCA3+ mDCs.36,37 These DCs 
responded to R848 and Poly I:C-stimulation by secretion of both TNF-α and IL-12 and 
phenotypical maturation. BDCA1+ mDCs on the other hand did not secrete IL-12 in 
Figure 7. Antigen-specific T cell activation by HSPC-DCs. (A) LRH-1- HSPC-DCs from HLA-B7+ donor 
were sorted from SR1-cultured G-CSF-mobilized CD34+ cells by flow cytometry at day 21 and loaded with 
or without 1 μM LRH-1 peptide. Subsequently, the DCs were matured with TLR ligands as depicted in the 
figure in medium supplemented with IL-3 or GM-CSF for pDCs and mDCs, respectively. Next, the DCs were 
co-cultured with CTLs specific for LRH-1 (RP1) at an 1:1 ratio. 24 hours later the concentration of IFN-γ was 
measured in the supernatant by ELISA. (B) Similarly, HLA-A2+, HA-1+ HSPC-DCs were loaded with 1 μM 
HA-1, matured with TLR ligands and used as stimulators for HA-1-specific CD8+ T cell bulk. Bars depict mean 
values ± SD. Statistical analysis was performed using one-way RM ANOVA followed by a Bonferroni post-hoc 
test. *P<0.05, **P<0.01, ***P<0.001.
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response to these TLR-ligands, which is in contrast to what has been described in the 
literature for their in vivo counterparts.27,38 Furthermore, only a portion of HSPC-BDCA1+ 
mDCs expressed CD11c, while BDCA1+ mDCs in blood all express CD11c.26 The lack of 
IL-12 secretion by BDCA1+ mDCs and heterogenous CD11c expression might indicate 
that they are more immature than the other two DC subsets found in the culture, and 
require an additional maturation stimulus with for example GM-CSF. Nevertheless, the 
BDCA1+ mDCs did potently activate antigen-specific T cells secreting high levels of IFN-γ, 
just as the other two DC subsets, indicating that their immunostimulatory capacity is 
not impaired.
Previously, various in vitro culture systems have been developed for understanding 
the molecular regulations of DC development from human HSPCs and for generating 
DCs for immune-based therapies.23,24,37,39-41 Recently, Poulin et al. reported that functional 
BDCA3+DNGR1+ mDCs could be generated from human HSPCs, by first expanding 
HSPCs for 7-11 days and then differentiating them with Flt3L, SCF, GM-CSF and IL-4 
in medium supplemented with FCS for an additional 12-14 days.37 On the other hand, 
Blom et al. were the first to describe the ex vivo generation of pDCs, where Flt3L alone was 
sufficient for inducing the differentiation of pDCs from CD34++CD45RA- hematopoietic 
stem cells.24 Later, Chen et al. reported that TPO acts in synergy with Flt3L in expanding 
and differentiating CD11c-CD123+ pDCs from CD34+ HSPCs in vitro.23 Another group later 
described that culturing G-CSF-mobilized CD34+ HSPC with TPO and Flt3L additionally 
resulted in the differentiation of CD11c-CD123+, CD1c/b+ and DNGR1+ DCs.40 However, 
their numbers of DCs generated were generally low, and the supposed pDC population 
showed low CD123 expression and secreted relatively low levels of IFN-α. Furthermore, 
the DNGR1+ mDCs found in their culture did not express BDCA3.40 According to our 
DC culture protocol, we would be able to simultaneously generate 75 x 106 pDCs, 100 
x 106 BDCA1+ mDCs and 25 x 106 BDCA3+ mDCs under serum-free conditions, given 
that on average 2 x 106 CD34+ cells can be isolated from one UCB unit.42 Moreover, 
since our culture protocol can also be applied to G-CSF-mobilized blood CD34+ cells, 
the clinical application of SR1-induced HSPC-DCs can be expanded to both autologous 
and allogeneic settings. From 10 x 106 G-CSF-mobilized CD34+ cells, 50 x 106 pDCs, 
50 x 106 BDCA1+ mDCs and 10 x 106 BDCA3+ mDCs could be generated. To the best of 
our knowledge this is the highest reported number of BDCA2+BDCA4+ pDCs, BDCA1+ 
mDCs and BDCA3+DNGR1+ mDCs that can be simultaneously generated ex vivo from 
CD34+ HSPCs, and additionally exceeds the numbers that can be isolated from peripheral 
blood. However, additionally to an initial CD34+ HSPC selection, our expansion protocol 
requires a 3-week culture in a clean room facility and several GMP-grade cytokines and 
SR1. But, paralleled isolation of BDCA4+ pDC and BDCA1+ mDC requires expensive 
magnetic bead isolation procedures. Furthermore, magnetic beads for isolating BDCA-
3+DNGR1+ mDCs are currently not available. In addition, generating DCs ex vivo from 
HSPCs offers additional advantages, for example the possibility to manipulate the cells 
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during differentiation, such as silencing their expression of co-inhibitory molecules. Such 
modulations could even result in stronger anti-tumor responses, as it has been published 
that siRNA silencing of the co-inhibitory molecules PD-L1 and PD-L2 on MoDCs 
augments expansion and function of antigen-specific T cells.43
In this study, the different DC subsets were generated by culturing CD34+ HSPCs 
with Flt3L, SCF, TPO, IL-6 and the AhR antagonist SR1. The AhR has been extensively 
studied through the years, in AhR knockout mice and in the context of activation by 
environmental contaminants. These studies demonstrate that AhR is involved in 
hematopoiesis and modulates immune responses in various mouse models of infectious 
and auto-immune diseases.44 Notably, HSPCs, DCs and T cells express high levels of AhR 
compared to other immune cells.45 Studies focused on T cell and DC functionality show 
that AhR activation differentially modulates their function, depending on the source of the 
cells and the AhR ligands used.46 Furthermore, AhR function has shown to regulate the 
balance between proliferation and quiescence of hematopoietic stem cells (HSCs). Young 
AhR knockout mice have increased numbers of HSCs with higher proliferation rate than 
stem cells from wild type mice. This is also reflected in higher numbers of white blood cells 
in bone marrow, spleen and blood of AhR knockout mice.47-50 The same effect was reported 
for human HSPCs by Boitano et al., demonstrating that culturing CD34+ cells with SR1 
strongly promotes their proliferation rate.18 With a comparable culture protocol, we now 
demonstrate for the first time that inhibition of human AhR promotes the differentiation 
of human pDC and mDC subtypes from CD34+ HSPCs. In line with our findings, Liu 
et al. recently reported that AhR knockout mice have a higher frequency and absolute 
numbers of pDCs in spleens and lymph nodes compared to wild type mice.51 In contrast, 
they found no differences in the proportion and absolute numbers of CD11chiCD11b+I-Ab+ 
mDCs. Vorderstrasse et al. similarly reported in 2001, that the number of splenic CD11chi 
mDCs was not significantly different between AhR knockout and wild type mice.52 These 
findings suggest that DC differentiation might be differently regulated by AhR in mice 
and humans. Since there is also increasing evidence for dysregulation of DC subtypes 
in distinct auto-inflammatory diseases, such as Rheumatoid Arthritis, Systemic Lupus 
Erythematosus and Psoriasis53-55, it is also tempting to speculate whether interfering with 
the AhR pathway could dampen the mDC and pDC activation status in these diseases.
In conclusion, we show that SR1 strongly promotes differentiation of BDCA2+BDCA4+ 
pDCs, BDCA1+ and BDCA3+DNGR1+ mDCs from CD34+ HSPCs. The SR1-induced 
HSPC-DCs are phenotypically and functionally comparable to their naturally occurring 
counterparts in blood and induce strong antigen-specific T cell responses. This culture 
system allows the generation of clinical-scale numbers of pDCs and mDCs relevant for 
DC-immunotherapy of cancer patients and patients with chronic infectious diseases. 
Furthermore, this protocol can be used for investigating molecular pathways driving 
aberrant DC development and function which has been shown to be instrumental for the 
pathogenesis of various auto-immune disorders.
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Supplementary Figure 1. Titration of SR1. UCB CD34+ cells were cultured with TPO, SCF, Flt3L and IL-6 
as well as titrated concentration of SR1 (0.1-2μM) and the frequency of pDCs (CD11c-CD123hiBDCA2+) was 
evaluated by flow cytometry at day 21. Data are expressed as mean ± SEM of two UCB donors.
 
Supplementary Figure 2. Phenotypical maturation of HSPC-DCs. pDCs, BDCA1+ and BDCA3+ mDCs were 
sorted by flow cytometry from SR1-cultured CD34+ cells at day 21 of culture and stimulated overnight with 
TLR agonists. Expression of CD80, CD86, CD83, CCR7 and HLA-DR was evaluated by flow cytometry and is 
depicted as % positive cells for non-TLR stimulated and TLR-stimulated pDCs, BDCA1+ and BDCA3+ mDCs. 
All conditions were supplemented with IL-3 or GM-CSF for survival of pDCs and mDCs, respectively. Data 
depict mean ± SEM of results from four (pDCs), two (BDCA1+ mDCS) or one (BDCA3+ mDCs) UCB donor.
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Supplementary Table 1. Fold increase, frequency and absolute numbers of pDCs, BDCA1+ and BDCA3+ mDCs 
at day 21 from different UCB donors cultured with 1 μM SR1.
Experiment 
number
Donor 
material
fresh/ 
frozen 
CD34+ 
cells
Fold 
increase 
of total 
cells
pDCs 
(%)‡
pDCs 
(x106)†
BDCA1+ 
mDCs 
(%)‡
BDCA1+ 
mDCs 
(x106)†
BDCA3+ 
mDCs 
(%)‡
BDCA3+ 
mDCs 
(x106)†
1 CB0612 frozen 460 2.96 1.36
2 CB0712 fresh 2079 4.18 8.69
3 CB2511 frozen 386* 7.04* 2.72*
4 CB1212 fresh 360 2.34 0.84 1.68 0.60 0.75 0.27
5 CB0512 frozen 1766 4.09 7.22 6.84 12.07 1.46 2.59
6 CB1312 fresh 655 1.12 0.73 4.28 2.80 1.05 0.69
7 CB1911 frozen 318 4.79 1.52
8 CB1411 frozen 309 5.80 1.79 2.93 0.91 3.08 0.95
9 CB1411 frozen 362 8.11 2.94
10 CB2111 frozen 306 2.67 0.82 4.36 1.34 1.94 0.59
11 CB0712 frozen 277 8.56 2.37 7.99 2.22 7.13 1.98
Mean 662 4.70 2.82 4.68 3.32 2.57 1.18
SD 636 2.44 2.67 2.36 4.36 2.38 0.90
Median 362 4.18 1.79 4.32 1.78 1.70 0.82
Min 277 1.12 0.73 1.68 0.60 0.75 0.27
Max 2079 8.56 8.69 7.99 12.07 7.13 2.59
*Analysed at day 19
‡Within total cultured cells. pDCs are gated as CD11c- cells and mDCs as Lin-HLA-DR+ cells
†Generated from 105 CD34+ cells
Supplementary Table 2. Fold increase, frequency and absolute numbers of pDCs, BDCA1+ and BDCA3+ mDCs 
at day 21 from different G-CSF-mobilized donors cultured with 1 μM SR1.
Experiment 
number
Donor 
material
fresh/ 
frozen 
CD34+ 
cells
Fold 
increase 
of total 
cells
pDCs 
(%)‡
pDCs 
(x106)†
BDCA1+ 
mDCs 
(%)‡
BDCA1+ 
mDCs 
(x106)†
BDCA3+ 
mDCs 
(%)‡
BDCA3+ 
mDCs 
(x106)†
1 PB0113 fresh 173 2.99 0.52 3.95 0.68 0.43 0.07
2 PB0213 fresh 158 2.57 0.41 2.74 0.43 0.80 0.13
3 PB0313 fresh 84 8.66 0.73 4.69 0.40 1.45 0.12
Mean 138 4.74 0.55 3.79 0.50 0.89 0.11
SD 47 3.40 0.16 0.98 0.16 0.52 0.03
Median 158 2.99 0.52 3.95 0.43 0.80 0.12
Min 84 2.57 0.41 2.74 0.40 0.43 0.07
Max 173 8.66 0.73 4.69 0.68 1.45 0.13
‡Within total cultured cells. pDCs are gated as CD11c- cells and mDCs as Lin-HLA-DR+ cells
†Generated from 105 CD34+ cells
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Supplementary Table 3. Expression levels of BDCA2, BDCA4, HLA-DR, CD62L, CD4, CD45RA, CD11b and 
CD11c on HSPC-pDCs.
Experiment 
number
Donor 
material
BDCA2+ 
pDCs 
(%)
BDCA4+ 
pDCs 
(%)
HLA-DR+ 
pDCs 
(%)
CD62L+ 
pDCs 
(%)
CD11b+ 
pDCs 
(%)
CD11c+ 
pDCs 
(%)
CD4+ 
pDCs 
(%)
CD45RA+ 
pDCs 
(%)
1 CB0612 41,9 76,8 98,9 5,8 15,7 77,6 99,7
2 CB0712 72,7 75,6 94,8 5,9 6,8 91,0 99,0
3 CB2511 83,7 57,0 83,1 11,7
4 CB1212 85,9 93,5 4,3
5 CB0512 75,9 67,9 91,8 69,6 8,3 9,8 83,4 99,8
6 CB1312 83,8 72,6 95,7 15,4 74,9 87,0
7 CB1911 95,9 97,0 97,0 12,6
8 CB1411 41,2 66,3 94,3 93,0 3,7 5,6 79,6
9 CB1411 84,4 88,4 5,4
10 CB2111 77,9 53,5 90,2 89,2 5,8 13,4 82,7 97,1
11 CB0712 92,7 58,1 97,5 85,0 5,5 6,3 95,2 99,5
Average 76,0 66,0 93,2 86,7 5,8 9,7 83,5 97,0
SD 18,3 8,9 4,6 10,6 1,5 4,2 7,3 5,0
Median 83,7 67,1 94,3 89,2 5,8 9,8 82,7 99,2
Min 41,2 53,5 83,1 69,6 3,7 4,3 74,9 87,0
Max 95,9 76,8 98,9 97,0 8,3 15,7 95,2 99,8
HSPC-pDCs (CD123hi cells) from SR1 cultured UCB CD34+ cells were analysed for the expression of BDCA2, 
BDCA4, HLA-DR, CD62L, CD4, CD45RA, CD11b and CD11c by flow cytometry. Expression is calculated as 
percentage positive HSPC-pDCs out of total HSPC-pDCs.
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Abstract
Because of the potent graft-versus-tumor (GVT) effect, allogeneic stem cell 
transplantation (alloSCT) can be a curative therapy for hematological malignancies. 
However, relapse remains the most frequent cause of treatment failure, illustrating 
the necessity for development of adjuvant post-transplant therapies to boost GVT-
immunity. Dendritic cell (DC) vaccination is a promising strategy in this respect, 
in particular where distinct biological functions of naturally occurring DC subsets, 
i.e. myeloid DCs (mDCs) and plasmacytoid DCs (pDCs), are harnessed. However, 
it is challenging to obtain high enough numbers of primary DC subsets from blood 
for immunotherapy due to their low frequencies. Therefore, we present here an 
ex vivo Good Manufacturing Practice (GMP)-compliant cell culture protocol for 
generating different DC subsets from CD34+ hematopoietic stem and progenitor 
cells (HSPCs) of alloSCT donor origin. High numbers of BDCA1+ mDCs and 
pDCs could be generated, sufficient for multiple vaccination cycles. These HSPC-
derived DC subsets were highly potent in inducing anti-tumor immune responses 
in vitro. Notably, HSPC-derived BDCA1+ mDCs were superior in eliciting T cell 
responses. They efficiently primed naïve T cells and robustly expanded patient-
derived minor histocompatibility antigen (MiHA)-specific T cells. Though the 
HSPC-pDCs also efficiently induced T cell responses, they exhibited superior 
capacity in activating NK cells. pDC-primed NK cells highly upregulated TRAIL 
and possessed strong cytolytic capacity against tumor cells. Collectively, these 
findings indicate that HSPC-derived DC vaccines, comprising both mDCs and 
pDCs, may possess superior potential to boost anti-tumor immunity post alloSCT, 
due to their exceptional T cell and NK cell stimulatory capacity.
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Introduction
Allogeneic stem cell transplantation (alloSCT) can be a curative treatment for patients 
with hematological malignancies. The therapeutic effect, the so called graft-versus-
tumor (GVT) effect, can be attributed to donor-derived CD8+ T cells directed against 
antigens expressed on the recipient tumor cells, including minor histocompatibility 
antigens (MiHAs) and tumor associated antigens (TAAs).1,2 In addition, multiple reports 
demonstrate that NK cells also contribute to GVT immunity, as a high number of NK 
cells in stem cell grafts3, as well as early NK cell repopulation4,5, have been associated with 
reduced relapse rates. Still, tumor relapse remains a leading cause of treatment failure, 
illustrating the necessity to develop potent adjuvant post-transplant immunotherapies in 
order to boost GVT immunity, and improve clinical outcome after alloSCT.
Dendritic cell (DC) vaccination is an attractive approach to induce and boost GVT 
responses, as DCs are the most powerful antigen-presenting cells.6,7 Exploiting DC 
vaccines, T cell responses directed against hematopoietic-restricted MiHAs or TAAs can 
be specifically boosted, thereby enhancing GVT activity without evoking potentially life-
threatening graft-versus-host disease (GVHD). In vivo, multiple blood DC subsets exist, 
each with their distinct phenotypic and functional characteristics.8,9 These subsets can 
broadly be divided into two groups, myeloid and plasmacytoid DCs (mDCs and pDCs, 
respectively), where mDCs can be further subdivided into BDCA1+ mDCs and BDCA3+ 
mDCs.10 mDCs are in the front line of defense against fungi and bacteria, which they 
detect via different pattern-recognition receptors, including Toll-like receptors (TLRs). 
They possess high antigen processing and presenting capacity and secrete interleukin 
(IL)-12, which makes them highly effective in promoting proinflammatory interferon 
(IFN)-γ secreting T helper (Th)-1 and cytotoxic T lymphocyte (CTL) responses.8,9,11,12 In 
contrast, pDCs play a key role in the detection and control of viral infections, primarily 
due to their specialized production of type I IFN (IFN-α/β) following TLR7 and TLR9 
stimulation.13 Their secretion of IFN-α provides an immunostimulatory environment 
for both innate and adaptive immune cells. Notably, IFN-α and contact-dependent 
interactions potentiate DC-mediated activation, IFN-γ secretion and cytolytic capacity 
of NK cells.14-18 Furthermore, studies have indicated that the different DC subsets act 
synergistically via cross-talk, thereby potentiating each others’ stimulatory capacity.19-23 
Together, these characteristics render vaccines composed of both mDCs and pDCs highly 
attractive for the induction of broad anti-tumor immune responses.
Recently, we reported an innovative ex vivo culture protocol to efficiently generate 
high numbers of functional BDCA1+ mDCs, BDCA3+ mDCs and pDCs from CD34+ 
hematopoietic stem and progenitor cells (HSPCs).24 We discovered that inhibition of the 
aryl hydrocarbon receptor, using the antagonist StemRegenin 1 (SR1), was essential for DC 
subset differentiation. In this paper, we describe optimizations of this SR1-based culture 
protocol, where culture conditions were improved for generation of higher amounts and 
better differentiated mDC and pDC subsets. In addition, culture conditions were adapted 
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to Good Manufacturing Practice (GMP). Notably, this protocol allows the generation 
of the different DC subsets from CD34+ HSPCs derived from the original donor grafts. 
Importantly, we demonstrated the superior capacity of HSPC-derived mDCs and pDCs in 
stimulating tumor-reactive T cells and NK cells. While the generated mDCs were better T 
cell stimulators, the cultured pDCs were superior in inducing cytotoxic NK cell responses. 
Cumulatively, HSPC-derived DC subset (HSPC-DC) vaccines hold great promise for 
future application as post-transplant therapy to selectively boost GVT immunity and 
improve relapse-free survival.
Materials and Methods
Patient and donor material
For generation of HSPC-DCs and monocyte-derived DCs (MoDCs), peripheral blood 
mononuclear cells (PBMCs) were obtained from leukapheresis material of granulocyte 
colony-stimulating factor (G-CSF)-mobilized stem cell donors. CD8+ T cells used for 
priming assays were isolated from the same material. For T cell expansion assays, PBMCs 
were obtained from patients with hematological malignancies who developed HA1-
specific CD8+ T cell responses following alloSCT.25 Samples were collected 6-31 months 
after alloSCT. Patient (Pt) 1 and 2 did not receive additional donor lymphocyte infusion 
post-transplant, whereas Pt 3 and 4 received a donor lymphocyte infusion 16 and 2 months 
prior to the sample date, respectively. Because no apheresis material of the corresponding 
transplant donors was available, HSPC-DCs and MoDCs used for expansion of these 
patient-derived HA1-specific T cells were generated from allogeneic HLA-A2+HA1- donors 
(from a third party apheresis). For isolation of NK cells, healthy donor buffy coats were 
obtained from Sanquin blood bank. Cellular material was obtained in accordance with 
the Declaration of Helsinki and institutional guidelines and regulations (CMO 2013/064).
Ex vivo generation of HSPC-DCs and MoDCs
CD34+ cells were isolated from G-CSF-mobilized PBMCs using anti-CD34 microbeads 
(Miltenyi Biotec, catalog# 130-046-702). Purity and viability was evaluated by flow 
cytometry. CD34+ HSPCs were either used directly for HSPC-DC generation, or 
cryopreserved in 50% human serum (HS; PAA Laboratories), 42.5% IMDM (Iscove-
modified Dulbecco medium, GIBCO Invitrogen, catalog# 21980-032) and 7.5% DMSO 
(dimethyl sulfoxide, Sigma-Aldrich) and thawed at a later time-point for HSPC-DC 
generation. To generate HSPC-DCs, CD34+ HSPCs were cultured for 14-20 days in 
Cellgro DC medium (GMP-compliant, Cellgenix, catalog# 20801-0500), supplemented 
with 1 µM SR1 (Cellagen Technology, catalog# C7710-5) as previously described.24 The 
medium was additionally supplemented with 2% HS and 50 µg/mL ascorbic acid (AA; 
Centrafarm) during the entire culture period. During the first 7 days of culture, the 
medium was supplemented with Flt3L (FMS-like tyrosine kinase 3 ligand), SCF (stem 
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cell factor) and TPO (thrombopoietin), 100 ng/mL each (all from Immunotools, catalog# 
11343305, 11343328 and 11344865, respectively). For the remaining culture period, the 
concentrations of SCF and TPO were reduced to 50 ng/mL. Alternatively, HSPC-DCs were 
generated in a two-step protocol: after 7-13 days expansion as described above, cells were 
harvested, washed and reseeded in Cellgro DC medium containing 800 IU/mL GM-CSF 
(granulocyte-macrophage colony-stimulating factor) and 500 IU/mL IL-4 (both from 
Immunotools, catalog# 11343125 and 11340048, respectively) and cultured for 7 additional 
days. At day 0, the CD34+ HSPCs were seeded at 1 x 105 - 2 x 105 cells/mL, while after 
day 7 their density was adjusted to 1 x 106 - 1.5 x 106 cells/mL every 2-3 days with growth 
factor-supplemented medium. Total number of viable cells was determined by trypan 
blue exclusion counting at fixed timepoints during the culture period. At the end of the 
culture, samples were taken for flow cytometric analysis, and absolute numbers of DCs 
were calculated by multiplying the frequency of DCs with the absolute number of total 
cells generated from 1 x 106 CD34+ cells. For functional experiments, BDCA1+ mDCs and 
pDCs were sorted from HSPC-DC cultures by labeling the cells with anti-BDCA1 (clone 
L161) and anti-CD123 (clone 6H6) antibodies (both from Biolegend), respectively, followed 
by fluorescence-activated cell sorting (FACS) using the FACS Aria (BD Biosciences). The 
sorted DC subsets were in all cases used directly (“fresh”) for functional assays, except 
in assays described in Figure 2A,B, where cryopreserved/thawed DCs were used for day 
7 re-stimulation of primed MiHA-specific T cells.
MoDCs were generated in 7 days from plastic adherent monocytes in Cellgro DC 
medium supplemented with 2% HS, 800 IU/mL GM-CSF and 500 IU/mL IL-4, as 
previously described.26
DC maturation and cytokine release
Sorted HSPC-DC subsets were resuspended in IMDM supplemented with 10% fetal calf 
serum (FCS, Integro) and matured overnight with TLR-ligands. pDCs were stimulated 
with 3.2 µg/mL CpG-A (ODN 2216) or 5 µg/mL R848 (Resiquimod; both from Enzo 
Life Sciences, catalog# ALX-746-005 and ALX-420-038, respectively) in medium 
supplemented with IL-3 (10 ng/mL, Immunotools, catalog# 11340035), while BDCA1+ 
mDCs were stimulated with a combination of 5 µg/mL R848 and 20 µg/mL Poly I:C 
(Polyinosinic:polycytidylic acid, Sigma-Aldrich, catalog# P0913), referred to as RPI:C, 
in the presence of GM-CSF (800 IU/mL) and IL-4 (500 IU/mL). MoDCs were matured 
with RPI:C or conventional cytokine mixture (cytomix) containing 5 ng/mL IL-1β, 15 
ng/mL IL-6, 20 ng/mL tumor necrosis factor (TNF)-α and 1 µg/mL PGE2 (prostaglandin 
E2), as previously described.27 Cell culture supernatants were analyzed with ELISA for 
IFN-α (pan-specific, MabTech, catalog# 3425-1H-20), IL-12p70 (eBioscience, catalog# 14-
8129 (standard), 16-8126 (coating Ab) and 13-7129 (detection Ab)) and TNF-α (Sanquin, 
catalog# M9323) levels, according to manufacturer’s instructions.
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Flow cytometry
Cells were pre-incubated on ice with total human IgG (Nanogam, Sanquin) to block Fc-
receptors, and subsequently stained with appropriate antibody combinations. HSPC-DCs 
were phenotyped with anti-BDCA1/CD1c (clone L161), anti-BDCA2/CD303 (clone 201A), 
anti-BDCA3/CD141 (clone M80), anti-BDCA4/CD304 (clone 12C2), anti-DNGR1/Clec9A/
CD370 (clone 8F9), anti-HLA-ABC (clone W6/32), anti-CD11c (clone 3.9), anti-CD15 (clone 
W6D3), anti-CD80 (2D10), anti-CD83 (clone HB15e), anti-CD86 (clone IT2.2), anti-CD123 
(clone 6H6, all from Biolegend), anti-HLA-DR (clone Immu357), anti-CD11b (clone 
Bear1), anti-CD14 (clone RMO52), anti-CD34 (clone 581, all from Beckman Coulter), 
anti-PD-L1/CD274 (clone MIH1) and anti-CD123 (clone 7G3, both from BD Bioscience). 
NK cell activation was determined with anti-TRAIL(tumor necrosis factor-related 
apoptosis-inducing ligand)/CD253 (clone RIK-2), anti-CD3 (clone UCHT1), anti-CD56 
(clone HCD56) and anti-CD69 (clone FN50, all from Biolegend). Relevant isotype control 
antibodies were used from Biolegend. MiHA-specific T cells were detected by staining 
with anti-CD3 (clone UCHT1, Biolegend), anti-CD8 (clone 3B5, Invitrogen) and peptide/
major histocompatibility complex (MHC)-tetramers (HA1.A2: VLHDDLLEA28, UTA2-1.
A2: QLLNSVLTL29, HA8.A2: RTLDKVLEV30), as previously described.27,31,32 Acquisition 
and data analysis was performed with a Gallios flow cytometer and Kaluza software (both 
from Beckman Coulter). Dead cells were excluded using Sytox blue (Invitrogen, catalog# 
S34857), 7AAD (Sigma, catalog# A9400) or eFluor780 fixable viability dye (eBioscience, 
catalog# 65-0865-14).
MiHA-specific T cell assays
In T cell priming experiments, CD8+ T cells were isolated from MiHA-negative HLA-A2+ 
G-CSF-mobilized PBMCs from male donors using CD8 microbeads (Miltenyi Biotec, 
catalog# 130-045-201). For HA1-specific T cell expansion assays, PBMC samples obtained 
from alloSCT patients containing HA1-reactive CD8+ T cells were used. For these assays, 
HSPC-DCs and MoDCs were generated from HLA-A2+ MiHA- donors. Matured MoDCs, 
HSPC-derived BDCA1+ mDCs and HSPC-derived pDCs were harvested, loaded with 5 µM 
MiHA-peptide (HA1, UTA2-1 or HA8, from LUMC-IHB peptide facility, the Netherlands 
or ThinkPeptides), washed and subsequently co-cultured with the isolated CD8+ T cells 
or patient PBMCs in IMDM/10%HS at a ratio of 1:0.2 to 1:0.1 (T cell/PBMC:DC), as 
previously described.27,31 For priming assays, a minimum of 9 x 106 CD8+ T cells were 
used per DC subset. At days 2 and 5, IL-2 (50 IU/mL, Proleukin®, Chiron) and IL-15 (5 
ng/mL, Immunotools, catalog# 11340155) were added to the co-cultures. At day 7, cells 
were counted and analyzed by flow cytometry, and when indicated, re-stimulated with 
the respective DC subset. For re-stimulation, cryopreserved/thawed DCs were used. To 
determine functionality, DC-stimulated T cells were rechallenged overnight with 5 µM 
MiHA peptide in the presence of anti-CD107a (BD Bioscience, clone H4A3), followed by 
97
mDC & pDC-based vaccines induce potent anti-tumor immunity
an intracellular staining for IFN-γ (BD Bioscience, clone B27) and CD137 (Biolegend, 
clone 4-1BB), as described previously.27,31
CTL activation
CD8+ T cell clones specific for HA1.A2 and cytomegalovirus (CMV).A2 were isolated from 
patient 4 and a healthy donor, respectively, and expanded following protocols previously 
described.33 Mature DCs were harvested, washed, seeded in triplicate in 96-well round-
bottom plate (Corning Costar, catalog# 3799, 104 DCs/well) in IMDM/10%FCS and loaded 
with 1 µM HA1 or CMV (NLVPMVATV34, LUMC-IHB peptide facility) peptide. After 
1 hour incubation at 37°C, HA1- or CMV-specific CTLs were added at 1:1 ratio. After 24 
hours co-incubation, supernatant was harvested and IFN-γ production was measured 
by ELISA (Thermo Scientific, catalog# M700A (coating Ab) and M701B (detection Ab)).
NK-DC co-culture
NK cells were isolated using the untouched NK cell isolation kit (Miltenyi Biotec, 130-092-
657), resulting in >87% NK cell purity (CD56+CD3- cells). HSPC-derived BDCA1+ mDCs 
or pDCs were resuspended in IMDM/10%FCS, whereupon 10 x 103, 2.5 x 103 or 1 x 103 cells 
were seeded per well in 96-well round-bottom plates. Subsequently, BDCA1+ mDCs were 
matured using GM-CSF/IL-4 or GM-CSF/IL-4/RPI:C, while pDCs were matured with 
IL-3, IL-3/CpG-A or IL-3/R848, as described above. Next, 5 x 104 freshly isolated allogeneic 
NK cells were added, resulting in NK:DC ratios of 1:0.2, 1:0.05 or 1:0.02. After 40 hours 
co-culture, CD69 and TRAIL expression on NK cells was evaluated by flow cytometry. 
Besides, a 4 hour cytotoxicity assay was performed with 1 µM carboxyfluorescein diacetate 
succinimidyl ester (CFSE)-labeled35 Daudi tumor cells in the presence/absence of 40-hour 
DC-primed NK cells at a NK:Daudi ratio of 1:0.5. Subsequently, cells were harvested and 
stained with 7AAD, followed by quantification of viable Daudi cells using the FC500 flow 
cytometer (Beckman Coulter). The percentage of specific killing was calculated as follows: 
100 – ((absolute number of viable CFSE+ Daudi cells co-cultured with NK cells/absolute 
number of viable CFSE+ Daudi cells cultured alone)*100).35-37
Statistics
Statistical analysis was performed using GraphPad Prism 5.0. Student’s t-test or one-way 
ANOVA, followed by Bonferroni post-hoc test, was used as indicated. P-values <0.05 were 
considered significant.
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Figure 1. Generation of high numbers of BDCA1+ mDCs, BDCA3+ mDCs and pDCs from HSPCs. G-CSF-
mobilized CD34+ HSPCs (either freshly isolated or thawed) were cultured for 14-20 days in Cellgro DC 
medium supplemented with 1 µM SR1, 2% HS and 50 µg/mL AA in a one- or two-step protocol. In the one-
step protocol, HSPCs were cultured for 14-20 days in the presence of Flt3L, SCF and TPO (FST), while in 
the two-step protocol, HSPCs were expanded for 7-13 days with FST, then washed and reseeded in medium 
containing GM-CSF and IL-4 (G4) and subsequently cultured for 7 additional days. (A) Schematic overview 
of the two different culture protocols, the FST culture (one-step protocol) and G4 culture (two-step protocol). 
(B) Cumulative fold expansion of total cells at the end of 14-20 days culture, where cells were expanded for 
7-9 days (filled circles) or 12-13 days (open circles), followed by 7 day differentiation. Each dot represents an 
independent donor, lines indicate the mean value (n=11). (C-E) After 14-20 days culture, the frequencies of 
BDCA1+ mDCs, BDCA3+ mDCs and pDCs were determined by flow cytometry. (C) Representative plots 
showing percentage of BDCA1+ mDCs, BDCA3+ mDCs and pDCs within total cultured cells. Gating strategy 
is depicted in Supplementary Figure 2. (D) The frequencies of BDCA1+ mDCs, BDCA3+ mDCs and pDCs 
within total cultured cells of 9-11 different donors. (E) Numbers of BDCA1+ mDCs, BDCA3+ mDCs and 
pDCs generated from 1 x 106 CD34+ cells. (D-E) Each dot represents an independent donor, lines indicate the 
mean value (n=9-11). (F-G) Surface expression of BDCA1, HLA-DR, CD11c and CD14 on HSPC-DCs in FST 
and G4 cultures was determined by flow cytometry. (F) Dot plots from one representative donor. (G) Mean 
fluorescence intensity (MFI) of HLA-DR and CD11c within the BDCA1+ mDC population. Data are depicted 
as mean ± SEM of 7 independent donors. Statistical analysis was performed using paired student’s t-test. * p 
< 0.05, ** p < 0.01, *** p < 0.001.
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Results
A GMP-compliant cell culture protocol for generation of high numbers of BDCA1+ 
mDCs and pDCs from HSPCs
The overall aim of this study was to generate a DC vaccine composed of both mDC and 
pDC subsets and to examine its potential to boost both anti-tumor T cell and NK cell 
responses. The first objective was to establish culture conditions compliant with GMP, 
where sufficient numbers of well differentiated and functional DC subsets were generated 
from HSPCs for eventual clinical application. Therefore, we first modified our recently 
established SR1-based culture protocol, where the different HSPC-DC subsets were 
generated under serum-free conditions in GBGM medium supplemented with FLT3L, 
SCF, TPO, IL-6 and SR1.24 Our first optimization steps were to omit IL-6 from the cytokine 
cocktail and to switch to the widely available GMP-compliant Cellgro DC medium from 
Cellgenix, supplemented with 2% HS and AA (50 µg/mL). We observed that IL-6 inhibited 
in vitro DC differentiation, while AA and HS had a positive effect on DC-generation 
(Supplementary Figure 1). As mDCs generated with the previously published protocol 
showed low CD11c expression and limited IL-12 secretion upon TLR stimulation,24 we next 
investigated whether the HSPC-DC generation protocol would benefit from an additional 
mDC-differentiation boost at the end of the culture. For this purpose, we compared a 
two-step protocol, where HSPCs were first expanded with Flt3L, SCF and TPO (FST) for 
7-13 days and then differentiated for one week in the presence of GM-CSF and IL-4 (G4 
culture), to the standard one-step protocol where HSPCs were cultured for 14-20 days in 
the presence of FST (FST culture, Figure 1A). After 14-20 days, FST-cultured cells had 
expanded 133-fold in average, while G4-cultured cells expanded only 82-fold in average 
(Figure 1B). The frequencies of the different DC subsets were determined in both cultures 
as depicted in Supplementary Figure 2. We observed a significant increase in the frequency 
of BDCA1+ mDCs in G4 cultures compared to FST cultures, while pDC differentiation 
and/or survival was significantly reduced in G4 cultures (Figure 1C,D). Nevertheless, low 
frequencies of pDCs were still detectable in short-term expanded G4 cultures, although 
these pDCs exhibited lower BDCA2 expression than their FST-cultured counterparts 
(Figure 1C and Supplementary Figure 2D). The absolute number of generated BDCA1+ 
mDCs was similar for FST and G4 cultures, where both protocols resulted in generation of 
18 x 106 BDCA1+ mDCs in average from only 1 x 106 CD34+ HSPCs (Figure 1E). Notably, 
the one-step protocol resulted in almost ten-fold higher absolute numbers of pDCs, where 
in average 16 x 106 pDCs were generated from only 1 x 106 CD34+ HSPCs (Figure 1E). 
Although of low occurrence, BDCA3+DNGR1+ mDCs were detected in both cultures 
(Figure 1C,E). Important for clinical implementation, we observed that cryopreserved/
thawed HSPCs performed equally well in terms of expansion and DC differentiation as 
freshly isolated CD34+ HSPCs (Supplementary Figure 3). Flow cytometric analysis showed 
that BDCA1+ mDCs expressed high HLA-DR in both cultures, while the expression of 
CD11c increased upon G4 culture, suggestive of a more differentiated phenotype (Figure 
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1F,G). Notably, the majority of the BDCA1+ mDCs were negative for the monocytic marker 
CD14 (Figure 1F).
Based on these data, we continued with the G4 culture for the generation of BDCA1+ 
mDCs, and the FST culture for pDC generation. For further characterization, sorted G4-
generated BDCA1+ mDCs and FST-generated pDCs were matured overnight with TLR-
ligands and evaluated for phenotypical maturation and cytokine secretion. Our previous 
studies on SR1-derived HSPC-DCs showed that the HSPC-mDCs express TLR3, TLR4, 
TLR7 and TLR8, while the HSPC-pDCs express TLR7 and TLR9.24 To optimally stimulate 
BDCA1+ mDCs, we used a combination of the TLR3 agonist Poly I:C and TLR7/8 agonist 
R848, as simultaneous stimulation with these two agents has shown a synergistic effect.38,39 
For stimulation of ex vivo-generated pDCs we used either R848, which induces both 
IFN-α secretion and upregulation of maturation markers, or the TLR9 agonist CpG-A, 
known to induce secretion of large amounts of IFN-α.40,41 Importantly, we observed high 
IL-12p70 secretion and TNF-α by the matured BDCA1+ mDCs (Supplementary Figure 
4A). Additionally, they upregulated co-stimulatory and HLA molecules upon TLR-
stimulation (Supplementary Figure 4B). Similarly, the HSPC-derived pDCs showed a 
mature phenotype and secreted high amounts of IFN-α and TNF-α (Supplementary Figure 
4A,B). Moreover, when the DCs were stimulated in the bulk of total cultured cells, high 
levels of IL-12p70 and IFN-α could be detected, indicating that the total bulk culture could 
potentially be used as a vaccine (Supplementary Figure 4C).
In conclusion, these data demonstrate that using the two-step culture we can generate 
a higher frequency of well differentiated, IL-12 producing BDCA1+ mDCs, while the FST 
culture is most optimal for generation of high numbers of IFN-α producing pDCs.
BDCA1+ HSPC-DCs efficiently prime naïve MiHA-specific T cells
After establishing the optimal culture conditions for generation of HSPC-derived DC 
subsets, we examined their T cell and NK cell stimulatory capacity. To evaluate the 
capacity of HSPC-DCs in priming naïve antigen-specific T cells, sorted HSPC-derived 
BDCA1+ mDCs and pDCs were matured, loaded with MiHA peptide and co-cultured with 
autologous purified CD8+ T cells from MiHA-negative donors. For these assays, we used 
three HLA-A2 restricted and hematopoietic-specific MiHAs named HA128, UTA2-129 and 
HA830. At day 7, a clear population of MiHA-specific CD8+ T cells could be observed upon 
BDCA1+ mDC stimulation (Figure 2A and Supplementary Figure 5), which efficiently 
expanded upon an additional week of stimulation with MiHA-loaded BDCA1+ mDCs 
(Figure 2A,B). After overnight peptide rechallenge, BDCA1+ mDC-primed MiHA-specific 
T cells upregulated the activation marker CD137 and were highly positive for both IFN-γ 
and the degranulation marker CD107a (Figure 2C). In contrast, no MiHA-specific CD8+ 
T cells could be detected in pDC-stimulated cultures (Figure 2D). These data demonstrate 
that the HSPC-derived BDCA1+ mDCs are highly effective in priming and activating CD8+ 
T cells from the naïve repertoire.
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Figure 2. HSPC-derived BDCA1+ mDCs efficiently prime and activate naïve MiHA-specific T cells. HSPC-
DCs were generated as described in Figure 1, and subsequently BDCA1+ mDCs were sorted from G4 culture 
and pDCs from FST culture. Next, BDCA1+ mDCs were stimulated with R848 and Poly I:C (RPI:C) in the 
presence of GM-CSF and IL-4, while pDCs were stimulated with R848 in the presence of IL-3. (A-B) Purified 
CD8+ T cells from MiHA-negative HLA-A2+ donors were cultured for two consecutive weeks with autologous 
MiHA peptide-loaded TLR-matured BDCA1+ mDCs. Cells were screened for the presence of MiHA-specific 
CD8+ T cells using flow cytometry on days 7 and 14. Density plots (A) and absolute MiHA-specific CD8+ T 
cell numbers (B). (C) BDCA1+ mDC-primed and expanded MiHA-specific T cells of donor B were overnight 
rechallenged with or without 5 µM HA1-peptide at day 14, followed by intracellular staining for CD137, 
IFN-γ and CD107a. (D) Purified CD8+ T cells from MiHA-negative HLA-A2+ donor were cultured for one 
week with MiHA-loaded TLR-matured pDCs. Presence of MiHA-specific CD8+ T cells was determined by 
flow cytometry on day 7. (A,C-D) The numbers in the dot plots represent the percentage of tetramer-positive 
cells within CD3+CD8+ T cells.
BDCA1+ HSPC-DCs and pDCs possess superior capacity to expand and activate CD8+ 
Tem cells
Next, we assessed the capacity of the HSPC-derived DC subsets, in comparison to 
autologous MoDCs, to expand and activate effector memory CD8+ T (Tem) cells. In 
these assays, we used PBMCs from four patients with a hematological malignancy who 
developed HA1-specific CD8+ T cell responses after alloSCT, and stimulated them for 
one week with TLR-matured HA1 peptide-loaded HSPC-DCs or MoDCs, generated from 
unrelated third-party HLA-A2+HA1- donors. Interestingly, HSPC-derived BDCA1+ mDCs 
and pDCs showed superior capacity to induce expansion of MiHA-specific Tem cells, 
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Figure 3. HSPC-derived BDCA1+ mDCs show superior capacity to expand and activate antigen-experienced 
CD8+ Tem cells. HSPC-DCs were generated as described in Figure 1, and subsequently BDCA1+ mDCs were 
sorted from G4 culture and pDCs from FST culture. Next, the BDCA1+ mDCs, pDCs and autologous MoDCs 
were activated with respective TLR-ligands as indicated in the figure, in the presence of GM-CSF and IL-4 
(MoDCs and BDCA1+ mDCs) or IL-3 (pDCs). Thereafter, TLR-matured HA-1 peptide-loaded DCs were co-
cultured for one week with patient PBMCs at a 1:0.1 ratio (PBMC:DC) (n=4). The HSPC-DCs and MoDCs 
used for expansion of patient HA1-specific CD8+ T cells were from unrelated third party donor apheresis 
products, as there was no apheresis material available of the corresponding transplant donors. The frequency 
of HA1-specific CD8+ T cells at day 0 was <0.02% in Pt. 1-3 and 0.61% in Pt. 4. (A) Density plots showing the 
percentage of HA1-specific CD8+ T cells at day 7. The numbers in the dot plots depict the percentage of positive 
cells within CD3+CD8+ T cells. (B) Absolute HA1-specific CD8+ T cell numbers after one week co-culture > 
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evident by higher frequencies and absolute numbers of HA1-tetramer+ CD8+ T cells as 
compared to MoDC stimulation (Figure 3A-C). In three out of four patients, the BDCA1+ 
mDCs were more efficient than pDCs in boosting T cell expansion. These responses 
were highly specific, as no expansion of HA1-tetramer+ CD8+ T cells was seen with non-
loaded DCs (Figure 3A and Supplementary Figure 6A). Additionally, the expanded T 
cells exhibited strong effector functionalities, as reflected by the high percentage of IFN-
γ+CD137+ CD8+ T cells from patient 4 after overnight HA1 peptide rechallenge (Figure 
3D). To explore their T cell stimulatory capacity further, we stimulated established CTL 
clones with peptide-loaded HSPC-DCs or MoDCs. Interestingly, the pDCs showed better 
potency for boosting IFN-γ production by HA1 and CMV effector CTLs than mDCs or 
MoDCs (Figure 4). Furthermore, TLR-stimulated bulk of total culture HSPC-DCs also 
efficiently activated HA1 and CMV effector CTLs (Supplementary Figure 6B). No IFN-γ 
secretion was observed in DC:T cell co-cultures in the absence of HA1 or CMV peptide 
(Supplementary Figure 6B). In summary, these data demonstrate the superior capacity 
of HSPC-derived BDCA1+ mDCs in expanding tumor-reactive CD8+ Tem cells, while the 
HSPC-derived pDCs appear to exhibit stronger potency to induce effector functions of 
antigen-experienced T cells.
< with  DCs. (C) Fold expansion of HA1-specific CD8+ T cells, calculated by dividing the number of HA1-
specific T cells at day 7 with the number of HA1-specific T cells at day 0. (D) 7-day DC-stimulated PBMCs of 
Pt. 4 were rechallenged overnight with 5 µM HA1-peptide and subsequently stained intracellular for CD137 
and IFN-γ. As control, a small portion of cultured cells from all conditions was pooled and cultured overnight 
without HA1-peptide (No peptide). Numbers in the dot plots indicate the percentage of IFN-γ+ CD8+ T cells 
within CD3+CD8+ T cells. Pt. = patient. N.d. = not determined.
Figure 4. HSPC-derived pDCs show superior capacity to induce IFN-γ secretion by CD8+ Tem cells. HSPC-
DCs were generated and activated as described in Figure 3. TLR-matured DCs were seeded in triplicate and 
loaded for 1 hour with 1 µM HA1 or CMV peptide at 37°C. Next, without washing, CTLs specific for HA1 
or CMV were added at 1:1 ratio and co-cultured for 24 hours. Concentrations of IFN-γ were determined by 
ELISA. Results are depicted as mean ± SD of a representative experiment (HA1 CTL: n=2, CMV CTL: n=1). 
Statistical analysis was performed by one-way ANOVA, followed by Bonferroni post-hoc test * p < 0.05, ** p 
< 0.01, *** p < 0.001. 4
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HSPC-pDCs superiorly induce activation of cytolytic NK cells
As there is accumulating evidence for the important role of DC-mediated NK cell 
activation in anti-tumor immunity,42-45 we next assessed the NK cell stimulatory capacity 
of HSPC-derived DC subsets. Therefore, NK cells were co-cultured with sorted allogeneic 
HSPC-derived BDCA1+ mDCs or pDCs in the presence of different DC maturation 
stimuli. After 40 hours of co-culture, a DC dose-dependent increase in CD69 expression 
on the NK cells was observed, where TLR-matured BDCA1+ mDCs and pDCs induced 
the highest expression (Figure 5A,B). In contrast, TRAIL expression on NK cells was 
primarily induced by pDCs (Figure 5A,C), especially by CpG-A-activated pDCs. TRAIL-
expression induced by R848-activated pDCs varied between donors, and was high in 
experiment 1 (Figure 5A), but low in experiments 2 and 3 (Figure 5C). This may possibly 
have correlated with the respective IFN-α secretion from the stimulated pDCs, which 
varied in response to R848 (19.5 fg/pDC in experiment 1, <0.1 fg/pDC in experiments 2-3), 
as studies indicate that TRAIL upregulation on NK cells is dependent upon signaling via 
type I IFN receptor.46-48 Interestingly, NK cells co-cultured at a lower ratio with non-TLR 
activated pDCs (in the presence of IL-3) also highly expressed TRAIL, despite very limited 
IFN-α secretion by non-TLR activated pDCs (<0.1 fg/pDC).
Importantly, NK-mediated cytotoxicity was greatly enhanced following DC priming, 
in particular with CpG-A-activated pDCs (Figure 6). NK cells co-cultured with as few 
as 2% pDCs (ratio 1:0.02) in the presence of CpG-A, killed over 88% of the Daudi cells 
compared to <30% killing by non-primed NK cells. In addition, correlating with the 
TRAIL expression, we observed efficient Daudi killing following co-culture of NK cells 
with IL-3-cultured pDCs. In control conditions, where NK cells were cultured without DCs 
in the presence of the different DC maturation stimuli, expression of CD69 and TRAIL 
remained low and Daudi killing was also low (Figure 5B,C and Figure 6). Furthermore, 
no Daudi killing was observed by DC:Daudi co-cultures in the absence of NK cells (data 
not shown). These findings show that HSPC-derived DCs can activate and potentiate 
cytolytic capacity of NK cells, where in particular pDCs possess superior capability for 
boosting NK tumor reactivity.
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Figure 5. HSPC-pDCs superiorly induce activation of cytolytic NK cells. HSPC-DCs were generated as 
described in Figure 1, and subsequently BDCA1+ mDCs were sorted from G4 culture and pDCs from FST 
culture. Next, the different HSPC-DCs were seeded and medium was added containing respective TLR-ligands 
and cytokines as indicated in the figure. Without washing, allogeneic NK cells were added to the DCs at 1:0.2, 
1:0.05 or 1:0.02 ratio (NK:DC). As control, NK cells were cultured without DCs in the absence (control=ctrl) 
or presence of the different DC maturation cocktails. By flow cytometry, expression of CD69 and TRAIL 
on NK cells was determined after 40 hours co-culture. (A) Histograms depicting expression of CD69 and 
TRAIL on DC-primed NK cells of experiment 1 at a NK:DC ratio of 1:0.2. (B-C) The percentage and mean 
fluorescent intensity (MFI) of CD69 (B) and TRAIL (C) on NK cells of experiments 2 and 3 at a NK:DC ratio 
of 1:0.2, 1:0.05 or 1:0.02. (A-C) Data shown are from three independent experiments using three different 
HSPC-DC and three different NK cell donors. NK cell purity was 97%, 87% and 97% for experiments 1, 2 and 
3, respectively. Exp. = Experiment.
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Figure 6. HSPC-pDCs superiorly potentiate 
cytolytic capacity of NK cells. NK cells 
were co-cultured with DCs for 40 hours 
as described in Figure 5. Subsequently, a 
4 hour flow cytometric cytotoxicity assay 
was performed, where Daudi tumor cells 
were added at a NK:Daudi ratio of 1:0.5. The 
graphs depict percentage of specific killing 
(mean ± SD of triplicates), and was calculated 
as follows: 100 - ((absolute number of viable 
CFSE+ Daudi cells co-cultured with NK cells 
/ absolute number of viable CFSE+ Daudi cells 
cultured alone)*100). Data depicted are from 
the same two experiments as are described in 
Figure 5B,C. Exp. = Experiment.
Discussion
Although alloSCT can be a curative therapy for patients with hematological malignancies, 
high relapse rates remain the leading cause of treatment failure. DC vaccination using 
a combination of different DC subsets may be an attractive adjuvant treatment to boost 
GVT immunity. We and others49 postulate that vaccination with multiple DC subsets 
could not only robustly activate tumor-antigen reactive T cells, but also alloreactive NK 
cells, the two key effector populations involved in tumor cell elimination post alloSCT. 
Previously, we reported a novel protocol for the generation of BDCA1+ mDCs, BDCA3+ 
mDCs and pDCs from CD34+ HSPCs, using the aryl hydrocarbon receptor antagonist SR1 
in combination with Flt3L, SCF, TPO and IL-6.24 Here, we developed an optimized GMP-
compliant culture protocol, where high amounts of mDCs and pDCs can be generated 
from G-CSF-mobilized CD34+ cells obtained from alloSCT donors. Notably, omission of 
IL-6 from the culture, as well as supplementation with AA and HS, had positive impact on 
ex vivo DC differentiation. Furthermore, an additional differentiation boost at the end of 
the culture, where GM-CSF and IL-4 were added instead of Flt3L, SCF and TPO (named 
G4 culture) resulted in a higher frequencies of BDCA1+ mDCs with high CD11c expression. 
However, this protocol was less ideal for pDC generation, as GM-CSF and IL-4 inhibited 
pDC differentiation, as also described by others.50 Therefore, we favored generation of 
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HSPC-mDCs using the G4 culture, and generation of HSPC-pDCs using the FST culture. 
Cumulatively, these changes allow ex vivo generation of clinically relevant dosages of 
HSPC-derived BDCA1+ mDCs and pDCs which, importantly, produce high amounts 
of IL-12 and IFN-α upon TLR stimulation. We envision that these immunostimulatory 
HSPC-derived DC subsets, presenting MiHAs and/or TAAs, might be a potent adjuvant 
therapy for patients with hematological malignancies post alloSCT.
As these HSPC-derived DC subsets could be suitable for pre-emptive or therapeutic 
vaccination post-alloSCT, we evaluated their stimulatory capacity. Importantly, we 
observed DC-subset specific characteristics of our cultured HSPC-DC subsets similar 
to what has been described in literature.8-10 Ex vivo-generated BDCA1+ mDCs were more 
efficient in priming naïve T cells and subsequent expansion of MiHA-specific Tem cells 
than pDCs. These characteristics are likely related to the higher co-stimulatory phenotype 
of BDCA1+ mDCs and their secretion of IL-12p70.8,11 Previously, we and others have 
demonstrated that DC-induced MiHA-specific Tem cells have efficient killing capacity 
against malignant cells of hematopoietic origin expressing the respective MiHA.31,51-53 
Notably, HSPC-derived pDCs were superior in inducing IFN-γ secretion by Tem cells, 
and additionally promoted superior NK cell activation and cytotoxicity. CpG-A activated 
pDCs, secreting high levels of IFN-α, showed the strongest NK cell activation. IFN-α is a 
potent NK cell modulator, and is known to enhance both TRAIL expression and cytolytic 
capacity of NK cells.46-48,54 Interestingly, we observed that non-TLR activated HSPC-pDCs 
also induced high TRAIL expression and NK cell-mediated cytotoxicity. In the presence 
of IL-3 alone, no IFN-α was detectable in those co-cultures (data not shown). However, 
studies indicate that cell-dependent contact with NK cells may enhance the maturation 
and IFN-α secretion capacity of pDCs.55 This may account for the reciprocal activation 
of NK cells observed.
Nowadays, the majority of alloSCT patients receive hematopoietic stem cells obtained 
from leukapheresis products of G-CSF-mobilized donors.56 As the yield of CD34+ cells 
is often sufficient for transplantation, it would be possible to cryopreserve ≤5% of the 
donor graft (i.e. max. 3 x 109 total cells or 25 x 106 CD34+ HSPCs) for eventual DC vaccine 
generation. Using the optimized HSPC-DC-generation protocol, the FST culture would 
result in average in 180 x 106 BDCA1+ mDCs and 160 x 106 pDCs from 10 x 106 G-CSF-
mobilized CD34+ HSPCs, and the G4 culture would result in average in 180 x 106 BDCA1+ 
mDCs from 10 x 106 HSPCs. Those achieved numbers are considerably higher than with 
the previously published protocol,24 and could be sufficient for ≥9 repetitive vaccinations. 
Importantly, by generating the DCs from a portion of the donor stem cell graft, these 
vaccines are obtained without extra apheresis burden for the alloSCT donor. Moreover, 
during their differentiation, HSPC-derived DCs can be modified to further augment their 
stimulatory capacity. For example, immature DCs could be silenced for co-inhibitory 
molecules such as PD-L1 and PD-L2, by transfection with small interfering RNAs. We 
have previously demonstrated that PD-L-silenced MoDCs show superior potential in 
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activating tumor-reactive T cells.27,57-59 Additionally, HSPC-DCs could be transfected with 
mRNA of the tumor target antigen (MiHA or TAA), to provide long-lasting presentation 
of multiple antigenic epitopes.58,60-62
Further pre-clinical studies are warranted to investigate whether enrichment of the 
different DC subsets will be needed or whether the whole bulk of cultured cells can be 
used as vaccine. Apart from the different DC subsets generated from the CD34+ HSPCs, 
the culture contained a heterogenous mixture of monocytic and myelocytic cells (defined 
by CD14, CD15, CD11b and CD34 expression; Supplementary Figure 7), but not allogeneic 
T cells nor B cells (data not shown). Of the total cultured cells, ~25% and ~50% within the 
FST culture and G4 culture, respectively, were HLA-DR negative cells (Supplementary 
Figure 7A,B), which may potentially suppress DC-mediated activation of T cells and NK 
cells. However, Haar et al. recently demonstrated that HSPC-derived HLA-DR- cells 
obtained with their culture system did not suppress T cell proliferation, but rather induced 
T cell proliferation.63 Within the HLA-DR negative fraction we could identify a population 
of cells double positive for CD15 and CD11b (Supplementary Figure 7D,E), a phenotype 
associated with myeloid-derived suppressor cells.64 Since we observed these cells primarily 
in the long (i.e. >19 days) G4 cultures (7-18% of total cultured cells), we favor the shorter 
culture procedure (i.e. <16 days), where the frequency of HLA-DR-CD15+CD11b+ cells 
was <4% out of total cultured cells. Shorter culture procedure is also more cost-effective 
and requires less handling.
It also remains to be investigated which vaccination and TLR stimulation scheme is 
most optimal for HSPC-DC vaccination. For repeated vaccinations, the HSPC-DCs will 
need to be cryopreserved. Whether it would be better to cryopreserve the DCs before or 
after TLR maturation needs to be established. At the same time, the optimal protocol for 
TLR stimulation, i.e. which GMP-grade TLR ligands and duration of stimulation will 
need to be investigated. Furthermore, there is accumulating evidence that the different 
DC subsets potentiate each other’s stimulatory capacity via cross-talk.19-23 For instance, 
Nierkens et al. described that vaccination of mice with mDCs activated in the presence 
of pDCs resulted in enhanced cross-priming capacity of the mDCs and subsequently 
augmented anti-tumor immune responses.19 Furthermore, Lou et al. demonstrated that 
immunization of mice with a combination of activated mDCs and pDCs resulted in 
increased levels of antigen-specific CD8+ T cells and facilitated better tumor clearance 
compared with immunization with either DC subset alone.20 It could therefore be favorable 
to stimulate and/or infuse the different DC subsets simultaneously. However, it could also 
be more beneficial to harness the distinct features of the different HSPC-derived DC 
subsets by independent vaccination with mDCs and pDCs, by infusing the different DC 
subsets at different locations, and/or at different time-points.
In conclusion, we have developed a GMP-compliant culture protocol where high 
numbers of different DC subsets, with unique characteristics and functionalities, can be 
differentiated from the alloSCT donor stem cell grafts. These HSPC-derived DC subsets 
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are highly potent stimulators of tumor-reactive T cells and NK cells. Together, these 
findings indicate that vaccination with HSPC-DCs may be an attractive adjuvant therapy 
post alloSCT to boost GVT immunity.
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Supplementary Figure 1. Addition of IL-6 during ex vivo culture of CD34+ HSPCs inhibits DC 
differentiation, while supplementation with HS and AA results in improved generation of HSPC-DCs. 
(A-C) G-CSF-mobilized CD34+ HSPCs were cultured in Stemspan ACF medium (Stemcell Technologies, 
catalog# 09855) supplemented with Flt3L, SCF and TPO (FST) and SR1 in the absence or presence of 1, 10 
or 100 ng/mL IL-6 (Immunotools, catalog# 11340066). After three weeks culture, the frequency of BDCA1+ 
mDCs and pDCs was determined by flow cytometry. (A) Representative plots showing percentage of BDCA1+ 
mDC and pDC with or without 100 ng/mL IL-6 (n=4). DC are gated from CD14-HLA-DR+ cells, but numbers 
in plots show percentage DC within total cultured cells. (B) Frequency within total cultured cells and (C) 
total yield from 106 CD34+ cells of BDCA1+ mDC and pDC. (B-C) Data are depicted as mean ± SEM of three 
independent donors. (D-E) G-CSF-mobilized CD34+ HSPCs were cultured for two weeks in GMP-compliant 
Cellgro DC medium supplemented with Flt3L, SCF and TPO (FST) and SR1 in the absence or presence of 2% 
HS and 50 µg/mL AA. Fresh medium containing SR1, FST, HS and AA was added every 2-3 days. At every 
medium-refreshment, AA was added to a final concentration of 50 µg/mL. After two weeks, the frequency 
of BDCA1+ mDC and pDC was determined by flow cytometry, followed by overnight TLR maturation. (D) 
Frequency within total cultured cells and (E) total yield from 106 CD34+ cells of BDCA1+ mDC and pDC. 
(D-E) Each dot represents an independent donor tested, lines indicate the mean value (n=3). Statistical analysis 
was performed by using one-way ANOVA, followed by Bonferroni’s multiple comparison test. (A-C) Each 
condition supplemented with IL-6 was compared to FST alone (0 ng/mL IL-6). *p<0.05, ** p<0.01, ***p<0.001
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Supplementary Figure 3. Performance of freshly isolated CD34+ HSPCs versus thawed CD34+ HSPCs. 
HSPC-DCs were generated as described in Figure 1 from either freshly isolated CD34+ HSPCs or CD34+ 
HSPCS that were cryopreserved and thawed for later use. Comparison of (A) total fold expansion and (B-C) 
frequency of (B) BDCA1+ mDCs and (C) pDCs. Each dot represents an independent donor, lines indicate the 
mean value ± SEM (n=3-6).
Supplementary Figure 2 (on the left). Gating strategy and phenotype of generated HSPC-DCs. HSPC-DCs 
were generated as described in Figure 1 and subsequently analyzed by flow cytometry. Density plots from a 
representative FST culture, where HSPC-DCs were first gated as (A) live (Sytox blue-, FS versus SS), singlets (FS/
SS TOF versus FS/SS INT) and autofluorescent negative (FL4-) cells. The frequencies of the different DC subsets 
were defined as follows: (B) BDCA1+ mDCs were defined as BDCA1+HLA-DR+ cells within autofluorescent 
negative cells. (C) BDCA3+ mDCs were defined as HLA-DR+BDCA3+DNGR1+ cells within autofluorescent 
negative cells. (D) pDCs were defined as CD14-HLA-DR+CD123+BDCA2+ cells within autofluorescent negative 
cells with a low FS/SS scatter. Supplementary Figure 2 further depicts the expression of other DC-related 
markers on the different DC subsets.
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Supplementary Figure 4. Phenotypical maturation and cytokine secretion by sorted CD34-derived DC 
subsets. (A-B) HSPC-DCs were generated as described in Figure 1, and subsequently BDCA1+ mDCs were 
sorted from G4 culture and pDCs from FST culture. Next, BDCA1+ mDCs were cultured with GM-CSF and 
IL-4 (G4, black lines)) with or without R848 and Poly I:C (RPI:C, green lines), while pDCs were cultured 
with IL-3 (black lines) with or without CpG-A (blue lines) or R848 (green lines). After overnight maturation, 
phenotypical maturation was assessed by flow cytometry and cytokine secretion by ELISA. (A) Secretion of 
IL12p70, TNF-α and IFN-α. Lines indicate median values (n=3-9). (B) Histograms of one representative donor 
show the expression of CD80, CD86, CD83, PD-L1, HLA-DR and HLA-ABC compared to isotype control 
(grey lines). (C) HSPC-DCs were generated as described in Figure 1. Next, total cultured cells were stimulated 
overnight with TLR ligands at 5 x 105 cells/mL. Secretion of IL-12p70 and IFN-α was evaluated by ELISA. Lines 
indicate median values (n=6-8).
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Supplementary Figure 5. HSPC-derived BDCA1+ mDCs efficiently 
prime naïve MiHA-specific T cells. HSPC-DCs were generated as 
described in Figure 1, and subsequently BDCA1+ mDCs were sorted 
from G4 culture. Next, BDCA1+ mDCs were stimulated with R848 
and Poly I:C (RPI:C) in the presence of GM-CSF and IL-4. Purified 
CD8+ T cells from HA8-negative HLA-A2+ donor were cultured 
for one week with autologous HA8 peptide-loaded TLR-matured 
BDCA1+ mDCs. Cells were screened for the presence of HA8-specific 
CD8+ T cells using flow cytometry on day 7. The number in the dot 
plot represents the percentage of tetramer-positive cells within 
CD3+CD8+ T cells.
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Supplementary Figure 6. CD8+ Tem cell responses. (A) HSPC-DCs were generated as described in Figure 1, 
and subsequently BDCA1+ mDCs were sorted from G4 culture and pDCs from FST culture. Next, the different 
DC subsets and autologous MoDCs were activated with respective TLR-ligands and cytokines (GM-CSF and 
IL-4 (MoDCs and BDCA1+ mDCs) or IL-3 (pDCs)) as indicated in the figure. Patient PBMCs containing low 
frequencies of HA1-specific CD8+ T cells were subsequently stimulated with TLR-matured non-peptide loaded 
DCs at 1:0.1 ratio. After one week stimulation, cells were screened for the presence of HA1-tetramer positive 
CD8+ T cells using flow cytometry. Density plots show tetramer stainings of cultures with PBMCs from Pt. 
3 and 4 stimulated with non-peptide loaded DC (the relevant controls for tetramer stains depicted in Figure 
3). The frequency of HA1-specific CD8+ T cells at day 0 was 0.01% and 0.61% in Pt. 3 and 4, respectively. The 
numbers in the dot plots represent the percentage of positive cells within the CD3+CD8+ T cells. Pt. = patient. 
(B) HSPC-DCs were generated as described in Figure 1. Next, total cultured cells were stimulated overnight 
with TLR ligands and cytokines: G4 culture was stimulated with G4+RPI:C, while FST culture with IL-
3+CpG-A. TLR-matured total cultured HSPC-DCs were seeded in triplicate and loaded for 1 hour with 1 
µM HA1 or CMV peptide at 37°C. Next, without washing, CTLs specific for HA1 or CMV were added at 1:1 
ratio and co-cultured for 24 hours. Concentrations of IFN-γ were determined by ELISA. Results are depicted 
as mean ± SD.
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Supplementary Figure 7. Flow cytometric analysis of HSPC-DC cultures. HSPC-DCs were generated as 
described in Figure 1 and subsequently analyzed by flow cytometry for HLA-DR, CD14, CD11b, CD15 and 
CD34 expression. (A) Density plots from one representative donor showing the frequencies of HLA-DR+ 
and HLA-DR- cells within total FST- and G4-cultured cells. (B) Frequencies of HLA-DR+ and HLA-DR- cells 
within total FST- and G4-cultured cells of 7 different donors. Lines indicate mean values. (C) Density plots 
from one representative donor depicting expression of CD14, CD11b, CD15 and CD34 within HLA-DR+ cells. 
Numbers in plots indicate percentage positive cells within gated cells (gates are indicated within brackets above 
FACS plots). (D) Density plots from one representative donor showing CD15 and CD11b expression within 
HLA-DR- cells. Numbers in plots indicate the percentage of positive cells within the HLA-DR- population. 
(E) Frequency of HLA-DR- cells expressing CD15 and CD11b out of total cultured cells. Lines indicate mean 
values of 7 independent donors.
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Abstract
Potent immunotherapies are urgently needed to boost anti-tumor immunity and 
control disease in cancer patients. As dendritic cells (DCs) are the most powerful 
antigen-presenting cells, they are attractive means to reinvigorate T cell responses. 
An appealing strategy to employ the effective antigen processing and presentation 
machinery, T cell stimulation and cross-talk capacity of natural DC subsets is in 
vivo tumor antigen delivery. In this context, endocytic C-type lectin receptors 
are attractive targeting molecules. Here, we investigated whether CLEC12A 
efficiently delivers tumor antigens into human DC subsets, facilitating effective 
induction of CD4+ and CD8+ T cell responses. We confirmed that CLEC12A is 
selectively expressed by myeloid cells, including myeloid and plasmacytoid DC 
subsets (mDCs and pDCs). Moreover, we demonstrated that these DC subsets 
efficiently internalize CLEC12A, whereupon it quickly translocates to the early 
endosomes and subsequently routes to the lysosomes. Notably, CLEC12A antibody 
targeting did not negatively affect DC maturation nor function. Furthermore, 
CLEC12A-mediated delivery of keyhole limpet hemocyanin (KLH) resulted in 
enhanced proliferation and cytokine secretion by KLH-experienced CD4+ T cells. 
Most importantly, CLEC12A-targeted delivery of HA-1 long peptide resulted in 
efficient antigen cross-presentation by mDCs and pDCs, leading to strong ex 
vivo activation of HA-1-specific CD8+ T cells of patients after allogeneic stem cell 
transplantation. Collectively, these data indicate that CLEC12A is an effective new 
candidate with great potential for in vivo antigen delivery into mDCs and pDCs, 
thereby employing the specialized functions and cross-talk capacity of these DC 
subsets to boost tumor-reactive T cell immunity in cancer patients.
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Introduction
The prominent role of dendritic cells (DCs) in orchestrating immune responses has 
provided the rationale for the development of DC-based strategies to boost anti-tumor 
immune responses in cancer patients.1 DCs are the most powerful antigen-presenting 
cells and efficiently initiate and reactivate CD4+ and CD8+ T cell responses.2 Importantly, 
they have the unique capacity to cross-present extracellular antigens, including tumor 
antigens, in major histocompatibility complex (MHC) class I molecules to CD8+ T cells.3,4 
Upon tumor antigen presentation and co-stimulation by the DCs, tumor-reactive T cells 
become activated, expand and attack tumor cells. Moreover, long-lasting memory against 
recurrent disease is formed. Importantly, tumor regression has been observed following 
DC-based vaccination in patients with hematological cancers.5-7 In addition, productive 
T cell responses could be boosted by DC vaccination of patients treated with allogeneic 
stem cell transplantation (alloSCT).8-11 In this context, T cells could be directed against 
tumor antigens or recipient-specific allo-antigens restricted to hematological tumor cells, 
known as minor histocompatibility antigen (MiHA).12,13
Nevertheless, we and others have observed that often the induction and/or reactivation 
of anti-tumor immune responses is inadequate, contributing to disease progression or 
relapse.14 This illustrates the urgency to develop alternative DC-based strategies to more 
effectively boost anti-tumor immunity. One such strategy involves the exploitation 
of the powerful antigen presentation capacity of natural DC subsets by in vivo tumor 
antigen delivery. Two key populations of human DCs are myeloid DCs (mDCs) and 
plasmacytoid DCs (pDCs).15 mDCs are further subdivided based on surface expression 
of BDCA1+ (CD1c) and BDCA3+ (CD141). Each DC subset has its specialized function 
in the induction and maintenance of immune responses.16 Notably, pre-clinical studies 
indicate that simultaneous engagement and cross-talk of multiple DC subsets is important 
for generating more potent and broader anti-tumor responses.17-19
Attractive cell surface molecules for antibody-mediated in vivo tumor antigen delivery 
into DC subsets are the endocytic C-type lectin receptors (CLRs).20-25 CLRs are pattern-
recognition receptors that mediate recognition and uptake of pathogens, as well as antigens 
exposed or released upon cell death. Furthermore, their ligation can induce intracellular 
signalling pathways regulating DC function. In this study, we investigated the potential 
of a relatively unexplored CLR, C-type lectin domain family 12 member A (CLEC12A), 
as antigen delivery receptor. CLEC12A is also known as myeloid inhibitory C-type lectin-
like receptor (MICL), C-type lectin-like molecule-1 (CLL-1), dendritic-cell-associated 
C-type lectin 2 (DCAL-2) and CD371. Notably, CLEC12A is an attractive candidate, as it 
is broadly expressed by all human DC subsets.26 The function of CLEC12A has not been 
fully elucidated, though recently Neumann et al. found CLEC12A to be involved in the 
control of sterile inflammation by neutrophils.27 They identified that CLEC12A binding 
to uric acid crystals, released by dying cells, inhibits neutrophil-derived reactive oxidant 
species production, thereby reducing infiltration of immune cells to the site of damage. 
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More recently, CLEC12A was reported to be involved in microbial defense in myeloid cells, 
in particular in bacterial autophagy.28 It was postulated that CLEC12A is involved early 
during bacterial autophagy at the level of pathogen recognition initiated upon membrane 
damage. Notably, Chen et al. demonstrated that targeting of human monocyte-derived 
DCs (MoDCs) with αCLEC12A antibody modulated Toll-like receptor (TLR)-mediated 
maturation and cytokine secretion.29 In addition, Lahoud et al. have proposed CLEC12A 
as a potential target for specific antigen delivery.30,31 They showed in vivo induction of 
OVA-specific CD4+ and CD8+ T cell responses after administration of OVA-conjugated 
αCLEC12A antibody in mouse models. Yet, still little is known about CLEC12A’s 
internalization mechanism, intracellular routing and fate, and most importantly whether 
CLEC12A can efficiently facilitate antigen cross-presentation by human DC subsets. Our 
aim was to acquire insight into these mechanisms and to explore CLEC12A’s potential for 
targeted antigen delivery into human DCs to promote CD4+ and CD8+ T cell responses. 
Here, we validated the discriminative expression pattern of CLEC12A, and showed that 
it is efficiently internalized by human BDCA1+ mDCs, BDCA3+ mDCs and pDCs upon 
targeting with specific antibodies. We observed that CLEC12A initially translocates to the 
endosomes, whereupon it quickly routes to the lysosomes. Notably, CLEC12A antibody 
binding did not negatively affect DC phenotype nor allogeneic T cell stimulation capacity. 
Importantly, we showed that antigens delivered via CLEC12A are efficiently processed by 
DCs and (cross-)presented to antigen-experienced T cells. These findings demonstrate that 
CLEC12A is an appealing targeting receptor for selective in vivo delivery of tumor antigens 
into mDC and pDC subsets to boost tumor-reactive immune responses in cancer patients.
Materials and Methods
Patient and donor material
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donor buffy 
coats (Sanquin, Nijmegen, the Netherlands) or from leukapheresis products using Ficoll-
Hypaque density centrifugation. PBMCs containing KLH-specific T cells were obtained 
from multiple myeloma patients following vaccination with KLH-pulsed tumor antigen-
presenting DCs. PBMCs containing HA-1 specific T cells were obtained from patients after 
alloSCT.9,10 Pre-vaccination leukapheresis material was used to isolate BDCA1+ mDCs, 
BDCA3+ mDCs and pDCs, and culture monocyte-derived DCs (MoDCs). All material 
of patients and healthy donors was obtained after written informed consent, according 
to institutional guidelines.
DC isolation and culture
To generate MoDCs, monocytes were isolated from PBMCs via plastic adherence in 
tissue culture flasks (Greiner Bio-One, Alphen a/d Rijn, the Netherlands) and cultured 
in X-VIVO 15 medium (Lonza, Verviers, Belgium) supplemented with 2% human serum 
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(HS; PAA laboratories, Pasching, Austria), 500 IU/mL interleukin (IL)-4 and 800 IU/
mL granulocyte-macrophage colony-stimulating factor (GM-CSF; both Immunotools, 
Friesoythe, Germany). At day 3, immature MoDCs were harvested and directly used 
in experiments or routinely matured for 48 hours with 500 IU/mL IL-4, 800 IU/mL 
GM-CSF, 5 ng/mL IL-1ß, 15 ng/mL IL-6, 20 ng/mL tumor necrosis factor (TNF)-α (all 
Immunotools), and 2.5 µg/mL PGE2 (prostaglandin E2, Pfizer; conventional cytokines).
PBMCs containing naturally occurring BDCA1+ mDCs, BDCA3+ mDCs and pDCs 
were labeled with fluorophore-conjugated αCD11c, αBDCA1, αBDCA2, αBDCA3 and 
αCD123 (all Biolegend, CA, USA). Subsequently, CD11c+BDCA1+ mDCs, CD11c+BDCA3+ 
mDCs and CD123+BDCA2+ pDCs (Supplementary Figure 1A) were sorted using the 
ARIA SORP (Becton Dickinson, Franklin Lakes, NJ, USA) with >95% purity. BDCA1+ 
mDCs and BDCA3+ mDCs were matured with 800 IU/mL GM-CSF, 10 µg/mL Poly 
I:C (Polyinosinic:polycytidylic acid, Sigma Aldrich) and 5 µg/mL R848 (Resiquimod, 
Enzo Life Sciences, Raamsdonkveer, the Netherlands), and pDCs with 10 ng/mL IL-3 
(Immunotools) and 5 µg/mL R848.
Expression and internalization
CLEC12A and DEC205 expression and their internalization capacity was analyzed by flow 
cytometry. Healthy donor PBMCs or day 3 MoDCs were incubated for 30 minutes with 
10 µg/mL αCLEC12A (clone 687317, R&D systems Minneapolis MN, USA) or mIgG2b 
isotype control (Biolegend) at 4°C. Subsequently, cells were incubated for 0-90 minutes 
at 37°C to allow endocytosis. Then, goat-anti-mouse Alexa Fluor-647 (Life Technologies, 
Carlsbad, CA, USA) was added. To inhibit clathrin-mediated endocytosis, cells were 
incubated in hypertonic 450mM sucrose solution (Boom, Meppel, the Netherlands).32 
Blockade of clathrin-mediated uptake was reversed by sucrose washout and resuspension 
in PBS. Subsequently, cells were labeled with fluorophore-conjugated αBDCA1, αBDCA2, 
αBDCA3, αCD123, αCD11c (Miltenyi Biotec, Bergisch Gladbach, Germany; BD or 
Biolegend). DCs were analyzed on a CyAn ADP or a Gallios flow cytometer (both 
Beckman Coulter) and gated as CD11c+BDCA1+ mDCs, CD11c+ BDCA3+ mDCs and 
BDCA2+CD123+ pDCs (Supplementary Figure 1B). Data was analyzed with Kaluza V1.3 
(Beckman Coulter).
Intracellular routing
To study CLEC12A internalization and investigate its intracellular routing, day 3 MoDCs 
were adhered to RetroNectin-coated (Takara, Otsu, Japan) coverslips. After blocking Fc-
receptors with total human IgG (hIgG; Sanquin) and goat serum (CDL, Nijmegen, the 
Netherlands), MoDCs were incubated for 30 minutes with 10 µg/mL αCLEC12A (mIgG2b, 
clone 687317, R&D systems) or αDEC205 (mIgG2b, clone MG38, eBioscience) at 4°C. 
Subsequently, cells were labeled with Alexa Fluor-488-conjugated goat-anti-mouse IgG2b 
(Life Technologies, Carlsbad, CA, USA) and DCs were incubated for 0-60 minutes at 
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37°C. Subsequently, cells were fixated with 4% paraformaldehyde and incubated with 
αHLA-DR/DP (mIgG2a, clone Q5/13). Thereafter, HLA-DR/DP staining was visualized 
using Alexa Fluor-564-conjugated goat-anti-mouse IgG2a (Life Technologies). Then, after 
permeabilization, αEEA-1 (rabbit IgG, Abcam, Cambridge, UK) or αLAMP-1 (rabbit 
IgG, Sigma Aldrich, St. Louis, MO, USA) was added for 30 minutes, followed by staining 
with Alexa Fluor-647-conjugated goat-anti-rabbit IgG (polyclonal, Life Technologies). 
Coverslips were mounted on slides with Mowiol (Sigma Aldrich). Images were acquired 
with an Olympus FV1000 Confocal laser scanning microscope (Olympus America Inc., 
Melville, NY, USA) or a LSM 510 META confocal microscope (Zeiss, Jena, Germany). 
Isotype controls mIgG2b, mIgG2a and rabbit IgG (Biolegend, Miltenyi Biotec, Jackson 
ImmunoResearch Laboratories, respectively) did not show fluorescent staining. Pictures 
were analyzed with Image J V1.46R and quantified with JACoP plugin V2.1.1.
DC phenotype and function upon CLEC12A antibody binding
Day 3 MoDCs were pre-incubated with 10 µg/mL αCLEC12A (hIgG1) or hIgG1 isotype 
control (Merus B.V., Utrecht, the Netherlands) and matured with conventional cytokines; 
1 µg/mL LPS (Lipopolysaccharide, Sigma Aldrich); 10 µg/mL Poly(I:C) or 5 µg/mL R848. 
After 48 hours, IL-6, IL-10 and TNF-α concentrations were quantified by ELISA according 
to manufacturer’s instructions (Human IL-6 and IL-10 ELISA Ready-SET-Go! Kit 
(eBioscience, San Diego, CA, USA); PeliPair human TNF-α ELISA reagent set (Sanquin)). 
MoDC phenotype was analyzed by flow cytometry using: αCD14, αCCR7, αCD80, αCD86, 
αHLA-ABC (all Biolegend), αHLA-DR (Beckman Coulter), αCD83 (BD) and appropriate 
isotype controls (all Biolegend). Cells were analyzed using a FC500 flow cytometer 
(Beckman Coulter). For allogeneic mixed lymphocyte reaction (alloMLR), T cells were 
prepared by depleting healthy donor PBMCs of CD14+ and CD19+ cells with magnetic 
beads (BD), and subsequently labeled with 1.25µM CFSE (carboxyfluorescein diacetate 
succinimidyl ester, Life technologies)33. Next, 1 x 105 T cell-enriched leukocytes and 1 x 
104 mature MoDCs were seeded in 200 µL IMDM (Iscove-modified Dulbecco medium, 
Life technologies) supplemented with 10% HS in round-bottom 96-well plates (Corning 
Costar) in triplicate or sixplicate. After 5 days of co-culture, supernatant was collected for 
interferon (IFN)-γ ELISA (Pierce Endogen, Rockford, IL, USA). Furthermore, cells were 
harvested, stained with αCD4, αCD3 (both Biolegend) and αCD8 (Life technologies), and 
subsequently analyzed for CFSE dilution within CD3+CD4+ and CD3+CD8+ T cells using 
a Gallios flow cytometer.
KLH-specific T cell activation
Day 3 MoDCs were generated, and BDCA1+ mDCs and pDCs were isolated from 
leukapheresis material. DCs were incubated for 30 minutes at 4°C with total hIgG 
(Sanquin) in the presence of 10 µg/mL αCLEC12A (mIgG2b or biotinylated hIgG1) or 
isotype control antibody. Then, in case of mouse antibodies, secondary labeling with 10 
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µg/mL biotinylated goat-anti-mouse IgG (Life technologies) was performed for 30 minutes 
at 4°C. Subsequently, DCs were washed and 2 µg/mL KLH-conjugated αbiotin antibody21 
was added for 30 minutes at 4°C. Finally, cells were washed and MoDCs were matured for 
48 hours, mDCs and pDCs for 24 hours. Then, patient PBMCs containing KLH-specific T 
cells were thawed, depleted from monocytes using CD14 IMag beads (BD), labeled with 
1.25µM CFSE and resuspended in IMDM/10% HS to a concentration of 0.5 x 106 cells/
mL. These were added to the DCs at a peripheral blood lymphocytes (PBLs):DCs ratio of 
1:0.1 in 96-well round-bottom plates (in triplicate). Cells were co-cultured in a volume 
of 200 µL at 37°C. After 4 days, supernatant was harvested and pooled for analysis of 
IFN-γ production by cytokine bead array (CBA; BD) and CD4+ T cell proliferation was 
evaluated, as described before.
HA-1 cross-presentation assay
To evaluate receptor-mediated antigen cross-presentation, synthetic long peptide for 
the MiHA HA-1 (azido propionic acid-KLKECVLHDDLLEARRPRAHE-biotin; Leiden 
University Medical Center (LUMC), the Netherlands) was conjugated to αCLEC12A 
(hIgG1), αDEC205 (IgG2b, clone MG38, BD) or respective isotype controls (hIgG1 and 
mIgG2b), using the copper-free click reaction.34 In short, a highly reactive succinimidyl-
cyclooctyne variant, 2,5-dioxopyrrolidin-1-yl4-((((1R,8S,9s)-bicyclo[6.1.0]non-4-yn-
9-ylmethoxy)carbonyl)amino) butanoate (BCN, Synaffix, Oss, the Netherlands), was 
incubated with the corresponding antibody at a 15 molar excess, following manufacturer’s 
instructions. Thereafter, the BCN-conjugated antibody was incubated overnight with a 3 
molar excess of HA-1 long peptide and purified using a 10kDa dialysis cassette (Thermo 
scientific). Conjugation efficiency was determined with ELISA. Furthermore, binding 
capacity and specificity of the HA-1 conjugated αCLEC12a and αDEC205 antibodies, as 
compared to the isotype controls, was validated by flow cytometry by staining the biotin-
tag on the HA-1 long peptide with αbiotin-FITC. DC subsets, isolated from leukapheresis 
material of HA-1 negative healthy donors, were pre-incubated for 30 minutes at 4°C with 
1 mg/mL total hIgG (Sanquin) to block Fc-receptors, followed by 30 minutes incubation 
at 4°C with 10 µg/mL αCLEC12A/HA-1, αDEC205/HA-1 or corresponding isotype/HA-1 
conjugates. Furthermore, as an additional control, DCs were labeled with αCLEC12A/
HA-1 or αDEC205/HA-1 conjugate in the presence of 100 µg/mL excess unconjugated 
αCLEC12A or αDEC205 antibody to demonstrate receptor-specific uptake. As the 
peptide conjugation efficiency slightly differed with the corresponding isotype control 
antibodies, the αCLEC12A or αDEC205 block with excess unconjugated antibody was 
used in all cross-presentation assays. Subsequently, DCs were washed and incubated 
at a concentration of 0.1 x 106 cells/mL in IMDM in 96-well round-bottom plates at 
37°C (in triplicate). As positive control, DCs were pulsed with 1µM HA-1 short peptide 
(VLHDDLLEA). After 3 hours of incubation, maturation stimuli and 10% HS were added 
and DCs were incubated overnight. Thereafter, DCs were co-cultured overnight with HA-1 
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T cell receptor (TCR) transduced T cells 35 at a T:DC ratio of 1:1 in a volume of 200 µL in 
the presence of αCD107a (BD). Then, supernatant was harvested for IFN-γ ELISA, and T 
cells were stained with αCD8 (Beckman Coulter) and αCD137 (Biolegend) and analyzed 
for activation using a Gallios flow cytometer.
In the antigen recall assay using primary patient T cells, BDCA1+ mDCs and pDCs 
were labeled with the αCLEC12A/HA-1 conjugate, as described before, and plated at a 
concentration of 0.8 x 106 cells/mL in IMDM in a 24-well plate. Due to limited availability 
of patient material these experiments were only performed with the αCLEC12A/HA-1 
conjugate in the presence/absence of excess unjugated antibody as negative control. After 
3 hours of incubation at 37°C, maturation stimuli and 10% HS were added and DCs 
were cultured overnight. Thereafter, DCs were co-cultured for 7 days with CD14-depleted 
PBMCs containing HA-1 specific memory T cells obtained from HA-1 mismatched 
patients after alloSCT, at a ratio of PBL:DC of 1:0.2 in a total volume of 1 ml. After 4 
days, 1 ml IMDM supplemented with 10% HS, 100 IU/mL IL-2 and 10 ng/mL IL-15 
(Immunotools) was added. At day 7, cells were harvested, counted and the percentage of 
HA-1-specific CD8+ T cells was determined by staining with αCD3 (biolegend), αCD8 
(Beckman Coulter), HA-1 PE and APC tetramers (both from LUMC). Cells were analyzed 
on a Gallios flow cytometer.
Statistical analysis
Data were analyzed using one-way ANOVA followed by a Bonferroni post-hoc test. 
P-values <0.05 were considered significant.
Results
CLEC12A is broadly expressed and efficiently internalized by human DC subsets
To study the suitability of CLEC12A as a targeting receptor for antigen delivery, we first 
validated its expression on human DC subsets using flow cytometry. We confirmed that 
MoDCs and naturally occurring BDCA1+ mDCs, BDCA3+ mDCs and pDCs highly 
expressed CLEC12A (Figure 1A and Supplementary Figure 2A). Since expression of 
CLEC12A was progressively lost during differentiation of MoDCs (Supplementary Figure 
2B), we selected day 3 MoDCs for further experiments.
Next, we investigated the CLEC12A internalization potential of day 3 MoDCs, BDCA1+ 
mDCs, BDCA3+ mDCs and pDCs using flow cytometry. Following incubation at 37°C, 
CLEC12A was quickly and efficiently internalized by all DC types (Figure 1B). Although, 
CLEC12A expression was lower on pDCs than on mDCs, their CLEC12A internalization 
efficacy was similar. These findings were confirmed by confocal microscopy. At start, 
CLEC12A was located on the plasma membrane and co-stained with MHC-II molecules 
(Figure 1C). Notably, after 1 hour incubation at 37°C, all DC types showed clear clusters 
of CLEC12A in intracellular compartments with hardly any CLEC12A expression on the 
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Figure 1. CLEC12A is highly expressed and efficiently internalized by human DC subsets. (A) CLEC12A 
expression on day 3 MoDCs and BDCA1+ mDCs, BDCA3+ mDCs and pDCs was analyzed by flow cytometry. 
Open black histograms correspond to cells stained with CLEC12A, while filled gray histograms represent the 
isotype control. Numbers in the plots represent the mean fluorescence intensity. Data of one representative 
donor out of 3 is shown. (B) Day 3 MoDCs and mDCs and pDCs were labeled with αCLEC12A, followed by 
0-90 minutes incubation at 37°C. Surface expression of bound αCLEC12A was analyzed by flow cytometry 
following labeling with goat-anti-mouse IgG. CLEC12A internalization is calculated relative to the surface 
expression at start based on the mean fluorescence intensity (MFI). Data are shown as mean ± SEM of 3 
independent experiments. (C) Confocal analysis of CLEC12A internalization in day 3 MoDCs and FACS-
sorted BDCA1+ mDCs and pDCs. DCs were stained with mouse αCLEC12A, followed by labeling with Alexa 
Fluor-488-conjugated goat-anti-mouse IgG2b (green). Then, internalization was allowed for 1 hour at 37°C, 
with subsequent staining for extracellular MHC class II with mouse-anti-human HLA-DR/DP, followed by 
Alexa Fluor-564-conjugated goat-anti-mouse IgG2a (red). Scale bar length is shown in the figure.
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cell surface. These data demonstrate that human BDCA1+ mDCs, BDCA3+ mDCs, pDCs 
and day 3 MoDCs highly express CLEC12A and efficiently internalize this CLR following 
antibody targeting.
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Clathrin-independent CLEC12A translocation to the endosomal/lysosomal 
compartments
Intracellular fate and antigen release are essential parameters determining the efficacy of 
antigen processing and presentation by DCs. Therefore, we investigated the internalization 
mechanism and intracellular routing of CLEC12A. The classical pathway for receptor-
mediated endocytosis is dependent on clathrin-coated pits.36 The CLR DEC205 is 
known to internalize via this classical route. To evaluate whether the same endocytosis 
mechanism applies to CLEC12A, we disrupted clathrin-coated pits using hypertonic 
solution.32 Interference with clathrin-mediated uptake almost completely blocked DEC205 
internalization by day 3 MoDCs, BDCA1+ mDCs and pDCs (Figure 2A), while CLEC12A 
endocytosis was not affected. By means of sucrose washout, we could restore DEC205 
internalization, indicating that the observed effects are the result of the hypertonic milieu.
Next, we studied the intracellular routing of CLEC12A, in comparison to DEC205, in 
time on day 3 MoDCs by analyzing their co-localization with EEA-1, an early endosome 
marker, or LAMP-1, a marker of the late endosomal/lysosomal compartment. At start, 
both DEC205 and CLEC12A were localized on the cell membrane, yet already after 5 
minutes of endocytosis co-localization was observed with the early endosomes (Figure 
2B and Supplementary Figure 3). Notably, while DEC205 co-localization with the early 
endosomes was lost after 15 minutes, CLEC12A still co-localized with EEA-1. Gradually, 
both receptors routed to the lysosomes with clear co-localization at 60 minutes after 
internalization. These co-localization patterns were confirmed with the Manders 
coefficient (Figure 2C-F).
Together, these data demonstrate that, in contrast to DEC205, CLEC12A is not 
internalized via the classical clathrin-coated pits, but follows a distinct endocytosis 
pathway. Yet, the intracellular routing of both receptors appears highly similar, as both 
Figure 2 (on the left). Clathrin-independent CLEC12A translocation to the endosomal/lysosomal 
compartments. (A) Day 3 MoDCs, BDCA1+ mDCs and pDCs were labeled with αDEC205 or αCLEC12A and 
incubated for 30 minutes in isotonic or hypertonic (450mM sucrose) medium at 37°C. DEC205 and CLEC12A 
surface expression was assessed by flow cytometry following Alexa Fluor-647-conjugated goat-anti-mouse 
IgG staining. CLEC12A internalization is calculated relative to the surface expression at start based on the 
MFI. Data are shown as mean ± SEM of 3 independent experiments. (B) Confocal laser scanning microscopy 
analysis of DEC205 and CLEC12A internalization in day 3 MoDCs and co-localization with early endosomes 
and lysosomes in time. MoDCs were incubated with αDEC205 or αCLEC12A, followed by staining with Alexa 
Fluor-488-conjugated goat-anti-mouse IgG2b (green). Receptors were allowed to internalize for 0-60 minutes at 
37°C. Then, MoDCs were stained for membrane MHC-II molecules using αHLA-DR/DP, which was visualized 
with Alexa Fluor-564-conjugated goat-anti-mouse IgG2a (blue). Finally, MoDCs were permeabilized, stained 
for early endosomes (EEA-1) or late endosomes (LAMP-1), whereupon visualization with Alexa Fluor-647-
conjugated goat-anti-rabbit IgG was performed (red). Images were acquired on a Olympus FV1000 Confocal 
laser scanning microscope, 60× oil objective (NA, 1.47). Data of one representative donor out of 3 independent 
experiments is shown. The size of the scale bar is 5μm. (C-F) The Manders coefficient was calculated for 
CLEC12A or DEC205 co-localization with EEA-1 or LAMP-1 using Image J V1.46R and quantified with 
JACoP plugin V2.1.1. Data are shown as mean ± SEM of 3 independent donors where ≥10 cells were analyzed 
per condition/donor. Data were analyzed using one-way ANOVA followed by a Bonferroni post-hoc test, *P 
<0.05, **P <0.01, ***P <0.001.
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co-localize with the early endosome after internalization and subsequently route to the 
lysosomes.
CLEC12A targeting does not affect DC maturation and T cell stimulatory capacity
As CLEC12A contains an ITIM motif in its cytoplasmic tail, it might function as an 
inhibitory receptor upon triggering. Therefore, we investigated whether CLEC12A 
antibody binding, alone or in combination with different maturation stimuli, modulated 
DC phenotype or function. CLEC12A antibody binding by itself did not affect expression 
levels of maturation marker CD83, co-stimulatory molecules CD80/CD86, co-inhibitory 
ligand PD-L1 nor HLA-DR (Figure 3A). Furthermore, 48 hours incubation of αCLEC12A 
labeled MoDCs in the presence of conventional cytokines, LPS, Poly(I:C) or R848 did not 
influence expression levels of DC maturation markers (Figure 3B), as compared to isotype 
control treated DCs. Additionally, CLEC12A antibody binding did not affect production 
of the immunoregulatory cytokine IL-10 nor the pro-inflammatory cytokine TNF-α 
(Figure 3C). In contrast, we observed an almost 2-fold increase in IL-6 secretion by LPS- 
and cytokine-matured MoDCs following CLEC12A targeting, as compared to isotype 
control treatment. Importantly, the capacity of mature MoDCs to promote allogeneic 
T cell proliferation and IFN-γ secretion was not affected by CLEC12A targeting (Figure 
3D,F). These data indicate that CLEC12A antibody targeting does not negatively affect 
DC maturation, phenotype, nor T cell stimulatory potential.
CLEC12A efficiently delivers KLH into DCs, resulting in potent CD4+ T cell recall 
responses
As CLEC12A is efficiently internalized and antibody binding does not affect DC function, 
we next investigated whether CLEC12A could be used for antigen delivery. Hereto, 
DC subsets were labeled with CLEC12A-biotin and αbiotin/KLH conjugates, matured 
and then co-cultured with patient PBMCs containing KLH-experienced CD4+ T cells. 
CLEC12A-mediated KLH delivery into day 3 MoDCs resulted in a 2-fold increase of 
CD4+ T cell proliferation (Figure 4A) and enhanced IFN-γ production (Figure 4B) as 
compared to isotype control treatment. Importantly, CLEC12A-mediated KLH uptake 
and release into BDCA1+ mDCs showed superior induction of KLH-specific T cell 
proliferation (Figure 4C). Moreover, these T cells secreted high levels of IFN-γ (Figure 
4D). Interestingly, despite lower CLEC12A expression, CLEC12A-mediated KLH delivery 
in pDCs efficiently promoted proliferation and IFN-γ production of KLH-experienced 
T cells (Figure 4E,F). Although, T cell proliferation was lower in pDC co-cultures as 
compared to mDC co-cultures, IFN-γ levels were equal in both co-cultures, indicating that 
pDC stimulation promotes higher IFN-γ secretion per T cell. These data demonstrate that 
CLEC12A efficiently enables KLH uptake, and its subsequent processing and presentation 
in MHC-II molecules, eliciting productive CD4+ T cell activation and proliferation.
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Figure 3. CLEC12A ligation does not negatively affect DC function. Day 3 MoDCs were incubated for 48 
hours with αCLEC12A or hIgG1 isotype control in the absence or presence of different maturation stimuli. 
(A) Expression of CD83, CD80, CD86, PD-L1 and HLA-DR on non-matured CLEC12A antibody-treated 
(black line) or isotype-treated (dark grey line) MoDCs was determined by flow cytometry. Isotype controls 
for the respective maturation markers are depicted in light grey. Data of one representative donor out of 4 
independent experiments is shown. (B) Relative expression of the DC maturation markers CD83, CD80, CD86 
and CCR7 and (C) relative secretion of IL-6, IL-10 and TNF-α for antibody-treated MoDCs cultured with 
various maturation stimuli. Data are calculated for αCLEC12A-treated cells relative to cells incubated with 
hIgG1 (αCLEC12A/IgG). Graphs show the median with range of 7 independent experiments. (D-F) Mature 
αCLEC12A (black lines/circles) or isotype-treated (grey lines/white circles) MoDCs were co-cultured with 
allogeneic CFSE-labeled T cells at a ratio of 1:10 for 5 days. Subsequently, T cell proliferation was determined 
by flow cytometry and IFN-γ secretion by ELISA. (D) Representative histograms show CSFE dilution of CD4+ 
and CD8+ T cells of one T cell donor out of 4 donors. (E) CD3+CD4+ and CD3+CD8+ T cell proliferation and 
(F) IFN-γ secretion of 4 different T cell donors tested. Data were analyzed using one-way ANOVA followed 
by a Bonferroni post-hoc test, *P <0.05.
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CLEC12A-targeted long peptide is efficiently cross-presented by natural DC subsets 
to CD8+ T cells
For effective boosting of anti-tumor immunity, cross-presentation of internalized tumor 
antigens to cytotoxic CD8+ T cells is essential.37 Therefore, we investigated whether 
CLEC12A-mediated delivery of MiHA long peptide leads to effective cross-presentation 
by BDCA1+ mDCs, BDCA3+ mDCs and pDCs. For this, DC subsets were labeled with 
αCLEC12A/HA-1 or αDEC205/HA-1 conjugates. Subsequently, DCs were matured and co-
Figure 4. CLEC12A-dependent antigen uptake leads to antigen presentation by different human DC subsets. 
(A-B) Day 3 MoDCs were labeled with αCLEC12A or mIgG2b isotype control, followed by labeling with 
biotinylated goat-anti-mouse IgG, and subsequently targeted with KLH-conjugated αbiotin. Next, MoDCs 
were matured for 48 hours with the conventional cytokines, harvested and co-cultured at 1:10 ratio with 
CFSE-labeled KLH-responsive PBMCs. (A) After 4 days of culture, CD4+ T cell proliferation was analyzed by 
flow cytometry. The mean ± SD of triplicate measurements is shown for one representative patient, out of 3 
patients. (B) IFN-γ levels at day 4 of co-culture were determined on pooled supernatant using CBA. Data of 1 
representative patient is shown. (C-F) FACS-sorted BDCA1+ mDCs or pDCs were incubated with biotinylated 
αCLEC12A or hIgG1 isotype control and subsequently targeted with KLH-conjugated αbiotin. DCs were 
matured overnight and subsequently co-cultured with CFSE-labeled KLH-responsive PBMCs at a 1:10 ratio. 
(C,E) CD4+ T cell proliferation was measured by flow cytometry and (D,F) IFN-γ production was analyzed 
by ELISA after 4 days of co-culture with (C,D) BDCA1+ mDCs or (E,F) pDCs. The mean ± SD of triplicate 
measurements is shown of two out of three representative patients. Data were analyzed using one-way ANOVA 
followed by a Bonferroni post-hoc test, *P <0.05, ***P <0.001.
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Figure 5. CLEC12A-delivered HA-1 long peptide is efficiently cross-presented by BDCA1+ mDCs, BDCA3+ 
mDCs and pDCs. FACS sorted BDCA1+ mDCs, BDCA3+ mDCs and pDCs were incubated with long HA-1 
peptide chemically conjugated to αCLEC12A (αCLEC12A/HA-1) or αDEC205 (αDEC205/HA-1). As negative 
controls, DCs were not labeled (DC-), labeled with isotype/HA-1 conjugates, or the specific conjugate in the 
presence of excess unconjugated antibody (blocked αCLEC12A/HA1 or αDEC205/HA1). As positive control, 
DCs were pulsed with 1µM short HA-1 peptide. BDCA1+ mDCs, BDCA3+ mDCs and pDCs were subsequently 
matured overnight, followed by 24 hour co-culture with HA-1-TCR transduced T cells (between 40% and 66% 
HA-1-tetramer positive, data not shown) at a ratio of 1:1. T cell activation was assessed by determining the 
percentage of CD107a positive CD8+ T cells using flow cytometry, and by analysis of IFN-γ secretion using 
ELISA. (A) Dot plots show CD107a expression after co-culture with αCLEC12A/HA-1 targeted or non-targeted 
BDCA1+ mDCs of one representative donor. (B-D) Percentage of CD107a+CD8+ T cells and IFN-γ production 
after co-culture with (B) BDCA1+ mDCs, (C) pDCs targeted with αCLEC12A/HA-1 or αDEC205/HA-1 or (D) 
BDCA3+ mDCs targeted with αCLEC12A/HA-1. Data are depicted as the mean ± SD of triplo measurements of 
one representative donor. For the αCLEC12A/HA-1 conjugate n=6 (BDCA1+ mDC), n=5 (pDC) or n=1 (BDCA3+ 
mDC) independent experiments were performed. For αDEC205/HA-1 n=2 independent experiments were 
performed. Data were analyzed using one-way ANOVA followed by a Bonferroni post-hoc test, ***P <0.001.
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cultured with HA-1 TCR transduced CD8+ T cells. Notably, we confirmed specific binding 
of the αCLEC12A/HA-1 and αDEC205/HA-1 conjugates to BDCA1+ mDCs, BDCA3+ 
mDCs and pDCs using flow cytometry by staining the biotin-tag on the HA-1 long peptide 
with αbiotin-FITC (Supplementary Figure 4B). DCs labeled with either αCLEC12A/HA-1 
or αDEC205/HA-1 conjugate in the presence of excess unconjugated specific antibody 
or isotype/HA-1 conjugates were incapable of activating HA-1 TCR-transduced CD8+ T 
cells (Figure 5A-D and Supplementary Figure 4C). Importantly, CLEC12A- and DEC205-
mediated HA-1 delivery and cross-presentation by BDCA1+ mDCs, BDCA3+ mDCs 
and pDCs resulted in significant activation of HA-1 TCR-transduced CD8+ T cells, as 
demonstrated by significant up-regulation of the degranulation marker CD107a (Figure 
5A-D) and activation marker CD137 (Supplementary Figure 4C). Furthermore, DC subsets 
targeted with αCLEC12A/HA-1 or αDEC205/HA-1 conjugates efficiently promoted IFN-γ 
secretion, as compared to the controls (Figure 5B-D). Interestingly, CLEC12A and DEC205 
showed similar capacity to deliver antigens for cross-presentation and activation of HA-
1-specific CD8+ T cells.
To evaluate the efficacy of CLEC12A as an attractive target for facilitating antigen 
cross-presentation to patient-derived T cells, we stimulated PBLs of alloSCT patients 
containing HA-1-reactive CD8+ memory T cells with BDCA1+ mDCs (Figure 6A) or 
pDCs (Figure 6B) loaded with the αCLEC12A/HA-1 conjugates or short HA-1 peptide (i.e. 
positive control). After 7 days of co-culture, increased percentages of HA-1-specific CD8+ 
memory T cells were observed as compared to stimulation with non-peptide loaded DCs. 
Moreover, when DCs were labeled with the αCLEC12A/HA-1 conjugate in the presence of 
excess unconjugated αCLEC12A, no increase in the percentage of HA-1-specific CD8+ T 
cell was observed. Furthermore, also augmented absolute numbers of HA-1-specific CD8+ 
T cells were detected upon stimulation with BDCA1+ mDCs (Figure 6C) or pDCs (Figure 
6D) labeled with the αCLEC12A/HA-1 conjugates or short HA-1 peptide. Collectively, 
these findings demonstrate that CLEC12A effectively mediates HA-1 long peptide delivery 
and cross-presentation by BDCA-1+ mDCs and pDCs, resulting in strong activation of 
HA-1-reactive CD8+ T cells of patients after alloSCT.
Discussion
Although the immune system is capable of eliciting tumor-reactive immune responses, 
the magnitude and functionality of these responses is often inadequate.38,39 Therefore, 
powerful strategies are needed to boost anti-tumor immunity in order to prevent disease 
progression. As DCs are the most powerful antigen-presenting cells, they are highly 
attractive vehicles for boosting T cell responses.40,41 An appealing strategy to employ the 
specialized functions and cross-talk of natural DC subsets and exploit their potent antigen 
processing and presentation machinery is targeted delivery of tumor antigens in vivo 
via endocytic receptors.24,25,42 In this study, we evaluated the potential of CLEC12A, an 
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endocytic CLR, as a new targeting candidate for simultaneous antigen delivery into all 
human DC subsets.
We confirmed that the expression pattern of CLEC12A is restricted to hematopoietic 
cells of myeloid origin, including monocytes, granulocytes, BDCA1+ mDCs, BDCA3+ 
mDCs and pDCs, as has been reported by others.26,43 Next, we demonstrated that CLEC12A 
is efficiently internalized by all human DC subsets. Most CLRs, such as DCIR44, DC-Sign45 
and DEC20521 endocytose via the classical clathrin pathway. Interestingly, CLEC12A 
endocytosis was not affected in hypertonic conditions, indicating that its mechanism of 
internalization does not involve clathrin-coated pits. Alternatively, similar to Langerin 
(CD207),46 CLEC12A might be endocytosed via the caveolin pathway. However, so far 
we were not able to demonstrate caveolin involvement in CLEC12A internalization (data 
Figure 6. CLEC12A-delivered HA-1 long peptide is efficiently cross-presented by BDCA1+ mDCs and 
pDCs to stimulate patient CD8+ T cells. FACS-sorted BDCA1+ mDCs and pDCs were incubated with long 
HA-1 peptide chemically conjugated to αCLEC12A (i.e. αCLEC12A/HA-1 conjugate). As controls, DCs were 
not labeled (DC-) or labeled with the conjugate in the presence of excess unconjugated αCLEC12A (blocked 
αCLEC12A/HA1; negative control) or with 1µM short HA-1 peptide (positive control). BDCA1+ mDCs and 
pDCs were subsequently matured overnight, and co-cultured with patient PBLs at a ratio of 1:5. At day 7, the 
expansion of HA-1-specific CD8+ memory T cells was assessed by determining the percentage HA-1 tetramer-
positive CD8+ T cells and absolute counts. (A-B) Dot plots show the percentage of HA-1 tetramer-positive CD8+ 
T cells out of total CD8+ T cells after co-culture with αCLEC12A/HA-1 targeted or control (A) mDCs or (B) 
pDCs. (C-D) Absolute number of HA-1-specific CD8+ T cells after co-culture with (C) mDCs or (D) pDCs; 
one out of two donors is shown.
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not shown). Next to the capacity to internalize, the intracellular fate and cargo release 
are key parameters determining the suitability and efficacy of CLEC12A for targeted 
antigen delivery and presentation via MHC-I and MHC-II molecules. In general, 
receptor/antigen trafficking to the lysosomes is considered to result in loading onto 
MHC-II molecules and subsequent CD4+ T cell activation.47 Whereas pre-lysosomal 
localization has been postulated to be more favourable for antigen processing and cross-
presentation via MHC-I molecules to CD8+ T cells.48-52 Nevertheless, DEC205, which 
quickly routes to the lysosomes, can efficiently facilitate antigen cross-presentation.52-55 
To elucidate the intracellular fate of CLEC12A we performed co-localization studies. 
CLEC12A and DEC205 showed similar intracellular routing: initial co-localization with 
the early endosomes, followed by further trafficking to the lysosomes where they were 
retained. However, CLEC12A co-localization with the early endosomes lasted longer. In 
accordance, Begun et al. recently reported CLEC12A co-localization with Rab5 another 
early endosome marker.28 These findings suggest that CLEC12A might provide a good 
window for endosomal escape of targeted antigen, thereby facilitating effective cross-
presentation.
CLRs are known to shape immune responses via the signaling motifs in their 
cytoplasmic tails or via the association with adaptor molecules that elicit downstream 
signaling cascades. CLEC12A contains an inhibitory ITIM motif in its cytoplasmic tail. 
Recently, Neumann et al. identified that CLEC12A expressed on neutrophils is involved in 
controlling sterile inflammation.27 They discovered that CLEC12A, upon triggering by uric 
acid crystals, inhibits Syk-dependent reactive oxygen species production, thereby limiting 
infiltration of immune cells to the site of damage. In contrast, Chen et al. observed positive 
as well as negative effects on DC phenotype and function upon αCLEC12A binding, 
dependent on the type of TLR activation.29 In this report, we showed that binding of 
our αCLEC12A did not promote DC maturation. Moreover, no effect on CD86, CD80, 
CD83 or CCR7 expression was observed following αCLEC12A binding in combination 
with different maturation stimuli. In contrast, Chen et al. observed increased expression 
of CCR7 following αCLEC12A ligation in combination with TLR4 stimulation.29 These 
opposite findings might be attributed to differences in epitope recognition of the used 
antibodies or isotype-related effects. Surprisingly, we observed augmented IL-6 secretion 
upon CLEC12A targeting in the presence of conventional cytokine maturation or LPS-
mediated TLR-4 stimulation. Despite this effect on IL-6 secretion, no difference in 
allogeneic T cell stimulatory capacity was observed for αCLEC12A versus isotype control-
treated MoDCs.
Because of its efficient internalization capacity and the lack of negative effects following 
antibody binding, we consider CLEC12A to be an interesting candidate for targeted antigen 
delivery into DCs. Importantly, we demonstrated that targeted delivery via CLEC12A 
enabled KLH presentation onto MHC-II molecules of human BDCA1+ mDCs, pDCs 
and MoDCs, thereby promoting profound proliferation and IFN-γ secretion by KLH-
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experienced CD4+ T cells. Furthermore, we provided the first mechanistic evidence that 
human mDCs and pDCs are capable of cross-presenting natural tumor antigens delivered 
via CLEC12A, facilitating strong activation of tumor-reactive CD8+ T cells of cancer 
patients. Although data on the BDCA3+ mDC are merely indicative as experiments were 
only performed for one donor. Previously, Lahoud et al. reported induction of humoral 
and cellular immune responses after CLEC12A-mediated ovalbumin delivery into mouse 
antigen presenting cells in vivo.30,31 Yet, they demonstrated CLEC9A and DEC205 to be 
more effective targets than CLEC12A. In contrast, in our studies CLEC12A performed 
equally good as DEC205 in antigen cross-presentation assays by human DC subsets. These 
opposing findings could possibly be attributed to differences in epitope recognition of 
the used antibodies and functionality after cargo conjugation, conjugation efficiency, or 
related to differences in the murine and human model systems.
In addition to other CLRs for which antibodies are currently in phase I/II clinical 
investigation, CLEC12A holds great promise for future cargo delivery applications. 
Using nanoparticles combined delivery of tumor antigens and immunomodulatory 
agents, such as TLR ligands or siRNA against co-inhibitory molecules, could be realized 
to further improve DC immunogenicity in vivo. Previously, we showed that silencing 
the co-inhibitory molecules PD-L1/L2 on DCs resulted in superior T cell stimulatory 
potential.56,57 Another interesting application for CLEC12A targeted cargo delivery is 
in the setting of acute myeloid leukemia and myeloid dysplastic syndrome. CLEC12A 
is differentially expressed by myeloid leukemia stem cells and blasts, but not by healthy 
hematopoietic stem cells.43,58 By favourably modulating the immunogenicity of leukemic 
stem cells and blasts, more powerful tumor-reactive T cell responses could be elicited.
In conclusion, we showed that human BDCA1+ mDCs, BDCA3+ mDCs, pDCs and ex 
vivo generated MoDCs highly express CLEC12A. CLEC12A is efficiently internalized via 
a clathrin-independent mechanism and is quickly translocated from the early endosomes 
to the lysosomes. Notably, we did not observe negative effects of CLEC12A antibody 
binding on DC phenotype or functionality. Most importantly, we demonstrated that 
CLEC12A targeted antigen delivery results in potent activation of KLH-reactive CD4+ 
T cell responses and highly effective cross-presentation to HA-1-reactive CD8+ T cells of 
alloSCT patients. These data indicate that CLEC12A is an attractive candidate for in vivo 
targeting of human DC subsets with tumor antigens, thereby employing the specialized 
functions and cross-talk of these DCs to boost tumor-reactive T cell immunity in cancer 
patients.
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Supplementary Figure 1. Flow cytometry gating 
strategies for human DC subsets. (A) Gating 
strategy for flow-assisted cell sorting of BDCA1+ 
mDCs, BDCA3+ mDCs and pDCs from leukapheresis 
products. First, single cell leukocytes were gated using 
forward- and sideward-scatter characteristics. Then, 
CD14- and CD19-negative cells were selected. Finally, 
BDCA1+ mDCs were defined as CD11c+BDCA1+ 
cells, and BDCA3+ mDCs as CD11c+ BDCA3+ cells. 
pDCs were characterized based on BDCA2+ and 
CD123+. Density dot plots of one representative 
donor are shown. (B) For phenotypical analyses 
and functional experiments, DC subsets were gated 
as follows: leukocytes were defined by forward-and 
sideward-scatter characteristics, and single cells were 
gated using time of flight (TOF). Next, dead cells 
were excluded using sytox blue staining. BDCA1+ 
mDCs were defined as CD11c+BDCA1+ cells, and 
BDCA3+ mDCs as CD11c+ BDCA3+ cells. pDCs were 
characterized as BDCA2+CD123+. Density dot plots 
of one representative donor are shown.
Supplementary Figure 2. Expression of CLEC12A 
is limited to cells of myeloid origin and immature 
MoDC. (A) Expression of CLEC12A on CD8+ T 
cells, CD4+ T cells, B cells, NK cells, monocytes, 
BDCA1+ mDCs, pDCs and granulocytes was 
analyzed using flow cytometry. Data are expressed 
as ΔMFI, N=5 healthy donors. Lines indicate the 
mean. (B) Expression of DEC205 and CLEC12A 
during MoDC differentiation was analyzed by flow 
cytometry. MoDCs were analyzed at the immature 
stage (day 3 and day 7), and after maturation with 
conventional cytokines (day 9). Expression of 
DEC205 and CLEC12A is shown in black lines, and 
the corresponding isotype controls are depicted in 
light grey. Numbers in the plots represent the mean 
fluorescence intensity. Data of one representative 
donor out of 3 independent experiments is shown.
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Supplementary Figure 3. CLEC12A co-localization with the endosomal/lysosomal compartments. Confocal 
laser scanning microscopy analyses of DEC205 (A,C) and CLEC12A (B,D) internalization in day 3 MoDCs 
and co-localization with early endosomes (A,B) and lysosomes (C,D) in time. MoDCs were incubated with 
αDEC205 or αCLEC12A, followed by staining with Alexa Fluor-488-conjugated goat-αmouse IgG2b (green). 
Receptors were allowed to internalize for 0-60 minutes at 37°C. Then, MoDCs were stained for membrane 
MHC-II molecules using anti-HLA-DR/DP, which was visualized with Alexa Fluor-564-conjugated goat-
αmouse IgG2a (blue). Finally, MoDCs were permeabilized, stained for early endosomes (EEA-1) or late 
endosomes (LAMP-1), whereupon visualization with Alexa Fluor-647-conjugated goat-αrabbit IgG was 
performed (red). Images were acquired on a Olympus FV1000 Confocal laser scanning microscope, 60x 
oil objective (Numerical Aperture, 1.47) and were analyzed using Image J V1.46R software. Data of one 
representative donor out of 3 independent experiments is shown. The size of the scale bar is 5μm.
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Supplementary Figure 4. αCLEC12A/HA-1 and αDEC205/HA-1 long peptide conjugates are efficiently 
generated, and specifically deliver antigen for cross-presented by human mDCs and pDCs. (A) To compare 
conjugation efficiency of HA-1 long peptide to αCLEC12A, αDEC205, hIgG1 and mIgG2b isotype controls, 
a direct ELISA was performed. For this, titrated concentrations of conjugated antibody/HA-1 constructs 
were allowed to adhere overnight to Nunc high immuno absorbance plates (Thermo scientific, Roskilde, 
Denmark). As the HA-1 long peptide has a biotin tag, conjugation efficiency was subsequently determined by 
incubation with streptavidin-HRP (Sanquin), followed by a color reaction with 3,3’,5,5’-Tetramethylbenzidine 
(TMB) peroxidase substrate solution (KPL, Gaithersburg, MD, USA). This enzymatic reaction was stopped 
with 1M H3PO4 (Merck) and absorbance was measured at 450 nm. Graphs show αCLEC12A and αDEC205 
conjugates (closed symbols), or isotype control conjugates (open symbols). (B) Binding efficacy of the antibody/
HA-1 conjugates was determined by flow cytometry. PBMCs of healthy donors were incubated with 1 mg/
mL total human IgG (sanquin) to block Fc-receptors, followed by staining with 10 µg/mL αCLEC12A/HA-1 
or αDEC205/HA-1 (green lines) or the corresponding isotype/HA-1 (black line) conjugates. As a control for 
specificity, 10x excess unconjugated αCLEC12A or αDEC205 (red line) was added to block specific binding prior 
to incubation with antibody/HA-1 conjugates. Finally, binding of antibody/HA-1 construct was visualized by 
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addition of αbiotin-FITC. Light grey lines in histograms depict staining with αbiotin-FITC alone. (C) BDCA1+ 
mDCs and pDCs were incubated αCLEC12A/HA-1 or αDEC205/HA-1 long peptide conjugates. As negative 
controls, DCs were not labeled (DC-), labeled with corresponding isotype control/HA-1 conjugates, or labeled 
with the antibody/HA-1 conjugate in the presence of excess unconjugated αCLEC12A or αDEC205 (blocked 
αCLEC12A/HA1 or αDEC205/HA1). As positive control, DCs were pulsed with 1µM short HA-1 peptide. 
BDCA1+ mDCs, and pDCs were subsequently matured overnight, followed by 24 hour co-culture with HA-1 
TCR transduced CD8+ T cells (between 40% and 66% HA-1-tetramer positive, data not shown) at a ratio of 
1:1. T cell activation was assessed by determining the percentage of CD107a- and CD137-positive CD8+ T cells 
using flow cytometry, and by analysis of IFN-γ secretion using ELISA. Data are depicted as the mean ± SD of 
triplo measurements of one representative donor. For the αCLEC12A/HA-1 conjugate n=6 (BDCA1+ mDC) 
or n=5 (pDC) independent experiments were performed. For αDEC205/HA-1 n=2 independent experiments 
were performed.
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Abstract
Early natural killer (NK) cell repopulation after allogeneic stem cell transplantation 
(alloSCT) has been associated with reduced relapse rates without an increased 
risk of graft-versus-host disease (GVHD), indicating that donor NK cells have 
specific anti-leukemic activity. Therefore, adoptive transfer of donor NK cells 
is an attractive strategy to reduce relapse rates after alloSCT. Since NK cells of 
donor origin will not be rejected, multiple NK cell infusions could be administered 
in this setting. However, isolation of high numbers of functional NK cells from 
transplant donors is challenging. Hence, we developed a cytokine-based ex vivo 
culture protocol to generate high numbers of functional NK cells from granulocyte 
colony-stimulating factor (G-CSF)-mobilized CD34+ hematopoietic stem and 
progenitor cells (HSPCs). In this study, we demonstrate that addition of aryl 
hydrocarbon receptor antagonist StemRegenin 1 (SR1) to our culture protocol 
potently enhances expansion of CD34+ HSPCs, and induces expression of NK 
cell-associated transcription factors promoting NK cell differentiation. As a result, 
high numbers of NK cells with an active phenotype can be generated using this 
culture protocol. These SR1-generated NK cells exert efficient cytolytic activity 
and IFN-γ production towards acute myeloid leukemia and multiple myeloma 
cells. Importantly, we observed that NK cell proliferation and function is not 
inhibited by cyclosporin A, an immunosuppressive drug often used after alloSCT. 
These findings demonstrate that SR1 can be exploited to generate high numbers of 
functional NK cells from G-CSF mobilized CD34+ HSPCs, providing great promise 
for effective NK cell based immunotherapy after alloSCT.
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Introduction
Natural killer cells (NK cells) are CD3-CD56+ lymphocytes, which are part of the innate 
immune system and play an important role in the defense against virus-infected and 
transformed cells. NK cell activation and subsequent killing of target cells is regulated 
by a balance in their expression levels of inhibitory receptors, including the killer-
immunoglobulin like receptors (KIRs) and CD94/NKG2A heterodimer, versus activating 
receptors, such as DNAX accessory molecule-1 (DNAM-1), natural cytotoxicity receptors 
(NCRs) and NKG2D. In homeostasis, NK cells are inhibited by their inhibitory receptors 
recognizing self human leukocyte antigen (HLA) class I molecules and/or HLA-E 
molecules presenting conserved HLA class I leader sequences. However, an NK cell-
mediated anti-tumor effect can be induced by upregulation of activating ligands or 
downregulation of HLA class I molecules on tumor cells. In addition, in the setting of 
haploidentical allogeneic stem cell transplantation (alloSCT), donor NK cells may lack 
expression of inhibitory KIRs for recipient HLA class I molecules and hence be activated. 
This phenomenon is called missing-self recognition and can contribute to the curative 
graft-versus-tumor (GVT) effect.1
Because of their ability to kill tumor cells, NK cells are considered potent effectors 
for adoptive immunotherapy against cancer. So far, promising results have been obtained 
by infusion of haploidentical NK cells after immunosuppressive chemotherapy in adult 
and childhood acute myeloid leukemia (AML).2-4 However, a limitation in these studies 
is the relatively low NK cell numbers that can be enriched from aphaeresis products for 
multiple infusions. Furthermore, contaminating allo-reactive T cells risk the induction 
of graft-versus-host disease (GVHD), especially when interleukin (IL)-2 or IL-15 are co-
administrated to boost NK cell survival and expansion. In order to generate high numbers 
of allogeneic NK cells completely devoid of T cell contamination, a Good Manufacturing 
Practice (GMP)-compliant, cytokine-based ex vivo culture protocol has been developed 
by our group.5,6 Using this procedure, CD34+ hematopoietic stem and progenitor cells 
(HSPCs) isolated from umbilical cord blood (UCB) can be expanded over 2000-fold in 
large-scale bioreactors into a mixture of immature and mature NK cells with a purity > 
80%. Pre-clinical studies conducted in NOD/SCID-IL2Rγnull mice demonstrated that 
these HSPC-NK cells have BM homing capacity, display IL-15-driven in vivo expansion, 
and prolong survival of leukemia-bearing mice.7 Currently, administration of this HSPC-
NK cell product following immunosuppressive chemotherapy is being investigated in a 
phase I clinical trial in older AML patients who are not eligible for alloSCT (see www.
trialregister.nl and search for 2818).
In HLA-matched non-myeloablative and T cell-depleted alloSCT, early NK cell 
repopulation has been associated with decreased relapse rates, without increasing GVHD 
incidence.8,9 Moreover, high NK cell numbers in stem cell grafts have been associated 
with a decreased incidence of GVHD.10 In addition, transplants from donors with 
KIR-B haplotypes, containing several activating KIRs, led to lower rates of relapse and 
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improved survival.11-13 For these reasons, it would be highly valuable to exploit HSPC-NK 
cell products for adoptive immunotherapy after alloSCT. Since NK cells of donor origin 
will not be rejected, multiple NK cell infusions without the need for immunosuppressive 
chemotherapy to prevent rejection, could be administered after alloSCT. Consequently, 
these cells may potentially induce long-term GVT effects. However, to obtain large 
numbers of NK cells from donor origin, peripheral blood (PB) or bone marrow (BM)-
derived CD34+ HSPCs, which have a lower expansion potential compared to UCB-derived 
CD34+ HSPCs, should be expanded and differentiated into NK cells.
Recently, it was described that expansion of CD34+ HSPCs can be enhanced by 
inhibition of the aryl hydrocarbon receptor (AhR) using the antagonist StemRegenin 1 
(SR1).14 AhR is a ligand-inducible transcription factor, which plays an important role in 
biological responses towards xenobiotic agents such as digoxin.15,16 Yet, it has become clear 
that AhR also has multiple naturally occurring ligands, like tryptophan metabolites and 
dietary compounds.15 Furthermore, AhR turned out to regulate differentiation of multiple 
immune cells including dendritic cells,17,18 regulatory T cells,19,20 γδ T cells,21 Th17 cells22 
and notably NK cells.23 Based on these findings, we hypothesized that addition of SR1 to 
our culture system might improve expansion of CD34+ HSPCs, and differentiation of these 
cells into NK cells. We found that SR1 not only enhances expansion of CD34+ HSPCs, 
but also upregulates the expression of early and late NK cell specific transcription factors, 
thereby potentiating differentiation of SR1-expanded CD34+ cells into NK cells. These 
SR1-induced NK cells have a high purity, express high levels of activating receptors and 
efficiently target AML and multiple myeloma (MM) cells. Importantly, proliferation and 
cytolytic functions of SR1-induced HSPC-NK cells are not inhibited by cyclosporin A 
(CsA), in contrast to mycophenolic acid (MPA), which is used only shortly after alloSCT, 
facilitating multiple infusions relatively shortly after alloSCT. Therefore, our SR1 culture 
system holds great promise for future donor HSPC-NK cell adoptive immunotherapy after 
alloSCT to boost anti-tumor and anti-viral immunity, leading to prolonged relapse-free 
survival.
Materials and Methods
Cell lines
Cell lines (K562, THP1, HL-60, U266, UM9, RPMI8226) were cultured in Iscove-
modified Dulbecco medium (IMDM; Invitrogen, Carlsbad, CA, USA) containing 50 U/
mL penicillin, 50 µg/mL streptomycin and 10% fetal calf serum (FCS; Integro, Zaandam, 
The Netherlands).
Isolation of CD34+ stem and progenitor cells
Bone marrow samples were collected from healthy donors after written informed consent. 
Bone marrow-derived mononuclear cells were isolated by Ficoll-hypaque (1.077 g/mL; GE 
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Healthcare, Uppsala, Sweden) density gradient centrifugation. Peripheral blood-derived 
mononuclear cells were obtained from aphaeresis material from stem cell donors who 
were treated with granulocyte colony-stimulating factor (G-CSF; Neupogen®) 10 µg/kg/
day subcutaneously for 5 to 6 days, after written informed consent. CD34+ HSPCs were 
isolated using anti-CD34 immunomagnetic beads (Miltenyi Biotech, Bergisch Gladbach, 
Germany) according to manufacturer’s instructions. CD34+ HSPCs were directly used 
for NK cell generation.
Ex vivo expansion of CD34+ HSPCs, and differentiation into NK cells
CD34+ HSPCs were plated into 24-well or 6-well tissue culture plates (Corning 
Incorporated, Corning, NY, USA). Cells were expanded during 9 or 10 days with a high-
dose cytokine cocktail (Expansion cocktail I) consisting of 25 ng/mL IL-7 (Immunotools), 
25 ng/mL SCF (stem cell factor, Immunotools), 25 ng/mL TPO (thrombopoietin, 
Cellgenix) and 25 ng/mL Flt3L (FMS-like tyrosine kinase 3 ligand, Immunotools). From 
day 9 or 10 until day 14 or 15, TPO was replaced by 20 ng/mL IL-15 (Miltenyi). After 
day 14 or 15, cell differentiation was initiated by replacing Expansion cocktail I by a 
new high-dose cytokine cocktail (Differentiation cocktail) consisting of 20 ng/mL IL-7, 
20 ng/mL SCF, 20 ng/mL IL-15 and 1000 U/mL IL-2 (Proleukin®; Chiron, München, 
Germany). Where mentioned, 2 µM SR1 (Cellagen Technology, San Diego, CA, USA) 
was added to the culture medium (see Figure 1A). Cells were cultured in Cellgro GMP 
DC medium (Cellgenix, Freiburg, Germany) supplemented with 10% human serum 
(HS; Sanquin Bloodbank, Nijmegen, The Netherlands) and a low dose cytokine cocktail 
consisting of 250 pg/mL G-CSF (Filgrastim, “Neupogen” - Amgen Corp. USA), 10 pg/
mL GM-CSF (granulocyte-macrophage colony-stimulating factor) and 50 pg/mL IL-6 
(both Immunotools, Friesoythe, Germany). During the first 14 or 15 days of culture, low 
molecular weight heparin (Clivarin®; Abbott, Wiesbaden, Germany) was added to the 
medium in a final concentration of 20 µg/mL. Freshly isolated CD34+ cells were plated at 
a concentration of 1 – 4 x 105/mL. After 3 days of culture, cells were transferred to a new 
plate in order to deplete for stromal cells. From day 14 or 15 onward, cell counts were kept 
above 2 x 106 cells/mL. Cell cultures were refreshed with at least 30% new medium every 
2 to 3 days. Cultures were maintained at 37˚C, in 95% humidity, and 5% CO2. NK cells 
were used in experiments after 5 weeks of culture.
RNA isolation and real-time quantitative reverse transcriptase polymerase chain 
reaction (qRT-PCR)
Total RNA from 0.5 - 2 x 105 cells, collected weekly from HSPC-NK cell cultures, was 
isolated using the Quick-RNATM MicroPrep Kit (Zymo Research, CA, USA). Next, cDNA 
was synthesized using M-MLV-reverse transcriptase (Invitrogen) in a standard reaction as 
described earlier24, after which real-time PCR was performed using the following Taqman 
Gene expression assays (Applied Biosystems, Forster City, CA, USA): AhRR (Hs01005075_
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m1); TOX (Hs01055573_m1); ID2 (Hs04187239_m1); EOMES (Hs00172872_m1); GATA3 
(Hs00231122_m1); SH2D1B (Hs01592483_m1); IFNG (Hs00989291_m1); GZMB 
(Hs01554355_m1); PRF1 (Hs99999108_m1). For all genes, Ct values were normalized to 
GAPDH (Hs02758991_g1) by calculating ΔCt = Cttarget gene – CtGAPDH per sample. Finally, 
gene expression levels were quantified relative to GAPDH as follows: 2^(-[ΔCt]).
Flow cytometry (FCM)
Cell numbers and expression of cell-surface markers were determined by FCM. Anti-
human CD45-ECD (J.33, Beckman Coulter, Woerden, The Netherlands) and anti-CD56-
PC7 (HCD56, Biolegend, San Diego, CA, USA) antibodies were used to follow cell number 
and NK cell differentiation during culture using the Coulter FC500 flow cytometer 
(Beckman Coulter). The population of viable CD45+ cells was determined by exclusion 
of 7-AAD (Sigma, St Louis, MO, USA) positive cells. For phenotypical analysis, cells were 
incubated with antibodies in FCM buffer (PBS/0.5% bovine serum albumin (BSA; Sigma) 
for 30 minutes at 4°C. After washing, cells were resuspended in FCM buffer and analyzed. 
The following conjugated monoclonal antibodies were used for NK cell phenotyping: 
anti-NKG2A-PE (Z199; Beckman Coulter), anti-DNAM-1-FITC (DX11; BD Biosciences 
Pharmingen, Breda, The Netherlands), anti-CD16-FITC (3G8), anti-CD3-FITC (UCHT1), 
anti-NKG2D-PE (1D11), anti-NKp30-PE (P30-15), anti-NKp44-PE (P44-8), anti-NKp46-
PD (9E5), anti-CD158b-PE (Dx27), anti-CD158e-PE (Dx9), anti-CD158a/h-PE (HP-MA4), 
anti-CD62L-PE (DREG56), anti-CD253-PE (RIK-2), anti-CXCR3-PE (G025H7), anti-
CXCR4-PE (12G5), anti-IgG1-PE (MOPC-21), anti-IgG2a-PE (MOPC-173), anti-IgG2b-PE 
(MCP-11), anti-IgG1-FITC (MOPC-21; all from Biolegend).
Fluorescence-activated cell sorting (FACS) of HSCP-NK cells
After 5 weeks of culture, CD56+ cells were isolated from the total cultured cells. For this 
purpose cells were stained for 15 minutes at 4°C using the appropriate concentration of 
anti-CD56-PECy7 (HCD56, Biolegend). Cells were washed and resuspended in FACS 
buffer at a concentration of 1.5 x 106/mL, and subsequently sorted at the FACS Aria Cell 
Sorter (BD Biosciences).
FCM-based cytotoxicity assays
Cell lines were labeled with 1 µM carboxyfluorescein diacetate succinimidyl ester (CFSE; 
Molecular Probes Invitrogen, Eugene, OR, USA) and primary AML blasts were labeled 
with 1.5 µM CFSE, both in a concentration of 1 x 107/mL for 10 minutes at 37°C. The 
reaction was terminated by adding an equal volume of FCS. After washing, cells were 
resuspended in IMDM/10% FCS to a final concentration of 3 x 105/mL. Target cells (3 x 
104) were co-cultured in triplicate with effector cells at different effector:target (E:T) ratios 
in a total volume of 200 µL IMDM/10% FCS in 96-wells round-bottom plates (Corning 
Incorporated). Effector cells and target cells alone were plated out in triplicate as controls. 
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In experiments with primary AML blasts, AML blasts were derived from bone marrow 
samples from 5 patients at the time of diagnosis and were supplemented with IL-3 (50 ng/
mL; Cellgenix), SCF (25 ng/mL), Flt3L (20 ng/mL), GM-CSF (100 ng/mL), G-CSF (100 
ng/mL) and IL-15 (5 ng/mL). To measure degranulation of NK cells, anti-CD107a-PC7 
Figure 1. SR1 enhances expansion of PB-derived CD34+ HSPCs and improves NK cell differentiation. 
(A) Representation of the ex vivo cytokine-based culture protocol used for the generation of NK cells. (B-D) 
Kinetics of differentiation (B) and expansion (C) of CD34+ HSPCs in our ex vivo culture protocol in the presence 
or absence of 2 µM SR1 in one representative donor, determined by FCM. (D) Summary of total expansion, NK 
cell yield (calculated by [total expansion x percentage of CD56+ cells]/100), and NK cell differentiation after 5 
weeks of culture in our ex vivo culture protocol in the presence or absence of 2 µM SR1 in 12 donors, determined 
by FCM. ** p<0.01, *** p<0.001, Wilcoxon matched-pairs signed rank test, Paired one-tailed student’s t-test.
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(H4A3, Biolegend) was added to the co-culture. After overnight co-culture at 37°C, 50 
µL supernatant was discarded and 50 µL Coulter® Isoton® II Dilutent containing 0.2 µL 
7-AAD was added instead. Cells were harvested and the number of viable target cells was 
quantified by FCM by gating on forward scatter and side scatter and exclusion of 7-AAD 
positive cells. Target cell survival was calculated as follows: % survival = ([absolute number 
of viable CFSE+ target cells co-cultured with NK cells]/[absolute number of viable CFSE+ 
target cells cultured in medium]) x 100%. The percentage specific lysis was calculated as 
follows: % lysis = (100-[% survival]), as described earlier by Jedema et al.25,26 Degranulation 
of NK cells during overnight co-culture was determined as the percentage of CD107a 
expressing cells measured by FCM.
Enzyme-linked immunosorbent assays (ELISA)
The production capacity of interferon (IFN)-γ and Granzyme B by NK cells were evaluated 
by ELISA according to manufacturer instructions (IFN-γ: Pierce Endogen, Rockfore, IL, 
USA; Granzyme B; Mabtech, Sweden). To this end, NK cells (1 x 105) were co-cultured in 
triplicate with target cells (1 x 105) in a total volume of 200 µL IMDM/10% FCS in 96-wells 
round-bottom plates (Corning Incorporated). NK cells alone were plated out in triplicate 
as controls. After incubation overnight at 37°C, 150 µL supernatant was collected and 
stored at -20°C until use.
Proliferation assays
HSPC-NK cells were cultured according to our culture protocol for 35 days. After 35 
days, NK cells were labeled with 1 µM CFSE as described previously. After staining, cells 
were resuspended in differentiation medium at a concentration of 2 x 106/mL and plated 
in duplicate in a 96-well plate. CsA (Biovision Incorporated, Milpitas, CA, USA) or MPA 
(Sigma-Aldrich, Zwijndrecht, The Netherlands) were added to final concentrations of 
0.01 to 1 µg/mL (CsA) or 0.1 to 10 µg/mL (MPA). Half of the medium containing MPA 
or CsA in the final concentration was refreshed every 2-3 days. After 7 days, cells were 
harvested. The number of viable target cells was quantified by FCM by gating on forward 
scatter and side scatter and exclusion of 7-AAD positive cells. Proliferation was analyzed 
by determining the CFSE dilution within CD56+ cells.
Statistical analysis
Results from different experiments are described as mean ± standard error of the mean 
(SEM). Statistical analysis was performed using a one-tailed paired student’s t-test, a two-
tailed unpaired student’s t-test or one-way ANOVA if values had a normal distribution 
(normality was determined using the Kolmogorov-Smirnov test). For values without 
normal distribution we used the Wilcoxon matched-pairs signed rank test. Differences 
were considered to be significant for p values <0.05.
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Results
SR1 enhances expansion of PB- and BM-derived CD34+ HSPCs and improves NK cell 
differentiation
In this study, we investigated whether NK cells could be generated in vitro from PB or 
BM-derived CD34+ HSPCs. We used the feeder-free culture protocol described in Figure 
1A, which was reported previously to generate high numbers of functional NK cells from 
UCB-derived CD34+ HSPCs.5,6 However, in our initial cultures using PB- or BM-derived 
HSPCs, expansion and differentiation were low, which was associated with high numbers 
of stroma-like cells observed in culture plates (data not shown). Therefore, we investigated 
transfer of non-adherent cells to a new culture plate after 3 days of culture. Although this 
resulted in much lower outgrowth of stromal cell layers in the culture plates, expansion 
and NK cell differentiation were still low. For that reason, we investigated whether addition 
of the AhR antagonist SR1 (2 µM), which is known to improve expansion of CD34+ 
HSPCs and to influence NK cell differentiation, could improve NK cell generation from 
HSPCs. Importantly, addition of SR1 strongly enhanced expansion of CD34+ cells from 
both PB-derived HSPCs (Figure 1), as well as BM-derived HSPCs (Supplementary Figure 
1A,B). Mean NK cell yield after 5 weeks of culture was 235 fold (range 115 – 904 fold; n 
= 10, Figure 1D) for G-CSF mobilized CD34+ cells, and 129 fold (range 33 – 301; n=4, 
Supplementary Figure 1B) for BM-derived CD34+ HSPCs. Interestingly, differentiation also 
improved by addition of SR1 to our cultures, resulting in a purity of 83% ± 9% for G-CSF-
mobilized CD34+ HSPCs, and 84% ± 18% for BM-derived CD34+ cells. The remaining 
non-NK cells in the cultures represented mainly CD14+ and/or CD15+ mature monocytic 
and myelocytic cells (11% ± 6%). A small frequency of CD34+ cells could also be detected 
at the end of the culture process (0.7% ± 0.4%). Most importantly, the amount of CD3+ T 
cells in the SR1-based NK cell cultures investigated was very low (0.1% ± 0.1%). Altogether, 
these data demonstrate that the AhR pathway negatively influences NK cell development, 
and that by combining SR1 with cytokine mixtures, high numbers of CD56+ NK cells can 
be generated from G-CSF-mobilized and BM-derived CD34+ HSPCs ex vivo. Since G-CSF-
mobilized CD34+ HSPCs are the main stem cell source for alloSCT, we concentrated on 
these HSPC-NK cells for further investigations.
SR1 influences expression of transcription factors important for NK cell 
differentiation and maturation
To gain insight into the molecular processes behind the SR1-enhanced differentiation 
of CD34+ HSPCs into NK cells, we analyzed the gene expression profile of several 
transcription factors that are described to be important for NK cell differentiation and 
maturation.27-31 To analyze the culture composition, we concomitantly determined the 
percentage of CD56+ cells in our cultures at different time points (Figure 2A). Next, we 
compared expression levels of several transcription factors in the presence or absence 
of SR1 in total cells at these time points in our ex vivo culture system (Figure 2B). We 
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observed efficient down regulation of AHR repressor (AhRR, i.e. direct target gene of AhR 
signaling14) in the presence of SR1, indicating that a concentration of 2 µM SR1 is sufficient 
for AhR inhibition. Interestingly, we observed higher expression of thymocyte selection-
associated HMG box factor (TOX), which is important in early NK cell differentiation,27 
from day 7 onward (Figure 2B,C). This suggests that SR1 increased the number of NK cell 
precursors, even before the induction of NK cell differentiation was initiated by addition to 
IL-15 to the culture, and before CD56 acquisition. Expression of ID2, which is important 
for NK cell maturation,28,29 was increased from day 14 onwards, after addition of IL-15 to 
the culture (Figure 2B). Eomesodermin (EOMES), another factor important for NK cell 
maturation, was upregulated from week three onward. Finally, expression of GATA-3 and 
Figure 2. SR1 reduces expression of AhRR and increases expression of several transcription factors 
important for NK cell differentiation and NK cell effector functions. Cells generated from CD34+ HSPCs 
in the presence or absence of SR1 were collected at different time points. (A) Kinetics of CD56 expression in 
the cultures used for weekly mRNA isolation were determined using FCM. Means ± SEM of 4 - 6 different 
donors. (B) Expression levels of AhRR and transcription factors relative to GAPDH at different time points 
during culture were determined using qRT-PCR. Means ± SEM of 4 - 6 different donors. (C) Expression levels 
of AhRR and TOX relative to GAPDH after 7 days of culture were determined using qRT-PCR. Means ± SEM 
of 6 different donors. (D) Expression levels of AhRR and transcription factors in CD56+ cells which were FACS 
sorted from cultures after 5 weeks of culture were determined using qRT-PCR. Means ± SEM of 4 different 
donors. *p<0.05. Paired one-tailed student’s t-test.
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Ewing’s sarcoma-associated transcript 2 (EAT-2; SH2D1B), required to develop cytotoxic 
functions,30,31 was increased in cells cultured in the presence of SR1 (Figure 2B).
To investigate whether the increased expression levels of these transcription factors 
reflected a difference between NK cells generated in the presence or absence of SR1, or 
resulted from the different composition of the cultures, CD56+ NK cells, generated in the 
presence or absence of SR1, were sorted by FACS from HSPC-NK cultures after 5 weeks. 
Subsequently, gene expression levels of the previously mentioned transcription factors 
were determined. We did not observe increased expression of the NK cell differentiation 
factors TOX, ID2 and EOMES suggesting that SR1 increases the number of NK cell 
progenitors resulting in more NK cells, but it does not intrinsically change HSPC-NK 
cells (Figure 2D). In addition, expression levels of GATA-3 and EAT-2 were similar in 
CD56+ NK cells cultured in the presence of SR1. Expression of GZMB and PERF was 
slightly higher, but not significantly increased. Furthermore, IFN-γ was not increased in 
NK cells cultured in the presence of SR1, but these cells were not exposed to target cells 
prior to mRNA analysis.
Collectively, these data demonstrate that addition of SR1 to our ex vivo culture system 
blocks function of AhR, resulting in the upregulation of several transcription factors that 
are required for NK cell differentiation and maturation.
SR1-generated HSPC-NK cells have an activated and mature phenotype
To further elucidate the effect of SR1 on NK cell activation status and function, we 
investigated the influence of SR1 on the phenotype of our ex vivo-generated CD56+ NK 
cells. After 35 days of culture in the presence of SR1, NK cell phenotype was analyzed using 
FCM (Figure 3A-D and Supplementary Figure 1C). SR1-generated NK cells expressed 
high levels of NKG2A, which indicates transition between stage 3 and stage 4 NK cell 
progenitors.32,33 CD16, important for antibody-dependent cell mediated cytotoxicity 
(ADCC), was expressed on 22.7 ± 2.6% of the CD56+ cells. Furthermore, we found high 
expression levels of the activating markers DNAM-1, NKG2D, NCRs, and TRAIL (tumor 
necrosis factor-related apoptosis-inducing ligand). Expression of KIRs was observed in 
a low percentage of CD56+ cells. However, expression levels were similar as observed 
for UCB-NK cells generated in our culture system.5,6,32 Importantly, our NK cells also 
expressed high levels of CD62L and chemokine (C-X-C motif) receptor 3 (CXCR3), 
which are involved in homing to the lymphoid organs and trafficking of NK cells towards 
inflammation in vivo.7,34,35 Interestingly, presence of CD62L, CXCR3, DNAM-1 and TRAIL 
were significantly higher in CD56+ cells generated in the presence of SR1 (Figure 3C,D). 
Increased expression of DNAM-1 and TRAIL suggests that NK cells generated in the 
presence of SR1 are more active as compared to NK cells generated in the absence of SR1. 
We did not find significant differences in expression of the other molecules in the cultures 
with SR1 compared to the cultures without SR1 (data not shown). Altogether, these results 
indicate that SR1-generated HSPC-NK cells consist of a mixture of immature and mature 
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Figure 3. NK cells generated in the presence of SR1 have an active and mature phenotype. NK cells were 
generated from CD34+ progenitor cells in the presence or absence of SR1. After 5 weeks a phenotypical analysis 
was performed by FCM. (A) Phenotype of a representative NK cell product. Density plot of live cells gated on 
forward scatter/ side scatter. (B) Expression level of several NK cell specific surface antigens on live CD56+ NK 
cells from 3 - 8 different donors (Mean ± SEM) are shown (C) Expression levels of NK cell-specific antigens 
on CD56+ NK cells generated in the presence (grey histograms) or absence (black histogram) of SR1 from one 
representative donor as compared to isotype controls (white histogram). Numbers represent % positive cells. 
(D) Expression levels of NK cell-specific antigens on CD56+ NK cells generated in the presence or absence of 
SR1 from 3 - 7 different donors (Mean ± SEM) are shown. *p<0.05, **p<0.01, Paired one-tailed student’s t-test.
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NK cells expressing various activating receptors, similarly to our previously described 
UCB-derived NK cells.6
SR1-generated HSPC-NK cells have efficient IFN-γ production capacity and cytolytic 
activity against AML and MM cells
Next, we investigated the functional activity of SR1-generated NK cells, and compared 
them with NK cells generated in the absence of SR1. After 5 weeks of culture, NK cell 
products were harvested and co-cultured overnight with AML or MM tumor cell 
lines. Target cell induced IFN-γ production was determined. We found that our SR1-
generated HSPC-NK cells have a good IFN-γ producing capacity, which is improved 
in cells generated in the presence of SR1 (Figure 4A). Subsequently, we compared the 
killing capacity of NK cells generated in the presence of absence of SR1. Therefore, 1 x 104 
CD56+ NK cells were co-cultured overnight with different AML cell lines. We observed 
significantly improved killing of K562 and HL-60 cells, and also a trend towards improved 
killing of THP-1 cells by SR1-generated NK cells (Figure 4B). To rule out an effect of 
non-NK cells in the cultures, we repeated the killing experiments using sorted NK cells. 
Therefore, CD56+ NK cells were sorted from the NK cell products after 5 weeks of culture. 
Next, NK cells were co-cultured overnight with AML or MM tumor cell lines as described 
earlier. Importantly, we also observed higher killing of K562, HL-60 and RPMI8226 cells 
by sorted SR1-generated NK cells (Figure 4C). In addition, granzyme B production was 
enhanced in SR1-generated HSPC-NK cells as compared to NK cells generated in the 
absence of SR1 (Figure 4D). These results indicate that addition of SR1 to our culture 
system not only increases the number of CD56+ cells we can generate, but also enhances 
the functional activity of the CD56+ NK cells.
To further confirm the functional activity of SR1-generated NK cells, we investigated 
degranulation of these cells after overnight co-culture with AML or MM tumor cell lines. 
We found marked degranulation of our SR1-generated NK cells upon co-culture with 
the different cell lines (Figure 4E,F). Most efficient degranulation was observed against 
major histocompatibility complex (MHC)neg K562 cells as well as the MHC-expressing 
AML cell line HL-60. We also observed marked degranulation upon co-culture with the 
MM cell lines U266 and RPMI8226. The MM cell line UM9 was the least potent cell line 
to induce degranulation.
Next, we performed cytotoxicity experiments using SR1-generated HSPC-NK cells 
harvested after 5 weeks of culture. For this, NK cells were co-cultured overnight with 
different CFSE-labeled AML (K562, HL-60 and THP-1) and MM (UM9, U266 and 
RPMI8226) cell lines. The next day, specific killing was determined by FCM. We observed 
very efficient killing of most AML and MM cell lines, even at an E:T ratio of 1:1 (Figure 
4G). Subsequently, we investigated whether patient-derived primary AML blasts were 
susceptible to killing by SR1-induced NK cells. Therefore, we performed cytotoxicity 
assays with AML blasts from 5 different patients. Importantly, AML blasts could be 
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potently killed within 3 days of co-culture (Figure 4H). We observed some variance in 
susceptibility between the different patients, but variance between HSPC-NK cell donors 
was small, indicating that the quality of the SR1-induced NK cell products is consistent.
Taken together, these data demonstrate that SR1-induced HSPC-NK cells, generated 
from G-CSF-mobilized CD34+ cells, mediate efficient IFN-γ production, degranulation 
and cytolytic activity against hematological tumor cells. Furthermore, as expected by 
increased expression of activating markers, SR1 augments IFN-γ production and cytotoxic 
activity of ex vivo-generated HSPC-NK cells.
HSPC-NK cell proliferation, viability and function is inhibited by MPA but not by CsA
Increased NK cell numbers after non-myeloablative alloSCT have been associated with 
decreased relapse rates, without an increased risk for GVHD.8,9 Hence, adoptive transfer 
of ex vivo-generated NK cells shortly after alloSCT is an attractive approach to improve 
patient outcome. Our therapeutic strategy is to apply HSPC-NK cell adoptive transfer 
for high-risk patients treated with non-myeloablative alloSCT (Figure 5A). For this 
purpose, we want to exploit 15-30 x 106 CD34+ cells from the G-CSF-mobilized donor 
stem cell graft, which represents approximately 5-10% of the total graft, for ex vivo NK cell 
generation. These HSPC-NK cells can be infused as a single infusion, or multiple infusions 
after alloSCT, to improve the GVT effect. However, these alloSCT patients are treated 
with immunosuppressive drugs to prevent GVHD, so the effect of these drugs on HSPC-
NK cell proliferation and viability should be known. For that reason, we investigated 
the effect of CsA and MPA, which are often used after non-myeloablative alloSCT, on 
SR1-induced NK cells. For this, week 5 HSPC-NK cells were cultured for 7 additional 
days in the presence of absence of therapeutic concentrations of MPA or CsA (Figure 
Figure 4 (on the left). NK cells generated in the presence of SR1 are functionally active. NK cells were 
generated from CD34+ HSPCs in the presence or absence of SR1. After 5 weeks the functional activity of the 
cells was investigated. (A-G) NK cells were co-cultured overnight with the leukemia cell lines K562, HL-60 
or THP-1, or the MM cell lines RPMI8226, U266 or UM9 at an E:T ratio 0.3:1, 1:1 or 3:1. (A) IFN-γ levels were 
determined by ELISA in the co-culture supernatants of 1 x 105 CD56+ NK cells and 1 x 105 target cells. Means 
± SEM of 3 – 4 donors generated in the presence or absences of SR1 are shown. (B) Specific killing of leukemia 
cell lines at an E:T ratio 0.3:1 was determined in a FCM-based cytotoxicity assay. Means ± SEM of 3 donors 
generated in the presence or absence of SR1 are shown. (C-D) After 5 weeks of culture, CD56+ NK cells were 
FACS sorted from the cultures, and co-cultured with leukemia cell lines or the MM cell line RPMI8226 at 
an E:T ratio 1:1. Cultures were supplemented with IL-15 (5 ng/mL). (C) Specific killing of the cell lines was 
determined in a FCM-based cytotoxicity assay. Data are depicted as mean ± SD. (D) Granzyme B production 
by the CD56+ NK cells was measured by ELISA. Data are depicted as mean ± SD. (E-F) Degranulation of SR1-
generated CD56+ cells after co-culture at an E:T ratio 1:1, determined by FCM as the percentage of CD107a 
expressing cells. One representative donor (E) and means ± SEM of 4 - 7 donors (F) are shown. (G) Specific 
killing of leukemia or MM cell lines by SR1-generated NK cells at different E:T ratios was determined in a 
FCM-based cytotoxicity assay. Means ± SEM of 3 - 7 donors are shown. (H) Specific killing of primary AML 
cells by SR1-generated NK cells from 5 different patients (#1 AML-M2, #2 AML-M2, #3 AML-M4, #4 AML-
M5, #5 AML-M0) was determined for 5 different HSPC donors. Specific killing was determined after 1, 2 and 
3 days of co-culture in a FCM-based cytotoxicity assay at an E:T ratio of 3:1. Data are displayed as mean ± SD 
of triplicate samples. *p<0.05, ** p<0.01, *** p<0.001. Paired one-tailed (A, B, F) or an unpaired two-tailed 
(C-D) student’s t-test.
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5B-F). After 7 days, we analyzed NK cell proliferation and viability using FCM (Figure 
5B-D). We found that proliferation of HSPC-NK cells was already inhibited by MPA in 
a therapeutic concentration of 0.1 µg/mL. In contrast, CsA, even at a concentration of 1 
µg/mL, did not inhibit HSPC-NK cell proliferation (Figure 5B,C). In addition, NK cell 
viability was not affected by CsA, while MPA induced dose-dependent cell death (Figure 
5D). Next, we investigated the effect of MPA and CsA on HSPC-NK cell function. For 
this, CD56+ NK cells cultured in the presence of MPA or CsA were co-cultured overnight 
with K562 cells at an E:T ratio of 1:1. As a control, week 6 CD56+ NK cells were used. We 
observed impaired killing by NK cells cultured in the presence of MPA; however, CsA did 
not inhibit NK cell-mediated killing (Figure 5E). In addition, we observed impaired IFN-γ 
production after incubation with MPA, while incubation with CsA even enhanced IFN-γ 
production (Figure 5F). These data indicate that adoptive transfer of SR1-generated HSPC-
NK cells can be applied in patients treated with CsA, but infusion should be postponed 
until cessation of MPA therapy.
Discussion
NK cells are the first lymphocyte population recovering after alloSCT, and have several 
important functions shortly after alloSCT.36 First of all, they are involved in defence 
against viral infections such as cytomegalovirus (CMV) infections,37,38 which can cause 
high morbidity shortly after alloSCT. Furthermore, high NK cell numbers shortly after 
non-myeloablative and T cell-depleted alloSCT have been associated with reduced relapse 
rates without an increased risk of GVHD,8,9 indicating that allogeneic donor NK cells 
have specific antitumor activity. Nevertheless, it was shown that early engrafting NK 
cells have decreased cytokine producing capacity.39 So, in order to further exploit the 
Figure 5 (on the left). NK cell viability, proliferation and function is inhibited by MPA but not by CsA. (A) 
Suggested strategy for adoptive transfer of ex vivo generated SR1-NK cells after non-myeloablative alloSCT. A 
patient is conditioned with non-myeloablative conditioning; subsequently, the patient receives a T cell replete 
stem cell graft. Ten percent of CD34+ cells of the donor graft are used for NK cell generation. To prevent GVHD, 
patients are treated with MPA and CsA. After cessation of MPA (around day 28 after transplantation), NK cells 
can be infused as a single infusion or multiple infusions. (B-F) The effect of immunosuppressive drugs used 
after non-myeloablative alloSCT was investigated. NK cells were generated from CD34+ HSPCs in the presence 
of SR1. After 5 weeks, NK cells were cultured for 7 more days in the presence or absence of different dosages of 
MPA or CsA. (B) Proliferation of CFSE-labelled NK cells cultured in the presence of absence of drugs measured 
by CFSE dilution in a representative donor. (C) Proliferation of NK cells in the presence or absence of drugs 
measured as CFSE dilution. Mean MFI relative to MFI of control cells ± SEM of 4 different donors is shown. 
(D) The number of living cells determined by forward scatter/side scatter and exclusion of 7-AAD positive cells. 
Percentage of living NK cells cultured for 7 days in the presence or absence of drugs. Mean viability relative 
to control cells ± SEM of 4 different donors is shown. (E-F) 1 x 105 CD56+ NK cells cultured in the presence 
or absence of MPA or CsA were co-cultured overnight with K562 cells in the presence of IL-15 (5 ng/mL), at 
an E:T ratio of 1:1. (E) Specific killing of K562 cells was determined in a FCM-based cytotoxicity assay. Data 
are depicted as mean ± SD and are representative of 2 different donors. (F) IFN-γ levels were measured in the 
supernatant after overnight co-culture using ELISA. Data are depicted as mean ± SD and are representative 
of 2 different donors. ** p<0.01, *** p<0.001, One-way ANOVA.
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beneficial effects of NK cells after alloSCT, adoptive transfer of functional and rapidly 
maturating NK cells would be an attractive immunotherapeutic strategy. Since donor-
derived NK cells will not be rejected post-transplant, multiple NK cells infusions without 
the need for immunosuppressive chemotherapy to prevent rejection, will be feasible in 
this setting. However, high numbers of functional NK cells of donor origin are needed to 
apply this strategy. Since isolation of sufficient numbers of NK cells from donors, without 
contaminating allo-reactive T cells, is challenging; we investigated if high numbers of 
functional NK cells could be generated from G-CSF mobilized CD34+ HSPCs, using an 
ex vivo cytokine-based culture protocol. This protocol was developed by our group earlier, 
and high numbers of pure and functional NK cells with in vivo maturation capacity, can 
be generated from UCB-derived CD34+ HSPCs using this GMP-compliant protocol.5-7
We found that NK cell expansion and differentiation from G-CSF-mobilized and 
BM-derived CD34+ cells in the absence of SR1 was very limited, as compared to NK cell 
expansion and differentiation of UCB-derived CD34+ HSPCs observed in our previously 
developed culture protocol. Interestingly, we found that addition of the AhR antagonist 
SR1 to our cultures greatly enhanced NK cell expansion and differentiation. As a result, we 
can expand G-CSF-mobilized CD34+ cells on average 268-fold using our newly developed 
SR1-based protocol. In addition, SR1-generated NK cell products are 83% ± 9% pure. The 
remaining non-NK cells in the cultures represented mainly CD14+ and/or CD15+ mature 
monocytic and myelocytic cells. Probably due to SR1 addition still some remaining low 
amount CD34+ cells could be detected. However, contaminating CD3+ T cells were either 
not detectable or at very low frequency (0.1% ± 0.1%). Furthermore, we found that SR1-NK 
cells have a similar phenotype as our NK cells previously generated from UCB-derived 
CD34+ HSPCs, which is a highly active phenotype, characterized by expression of high 
levels of activating NK cell receptors.5-7 Interestingly, expression levels of CD62L, CXCR3, 
DNAM-1 and TRAIL were even higher on NK cells generated in the presence of SR1. 
CD62L and CXCR3 are involved in homing to lymphoid organs and trafficking towards 
inflammation in vivo, so high expression of these markers can contribute to trafficking of 
NK cells toward hematological tumor cells in the lymphoid organs.7,34,35 In addition, it was 
described that CD62L indicates an unique subset of polyfunctional NK cells combining the 
ability to produce IFN-γ with cytotoxic properties.40 DNAM-1 and TRAIL are activation 
markers, increased expression levels of these markers suggests that SR1-generated NK 
cells are more active as compared to NK cells generated in the absence of SR1. This was 
indeed confirmed in functional studies showing that SR1-induced NK cells have increased 
INF-γ production capacity and an increased capability to kill AML cell lines, as compared 
to NK cells generated in the absence of SR1. Furthermore, SR1-generated NK cells show 
efficient degranulation against AML and MM cell lines. Besides, even at low E:T ratios, 
these cells efficiently kill hematological tumor cell lines, and most importantly, patient-
derived primary AML blasts. To further investigate the applicability of our SR1-NK cell 
product after alloSCT, we investigated the effect of the immunosuppressive drugs MPA 
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en CsA, which are commonly used after non-myeloablative alloSCT, on our SR1-NK 
cell product. Importantly, we found that therapeutic CsA concentrations do not affect 
HSPC-NK cell viability, proliferation or function, while exposure to therapeutic levels of 
MPA did have a negative effect. Exposure to CsA did even enhance IFN-γ production by 
the HSPC-NK cells. This is in accordance with the effect of CsA and MPA on naturally 
occurring NK cells described in literature.41,42 These results provide strong rational to 
infuse SR1-generated HSPC-NK cells relatively short after alloSCT, since MPA treatment 
is generally stopped at day 28 after alloSCT. CsA, which is usually prescribed for at least 
six months, will most likely not affect NK cell viability, proliferation or function in vivo 
upon transfer.
Several methods to generate NK cell products from donor origin for immunotherapy 
have been reported.43-48 In most studies, NK cells are isolated from aphaeresis products 
using magnetic cell sorting systems. However, poor recovery and viability is a common 
problem in these procedures, therefore NK cells require cytokine stimulation and 
expansion before infusion.2,46-50 NK cell numbers up to 7.6 x 108 have been reported using 
this method.49 Nevertheless, large-scale aphaeresis procedures are necessary to obtain 
this amount of NK cells, and contaminating T cells can potentially cause GVHD. To 
circumvent these problems, NK cell generation from CD34+ HSPCs is an attractive option. 
Yoon et al. recently reported safe infusion of NK cells generated using a feeder-free 6-week 
culture procedure after HLA-mismatched alloSCT. Using this procedure, an average 
number of 9.28 x 106 NK cells/kg was generated from 2.22 x 106 donor CD34+ HSPCs/
kg.45 In our system, the average NK cell expansion from CD34+ HSPCs was 235 fold (range 
115 – 904 fold). Therefore, if we use 10% of the G-CSF-mobilized CD34+ HSPCs isolated 
from donors for alloSCT, we will have on average 0.5 x 106 CD34+ cells/kg. In case of a 70 
kg donor and patient, we will get on average 8 x 109 NK cells (> 1 x 108 NK cells/kg). So we 
will be able to infuse large numbers of NK cells from donor origin using our SR1- based 
NK cell generation protocol.
In the present study, we showed that the AhR antagonist SR1 greatly enhances NK 
cell expansion and differentiation. AhR is a ligand-inducible transcription factor which 
has extensively been studied in the context of its activation by environmental pollutants, 
such as dioxins and polycyclic aromatic hydrocarbons.51,52 Until recently, little was known 
about the physiological role of AhR, but a growing body of evidence shows that AhR has 
multiple endogenous activators,15 and is involved in several physiological processes.22,53,54 
Examples of endogenous ligands are metabolites of dietary substances15,55 and tryptophan 
metabolites like cinnabarinic acid,56 6-formylindolo[3,2-b]carbazole (FICZ), which can 
be produces in the skin upon light exposure,57 and the indoleamine 2,3-dioxygenase 1 
(IDO1)-metabolite kynurenin.58 AhR also regulates differentiation of various immune 
cells like T helper 17 (TH17) cells,22 dendritic cells,17,18 regulatory T cells19,20 and γδ T cells.21 
Recently, Hughes et al. reported that antagonism of AhR promotes differentiation of 
immature innate lymphoid cells into NK cells expressing EOMES and TBET.23 In our SR1-
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based HSPC-derived NK cell culture, we also observed upregulation of EOMES, which 
is involved in NK cell maturation,29 and additionally we found upregulated expression 
of TOX, ID2, GATA-3 and EAT-2 after AhR inhibition. TOX is important for early NK 
cell development,27 ID2 is involved in NK cell maturation28 and GATA-3 and EAT-2 are 
important for NK cell effector functions.30,31 Interestingly, expression of TOX markedly 
decreased in the first week of culture in our culture system in the absence of SR1. In 
the presence of SR1, TOX expression is more preserved, resulting is significantly higher 
TOX expression after one week. This suggests that before induction of differentiation 
by addition of IL-15, early NK cell progenitors are expanded in the presence of SR1, 
explaining increased NK cell numbers generated in the presence of SR1, IL-15 and IL-2. 
To our knowledge, this is the first report of an applying AhR blocking in an in vitro system 
to generate high numbers of functional NK cells.
In conclusion, we developed a cytokine-based ex vivo culture system, which enables us 
to generate high numbers of very potent NK cells from G-CSF mobilized CD34+ HSPCs. 
Addition of SR1 to the culture system induced upregulation of multiple NK cell-related 
transcription factors, and resulted in generation of NK cell products with very high cell 
numbers and purity. These NK cells have an active phenotype and are highly functional 
in vitro, therefore they hold great promise for future adoptive HSPC-NK cell therapy 
after alloSCT.
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Supplementary Figure 1. SR1 enhances expansion and NK cell differentiation of bone marrow (BM)-derived 
CD34+ HSPCs, thereby NK cells with a mature and active phenotype can be generated. CD34+ HSPCs 
were isolated from BM samples. The cells were cultured for 5 weeks in the ex vivo cytokine-based culture 
protocol described in the Materials and Method section and Figure 1A. (A) Kinetics of differentiation and 
expansion of CD56+ cells in the presence or absence of 2 µM SR1 from one representative donor. (B) Summary 
of total expansion, NK cell yield (calculated by [total expansion x percentage of CD56+ cells]/100), and NK cell 
differentiation after 5 weeks of culture in our ex vivo culture protocol in the presence or absence of 2 µM SR1 
in 4 donors. (C) After 5 weeks of culture, expression of NK cell markers was analyzed using FCM. Expression 
levels and MFI of several NK cell specific surface antigens on living cells. Mean ± SEM of 2 - 3 different donors 
are shown. Paired one-tailed student’s t-test.
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Thesis objective
Though the cure rate for patients with hematological malignancies has significantly 
increased in the last decades with optimized therapeutic strategies, many patients still 
succumb to the disease. They are either non-responsive or develop resistance to current 
therapies, or minimal residual disease remains which can eventually lead to relapse. 
To date, the most effective and the only curative treatment option available for many 
aggressive hematological cancers, is allogeneic stem cell transplantation (alloSCT) 
followed by donor lymphocyte infusion (DLI). AlloSCT has the potential to be curative due 
to induction of a potent and long-lasting anti-tumor immune response, called the graft-
versus-tumor (GVT) response. In the GVT response, it has been shown that donor-derived 
natural killer (NK) cells and cytotoxic CD8+ T cells specific for minor histocompatibility 
antigens (MiHAs) and tumor-associated antigens (TAAs) are the prime effector cells 
that are responsible for elimination of the residual malignant cells. Furthermore, tumor-
specific memory T cells are formed after the initial anti-tumor response, which have the 
potential to convey life-long protection against tumor cell recurrence. However, relapses 
do frequently occur in transplanted patients, which is the major cause of treatment failure 
and mortality.
There are various reasons why patients relapse. Patients can relapse early after 
transplant if the malignant clone grows out before GVT-effector cells are at sufficient 
levels to control the disease. In this regard the efficacy of the conditioning regimen prior to 
transplant plays an important role; reduced-intensity and non-myeloablative conditioning 
regimens that have been developed to make alloSCT feasible for older and medically less 
fit patients, are associated with higher relapse rates due to less effective reduction of tumor 
load, thereby hampering productive GVT immunity. Relapse can also occur due to failure 
of donor-derived lymphocytes to launch anti-tumor responses (e.g. minimal/unfavorable 
MiHA mismatch between patient and donor, insufficient antigen presentation or limited 
NK cell activation). Additionally, relapse can occur after an initial period of effective 
GVT immunity, if no long-term memory against the malignant disease is formed, the 
immune system is weakened or the immune effector cells become tolerant to the residual 
disease. Furthermore, the malignant cells in some cases employ various mechanisms 
and establish an immunosuppressive microenvironment, to escape immune recognition 
and elimination. Besides relapse, other transplant-related complications can arise, such 
as graft-versus-host disease (GVHD) and opportunistic infections. As alloSCT, despite 
these limitations, has the potency to cure patients, great efforts are being made to tailor 
this treatment strategy for improved outcome. These improvements focus on reducing 
the incidence and severity of GVHD and infectious complications, while boosting GVT 
immunity to increase the remission rate and duration of remission.
In this thesis, we focused on the pre-clinical development of immunotherapeutic 
strategies that have the potential to specifically boost the GVT effect, without increasing 
the risk of GVHD. We describe protocols for ex vivo generation of different dendritic 
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cell (DC) subsets and NK cells from CD34+ hematopoietic stem and progenitor cells 
(HSPCs), that could potentially be used for DC vaccination and adoptive NK cell transfer, 
respectively. Furthermore, we evaluated the potential of CLEC12A, an endocytic receptor 
expressed on the surface of DCs, as a new targeting candidate for in vivo delivery of 
MiHAs and TAAs.
DC vaccination using ex vivo-loaded HSPC-derived DC 
subsets
DC-based cancer vaccination has been widely investigated for the past two decades due to 
the central role of DCs in orchestrating adaptive and innate immunity. The basic concept is 
to use tumor antigen-loaded DCs to induce tumor-specific T cell responses that are capable 
of lysing malignant cells that express the respective antigen. In this respect, multiple 
clinical trials using monocyte-derived DCs (MoDCs) have been performed in a wide range 
of different types of cancer. These trials have demonstrated that DC vaccination is feasible, 
safe and capable of promoting in vivo tumor-specific immune responses. However, only a 
minority of patients experiences objective clinical responses, which has impeded routine 
implementation of DC vaccination in standard clinical practice. Hence, efforts to improve 
and optimize this personalized immunotherapy are ongoing. One strategy is to optimize 
the efficacy of the commonly used MoDCs, and is the focus of extensive pre-clinical and 
clinical research. In this regard, our group is investigating whether the immunogenicity of 
MoDCs can be enhanced by silencing their expression of co-inhibitory molecules such as 
PD-L1 and PD-L2.1-3 Furthermore, van den Bergh et al. presented a strategy for enhancing 
the capacity of MoDCs to engage NK cells in the anti-tumor response, by engineering the 
DCs to trans-present and secrete interleukin (IL)-15.4,5 Another promising strategy was 
developed by Prof. Kris Thielemans and his colleagues, where MoDCs are electroporated 
with mRNA encoding CD40 ligand (CD40L), constitutive active form of TLR4, and CD70 
(referred to as TriMix-DCs). The major advantage of this vaccine formula is that the DCs 
can be infused within few hours after electroporation, which means that they will mature 
and secrete most of their stimulatory cytokines in vivo.6
Besides increasing the immunogenicity of MoDCs, it is promising to use different 
DC subsets for vaccination such as plasmacytoid DCs (pDCs), BDCA1+ myeloid DCs 
(mDCs) and BDCA3+ mDCs. Each of these DC subsets have a distinct role in the immune 
system and a different cytokine secretion profile. For example pDCs secrete high levels of 
type I interferons (IFN-α/β), which have pleiotropic effects on multiple cell types and is 
particularly important for NK cell functions and anti-viral immunity. On the other hand, 
the mDC subsets secrete interleukin (IL)-12, which together with their high expression 
levels of major histocompatibility complex (MHC) and co-stimulatory molecules, makes 
them particularly efficient in generating CD4+ T-helper 1 (Th1) T cell responses and 
priming naïve CD8+ T cells. Moreover, studies indicate that the different DC subsets act 
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synergistically via cross-talk, thereby potentiating each other’s stimulatory capacity. Thus 
simultaneous vaccination with multiple different subsets might result in a broader and 
more potent immune response (i.e. due to DC cross-talk and engagement of both T cells 
and NK cells) and thereby better therapeutic efficacy than “standard” MoDC vaccines. 
In chapters 2-4, we therefore explored the possibility of generating different DC subsets 
from HSPCs ex vivo.
In chapter 2, we optimized a protocol for generation of myeloid-like DC subsets from 
umbilical cord blood (UCB) CD34+ HSPCs. HSPCs were expanded for 11 days in medium 
supplemented with Flt3L (FMS-like tyrosine kinase 3 ligand), SCF (stem cell factor), IL-3, 
IL-6 and TPO (thrombopoietin). After 11 days culture, the expanded precursor cells were 
washed, reseeded and continued in culture in medium containing GM-CSF (granulocyte-
macrophage colony-stimulating factor) and IL-4 with or without transforming growth 
factor (TGF)-β1, thereby inducing their differentiation into DCs. Within this culture 
system, >60% of the cells co-expressed CD11c and HLA-DR, markers that are characteristic 
for monocytes and DCs. Furthermore, DCs with a phenotype similar to interstitial/dermal 
DCs and Langerhans cells (LCs) could be identified, based on the expression of CD1a and 
CD207 (langerin), respectively. The proportion of langerin-expressing cells was higher in 
cultures supplemented with TGF-β1, which is in line with findings by others.7,8 These UCB-
derived DCs efficiently activated and induced proliferation of both viral antigen-specific 
and MiHA-specific human CD8+ T cells in vitro, as well as in vivo in immunodeficient 
mice. However, within this culture system, DCs with a phenotype of genuine blood DC 
subsets, such as pDCs, BDCA1+ mDCs and BDCA3+ mDCs were not identified. In chapter 
3, we therefore explored other means to generate these subsets from CD34+ HSPCs. 
Here, we discovered that inhibition of the aryl hydrocarbon receptor (AhR), using the 
antagonist StemRegenin 1 (SR1), significantly promoted the development of pDCs and 
mDCs from HSPCs in vitro. For this, CD34+ HSPCs were expanded in medium containing 
Flt3L, SCF, TPO and IL-6 with or without SR1 for three weeks. In SR1-supplemented 
cultures, the different DC subsets (pDCs, BDCA1+ mDCs and BDCA3+ mDCs) could be 
identified, while their frequency in cultures without SR1 was negligible. Furthermore, 
we confirmed that the SR1-induced DC differentiation was AhR-dependent, by addition 
of the agonist VAF347, which dose-dependently blocked the observed SR1-induced DC 
development. We further characterized the SR1-generated DC subsets, and found them 
to be phenotypically and functionally comparable to their peripheral blood counterparts. 
After Toll-like receptor (TLR) stimulation, they secreted high levels of subset-specific 
inflammatory cytokines, upregulated co-stimulatory molecules and maturation markers, 
and were capable of activating T cells.
In chapter 4, we set out to optimize this SR1-based culture protocol further for 
eventual clinical application, by establishing culture conditions translatable to good 
manufacturing practice (GMP) which would result in sufficient numbers of functional 
DC subsets for vaccination. In this study, we focused on the generation of DCs from 
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CD34+ HSPCs obtained from granulocyte colony-stimulating factor (G-CSF)-mobilized 
peripheral blood, as this stem cell source is most commonly used for transplantation of 
patients with hematological cancers. Hereby, HSPC-derived DC subset vaccines could be 
generated from a portion of the donor graft to boost GVT immunity post-transplantation. 
The established GMP-compliant protocol combined aspects from the two different culture 
systems presented in chapters 2 and 3, with some additional modifications: in brief, HSPCs 
were expanded for 7-13 days using Flt3L, SCF, TPO (abbreviated as FST) and SR1, where 
after the culture was split into two differentiation protocols. One part of the expanded 
cells was continued in culture for one week in FST and SR1-supplemented medium (FST 
culture) which favoured generation of IFN-α-producing pDCs, though both BDCA1+ 
mDCs and BDCA3+ mDCs were also present. The other part of the expanded cells was 
provided with a myeloid differentiation boost by addition of GM-CSF and IL-4 (called 
G4 culture) which resulted in high numbers of IL-12-producing BDCA1+ mDCs. To the 
best of our knowledge, this protocol resulted in the highest reported numbers of pDCs, 
BDCA1+ mDCs and BDCA3+ mDCs that can be simultaneously generated ex vivo from 
HSPCs using GMP-compliant components, and additionally exceeds the numbers that 
can be isolated from peripheral blood.
In chapter 4, we next assessed the potential of HSPC-derived pDCs (enriched from 
the FST culture) and HSPC-derived BDCA1+ mDCs (enriched from the G4 culture) to 
induce anti-tumor T cell and NK cell responses ex vivo. To this end, BDCA1+ mDCs were 
superior in priming naïve T cells and expanding patient-derived MiHA-specific CD8+ T 
cells. These T cells were highly functional, as determined by IFN-γ and degranulation 
responses upon peptide restimulation. On the other hand, HSPC-derived pDCs were 
superior in inducing IFN-γ secretion by effector memory T (Tem) cells and cytolytic activity 
of NK cells, which can likely be attributed to their high secretion of IFN-α. pDC-priming 
of NK cells resulted in augmented TRAIL (tumor necrosis factor-related apoptosis-
inducing ligand) expression and significantly increased lysis of tumor cells. Collectively, 
these results show that the different HSPC-DCs are potent stimulators of anti-tumor 
effector cells and display subset-specific characteristics in line with the literature, i.e. 
the mDCs were better T cell stimulators, while the pDCs were superior in induction of 
NK cell responses. These results encourage us to believe that a vaccine composed of the 
different HSPC-derived DC subsets would induce a broader immune response by engaging 
both adaptive and innate immune effector cells (i.e. T cells and NK cells, respectively), 
which hopefully would result in superior therapeutic efficacy than has been obtained with 
previous MoDC-based vaccination trials.
In vivo-targeting of DCs
An alternative to using ex vivo-generated and tumor antigen-loaded DCs for 
immunotherapy, is to target the different DC subsets in vivo. The concept of this approach 
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is to deliver tumor antigens to the DCs, via antibodies directed against specific antigen-
uptake receptors, and simultaneously deliver adjuvants (such as TLR ligands) to promote 
maturation of the targeted DCs to facilitate antigen (cross-)presentation and activation of 
cellular immune responses. Hereby, extensive, labour intensive and costly ex vivo culturing 
and handling of DCs can be avoided. Furthermore, in vivo targeting has the potential to 
be more broadly applicable, since the vaccine does not need to be tailor-made for each 
individual patient. However, this strategy is not yet as far developed as ex vivo-loaded DC 
vaccination and only few clinical trials have been performed using this approach. For 
implementation, multiple parameters need to be further researched, including a thorough 
characterization of antigen-uptake receptors.
A potential targeting receptor needs to facilitate efficient delivery of the antigen 
into intracellular compartments for processing and loading onto MHC. To this end, we 
have investigated the potential of CLEC12A, an endocytic C-type lectin receptor, for 
targeting of human DC subsets in chapter 5. In this study, we validated the discriminative 
expression pattern of CLEC12A and confirmed that it is selectively expressed by myeloid 
cells, including monocytes and granulocytes, and the different DC subsets: BDCA1+ 
mDCs, BDCA3+ mDCs and pDCs. Furthermore, we demonstrated that upon binding by 
CLEC12A antibodies, CLEC12A is efficiently internalized by all the different DC subsets 
and traffics to intracellular compartments involved in the antigen-presentation process. 
Besides facilitating endocytosis, C-type lectin receptors like CLEC12A can also shape 
immune responses by involvement of their intracellular signaling domains. CLEC12A 
contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic 
tail, and might therefore impair DC maturation and function upon triggering. However, 
we did not observe negative effects after antibody targeting of CLEC12A on TLR-induced 
expression of DC maturation markers or cytokine secretion, nor on the capacity of the 
targeted DCs to induce activation of allogeneic T cells. With regards to antigen delivery, 
we demonstrated that CLEC12A-dependent antigen uptake lead to efficient antigen 
presentation to both CD4+ and CD8+ T cells by the different DC subsets. We showed 
that delivery of keyhole limpet hemocyanin (KLH) resulted in expansion of and IFN-γ-
secretion by KLH-experienced CD4+ T cells. Importantly, all primary DC subsets, BDCA1+ 
mDCs, BDCA3+ mDCs and pDCs, were capable of cross-presenting a long MiHA peptide 
delivered via CLEC12A, resulting in strong ex vivo activation of patient-derived MiHA-
specific CD8+ T cells. Cumulatively, these data indicate that CLEC12A is an interesting 
candidate for targeted antigen delivery into DCs.
Adoptive transfer of NK cells
Besides T cells, allo-reactive NK cells are important players in the GVT response and 
have been associated with reduced relapse rates and prolonged disease-free survival. The 
beneficial effect is attributed to NK cell activation because of selective (stress-induced) 
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upregulation of NK-activating ligands and/or downregulation of MHC class I molecules 
(NK-inhibitory ligands) on the targeted tumor cells. Of importance, allo-reactive NK cells 
do not cause GVHD, and may even suppress the induction and/or severity of GVHD. These 
observations have sparked the interest of many research groups to apply adoptive transfer 
of NK cells as adjuvant therapy post-transplantation, with the goal to eliminate residual 
or refractory disease without induction of GVHD. Furthermore, NK cells participate in 
the defence against viral and fungal infections post-transplantation, which additionally 
makes them attractive for adoptive transfer. Despite reports of clinical efficacy using NK 
cells isolated from peripheral blood, their use as immunotherapy for cancer has been 
limited by several factors, including low cell numbers, relatively low activation status and 
contaminating allogeneic T cells that can cause GVHD. To surpass these limitations, our 
group has developed a novel GMP-compliant NK cell product by ex vivo differentiation of 
NK cells from UCB-derived CD34+ HSPCs using a cytokine-based culture protocol. With 
this approach, high yield of cytotoxic NK cells, devoid of contaminating T and B cells, 
can be achieved.9,10 These UCB-derived NK cells have recently been examined for safety, 
toxicity and biological properties in a phase I clinical study. Though the trial was not 
designed to evaluate clinical benefit, a temporary decrease in residual disease was observed 
in the bone marrow of some patients after cyclophosphamide/fludarabine conditioning 
and UCB-NK cell infusion.11 These results are promising for further development of 
adoptive cell therapy using HSPC-derived NK cells.
In chapter 6, we explored the feasibility of generating NK cells from other HSPC 
sources than UCB, namely G-CSF-mobilized peripheral blood and bone marrow, for the 
same reasons as listed above for HSPC-DCs: to facilitate the generation of adjuvant cellular 
therapeutic products from the stem cell donor. However, adult CD34+ HSPCs have a lower 
expansion potential and NK cell differentiation capacity than young, UCB-derived CD34+ 
HSPCs. This illustrates that modifications of the ex vivo NK cell generation protocol were 
necessary. Therefore, based on findings described in the literature and our own experience 
with SR1 in the HSPC-DC culture system, we explored whether exposure of CD34+ HSPCs 
to SR1 would augment their expansion rate and potentiate NK cell differentiation. Indeed, 
addition of SR1 to our cytokine-based ex vivo NK cell culture protocol significantly 
enhanced the expansion of adult CD34+ HSPCs. Furthermore, SR1-exposure induced 
expression of transcription factors important in NK cell differentiation, such as TOX 
(thymocyte selection-associated HMG box factor), thereby promoting differentiation 
of the SR1-expanded HSPCs into NK cells. As a result, SR1-addition enabled routine 
generation of high numbers of CD56+CD3- NK cells from adult HSPC with 83% purity 
in average. The generated NK cells uniformly expressed high levels of activating NKG2D 
and natural cytotoxicity receptors (NCRs) and efficiently lysed myeloid leukemia and 
multiple myeloma cell lines, as well as patient-derived acute myeloid leukemia (AML) 
blasts. Interestingly, we observed that SR1-generated NK cells showed enhanced functional 
activity compared to NK cells generated in the absence of SR1: they had elevated expression 
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of DNAM-1 and TRAIL, secreted higher levels of IFN-γ and granzyme B, and exhibited 
increased cytolytic potential. Furthermore, SR1 augmented their expression of the homing 
receptors CD62L and CXCR3, which could promote trafficking of HSPC-NK cells towards 
hematological tumor cells in lymphoid organs.
We are interested in exploring the application of these SR1-generated NK cells as 
adjuvant therapy shortly after alloSCT, however patients then frequently receive the 
immunosuppressive drugs cyclosporin A (CsA) and mycophenolic acid (MPA) for 
suppression of allo-reactive T cells and prevention of GVHD. Therefore, we studied the 
effect of CsA and MPA on the viability, proliferation and functionality of the generated 
NK cell product in vitro. Therapeutic concentrations of CsA did not negatively affect any 
of these parameters, which indicates that HSPC-NK cell therapy could be given parallel 
to CsA administration (which usually lasts at least 6 months post-transplantation). 
In contrast, MPA inhibited the proliferation, viability, cytolytic potential and IFN-γ 
secretion of the NK cells. MPA treatment is generally only applied in the first month 
post-transplant, thus indicating that NK cell adoptive transfer could be realised from 
the 2nd month onwards.
Conclusion
In conclusion, this thesis describes the pre-clinical development of various 
immunotherapeutic strategies that could potentially be applied as adjuvant therapies post-
alloSCT to improve its therapeutic efficacy. The HSPC-derived DC subsets, presenting 
hematopoietic-restricted MiHAs or TAAs, could potentially be used as vaccine post-
alloSCT for selective induction of GVT immunity. Alternatively, targeted nanovaccines, 
containing MiHAs and/or TAAs, could be directly delivered to multiple DC subsets in vivo 
via the C-type lectin receptor CLEC12A. Finally, HSPC-NK cells could be applicable for 
adoptive transfer early after alloSCT, to mediate tumor clearance and anti-viral defense/
control. Besides the potential therapeutic implication of these strategies, the DC- and 
NK-generation protocols described in this thesis may provide a tool for mechanistic 
studies of human DC and NK cell development and biology ex vivo. Further discussion 
on the findings described in this thesis, and their potential implication in future treatment 
schemes is presented in chapter 8.
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Chapter 8
Aryl hydrocarbon receptor antagonism for generation of 
immunocellular therapeutic products
In chapters 3 and 6, we describe how the synthetic small-molecule compound StemRegenin 
1 (SR1) greatly improves ex vivo generation of dendritic cells (DCs) and natural killer (NK) 
cells from CD34+ hematopoietic stem and progenitor cells (HSPCs).1,2 SR1 was identified 
by Boitano et al. in 2010, when they performed a library screening for a compound that 
could promote ex vivo expansion of CD34+ HSPCs.3 In their study, SR1 induced a 17-
fold increase in the number of cells with engraftment capacity in immunodeficient mice. 
The therapeutic potential of SR1 was tested in the allogeneic stem cell transplantation 
(alloSCT) setting, where transplantation with SR1-expanded umbilical cord blood 
(UCB)-HSPCs resulted in significantly faster engraftment in patients as compared to 
unmanipulated UCB units.4 The discovery of SR1 has improved the potential of UCB 
units as HSPC source for alloSCT in the future, which so far was limited due to the low 
number of cells in UCBs. This facilitates the selection of suitable donor for adult patients 
in need of SCT.
Boitano et al. demonstrated that SR1 is an antagonist of the aryl hydrocarbon 
receptor (AhR).3 The AhR is a ligand-inducible transcription factor belonging to the 
basic helix-loop-helix transcription factor family.5 AhR regulates the transcription of 
a number of genes, involved in an array of physiological and pathological pathways. It 
is best known for its dominant role in xenobiotic-induced toxicity and carcinogenesis, 
as it mediates transcriptional responses to environmental toxins such as TCDD 
(2,3,7,8-tetrachlorodibenzo-p-dioxin) and polycyclic hydrocarbons. These toxins are 
the prototypic ligands for AhR, and have been extensively studied. However, once AhR 
knockout mice were investigated, the additional role of AhR in normal developmental and 
physiological pathways became evident. These mice showed developmental defects in the 
reproductive, hepatic, hematopoietic and cardiovascular system. Furthermore, in vitro 
and in vivo studies demonstrated an important role of AhR within the immune system, 
including regulation of the acute phase response, Th17 (T-helper (Th) type 17) immune 
cell differentiation and modulation of NF-κB activity and cytokine signaling.6-9 These 
findings supported the existence of endogenous AhR ligands.10 The majority of the natural/
endogenous AhR ligands that have been identified so far are either heme-, arachidonic 
acid-, or tryptophan-derived metabolites.11 Heme-derived metabolites include bilirubin 
and biliverdin, while examples of arachidonic acid metabolites are prostaglandins, such 
as PGG2 (prostaglandin G2). However, the most prominent endogenous AhR ligands 
are derived from tryptophan metabolism. These include compounds derived from 
1) indoleamine 2,3-dioxygenase (IDO) or tryptophan-2,3-dioxygenase activity (e.g. 
kynurenine, kynurenic acid and xanthurenic acid) 2) serotonin pathway (e.g. 5-hydroxy-
tryptophan) 3) photometabolism, i.e. metabolism in response to UV-light exposure (e.g. 
6-formylindolo[3,2-b]carbazole (FICZ)), and 4) metabolism by commensal gut microflora 
of dietary substances (e.g. indirubin, indigo and indole-3-carbinol). Given the versatility 
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of ligands, they probably act in a tissue- and context-specific manner. Furthermore, some 
bind with high affinity, while others are only weak agonists or found at very low levels that 
are likely insufficient to activate the AhR. It could also be that endogenous ligands exist 
that have an antagonistic effect on AhR activity. However, these have not been described 
so far.
Upon activation, the prototypic way of AhR-mediated gene transcription is as follows5. 
In its non-activated/unligated state, AhR resides in the cytoplasm, but upon ligation 
it translocates to the nucleus where it forms a heterodimer with ARNT (AhR nuclear 
translocator). This heterodimer binds to so called xenobiotic responsive elements (also 
termed dioxin responsive elements (DREs)) located in the upstream regulatory region of 
target genes, thereby initiating transcription. AhR signaling is fine-tuned and controlled 
by an elegant negative feedback loop, where the AhR induces expression of the AhR 
repressor (AhRR), which then competes with AhR for heterodimerization with ARNT. 
As AhRR-ARNT heterodimers are transcriptionally inactive, this abolishes AhR-induced 
gene expression. AhR-mediated gene regulation is though more complex than this, as AhR 
does not only induce transcription of genes, but can also repress gene expression, even 
in a DRE-independent manner. It has for example been reported that AhR regulates the 
proteasome-dependent degradation of specific transcription factors, such as the estrogen 
receptor α (ERα), by acting as a ligand-dependent E3 ubiquitin ligase.12 AhR activation can 
also facilitate gene transcription by indirectly promoting binding of other transcription 
factors to the genome. One mechanism through which this occurs is that AhR binds to 
DREs upstream of the transcriptional start site, where it dismisses histone deacetylase 
(HDAC)-containing co-repressor complexes, thereby lifting the repressive state of the 
promoter. This allows other transcription factors and RNA (ribonucleic acid) polymerase 
to bind to the promoter and initiate transcription.13,14 Thus, the AhR may either stabilize or 
promote the binding of other transcription factors to the genome, or inhibit the functions 
of those proteins by promoting their degradation. These examples illustrate that AhR 
signaling and its regulatory activity is very complex to study.
Because of the findings of Boitano et al., we tested the addition of SR1 to improve 
expansion of HSPCs when we were developing a culture protocol for ex vivo generation of 
plasmacytoid and myeloid DCs (pDCs and mDCs, respectively) from HSPCs. By that time, 
there were no publications describing that AhR was involved in human DC development, 
besides one publication implicating AhR in Langerhans cell (LC) differentiation.15 It 
was thus an exciting finding when we noticed that SR1 addition strongly promoted 
differentiation of pDCs, BDCA1+ mDCs and BDCA3+ mDCs in our cultures, even before 
we initiated specific DC differentiation protocols. This was probably one of the more 
memorable days of mine in the lab during the PhD track. During the revision of our 
manuscript, Liu et al. corroborated our findings by showing that AhR knockout mice have 
a higher frequency and number of pDCs in lymphoid organs compared to wild-type mice, 
and that ex vivo FMS-like tyrosine kinase 3 ligand (Flt3L)-induced pDC differentiation 
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from mouse bone marrow HSPCs is promoted by AhR antagonism (using CH223191 
compound) and inhibited by AhR activation (using TCDD).16 However, in their models, 
mDC development was not affected, illustrating that there might be intrinsic differences 
in AhR involvement in human and murine DC development. We focused on the direct 
clinical utilization of our discovery (i.e. generation of HSPC-pDC/mDC vaccines) and 
did not look further into the mechanism underlying SR1-induced DC differentiation, 
though of course this is highly interesting. DC development is governed by complex 
transcriptional control, where different transcription factors are involved in the (later 
stages of) differentiation of each subset.17 The E2-2/TCF4 transcription factor is a central 
regulator of pDC differentiation, BATF3 regulates BDCA3+ mDC differentiation and IRF4 
has been implicated as the transcription factor regulating BDCA1+ mDC development. 
Other transcription factors that have been implicated to play a pivotal role in DC 
development, but are not specific for one subset, include GATA2, ID2, IRF8, PU.1 and 
members of the NF-κB pathway. AhR could influence DC development by either directly 
or indirectly regulating the expression or activity of one or more of these transcription 
factors. It is interesting that AhR inhibition promoted the differentiation of all the 
different DC subsets, pDCs as well as mDCs, indicating that AhR-mediated regulation 
is involved somewhere early in the DC developmental pathway, before pDC- and mDC-
specific transcription factors become active. On the other hand, it could be that AhR 
influences pathways common to later stages of differentiation. A publication by Platzer 
et al., implies that AhR controls human monocyte and LC differentiation by modulation 
of PU.1 expression.15 They demonstrate that AhR activation (using the agonist VAF347) 
inhibits PU.1 induction, and that the lack of PU.1 results in the arrest of monocyte and LC 
development at a precursor cell stage. Interestingly, Angelos et al. recently demonstrated 
that SR1 inhibition results in upregulation of PU.1 (and also GATA2) during ex vivo 
differentiation of CD34+ HSPCs from human embryonic stem cells.18 Studies in murine 
models have shown that deletion of PU.1 hampers pDC and mDC development.19,20 Thus 
it could be that SR1-induced DC differentiation might be related to AhR-mediated control 
of PU.1 transcriptional activity in HSPCs. AhR-mediated regulation of DC differentiation 
could also be on the cytokine level, such as by maintaining interleukin (IL)-6 secretion. 
We and others have demonstrated that IL-6 hampers DC differentiation (chapter 4).21-23 
Multiple studies have shown that natural AhR ligands are present at biologically active 
concentrations in culture medium, which can contribute to basal activation of the AhR 
during cell culture.24,25 These ligands are primarily tryptophan-derived metabolites, that 
form due to light exposure or IDO activity of the cultured cells.25,26 Studies have shown 
that in vitro AhR activation (by e.g. kynurenic acid) synergistically enhances NF-κB-
induced IL-1β and IL-6 secretion (by the before-mentioned mechanism where ligated 
AhR lifts the repressive state of promoters, allowing binding of other transcription factors, 
in this case NF-κB).7,13,14,27-29 Furthermore, DiNatale et al. showed that IL-6 signaling 
can be abrogated in tumor cell lines that depend on autocrine IL-6 for their growth by 
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applying AhR antagonists.27 As we observed that IL-6 strongly hampers SR1-induced 
DC differentiation (chapter 4), it is tempting to speculate whether SR1 improves DC 
differentiation by blocking basal levels of AhR-induced IL-6 secretion. Why and how 
IL-6 inhibits DC differentiation needs to be further elucidated, just like AhR involvement 
itself. Furthermore, it also remains to be demonstrated to which extend these pathways 
are involved in natural DC development in vivo.
The role of AhR inhibition in NK cell development is more extensively researched 
than in DC development. In our ex vivo NK-generation culture protocol, addition of SR1 
enhanced proliferation of HSPCs and promoted NK cell differentiation, resulting in high 
numbers of functional NK cells.1 Beside our study, three other studies have shown that ex 
vivo AhR inhibition, using for example SR1, promotes differentiation of human NK cell 
precursors into interferon (IFN)-y producing, cytolytic mature NK cells.18,30,31 NK cells 
belong to the group of innate lymphoid cells (ILCs), and differentiate (at least partially) 
from bone marrow CD34+ HSPCs via the same pathway as IL-22- and IL-17-producing 
ILCs.32 Hughes et al. identified one potential NK cell differentiation pathway, where NK 
cells differentiate from ILCs that secrete IL-22 and highly express IL-1 receptor type 1 
(called ILC3s).30 They demonstrated that this transition, from ILC3 to NK cell, is controlled 
by AhR activity. They show that ILC3s have high expression of AhR, and that silencing 
or blocking AhR reduces RORC expression (i.e. the main transcription factor used for 
characterizing ILC3s), while it promotes expression of the transcription factors TBET and 
EOMES. EOMES in particular, is indispensible for NK cell differentiation. During our 
SR1-induced NK cell differentiation from CD34+ HSCPs, we also saw EOMES gradually 
increase during the culture. It would be interesting to investigate whether we can identify 
the ILC3-NK cell transition stage described by Hughes et al. as an intermediate stage in 
the differentiation of NK cells from CD34+ HSPCs in our culture system, and whether 
increased SR1-mediated transition through this stage is responsible for the increased 
NK cell differentiation we see. It could also be that SR1 blockade enhances NK cell 
differentiation because of AhR-mediated control at other stages of NK cell development. 
Interestingly, we observed a significant SR1-mediated increase in TOX expression after 1 
week expansion of CD34+ HSPCs, before NK differentiation was induced by addition of 
IL-15.1 TOX is a multifunctional transcription factor, that has been demonstrated to be 
pivotal for development of ILCs, including NK cells.33-35 Seehus et al. demonstrated that 
TOX deficiency resulted in early defects in the survival or proliferation of ILC progenitor 
cells in mice, and also affected ILC differentiation at a later stage.34 Thus it might be that 
AhR is involved in different developmental phases of NK cells in humans, but that, as 
well as the molecular mechanism behind AhR-mediated control of NK cell development, 
needs to be further elucidated.
Cumulatively, this overview shows that AhR regulation of immune cell differentiation 
and functionality is very complex and not yet well understood. But the identification 
of SR1 has provided means of exploiting this pathway for more efficient generation of 
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cellular immunotherapeutic products for clinical application. It would be interesting to 
see if addition of SR1, or other AhR-modulating agents, would be suitable for enhancing 
the efficiency and potency of other cellular products that are generated ex vivo.
Primary DC subset vaccinations and synergistic cross-talk
It is postulated that by using primary DC subsets, such as pDCs and mDCs, better efficacy 
of DC vaccination may be reached than by using monocyte-derived DCs (MoDCs).36 
However, the low frequency of primary DC subsets in blood has limited their use in DC 
vaccination trials so far. Nevertheless, three trials have recently been performed where 
pDCs or BDCA1+ mDCs isolated from peripheral blood of patients were used. Prof. de 
Vries and colleagues performed the first clinical study utilizing activated pDCs,37 and 
also carried out a trial with BDCA1+ mDCs.38 Both these trials were performed in end-
stage melanoma patients. To allow maximal efficacy of low DC numbers, vaccines were 
directly administered to the lymph nodes. Although these trials were designed as safety 
and feasibility studies, promising immunological and clinical results were obtained. 
Patients treated with activated and antigen-loaded pDCs showed an enhanced systemic 
expression of IFN-α-induced genes, indicating systemic secretion of type I IFNs, and a 
portion of the patients increased their number of circulating tumor-specific CD4+ and 
CD8+ T cells. Remarkably, pDC vaccinated patients had significantly improved overall 
survival compared to historical control patients treated with standard chemotherapy. 
However, their progression free survival was similar to these controls. Unfortunately, NK 
cell responses were not reported for these patients, which would have been very interesting 
to observe in the light of the enhanced IFN-α signature. Out of the 14 melanoma patients 
treated with BDCA1+ mDCs, three patients had detectable multifunctional tumor-specific 
CD8+ T cells in their circulation following vaccination. Notably, the presence of these 
T cell responses coincided with significantly improved progression-free and overall 
survival. The third clinical trial using primary DC subset was reported by Prue et al., 
where metastatic prostate cancer patients were vaccinated with immature, tumor peptide-
loaded BDCA1+ mDCs.39 In this trial, no tumor-specific immune responses were detected. 
In the melanoma trial, GM-CSF (granulocyte-macrophage colony-stimulating factor) 
was used for maturation of the BDCA1+ mDCs, while immature DCs were used in the 
trial of Prue et al. For both trials, one can hypothesise that a stronger maturation signal, 
e.g. with TLR (Toll-like receptor) ligands, might have induced a more robust immune 
response than was currently achieved, as non-activated or improperly activated DCs can 
cause T cell tolerance rather than productive T cell immunity. Importantly, these three 
trials demonstrated the feasibility of isolating primary DC subsets from blood and using 
them for vaccination studies, and the results are promising for future exploration of their 
capacity to induce productive anti-tumor immunity.
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These three trials investigated the potency of each subset separately, however it would 
be very interesting to combine the different subsets in one vaccine for two reasons. First, 
a combined vaccine, where both pDCs and mDCs are present, might induce a broader 
immune response (e.g. potent T cell priming as well as NK cell stimulation) because the 
specialized function of each subset is harnessed. Second, there are reports that the different 
DC subsets interact, and that bi-directional crosstalk between them can potentiate 
the function of each subset, resulting in enhanced anti-tumor responses (reviewed by 
Bakdash et al.40). Murine tumor models have demonstrated that vaccines that either are 
composed of both pDCs and mDCs,41 or mDCs that were activated in the presence of 
pDCs,42 induce enhanced T cell responses against the tumor and generate long-term 
anti-tumor immunity. The observed synergistic efficacy can be attributed to pDC-derived 
IFN-α and pDC-mDC cell contact, which enhances the differentiation, maturation and 
cross-priming capacity of mDC subsets.43,44 In vivo administration of TLR agonists has 
also been shown to result in synergistic activation of DCs. For example, injection of pDC-
activating TLR ligands results in tumor clearance and protective anti-tumor immunity by 
activating pDCs which subsequently results in activation and engagement of residential 
mDCs to present tumor-derived antigens.42,45 This effect is not only mediated by direct 
cross-talk between the different DC subsets, but also involves other innate immune cells, 
such as NK cells and NKT cells.45-48 Liu et al. demonstrated that adoptively transferred 
TLR-activated pDCs enhanced the recruitment and activation of NK cells to the tumor 
site, and their data indicate that the NK cells, through their lysis of tumor cells and IFN-y 
secretion, provided mDCs with antigens and additional maturation signals and T cell 
cross-priming capacities.45 CpG-activated pDCs have also been shown to license NKT 
cells to interact with mDCs, which then can activate NKT cells through CD1d-presented 
lipids.47,48 NKT cells do not have a strong cytolytic capacity by themselves, but they provide 
IFN-y and IL-2 which is important for the activation of cytotoxic NK cells and T cells.49,50 
In addition, NKT cells can also help with further maturation and enhanced cross-priming 
capacity of the DCs.46 Most of these data are derived from mouse experiments, but DC 
cross-talk has also been demonstrated in the human setting.44,51-53 For example a study 
by Beek et al. demonstrated that human BDCA1+ mDCs and pDCs cross-activate each 
other when co-cultured in vitro, enhancing DC-induced NK cell-mediated cytotoxicity.53 
Cumulatively, these data demonstrate that both pDCs and mDCs are important for the 
formation of long-lasting anti-tumor immunity, and that vaccination using multiple DC 
subsets is therefore a very promising strategy (Figure 1). The first clinical studies using a 
combination of pDCs and BDCA1+ mDCs for vaccination are ongoing in patients with 
melanoma54 (the MIND-DC (Melanoma patients Immunized with Natural DenDritic 
Cells) study) and prostate cancer55 at the Radboudumc lead by Prof. de Vries. The results 
of these studies are eagerly awaited.
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Figure 1. The ultimate aim with DC subset vaccination strategies. Each DC subset has unique stimulatory 
capacity and features which makes them attractive for vaccination, but they are also capable of potentiating 
each others’ stimulatory capacity via cross-talk. DC subset vaccination is therefore a promising approach 
for generating a broad and potent anti-tumor immune response. Cancer patients could be vaccinated either 
with TLR-activated ex vivo-loaded (HSPC)-DC subsets or with in vivo-targeting nanovaccines containing 
TLR ligands and tumor antigens. After vaccination, the activated DCs interact with immune effector cells 
in vivo, via cell surface molecules (e.g. MHC-TCR interaction, and co-stimulatory molecules) and cytokine 
secretion (e.g. IL-12 and IFN-α). Subsequently, these cells become activated and acquire effector functions 
(e.g. IFN-γ, IL-2 and granzyme secretion). Interaction of DCs with CD4+ T cells promotes pro-inflammatory 
Th1 responses, which provides additional help to CD8+ CTLs and NK cells for strong and sustained effector 
functions. Eventually, the activated CTLs and NK cells kill the tumor cells. The activated tumor-specific CD4+ 
and CD8+ T cells can thereafter become long-lived memory cells, important for long-term remission and 
tumor control in patients. pDC, plasmacytoid dendritic cell; mDC, myeloid DC; HSPC, hematopoietic stem 
and progenitor cell; MHC, major histocompatibility complex; CSM, co-stimulatory molecule; IFN, interferon; 
IL-12, interleukin-12; NK cell, natural killer cell; Th1, T helper type 1; CTL, cytotoxic T lymphocyte; TCR, T 
cell receptor; TLR, Toll-like receptor.
Clinical implementation of HSPC-DC vaccines
Combined vaccination with pDCs and mDCs is also an interesting approach in the 
alloSCT setting, as an adjuvant therapy for boosting GVT immunity to prevent relapse 
of haematological malignancies. GVT immunity is primarily mediated by donor-
derived allo-reactive NK cells, as well as CD8+ cytotoxic T lymphocytes (CTLs) specific 
for minor histocompatibility antigens (MiHAs) or tumor-associated antigens (TAAs). 
These tumor-reactive lymphocytes are either derived from the stem cell graft or from 
a donor lymphocyte infusion (DLI) administered post-transplantation after stopping 
immunosuppression. DLI is one of the current adjuvant therapies applied for treatment 
and prevention of relapse. Despite the induction of tumor-reactive responses in patients 
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treated with DLI, the numbers and/or functionality of the immune effector cells are often 
inadequate for keeping the tumor growth under control. Thus, for boosting the efficacy of 
the alloSCT and DLI, few clinical trials performed by us and others have investigated the 
accompanying infusion of MiHA- or TAA-loaded MoDCs.56-59 These studies demonstrated 
that DC vaccination in this setting is safe and does not induce or exacerbate graft-versus-
host disease (GVHD). However, similar to MoDC vaccinations in solid cancers, objective 
clinical responses have been limited. We envision that by using pDC and mDC vaccines 
instead of MoDCs, better clinical efficacy might be reached because of the simultaneous 
induction of both donor-derived tumor-specific T cells and cytotoxic NK cells, and the 
potential of the DC subsets to synergistically enhance each other’s stimulatory capacity. 
Instead of isolating the primary DC subsets directly from peripheral blood of the donors, 
chapters 3 and 4 of this thesis describe the development of a protocol to generate genuine 
DC subsets from CD34+ HSPCs of the donor stem cell graft.2,22 By generating the DCs 
from HSPCs, higher numbers of DCs for multiple vaccination rounds can be achieved 
than would be possible by isolation from peripheral blood. Furthermore, direct generation 
of DC subset vaccines from a small part of the stem cell graft would limit the burden for 
the donor, as a second apheresis would not be needed. We demonstrated that the HSPC-
derived DC subsets are highly potent inducers of ex vivo tumor-reactive T cell and NK 
cell responses, with the generated BDCA1+ mDCs being better T cell stimulators, while 
the pDCs were superior NK cell stimulators. Their potential synergistic interplay remains 
to be further explored, as well as their in vivo efficacy.
We would like to further explore the pre-clinical development of HSPC-derived DC 
subsets and eventually translate it into a clinical study, where patients are vaccinated 
with MiHA- and/or TAA-loaded HSPC-DCs post-transplantation. With careful selection 
of MiHA that have a hematopoietic-restricted expression, and/or TAAs that are highly 
expressed by the malignant cells, a specific GVT immunity could be induced, with 
minimal risk of inducing GVHD. But before HSPC-DCs can be tested in the clinic for 
assessing feasibility, safety and efficacy, multiple aspects need to be further investigated. 
We need to develop and validate a (closed) culture system for large-scale production 
of HSPC-DCs under GMP (good manufacturing practice) conditions, and, if needed, 
optimize the culture conditions accordingly to obtain high yields of the different DC 
subsets. Furthermore, we need to investigate whether isolation or enrichment of the 
different DC subsets will be needed, or whether the whole bulk of cultured cells can be 
used as vaccine. To be able to use the whole bulk as a vaccine, we need to exclude that the 
non-DCs in the culture (which are mainly monocytic, myelocytic and other hematopoietic 
progenitor cells) exert suppressive effects on the activation and function of tumor-reactive 
effector cells. Additionally, we need to determine which setting would be most optimal 
for the maturation of the DCs. For example, is it best to simultaneously activate the 
pDCs and mDCs during co-culture or to stimulate them separately? Here we need to 
take into account whether isolated DCs or whole bulk would be used. Related to this, 
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other questions need to be resolved, such as which maturation cocktail/agent should be 
used and what is the ideal duration of stimulation? And dependent on whether DCs are 
co-activated or not; should they be injected separately or together? If together, at which 
ratio? If separately, should they be infused simultaneously (e.g. at the same or different 
location) or consecutively (e.g. on different days)?
The protocol chosen for maturation of DCs for vaccination should ideally generate 
DCs that secrete pro-inflammatory and Th1-skewing cytokines/chemokines and highly 
express co-stimulatory receptors, antigen-presenting molecules and lymph node homing 
receptors such as CCR7. Pre-clinical studies have demonstrated that the most optimal 
maturation can be achieved by using TLR agonists, with or without pro-inflammatory 
cytokines. TLR agonists are for example essential for proper secretion of the Th1-skewing 
and CTL-stimulatory cytokine IL-12 by BDCA1+ mDCs and BDCA3+ mDCs. Moreover, 
numerous studies have shown that combination of two or more TLR agonists, for example 
R848 (Resiquimod; TLR7/8 agonist) with Poly I:C (Polyinosinic:polycytidylic acid; TLR3 
agonist) or LPS (Lipopolysaccharide; TLR4 agonist), induces significantly higher IL-12 
secretion than stimulation with only one TLR agonist.60-63 Gautier et al. report a role 
for secreted IFN-α that works in an autocrine loop to induce the observed synergism.60 
These results were corroborated by Kreutz et al., who additionally demonstrated how 
IFN-α production, initiated upon ligation of one TLR, induces expression of other TLRs, 
even TLRs that have been reported to be absent in the steady state.64 For example, poly 
I:C-induced IFN-α secretion resulted in upregulation of TLR7 in BDCA1+ mDCs, which 
thereby rendered them more responsive to TLR7 agonists, facilitating amplified cytokine 
production upon dual stimulation with Poly I:C and R848.64 This same mechanism 
likely plays a role in the synergistic cross-talk between the different DCs subsets that is 
discussed above, i.e. pDC-derived IFN-α may directly modulate the TLR levels of mDCs, 
making them more responsive to danger signals in the local environment. Because of 
the synergistic induction of IL-12 production upon dual TLR stimulation, we chose 
to use a combination of R848 and Poly I:C for activating HSPC-derived mDCs in our 
studies (chapter 3 and 4). In line with literature, this maturation regimen resulted in 
IL-12 secretion, and the DCs could efficiently activate both anti-tumor T cell and NK cell 
responses.2,22 In general, these findings provide a rational for combining multiple TLR 
agonists for maturation of the primary DC subsets in the DC vaccination setting. Care 
needs to be taken though, that for simultaneous maturation of co-cultured mDCs and 
pDCs, a maturation mix/agent would be needed that optimally activates all DC subsets, 
without interfering with the maturation of the other subset(s). The TLR repertoire of pDCs 
is more limited than of mDCs, as they primarily express TLR7 and TLR9, which can be 
activated using synthetic agonists such as R848 and CpG oligodeoxynucleotides (CpG 
ODNs), respectively. In our studies, we stimulated the HSPC-derived pDCs with CpG-A 
which induces high secretion of type 1 IFNs. We also used R848 which induces lower IFN 
levels than CpG-A, but stimulates better phenotypical maturation (i.e. upregulation of 
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co-stimulatory molecules and chemokine receptors). Combining TLR7 or TLR9 agonists 
with the agents that are most favourable for mDCs, for simultaneous maturation of pDCs 
and mDCs, is not straightforward. For example, studies show that CpG ODNs can have an 
inhibitory effect on poly I:C-induced maturation of mDCs.53,65 Moreover, TLR7 agonists 
have been demonstrated to inhibit CpG-induced IFN-α production.66-68 These findings 
likely restrict the selection of maturation agent for both subsets to just one TLR agonist. 
Even though pDCs and mDCs do not have an overlapping TLR repertoire, there is one 
type of danger signal that both subsets can respond to, which is single stranded RNA 
(ssRNA). ssRNA and synthetic analogs such as R848 are recognized by TLR7 (by pDCs) 
and TLR8 (by mDCs), and are therefore possible candidates to use for simultaneous pDC 
and mDC maturation. Besides the issues with distinct TLR responsiveness of the different 
DC subsets, the choice and combinations of stimulants are also limited due to the scarce 
availability of clinical-grade TLR agonists. In this regard, Skold et al. recently developed 
a formula based on clinically applicable reagents, where RNA is stabilized with protamine 
to use as universal DC stimulation agent.69 These protamine-RNA complexes induced a 
mature phenotype of both pDCs and BDCA1+ mDCs, and their respective secretion of 
IFN-α and IL-12 in vitro. In the ongoing clinical trial with primary pDCs and mDCs in 
patients with prostate and melanoma cancers mentioned above, protamine-RNA is used 
as the maturation agent.54,55 It would be interesting to evaluate whether protamine-RNA 
or other TLR7/8 agonists could be utilized in the clinical implementation of HSPC-DC 
vaccines.
Besides finding the optimal maturation agent, other strategies could be applied 
to enhance the immunogenicity of HSPC-DC vaccines. As the culture protocol for 
generation of the DC subsets from CD34+ HSPCs takes 2-3 weeks, there is room to perform 
additional in vitro manipulations. Mature DCs do not only express T cell co-stimulatory 
molecules on their surface, but also co-inhibitory molecules (CIMs), such as PD-L1 
and PD-L2 (programmed death-1 (PD-1) ligand 1 and 2, respectively). Multiple studies 
demonstrated how interference with the PD-1/PD-L pathway augments the activation 
and expansion of tumor-reactive T cells. In our group we have developed a strategy to 
silence PD-L molecules on the surface of MoDCs, by PD-L siRNAs (small interfering 
RNAs) transfection technology. These PD-L-silenced MoDCs have superior efficacy in 
boosting MiHA-specific T cell responses, both in vitro and in murine models,70-73 and 
are currently being investigated for safety, toxicity and immunostimulatory capacity 
in a phase I study. Preliminary data of the first four patients show promising results, 
where three of them show a clear increase in the frequency of MiHA-specific T cells 
post-vaccination (personal communication W.Hobo). It would therefore be interesting to 
silence these molecules during generation of HSPC-DCs, for enhanced vaccine efficacy. 
Next to the PD-1/PD-L1 pathway, there are other inhibitory molecules expressed by T cells 
that can interfere with induction of anti-tumor immunity, such as LAG-3 (lymphocyte-
activating gene 3), TIM-3 (T cell immunoglobulin and mucin-domain containing 3) and 
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TIGIT (T cell immunoreceptor with Ig and ITIM domains).74,75 Interestingly, recent studies 
demonstrated that also NK cells express PD-L1, TIM-3 and TIGIT, and indicated that 
these molecules are involved in inhibiting NK cell function following ligation with cognate 
ligands on DCs, tumor cells and other cells in the tumor microenvironment.49,76-79 Further 
research is needed to elucidate the specialized function of these molecules and whether 
modulation of these pathways, in T cells and NK cells, has therapeutic implications. It 
would be interesting to map the expression of TIM-3 and TIGIT ligands on HSPC-DCs 
and to investigate whether silencing their expression level (in addition to silencing PD-1 
ligands) can improve DC-mediated activation of NK cells and T cells.
In vivo-targeted DC vaccination
The powerful antigen-presenting capacity of DCs, the specialized features of the different 
DC subsets and their potential synergistic cross-talk can also be utilized for induction 
of anti-tumor immunity by direct antigen-targeting in vivo (Figure 1).80,81 In this setting, 
besides the delivery of an antigen to the DCs, it is pivotal to simultaneously deliver a 
maturation agent (e.g. TLR agonists), for induction of productive immune response rather 
than tolerance. Moreover, studies demonstrated that delivery of antigens and TLR agonists 
to the same cellular compartment is essential for effective antigen presentation.82-85 The 
most promising approach for achieving such co-delivery is encapsulating the antigens 
and maturation agent(s) in a polymer-based or lipid-based nanoparticles.80 Furthermore, 
linking these nanoparticles to antibodies directed against endocytic receptors expressed 
on the surface of the DCs is an elegant strategy for specific delivery of the cargo into DCs 
and induction of anti-tumor immune responses. Multiple endocytic receptors have been 
studied for this purpose.86 These receptors have varying cell type specificity, some are 
specifically expressed by only one DC subset, while others are more broadly expressed. 
Thus the choice of targeting receptor will determine to which cell the antigen is delivered. 
As activation of tumor-specific CD8+ CTLs is instrumental for productive anti-tumor 
immunity, DC subsets that are capable of cross-presentation are considered the most 
interesting targets. Interestingly, a study by Idoyaga et al. implies that the targeted DC 
subset and not the antigen-capturing receptor is a dominant force that determines the 
magnitude of T cell responses following directed antigen delivery.87 They demonstrated 
how antigen targeting to murine CD8α+ mDC subsets (the superior cross-presenting DC 
subset in mice) induced a stronger immune response than via CD8α- mDCs, no matter 
whether the antigen was delivered via DEC-205, CLEC9A or Langerin.87 This notion may 
not necessarily apply to the human setting, because the functional division between the 
two human mDC subsets is not as straightforward as in mice. Based on their (gene) 
expression profile and excellent cross-presentation capacity, human BDCA3+ mDCs have 
been described as the human equivalent of mouse CD8α+ mDCs.88 However, we (chapter 
5) and others demonstrated that BDCA1+ mDCs are also highly capable of priming 
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CD8+ T cells, and are in many settings equally efficient at cross-presentation as BDCA3+ 
mDCs.89-94 Human pDCs have also been shown to be very good cross-presenters.89,90,94 
However, studies have shown that pDCs have a limited ability to phagocytose large 
particles and dead cells, making them less efficient at cross-presenting particulate or 
necrotic cell-derived antigens.90,94 Nevertheless, they process and (cross-)present small 
exogenous antigens, and antigens that are delivered via endocytic receptors with equal 
efficiency as the mDC subsets.90,94 Thus, in the human setting, it is most interesting to 
assess the efficacy of targeting multiple DC subsets at once, to maximize the potency 
of in vivo-targeted vaccines. There are few candidate receptors that are universally 
expressed by all the primary human DC subsets. These include DEC-205, CD40, CD32 
and CLEC12A.86,89 Importantly, it has been demonstrated for CLEC12A (chapter 5) and 
the other three receptors that they can facilitate in vitro targeted delivery of antigens to 
pDCs, BDCA1+ mDCs and BDCA3+ mDCs, leading to uptake, processing and (cross)-
presentation of antigens to both CD4+ and CD8+ T cells.89,91,93,95,96 The different studies 
are not yet conclusive whether one receptor is superior for cargo delivery over another, 
as the different receptors have not been compared head-to-head for all the different DC 
subsets. Of note, when performing such comparisons, the targeting compounds need to 
have similar characteristics, such as similar amount of coupled antigen and antibodies of 
similar affinity. As this can be technically challenging to obtain, no proper head-to-head 
comparisons have been made so far.
A DEC-205 targeting antibody is most advanced in clinical development. Currently 
a number of clinical trials are ongoing using DEC-205 antibody fused to an antigen, 
including the NY-ESO-1 tumor antigen (CDX-1401)97-100 or HIV gag p24 protein 
(DCvax-001)101. These anti-DEC-205 drug conjugates are being investigated together 
with subcutaneous (sc) PolyICLC (Hiltonol), topical/sc R848 (resiquimod) and/or sc 
recombinant Flt3L (CDX-301) for providing enhanced DC responses. The results of the 
first trial have been published by Dhodapkar et al., where CDX-1401 together with TLR 
agonists was well tolerated and induced humoral and cellular NY-ESO-1-specific immune 
responses in most of the patients.102 It will be interesting to see whether this treatment 
can induce durable clinical responses in cancer patients in other (randomized follow-up) 
trials. It will also be interesting to observe whether the separate administration of TLR 
is sufficient, or whether use of nanoparticle carriers, that co-deliver antigens and TLR 
ligands to the same cell, results in most optimal anti-tumor responses.
As mentioned above, co-administration of maturation agents is important for efficient 
activation and function of the DCs. Like for ex vivo-loaded primary DC vaccines, the 
choice of maturation agent would depend on the DC subset targeted. Thus, some type of a 
TLR7/8 agonists would likely be the best choice for optimal maturation of all the different 
DC types. Notably, targeted delivery to DC surface receptors is not limited to delivery of 
antigens and TLRs, but could also be applied for other immunomodulatory agents, such 
as CIM-silencing siRNAs. By combining such siRNAs with TLR ligands and antigens in 
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nanocarriers, activated DCs with superior potential to stimulate tumor-specific T cell 
(and NK cell) responses could potentially be generated. It will be interesting to follow the 
development in this field in the coming years.
Potential (combination) therapies post-alloSCT
The different immunotherapeutic strategies that are described in this thesis could 
potentially be used as adjuvant therapies post-alloSCT to boost GVT immunity (Figure 
2). It is the plan to investigate their safety and potency in vivo in the forthcoming years. In 
this regard, it would be interesting to evaluate whether their efficacy could be enhanced 
by combination with other immunotherapies or anti-cancer drugs. Hypomethylating 
agents (HMAs) such as decitabine and azacitidine are for example attractive drugs 
for combination therapies. HMAs are currently standard of care for higher-risk MDS 
(myelodysplastic syndrome) patients and AML (acute myeloid leukemia) patients that 
relapse early post-alloSCT. HMAs are also being evaluated for other haematological 
malignancies, both in the non-transplant and transplant setting. HMAs are well tolerated 
and have a direct anti-proliferative and pro-apoptotic effect on tumor cells. Besides these 
direct anti-tumor effect, HMAs possess immunomodulatory efficacy and can thereby 
promote anti-tumor immunity. It has been shown that HMAs upregulate expression levels 
of epigenetically-silenced TAAs and MiHAs (including MAGE, NY-ESO-1, PRAME, 
WT1 and HA1), and thereby render the tumor cells more susceptible to recognition and 
destruction by antigen-specific T cells.103-109 Also, the HMAs may improve the priming of 
antigen-presenting T cells by providing host DCs with necrotic tumor cell material (re-
expressing silenced TAAs and MiHAs) as a result of their direct pro-apoptotic activity. 
HMAs may also further modulate immune responses by upregulating co-stimulatory 
molecules (CD80, CD86) and CIMs (PD-L1, PD-L2) on tumor cells and DCs.110-112 Studies 
also indicated that HMA treatment can enhance anti-tumor NK cell responses. With 
their epigenetic modulation, HMAs have been described to upregulate NK-activating 
molecules on tumor cells, like NKG2D and DNAM-1 ligands, and thereby sensitize tumors 
to NK cell-mediated killing.113-116 Furthermore, HMAs induce the expression of killer 
immunoglobulin-like receptors (KIR) on the surface of NK cells, which further aids their 
recognition of aberrant cells.116-118 Decitabine, rather than azacitidine, seems to be the 
favourable combination with NK cells.114,116 A new publication by Cany et al. shows that 
decitabine, but not azacitidine, positively modulated the in vivo anti-leukemic potential of 
NK cells by sensitizing leukemic cells to lysis, enhancing NK cell maturation and cytolytic 
function and improving NK cell trafficking and accumulation at the tumor site.116 In the 
alloSCT setting, HMAs have either been included as part of the conditioning regimen 
prior to alloSCT or as maintenance therapy post-alloSCT.119,120 In these patients, increased 
diversity and frequencies of tumor-specific T cell responses has been observed, which 
correlated with improved relapse-free survival after alloSCT.119,120 The effect of HMAs on 
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NK cell numbers and activity in HMA-treated alloSCT patients have not been reported 
yet, but one could imagine that those can be positively influenced. Taken all together, these 
data indicate that it would be very interesting to combine HMA treatment post-alloSCT 
with ex vivo antigen-loaded HSPC-DC subset vaccines, in vivo-targeting nanovaccines 
or adoptive transfer of HSPC-NK cells, for boosting GVT immunity.
Figure 2. HSPC-derived products for boosting GVT immunity. It is appealing to harness HSPCs for 
generating cellular immunotherapeutic products, such as NK cells and different DC subsets. These cells can 
efficiently be generated from HSPCs by blocking AhR activity using the antagonist SR1 in combination with 
specific cytokine mixtures. HSPC-derived NK cells could be used as therapy early after alloSCT to boost 
anti-tumor immunity, even while cyclosporine A therapy (an immune suppressive treatment commonly used 
after alloSCT to suppress allo-reactive GVHD-inducing T cell responses) is still ongoing. HSPC-derived DC 
subsets could be cryopreserved in multiple aliquots and given in several cycles post-alloSCT to boost tumor-
reactive T cell and NK cell responses. These HSPC-derived cellular products can potentially be combined 
with other (immuno-)therapeutic strategies to further enhance GVT immunity. AlloSCT, allogeneic stem 
cell transplantation; HSPC, hematopoietic stem and progenitor cells; IS, immune suppressive therapy; DC, 
dendritic cell; NK cell, natural killer cell; SR1, StemRegenin 1; DLI, donor lymphocyte infusion; HMAs, 
hypomethylating agents; KIR, killer immunoglobulin receptor; ALT-803, IL-15 superagonist complex.
As previously mentioned, one of the current adjuvant therapies applied for boosting 
GVT immunity and treating or preventing relapse is DLI. The DLI is a non-purified 
product, that has only a relatively low frequency of T cells that are capable of targeting 
tumor-specific MiHAs or TAAs. To improve GVT immunity, strategies have been 
developed to enrich and expand the tumor-specific T cells ex vivo before infusion. 
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However, ex vivo expansion protocols are often associated with expansion of effector 
memory T cells (Tem) and terminal differentiated T cells, which are quickly exhausted and 
less efficient in maintaining long-lasting T cell response in vivo than less differentiated 
memory T cells (e.g. stem cell memory T cells (Tscm) and central memory T cells (Tcm)).121 
Van der Waart et al. recently demonstrated that by inhibiting the Akt signaling pathway 
during ex vivo expansion of MiHA-specific CD8+ T cells, T cell differentiation could 
be limited. Thereby, highly potent early-memory MiHA-specific T cells were generated. 
These Akt-inhibited T cells showed superior expansion potential in vivo, and importantly, 
a superior anti-tumor efficacy in mice.122 Instead of combining HSPC-DC vaccination 
with DLI, it would therefore be interesting to combine them with ex vivo-expanded Akt-
inhibited tumor-reactive T cells, for enhancing GVT immunity.
Even though strategies such as DC vaccination or adoptive T cell transfer can increase 
the number of tumor-reactive T cells, the induced T cells may become functionally impaired 
when they encounter residual tumor cells and bystander cells in the microenvironment 
that express CIMs or exploit other immunosuppressive mechanisms.123,124 Therapies that 
target these inhibitory pathways are therefore promising to combine with DC vaccination. 
Antibodies targeting the PD-1/PD-L pathway and the CTLA-4 pathway, cumulatively 
referred to as checkpoint inhibitors, have shown impressive therapeutic benefit in various 
solid tumors. Because of the success, these therapies are now also being evaluated in 
haematological malignancies, either as monotherapy or together with other drugs such as 
HMAs, with promising results (reviewed by Boddu et al.125). For example, clinical benefit 
of checkpoint blockade has been demonstrated in patients with Hodgkin lymphoma.126 As 
with any potent cancer therapy, checkpoint inhibitors are accompanied by side effects, and 
often induce systemic autoimmune-related adverse events. Because of this, these antibodies 
have been introduced with caution in the alloSCT setting, as systemic blockade might 
release the brake on GVHD-inducing T cells.127,128 Indeed, a multicenter retrospective 
analysis of 31 lymphoma patients receiving anti-PD-1 antibody post-transplantation, 
showed that 55% of the patients developed GVHD following administration, of which half 
died due to this complication.127 Therefore, to safely boost GVT immunity post-alloSCT (in 
the absence or presence of DC vaccination), more specific approaches for interference with 
the inhibitory microenvironment are needed. One strategy to enhance tumor selectivity 
of checkpoint blockade would be using bispecific antibodies, where for example one arm 
binds to PD-L1 or another checkpoint protein and the other arm recognizes the tumor 
cell (e.g. via CD19 or CD20 for B cell malignancies and CD33, CD123 or CLEC12A for 
myeloid malignancies). This concept is in pre-clinical development for EGFR-positive 
cancers, where a PD-L1xEGFR bispecific antibody is under assessment for its efficacy 
to direct PD-1/PD-L1 inhibition to EGFR-positive cancer cells (conference abstract 
DTIM 2017, Koopmans et al.). Another strategy is to exploit nanovaccine technology, 
and specifically deliver nanoparticles containing siRNA against CIMs to the tumor cells. 
This type of strategy is not only limited to silencing checkpoint molecules like PD-L1, but 
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could also target other immunosuppressive factors such as IL-10, transforming growth 
factor (TGF)-β and IDO.129-131 In patients with AML and MDS, such siRNA-carrying 
nanoparticles could be delivered via CLEC12A, as CLEC12A is not only expressed by 
DCs, but is also highly expressed by myeloid leukemic blasts and stem cells.132,133 Similar 
as we have shown for DCs in chapter 5, we and others have demonstrated that AML cells 
efficiently internalize CLEC12A upon ligation, making it an attractive target for delivering 
immunomodulatory siRNAs to leukemic cells (Hutten et al. manuscript in preparation).133 
All together, we believe that strategies that actively boost tumor-reactive immune effector 
cells (e.g. DC vaccination) combined with strategies that specifically interfere with the local 
immunosuppressive environment are promising for improving anti-tumor immunity in 
alloSCT patients, without inducing severe adverse systemic effects.
Multiple studies have shown that donor-derived NK cells have a potent anti-tumor 
effect in alloSCT patients, as early repopulation and high numbers of NK cells correlate 
with reduced relapse rate of transplanted patients.134-138 It is therefore an appealing strategy 
to adoptively transfer additional NK cells of donor origin to boost GVT immunity. In 
chapter 6, we describe the generation of high numbers of NK cells, with a an active 
phenotype and high cytolytic capacity, from donor CD34+ HSPCs, that can be used for 
adoptive immunotherapy post-transplantation.1 For maximizing their tumor killing 
potency, combination treatment with other therapeutic agents could be considered. 
One strategy is combination with HMAs, as has already been described above. Another 
strategy is combination with anti-KIR antibodies, such as Lirilumab.139,140 Anti-KIR 
antibodies block inhibitory signals delivered by the tumor target cells to the NK cells, 
and can thereby increase the activation of NK cells and augment their killing of malignant 
cells.141 This might be particularly interesting in combination with HMAs, as they enhance 
KIR expression on NK cells.117,118,142 The pleiotropic cytokine IL-15 is a key regulator of NK 
cell development, expansion, maintenance and function, and is therefore a very interesting 
candidate to combine with NK cell therapy.143 For this reason, an IL-15 super-agonist ALT-
803, which displays high in vivo stability and enhanced biological activity on NK cells, 
has been developed for therapeutic use.144,145 ALT-803 might not only potentiate NK cell 
responses, but could also positively influence the tumor-reactive T cells, as IL-15 is also 
important for T cell maintenance and proliferation. Indeed, a study in a murine transplant 
model demonstrated increased number of NK cells and IFN-γ-secreting CD8+ T cells 
following ALT-803 treatment, which resulted in enhanced anti-tumor activity without 
eliciting GVHD.146 It is therefore a promising strategy to administer ALT-803 together 
with (HSPC-)NK cells or (HSPC-)DC vaccines for potentiating GVT responses post-
transplantation. Other candidates that are promising to combine with NK cell adoptive 
transfer are the immune modulatory drugs Lenalidomide and Bortezomib, that have 
both been shown to exert direct anti-leukemic effects, but can also potentiate NK cell 
expansion and functionality.147-150
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In chapter 4, we demonstrate how HSPC-derived DCs, in particular HSPC-pDCs, 
potently enhance NK cell activation and cytotoxicity.22 One could thus envision combining 
HSPC-DC vaccination with HSPC-NK cell adoptive transfer to enhance the therapeutic 
efficacy of alloSCT. However, the proportion of the donor stem cell graft that could be 
cryopreserved for generation of adjuvant immunotherapeutic products might not be 
enough to generate both HSPC-DCs and HSPC-NK cells. The benefit of asking for a 
second granulocyte colony-stimulating factor (G-CSF) mobilization and apheresis of the 
donor for obtaining additional HSPCs would need to be weighed against the associated 
risk and discomfort for the donor. I think therefore, that combination of HSPC-NK cells 
with HMAs, ALT-803, anti-KIR antibodies or even in vivo DC vaccination is a better 
and more realistic option for enhancing their in vivo efficacy than combination with ex 
vivo-loaded HSPC-DC vaccines.
In summary, there are multiple different (combination) therapies that can be 
considered as adjuvant therapy post transplantation (Figure 2). This calls for identification 
of the patients who would benefit from a certain type of (combination) treatment. DC 
vaccination is in particular interesting for those patients that have a MiHA mismatch with 
their donor, because MiHAs are very immunogenic antigens. Selecting hematopoietic-
restricted MiHAs as targets, the immune response can specifically be skewed towards 
GVT effects, with low risk of GVHD induction. However, only a small portion of patient-
donor couples have a MiHA mismatch. Therefore, exploiting vaccination with TAA-loaded 
DCs, particular in combination with HMAs, makes HSPC-DC vaccination a feasible 
approach for a larger group of patients. NK cell-based therapies are especially attractive 
in settings of HLA-mismatch, e.g. after haplo-identical transplant, and in a HLA-matched 
setting where donors have a KIR B/x genotype (genotype associated with more activating 
KIRs). In all cases, development and implementation of new (combination) therapies 
in the alloSCT setting needs to be done with great consideration and care, because of 
the lingering danger of inducing or exacerbating GVHD. But cumulatively, these novel 
therapies hold great promise for boosting GVT immunity and reducing the relapse rate, 
thereby improving overall survival after alloSCT.
Concluding remarks
Taken together, this thesis describes the pre-clinical development and characterization of 
various immunotherapeutic strategies. We demonstrate how high numbers of different 
DC subsets (pDCs, BDCA1+ mDCs and BDCA3+ mDCs) and cytotoxic NK cells can be 
efficiently generated ex vivo from CD34+ HSPCs, by blocking activity of the AhR using 
the antagonist SR1. This thesis mainly focused on the clinical translational utility of this 
finding, i.e. evaluating the ex vivo anti-tumor efficacy of the SR1-generated, HSPC-derived 
cellular immunotherapeutic products. Importantly, we demonstrated that the generated 
HSPC-DCs were comparable to their natural counterparts in blood, and strongly boosted 
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both T cell and NK cell responses ex vivo. The generated HSPC-NK cells had a highly 
active phenotype, and exhibited strong cytolytic capacity. In terms of clinical application 
of HSPC-derived DCs and NK cells, the next step will be designing clinical trials to 
investigate their potency, alone or in combination with other therapies, to boost GVT 
immunity in patients after alloSCT. Furthermore, the established SR1-dependent culture 
protocols will aid in new research to gain more insight into the physiological role of the 
AhR in DC and NK cell development. In this thesis, we also present results indicating that 
the C-type lectin receptor CLEC12A could be used for DC vaccination, by serving as an 
in vivo target receptor for nanovaccines. Via CLEC12A, tumor antigens could efficiently 
be delivered into DC subsets, which were subsequently processed and presented to CD4+ 
and CD8+ T cells, thereby facilitating effective induction of T cell responses. More pre-
clinical research on the potential of CLEC12A as an in vivo DC-targeting receptor is 
required, for example a comparison to other targeting receptors that are currently under 
investigation, such as DEC-205. Overall, the results described in this thesis pave the way 
for the development of new and potent therapies that can boost anti-tumor immunity 
and improve the quality of life and overall survival of patients with haematological 
malignancies.
8
206
Chapter 8
References
1. Roeven MW, Thordardottir S, Kohela A, 
Maas F, Preijers F, Jansen JH, Blijlevens 
NM, Cany J, Schaap N, Dolstra H. The 
Aryl Hydrocarbon Receptor Antagonist 
StemRegenin1 Improves In Vitro Generation 
of Highly Functional Natural Killer Cells from 
CD34(+) Hematopoietic Stem and Progenitor 
Cells. Stem Cells Dev. 2015;24(24):2886-2898.
2. Thordardottir S, Hangalapura BN, Hutten 
T, Cossu M, Spanholtz J, Schaap N, 
Radstake TR, van der Voort R, Dolstra H. 
The aryl hydrocarbon receptor antagonist 
StemRegenin 1 promotes human plasmacytoid 
and myeloid dendritic cell development from 
CD34+ hematopoietic progenitor cells. Stem 
Cells Dev. 2014;23(9):955-967.
3. Boitano AE, Wang J, Romeo R, Bouchez LC, 
Parker AE, Sutton SE, Walker JR, Flaveny 
CA, Perdew GH, Denison MS, Schultz PG, 
Cooke MP. Aryl hydrocarbon receptor 
antagonists promote the expansion of 
human hematopoietic stem cells. Science. 
2010;329(5997):1345-1348.
4. Wagner JE, Jr., Brunstein CG, Boitano AE, 
DeFor TE, McKenna D, Sumstad D, Blazar BR, 
Tolar J, Le C, Jones J, Cooke MP, Bleul CC. 
Phase I/II Trial of StemRegenin-1 Expanded 
Umbilical Cord Blood Hematopoietic Stem 
Cells Supports Testing as a Stand-Alone Graft. 
Cell Stem Cell. 2016;18(1):144-155.
5. Mulero-Navarro S, Fernandez-Salguero PM. 
New Trends in Aryl Hydrocarbon Receptor 
Biology. Front Cell Dev Biol. 2016;4:45.
6. Murray IA, Krishnegowda G, DiNatale 
BC, Flaveny C, Chiaro C, Lin JM, Sharma 
AK, Amin S, Perdew GH. Development of 
a selective modulator of aryl hydrocarbon 
(Ah) receptor activity that exhibits anti-
inflammatory properties. Chem Res Toxicol. 
2010;23(5):955-966.
7. Hollingshead BD, Beischlag TV, Dinatale 
BC, Ramadoss P, Perdew GH. Inflammatory 
signaling and aryl hydrocarbon receptor 
mediate synergistic induction of interleukin 6 
in MCF-7 cells. Cancer Res. 2008;68(10):3609-
3617.
8. Tian Y, Ke S, Denison MS, Rabson AB, Gallo 
MA. Ah receptor and NF-kappaB interactions, 
a potential mechanism for dioxin toxicity. J 
Biol Chem. 1999;274(1):510-515.
9. Cui G, Qin X, Wu L, Zhang Y, Sheng X, Yu Q, 
Sheng H, Xi B, Zhang JZ, Zang YQ. Liver X 
receptor (LXR) mediates negative regulation 
of mouse and human Th17 differentiation. J 
Clin Invest. 2011;121(2):658-670.
10. Nguyen LP, Bradfield CA. The search for 
endogenous activators of the aryl hydrocarbon 
receptor. Chem Res Toxicol. 2008;21(1):102-
116.
11. Quintana FJ, Sherr DH. Aryl hydrocarbon 
receptor control of adaptive immunity. 
Pharmacol Rev. 2013;65(4):1148-1161.
12. Ohtake F, Baba A, Takada I, Okada M, Iwasaki 
K, Miki H, Takahashi S, Kouzmenko A, 
Nohara K, Chiba T, Fujii-Kuriyama Y, Kato 
S. Dioxin receptor is a ligand-dependent E3 
ubiquitin ligase. Nature. 2007;446(7135):562-
566.
13. DiNatale BC, Schroeder JC, Francey LJ, 
Kusnadi A, Perdew GH. Mechanistic insights 
into the events that lead to synergistic 
induction of interleukin 6 transcription upon 
activation of the aryl hydrocarbon receptor 
and inflammatory signaling. J Biol Chem. 
2010;285(32):24388-24397.
14. DiNatale BC, Schroeder JC, Perdew GH. Ah 
receptor antagonism inhibits constitutive 
and cytokine inducible IL6 production in 
head and neck tumor cell lines. Mol Carcinog. 
2011;50(3):173-183.
15. Platzer B, Richter S, Kneidinger D, 
Waltenberger D, Woisetschlager M, Strobl H. 
Aryl hydrocarbon receptor activation inhibits 
in vitro differentiation of human monocytes 
and Langerhans dendritic cells. J Immunol. 
2009;183(1):66-74.
16. Liu H, Ramachandran I, Gabrilovich DI. 
Regulation of plasmacytoid dendritic cell 
development in mice by aryl hydrocarbon 
receptor. Immunol Cell Biol. 2013.
17. Collin M, Bigley V. Monocyte, Macrophage, 
and Dendritic Cell Development: the Human 
Perspective. Microbiol Spectr. 2016;4(5).
18. Angelos MG, Ruh PN, Webber BR, Blum 
RH, Ryan CD, Bendzick L, Shim S, Yingst 
AM, Tufa DM, Verneris MR, Kaufman 
DS. Aryl hydrocarbon receptor inhibition 
promotes hematolymphoid development 
207
General discussion and future perspectives
from human pluripotent stem cells. Blood. 
2017;129(26):3428-3439.
19. Zhu XJ, Yang ZF, Chen Y, Wang J, Rosmarin 
AG. PU.1 is essential for CD11c expression 
in CD8(+)/CD8(-) lymphoid and monocyte-
derived dendritic cells during GM-CSF or 
FLT3L-induced differentiation. PLoS One. 
2012;7(12):e52141.
20. Guerriero A, Langmuir PB, Spain LM, Scott 
EW. PU.1 is required for myeloid-derived but 
not lymphoid-derived dendritic cells. Blood. 
2000;95(3):879-885.
21. Chomarat P, Banchereau J, Davoust J, 
Palucka AK. IL-6 switches the differentiation 
of monocytes from dendritic cells to 
macrophages. Nat Immunol. 2000;1(6):510-
514.
22. Thordardottir S, Schaap N, Louer E, Kester 
MG, Falkenburg JH, Jansen J, Radstake TR, 
Hobo W, Dolstra H. Hematopoietic stem cell-
derived myeloid and plasmacytoid DC-based 
vaccines are highly potent inducers of tumor-
reactive T cell and NK cell responses ex vivo. 
Oncoimmunology. 2017;6(3):e1285991.
23. Bernal CE, Zorro MM, Sierra J, Gilchrist 
K, Botero JH, Baena A, Ramirez-Pineda 
JR. Encephalitozoon intestinalis Inhibits 
Dendritic Cell Differentiation through an IL-
6-Dependent Mechanism. Front Cell Infect 
Microbiol. 2016;6:4.
24. Veldhoen M, Hirota K, Christensen J, O’Garra 
A, Stockinger B. Natural agonists for aryl 
hydrocarbon receptor in culture medium are 
essential for optimal differentiation of Th17 T 
cells. J Exp Med. 2009;206(1):43-49.
25. Oberg M, Bergander L, Hakansson H, Rannug 
U, Rannug A. Identification of the tryptophan 
photoproduct 6-formylindolo[3,2-b]carbazole, 
in cell culture medium, as a factor that 
controls the background aryl hydrocarbon 
receptor activity. Toxicol Sci. 2005;85(2):935-
943.
26. Fujigaki H, Saito K, Fujigaki S, Takemura M, 
Sudo K, Ishiguro H, Seishima M. The signal 
transducer and activator of transcription 
1alpha and interferon regulatory factor 1 are 
not essential for the induction of indoleamine 
2,3-dioxygenase by lipopolysaccharide: 
involvement of p38 mitogen-activated 
protein kinase and nuclear factor-kappaB 
pathways, and synergistic effect of several 
proinf lammatory cytokines. J Biochem. 
2006;139(4):655-662.
27. DiNatale BC, Smith K, John K, Krishnegowda 
G, Amin SG, Perdew GH. Ah receptor 
antagonism represses head and neck tumor 
cell aggressive phenotype. Mol Cancer Res. 
2012;10(10):1369-1379.
28. DiNatale BC, Murray IA, Schroeder JC, 
Flaveny CA, Lahoti TS, Laurenzana EM, 
Omiecinski CJ, Perdew GH. Kynurenic acid 
is a potent endogenous aryl hydrocarbon 
receptor ligand that synergistically induces 
interleukin-6 in the presence of inflammatory 
signaling. Toxicol Sci. 2010;115(1):89-97.
29. Lahoti TS, John K, Hughes JM, Kusnadi 
A, Murray IA, Krishnegowda G, Amin S, 
Perdew GH. Aryl hydrocarbon receptor 
antagonism mitigates cytokine-mediated 
inflammatory signalling in primary human 
fibroblast-like synoviocytes. Ann Rheum Dis. 
2013;72(10):1708-1716.
30. Hughes T, Briercheck EL, Freud AG, Trotta R, 
McClory S, Scoville SD, Keller K, Deng Y, Cole 
J, Harrison N, Mao C, Zhang J, Benson DM, 
Yu J, Caligiuri MA. The transcription Factor 
AHR prevents the differentiation of a stage 3 
innate lymphoid cell subset to natural killer 
cells. Cell Rep. 2014;8(1):150-162.
31. Montaldo E, Teixeira-Alves LG, Glatzer T, 
Durek P, Stervbo U, Hamann W, Babic M, 
Paclik D, Stolzel K, Grone J, Lozza L, Juelke 
K, Matzmohr N, Loiacono F, Petronelli F, 
Huntington ND, Moretta L, Mingari MC, 
Romagnani C. Human RORgammat(+)
CD34(+) cells are lineage-specified progenitors 
of group 3 RORgammat(+) innate lymphoid 
cells. Immunity. 2014;41(6):988-1000.
32. Freud AG, Yu J, Caligiuri MA. Human natural 
killer cell development in secondary lymphoid 
tissues. Semin Immunol. 2014;26(2):132-137.
33. Aliahmad P, de la Torre B, Kaye J. Shared 
dependence on the DNA-binding factor 
TOX for the development of lymphoid 
tissue-inducer cell and NK cell lineages. Nat 
Immunol. 2010;11(10):945-952.
34. Seehus CR, Aliahmad P, de la Torre B, Iliev ID, 
Spurka L, Funari VA, Kaye J. The development 
of innate lymphoid cells requires TOX-
dependent generation of a common innate 
8
208
Chapter 8
lymphoid cell progenitor. Nat Immunol. 
2015;16(6):599-608.
35. Yun S, Lee SH, Yoon SR, Kim MS, Piao ZH, 
Myung PK, Kim TD, Jung H, Choi I. TOX 
regulates the differentiation of human natural 
killer cells from hematopoietic stem cells in 
vitro. Immunol Lett. 2011;136(1):29-36.
36. Wimmers F, Schreibelt G, Skold AE, Figdor 
CG, De Vries IJ. Paradigm Shift in Dendritic 
Cell-Based Immunotherapy: From in vitro 
Generated Monocyte-Derived DCs to 
Naturally Circulating DC Subsets. Front 
Immunol. 2014;5:165.
37. Tel J, Aarntzen EH, Baba T, Schreibelt G, 
Schulte BM, Benitez-Ribas D, Boerman OC, 
Croockewit S, Oyen WJ, van Rossum M, 
Winkels G, Coulie PG, Punt CJ, Figdor CG, 
de Vries IJ. Natural human plasmacytoid 
dendritic cells induce antigen-specific T-cell 
responses in melanoma patients. Cancer Res. 
2013;73(3):1063-1075.
38. Schreibelt G, Bol KF, Westdorp H, Wimmers 
F, Aarntzen EH, Duiveman-de Boer T, van 
de Rakt MW, Scharenborg NM, de Boer AJ, 
Pots JM, Olde Nordkamp MA, van Oorschot 
TG, Tel J, Winkels G, Petry K, Blokx WA, 
van Rossum MM, Welzen ME, Mus RD, 
Croockewit SA, Koornstra RH, Jacobs JF, 
Kelderman S, Blank CU, Gerritsen WR, 
Punt CJ, Figdor CG, de Vries IJ. Effective 
Clinical Responses in Metastatic Melanoma 
Patients after Vaccination with Primary 
Myeloid Dendritic Cells. Clin Cancer Res. 
2016;22(9):2155-2166.
39. Prue RL, Vari F, Radford KJ, Tong H, Hardy 
MY, D’Rozario R, Waterhouse NJ, Rossetti T, 
Coleman R, Tracey C, Goossen H, Gounder 
V, Crosbie G, Hancock S, Diaz-Guilas S, 
Mainwaring P, Swindle P, Hart DN. A phase 
I clinical trial of CD1c (BDCA-1)+ dendritic 
cells pulsed with HLA-A*0201 peptides for 
immunotherapy of metastatic hormone 
refractory prostate cancer. J Immunother. 
2015;38(2):71-76.
40. Bakdash G, Schreurs I, Schreibelt G, Tel J. 
Crosstalk between dendritic cell subsets 
and implications for dendritic cell-based 
anticancer immunotherapy. Expert Rev Clin 
Immunol. 2014;10(7):915-926.
41. Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P, Wang 
G. Plasmacytoid dendritic cells synergize 
with myeloid dendritic cells in the induction 
of antigen-specific antitumor immune 
responses. J Immunol. 2007;178(3):1534-1541.
42. Nierkens S, den Brok MH, Garcia Z, Togher 
S, Wagenaars J, Wassink M, Boon L, Ruers 
TJ, Figdor CG, Schoenberger SP, Adema GJ, 
Janssen EM. Immune adjuvant efficacy of 
CpG oligonucleotide in cancer treatment is 
founded specifically upon TLR9 function 
in plasmacytoid dendritic cells. Cancer Res. 
2011;71(20):6428-6437.
43. Diamond MS, Kinder M, Matsushita H, 
Mashayekhi M, Dunn GP, Archambault JM, 
Lee H, Arthur CD, White JM, Kalinke U, 
Murphy KM, Schreiber RD. Type I interferon 
is selectively required by dendritic cells for 
immune rejection of tumors. J Exp Med. 
2011;208(10):1989-2003.
44. Fonteneau JF, Larsson M, Beignon AS, 
McKenna K, Dasilva I, Amara A, Liu 
YJ, Lifson JD, Littman DR, Bhardwaj N. 
Human immunodeficiency virus type 
1 activates plasmacytoid dendritic cells 
and concomitantly induces the bystander 
maturation of myeloid dendritic cells. J Virol. 
2004;78(10):5223-5232.
45. Liu C, Lou Y, Lizee G, Qin H, Liu S, 
Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora 
AG, Overwijk WW, Liu YJ, Wang G, Hwu P. 
Plasmacytoid dendritic cells induce NK cell-
dependent, tumor antigen-specific T cell 
cross-priming and tumor regression in mice. 
J Clin Invest. 2008;118(3):1165-1175.
46. Shimizu K, Asakura M, Shinga J, Sato 
Y, Kitahara S, Hoshino K, Kaisho T, 
Schoenberger SP, Ezaki T, Fujii S. Invariant 
NKT cells induce plasmacytoid dendritic cell 
(DC) cross-talk with conventional DCs for 
efficient memory CD8+ T cell induction. J 
Immunol. 2013;190(11):5609-5619.
47. Montoya CJ, Jie HB, Al-Harthi L, Mulder C, 
Patino PJ, Rugeles MT, Krieg AM, Landay 
AL, Wilson SB. Activation of plasmacytoid 
dendritic cells with TLR9 agonists initiates 
invariant NKT cell-mediated cross-talk 
with myeloid dendritic cells. J Immunol. 
2006;177(2):1028-1039.
48. Marschner A, Rothenfusser S, Hornung 
V, Prell D, Krug A, Kerkmann M, Wellisch 
209
General discussion and future perspectives
D, Poeck H, Greinacher A, Giese T, Endres 
S, Hartmann G. CpG ODN enhance 
antigen-specific NKT cell activation via 
plasmacytoid dendritic cells. Eur J Immunol. 
2005;35(8):2347-2357.
49. Seo H, Jeon I, Kim BS, Park M, Bae EA, Song 
B, Koh CH, Shin KS, Kim IK, Choi K, Oh T, 
Min J, Min BS, Han YD, Kang SJ, Shin SJ, 
Chung Y, Kang CY. IL-21-mediated reversal 
of NK cell exhaustion facilitates anti-tumour 
immunity in MHC class I-deficient tumours. 
Nat Commun. 2017;8:15776.
50. Carnaud C, Lee D, Donnars O, Park SH, 
Beavis A, Koezuka Y, Bendelac A. Cutting 
edge: Cross-talk between cells of the innate 
immune system: NKT cells rapidly activate 
NK cells. J Immunol. 1999;163(9):4647-4650.
51. Perez-Cabezas B, Naranjo-Gomez M, 
Ruiz-Riol M, Bastos-Amador P, Fernandez 
MA, Carmona F, Nunez F, Pujol-Borrell 
R, Borras FE. TLR-activated conventional 
DCs promote gamma-secretase-mediated 
conditioning of plasmacytoid DCs. J Leukoc 
Biol. 2012;92(1):133-143.
52. Piccioli D, Sammicheli C, Tavarini S, Nuti 
S, Frigimelica E, Manetti AG, Nuccitelli A, 
Aprea S, Valentini S, Borgogni E, Wack A, 
Valiante NM. Human plasmacytoid dendritic 
cells are unresponsive to bacterial stimulation 
and require a novel type of cooperation with 
myeloid dendritic cells for maturation. Blood. 
2009;113(18):4232-4239.
53. van Beek JJ, Gorris MA, Skold AE, Hatipoglu I, 
Van Acker HH, Smits EL, de Vries IJ, Bakdash 
G. Human blood myeloid and plasmacytoid 
dendritic cells cross activate each other and 
synergize in inducing NK cell cytotoxicity. 
Oncoimmunology. 2016;5(10):e1227902.
54. Melanoma Patients Immunized With Natural 
DenDritic Cells. https://ClinicalTrials.gov/
show/NCT02993315.
55. Natural Dendritic Cells for Immunotherapy 
of Chemo-naive Metastatic Castration-
resistant Prostate Cancer Patients. https://
ClinicalTrials.gov/show/NCT02692976.
56. Van Tendeloo VF, Van de Velde A, Van 
Driessche A, Cools N, Anguille S, Ladell K, 
Gostick E, Vermeulen K, Pieters K, Nijs G, 
Stein B, Smits EL, Schroyens WA, Gadisseur 
AP, Vrelust I, Jorens PG, Goossens H, de 
Vries IJ, Price DA, Oji Y, Oka Y, Sugiyama 
H, Berneman ZN. Induction of complete 
and molecular remissions in acute myeloid 
leukemia by Wilms’ tumor 1 antigen-targeted 
dendritic cell vaccination. Proc Natl Acad Sci 
U S A. 2010;107(31):13824-13829.
57. Shah NN, Loeb DM, Khuu H, Stroncek D, 
Ariyo T, Raffeld M, Delbrook C, Mackall 
CL, Wayne AS, Fry TJ. Induction of 
Immune Response after Allogeneic Wilms’ 
Tumor 1 Dendritic Cell Vaccination and 
Donor Lymphocyte Infusion in Patients 
with Hematologic Malignancies and Post-
Transplantation Relapse. Biol Blood Marrow 
Transplant. 2016;22(12):2149-2154.
58. Franssen LE, Roeven MWH, Hobo W, Doorn 
R, Oostvogels R, Falkenburg JHF, van de 
Donk NW, Kester MGD, Fredrix H, Westinga 
K, Slaper-Cortenbach I, Spierings E, Kersten 
MJ, Dolstra H, Mutis T, Schaap N, Lokhorst 
HM. A phase I/II minor histocompatibility 
antigen-loaded dendritic cell vaccination 
trial to safely improve the efficacy of donor 
lymphocyte infusions in myeloma. Bone 
Marrow Transplant. 2017.
59. Oostvogels R, Kneppers E, Minnema MC, 
Doorn RC, Franssen LE, Aarts T, Emmelot 
ME, Spierings E, Slaper-Cortenbach I, 
Westinga K, Goulmy E, Lokhorst HM, Mutis 
T. Efficacy of host-dendritic cell vaccinations 
with or without minor histocompatibility 
antigen loading, combined with donor 
lymphocyte infusion in multiple myeloma 
patients. Bone Marrow Transplant . 
2017;52(2):228-237.
60. Gautier G, Humbert M, Deauvieau F, Scuiller 
M, Hiscott J, Bates EE, Trinchieri G, Caux 
C, Garrone P. A type I interferon autocrine-
paracrine loop is involved in Toll-like 
receptor-induced interleukin-12p70 secretion 
by dendritic cells. J Exp Med. 2005;201(9):1435-
1446.
61. Napolitani G, Rinaldi A, Bertoni F, Sallusto 
F, Lanzavecchia A. Selected Toll-like receptor 
agonist combinations synergistically trigger 
a T helper type 1-polarizing program in 
dendritic cells. Nat Immunol. 2005;6(8):769-
776.
62. Nizzoli G, Krietsch J, Weick A, Steinfelder 
S, Facciotti F, Gruarin P, Bianco A, Steckel 
8
210
Chapter 8
B, Moro M, Crosti M, Romagnani C, Stolzel 
K, Torretta S, Pignataro L, Scheibenbogen C, 
Neddermann P, De Francesco R, Abrignani 
S, Geginat J. Human CD1c+ dendritic cells 
secrete high levels of IL-12 and potently 
prime cytotoxic T-cell responses. Blood. 
2013;122(6):932-942.
63. Sittig SP, Bakdash G, Weiden J, Skold AE, 
Tel J, Figdor CG, de Vries IJ, Schreibelt G. A 
Comparative Study of the T Cell Stimulatory 
and Polarizing Capacity of Human Primary 
Blood Dendritic Cell Subsets. Mediators 
Inflamm. 2016;2016:3605643.
64. Kreutz M, Bakdash G, Dolen Y, Skold AE, 
van Hout-Kuijer MA, de Vries IJ, Figdor CG. 
Type I IFN-mediated synergistic activation 
of mouse and human DC subsets by TLR 
agonists. Eur J Immunol. 2015;45(10):2798-
2809.
65. Skold AE, Hasan M, Vargas L, Saidi H, 
Bosquet N, Le Grand R, Smith CI, Spetz 
AL. Single-stranded DNA oligonucleotides 
inhibit TLR3-mediated responses in human 
monocyte-derived dendritic cells and in 
vivo in cynomolgus macaques. Blood. 
2012;120(4):768-777.
66. Moreno Ayala MA, Gottardo MF, Gori MS, 
Nicola Candia AJ, Caruso C, De Laurentiis A, 
Imsen M, Klein S, Bal de Kier Joffe E, Salamone 
G, Castro MG, Seilicovich A, Candolfi M. 
Dual activation of Toll-like receptors 7 and 9 
impairs the efficacy of antitumor vaccines in 
murine models of metastatic breast cancer. J 
Cancer Res Clin Oncol. 2017.
67. Marshall JD, Heeke DS, Gesner ML, 
Livingston B, Van Nest G. Negative regulation 
of TLR9-mediated IFN-alpha induction by a 
small-molecule, synthetic TLR7 ligand. J 
Leukoc Biol. 2007;82(3):497-508.
68. Berghofer B, Haley G, Frommer T, Bein 
G, Hackstein H. Natural and synthetic 
TLR7 ligands inhibit CpG-A- and CpG-C-
oligodeoxynucleotide-induced IFN-alpha 
production. J Immunol. 2007;178(7):4072-
4079.
69. Skold AE, van Beek JJ, Sittig SP, Bakdash G, 
Tel J, Schreibelt G, de Vries IJ. Protamine-
stabilized RNA as an ex vivo stimulant of 
primary human dendritic cell subsets. Cancer 
Immunol Immunother. 2015;64(11):1461-1473.
70. van der Waart AB, Fredrix H, van der Voort 
R, Schaap N, Hobo W, Dolstra H. siRNA 
silencing of PD-1 ligands on dendritic cell 
vaccines boosts the expansion of minor 
histocompatibility antigen-specific CD8(+) T 
cells in NOD/SCID/IL2Rg(null) mice. Cancer 
Immunol Immunother. 2015;64(5):645-654.
71. Roeven MW, Hobo W, van der Voort R, 
Fredrix H, Norde WJ, Teijgeler K, Ruiters 
MH, Schaap N, Dolstra H. Efficient nontoxic 
delivery of PD-L1 and PD-L2 siRNA into 
dendritic cell vaccines using the cationic lipid 
SAINT-18. J Immunother. 2015;38(4):145-154.
72. Hobo W, Maas F, Adisty N, de Witte T, 
Schaap N, van der Voort R, Dolstra H. siRNA 
silencing of PD-L1 and PD-L2 on dendritic 
cells augments expansion and function of 
minor histocompatibility antigen-specific 
CD8+ T cells. Blood. 2010;116(22):4501-4511.
73. Hobo W, Novobrantseva TI, Fredrix H, Wong 
J, Milstein S, Epstein-Barash H, Liu J, Schaap 
N, van der Voort R, Dolstra H. Improving 
dendritic cell vaccine immunogenicity 
by silencing PD-1 ligands using siRNA-
lipid nanoparticles combined with antigen 
mRNA electroporation. Cancer Immunol 
Immunother. 2013;62(2):285-297.
74. Anderson AC, Joller N, Kuchroo VK. Lag-3, 
Tim-3, and TIGIT: Co-inhibitory Receptors 
with Specialized Functions in Immune 
Regulation. Immunity. 2016;44(5):989-1004.
75. Hutten TJA, Norde WJ, Woestenenk R, Wang 
RC, Maas F, Kester M, Falkenburg JHF, 
Berglund S, Luznik L, Jansen JH, Schaap N, 
Dolstra H, Hobo W. Increased Coexpression 
of PD-1, TIGIT, and KLRG-1 on Tumor-
Reactive CD8(+) T Cells During Relapse after 
Allogeneic Stem Cell Transplantation. Biol 
Blood Marrow Transplant. 2017.
76. da Silva IP, Gallois A, Jimenez-Baranda S, 
Khan S, Anderson AC, Kuchroo VK, Osman 
I, Bhardwaj N. Reversal of NK-cell exhaustion 
in advanced melanoma by Tim-3 blockade. 
Cancer Immunol Res. 2014;2(5):410-422.
77. Xu L, Huang Y, Tan L, Yu W, Chen D, Lu C, 
He J, Wu G, Liu X, Zhang Y. Increased Tim-3 
expression in peripheral NK cells predicts 
a poorer prognosis and Tim-3 blockade 
improves NK cell-mediated cytotoxicity 
in human lung adenocarcinoma. Int 
211
General discussion and future perspectives
Immunopharmacol. 2015;29(2):635-641.
78. Stanietsky N, Simic H, Arapovic J, Toporik A, 
Levy O, Novik A, Levine Z, Beiman M, Dassa 
L, Achdout H, Stern-Ginossar N, Tsukerman 
P, Jonjic S, Mandelboim O. The interaction of 
TIGIT with PVR and PVRL2 inhibits human 
NK cell cytotoxicity. Proc Natl Acad Sci U S A. 
2009;106(42):17858-17863.
79. Stanietsky N, Rovis TL, Glasner A, Seidel 
E, Tsukerman P, Yamin R, Enk J, Jonjic S, 
Mandelboim O. Mouse TIGIT inhibits NK-
cell cytotoxicity upon interaction with PVR. 
Eur J Immunol. 2013;43(8):2138-2150.
80. Paulis LE, Mandal S, Kreutz M, Figdor 
CG. Dendritic cell-based nanovaccines for 
cancer immunotherapy. Curr Opin Immunol. 
2013;25(3):389-395.
81. Zhu G, Zhang F, Ni Q, Niu G, Chen X. 
Efficient Nanovaccine Delivery in Cancer 
Immunotherapy. ACS Nano. 2017;11(3):2387-
2392.
82. Cho HJ, Takabayashi K, Cheng PM, 
Nguyen MD, Corr M, Tuck S, Raz E. 
Immunostimulatory DNA-based vaccines 
induce cytotoxic lymphocyte activity by a 
T-helper cell-independent mechanism. Nat 
Biotechnol. 2000;18(5):509-514.
83. Blander JM, Medzhitov R. Toll-dependent 
selection of microbial antigens for 
presentation by dendritic cells. Nature. 
2006;440(7085):808-812.
84. Burgdorf S, Scholz C, Kautz A, Tampe R, 
Kurts C. Spatial and mechanistic separation 
of cross-presentation and endogenous antigen 
presentation. Nat Immunol. 2008;9(5):558-
566.
85. Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-
Kuijer MA, van de Glind G, Fokkink RG, 
Lambeck AJ, Figdor CG. Targeted delivery of 
TLR ligands to human and mouse dendritic 
cells strongly enhances adjuvanticity. Blood. 
2011;118(26):6836-6844.
86. Cohn L, Delamarre L. Dendritic cell-targeted 
vaccines. Front Immunol. 2014;5:255.
87. Idoyaga J, Lubkin A, Fiorese C, Lahoud MH, 
Caminschi I, Huang Y, Rodriguez A, Clausen 
BE, Park CG, Trumpfheller C, Steinman RM. 
Comparable T helper 1 (Th1) and CD8 T-cell 
immunity by targeting HIV gag p24 to CD8 
dendritic cells within antibodies to Langerin, 
DEC205, and Clec9A. Proc Natl Acad Sci U S 
A. 2011;108(6):2384-2389.
88. van der Aa E, van Montfoort N, Woltman AM. 
BDCA3(+)CLEC9A(+) human dendritic cell 
function and development. Semin Cell Dev 
Biol. 2015;41:39-48.
89. Hutten TJ, Thordardottir S, Fredrix H, Janssen 
L, Woestenenk R, Tel J, Joosten B, Cambi A, 
Heemskerk MH, Franssen GM, Boerman 
OC, Bakker LB, Jansen JH, Schaap N, Dolstra 
H, Hobo W. CLEC12A-Mediated Antigen 
Uptake and Cross-Presentation by Human 
Dendritic Cell Subsets Efficiently Boost 
Tumor-Reactive T Cell Responses. J Immunol. 
2016;197(7):2715-2725.
90. Tel J, Schreibelt G, Sittig SP, Mathan TS, 
Buschow SI, Cruz LJ, Lambeck AJ, Figdor CG, 
de Vries IJ. Human plasmacytoid dendritic 
cells efficiently cross-present exogenous Ags 
to CD8+ T cells despite lower Ag uptake 
than myeloid dendritic cell subsets. Blood. 
2013;121(3):459-467.
91. Cohn L, Chatterjee B, Esselborn F, Smed-
Sorensen A, Nakamura N, Chalouni C, Lee 
BC, Vandlen R, Keler T, Lauer P, Brockstedt D, 
Mellman I, Delamarre L. Antigen delivery to 
early endosomes eliminates the superiority of 
human blood BDCA3+ dendritic cells at cross 
presentation. J Exp Med. 2013;210(5):1049-
1063.
92. Mittag D, Proietto AI, Loudovaris T, 
Mannering SI, Vremec D, Shortman K, 
Wu L, Harrison LC. Human dendritic cell 
subsets from spleen and blood are similar in 
phenotype and function but modified by donor 
health status. J Immunol. 2011;186(11):6207-
6217.
93. Chatterjee B, Smed-Sorensen A, Cohn L, 
Chalouni C, Vandlen R, Lee BC, Widger 
J, Keler T, Delamarre L, Mellman I. 
Internalization and endosomal degradation 
of receptor-bound antigens regulate the 
efficiency of cross presentation by human 
dendritic cells. Blood. 2012;120(10):2011-2020.
94. Segura E, Durand M, Amigorena S. Similar 
antigen cross-presentation capacity and 
phagocytic functions in all freshly isolated 
human lymphoid organ-resident dendritic 
cells. J Exp Med. 2013;210(5):1035-1047.
95. Tel J, Sittig SP, Blom RA, Cruz LJ, Schreibelt 
8
212
Chapter 8
G, Figdor CG, de Vries IJ. Targeting uptake 
receptors on human plasmacytoid dendritic 
cells triggers antigen cross-presentation 
and robust type I IFN secretion. J Immunol. 
2013;191(10):5005-5012.
96. Flinsenberg TW, Compeer EB, Koning D, 
Klein M, Amelung FJ, van Baarle D, Boelens 
JJ, Boes M. Fcgamma receptor antigen 
targeting potentiates cross-presentation by 
human blood and lymphoid tissue BDCA-3+ 
dendritic cells. Blood. 2012;120(26):5163-5172.
97. CDX-1401 and Poly-ICLC Vaccine Therapy 
With or Without CDX-301in Treating 
Patients With Stage IIB-IV Melanoma. https://
ClinicalTrials.gov/show/NCT02129075.
98. DEC-205/NY-ESO-1 Fusion Protein CDX-
1401 and Decitabine in Treating Patients With 
Myelodysplastic Syndrome or Acute Myeloid 
Leukemia. https://ClinicalTrials.gov/show/
NCT01834248.
99. DEC-205/NY-ESO-1 Fusion Protein CDX-
1401, Poly ICLC, and IDO1 Inhibitor 
INCB024360 in Treating Patients With 
Ovarian, Fallopian Tube, or Primary 
Peritoneal Cancer in Remission. https://
ClinicalTrials.gov/show/NCT02166905.
100. Vaccine Therapy With or Without Sirolimus in 
Treating Patients With NY-ESO-1 Expressing 
Solid Tumors. https://ClinicalTrials.gov/show/
NCT01522820.
101. DCVax Plus Poly ICLC in Healthy 
Volunteers. https://ClinicalTrials.gov/show/
NCT01127464.
102. Dhodapkar MV, Sznol M, Zhao B, Wang 
D, Carvajal RD, Keohan ML, Chuang E, 
Sanborn RE, Lutzky J, Powderly J, Kluger 
H, Tejwani S, Green J, Ramakrishna V, 
Crocker A, Vitale L, Yellin M, Davis T, Keler 
T. Induction of antigen-specific immunity 
with a vaccine targeting NY-ESO-1 to the 
dendritic cell receptor DEC-205. Sci Transl 
Med. 2014;6(232):232ra251.
103. Almstedt M, Blagitko-Dorfs N, Duque-Afonso 
J, Karbach J, Pfeifer D, Jager E, Lubbert M. 
The DNA demethylating agent 5-aza-2’-
deoxycytidine induces expression of NY-ESO-
1 and other cancer/testis antigens in myeloid 
leukemia cells. Leuk Res. 2010;34(7):899-905.
104. Gang AO, Frosig TM, Brimnes MK, Lyngaa 
R, Treppendahl MB, Gronbaek K, Dufva 
IH, Straten PT, Hadrup SR. 5-Azacytidine 
treatment sensitizes tumor cells to T-cell 
mediated cytotoxicity and modulates NK cells 
in patients with myeloid malignancies. Blood 
Cancer J. 2014;4:e197.
105. Goodyear O, Agathanggelou A, Novitzky-
Basso I, Siddique S, McSkeane T, Ryan G, 
Vyas P, Cavenagh J, Stankovic T, Moss P, 
Craddock C. Induction of a CD8+ T-cell 
response to the MAGE cancer testis antigen 
by combined treatment with azacitidine 
and sodium valproate in patients with acute 
myeloid leukemia and myelodysplasia. Blood. 
2010;116(11):1908-1918.
106. Atanackovic D, Luetkens T, Kloth B, Fuchs 
G, Cao Y, Hildebrandt Y, Meyer S, Bartels 
K, Reinhard H, Lajmi N, Hegewisch-Becker 
S, Schilling G, Platzbecker U, Kobbe G, 
Schroeder T, Bokemeyer C, Kroger N. Cancer-
testis antigen expression and its epigenetic 
modulation in acute myeloid leukemia. Am J 
Hematol. 2011;86(11):918-922.
107. Klar AS, Gopinadh J, Kleber S, Wadle 
A, Renner C. Treatment with 5-Aza-2’-
Deoxycytidine Induces Expression of 
NY-ESO-1 and Facilitates Cytotoxic T 
Lymphocyte-Mediated Tumor Cell Killing. 
PLoS One. 2015;10(10):e0139221.
108. Srivastava P, Paluch BE, Matsuzaki J, James 
SR, Collamat-Lai G, Blagitko-Dorfs N, 
Ford LA, Naqash R, Lubbert M, Karpf AR, 
Nemeth MJ, Griffiths EA. Induction of 
cancer testis antigen expression in circulating 
acute myeloid leukemia blasts following 
hypomethylating agent monotherapy. 
Oncotarget. 2016;7(11):12840-12856.
109. Hambach L, Ling KW, Pool J, Aghai Z, 
Blokland E, Tanke HJ, Bruijn JA, Halfwerk 
H, van Boven H, Wieles B, Goulmy E. 
Hypomethylating drugs convert HA-
1-negative solid tumors into targets for 
stem cell-based immunotherapy. Blood. 
2009;113(12):2715-2722.
110. Wang LX, Mei ZY, Zhou JH, Yao YS, Li YH, 
Xu YH, Li JX, Gao XN, Zhou MH, Jiang MM, 
Gao L, Ding Y, Lu XC, Shi JL, Luo XF, Wang 
J, Wang LL, Qu C, Bai XF, Yu L. Low dose 
decitabine treatment induces CD80 expression 
in cancer cells and stimulates tumor specific 
cytotoxic T lymphocyte responses. PLoS One. 
213
General discussion and future perspectives
2013;8(5):e62924.
111. Yang H, Bueso-Ramos C, DiNardo C, Estecio 
MR, Davanlou M, Geng QR, Fang Z, Nguyen 
M, Pierce S, Wei Y, Parmar S, Cortes J, 
Kantarjian H, Garcia-Manero G. Expression 
of PD-L1, PD-L2, PD-1 and CTLA4 in 
myelodysplastic syndromes is enhanced by 
treatment with hypomethylating agents. 
Leukemia. 2014;28(6):1280-1288.
112. Srivastava P, Paluch BE, Matsuzaki J, James 
SR, Collamat-Lai G, Karbach J, Nemeth 
MJ, Taverna P, Karpf AR, Griffiths EA. 
Immunomodulatory action of SGI-110, a 
hypomethylating agent, in acute myeloid 
leukemia cells and xenografts. Leuk Res. 
2014;38(11):1332-1341.
113. Rohner A, Langenkamp U, Siegler U, Kalberer 
CP, Wodnar-Filipowicz A. Differentiation-
promoting drugs up-regulate NKG2D ligand 
expression and enhance the susceptibility of 
acute myeloid leukemia cells to natural killer 
cell-mediated lysis. Leuk Res. 2007;31(10):1393-
1402.
114. Schmiedel BJ, Arelin V, Gruenebach F, Krusch 
M, Schmidt SM, Salih HR. Azacytidine 
impairs NK cell reactivity while decitabine 
augments NK cell responsiveness toward 
stimulation. Int J Cancer. 2011;128(12):2911-
2922.
115. Zhu Z, Lu X, Jiang L, Sun X, Zhou H, 
Jia Z, Zhang X, Ma L. STAT3 signaling 
pathway is involved in decitabine induced 
biological phenotype regulation of acute 
myeloid leukemia cells. Am J Transl Res. 
2015;7(10):1896-1907.
116. Cany J, Roeven MWH, Hoogstad-van Evert 
JS, Hobo W, Maas F, Franco Fernandez R, 
Blijlevens NMA, van der Velden WJ, Huls 
G, Jansen JH, Schaap NPM, Dolstra H. 
Decitabine enhances targeting of AML cells 
by CD34(+) progenitor-derived NK cells 
in NOD/SCID/IL2Rg(null) mice. Blood. 
2018;131(2):202-214.
117. Chan HW, Kurago ZB, Stewart CA, Wilson 
MJ, Martin MP, Mace BE, Carrington M, 
Trowsdale J, Lutz CT. DNA methylation 
maintains allele-specific KIR gene expression 
in human natural killer cells. J Exp Med. 
2003;197(2):245-255.
118. Santourlidis S, Trompeter HI, Weinhold S, 
Eisermann B, Meyer KL, Wernet P, Uhrberg 
M. Crucial role of DNA methylation in 
determination of clonally distributed killer 
cell Ig-like receptor expression patterns in NK 
cells. J Immunol. 2002;169(8):4253-4261.
119. Cruijsen M, Hobo W, van der Velden WJ, 
Bremmers ME, Woestenenk R, Bar B, 
Falkenburg JH, Kester M, Schaap NP, Jansen 
J, Blijlevens NN, Dolstra H, Huls G. Addition 
of 10-Day Decitabine to Fludarabine/Total 
Body Irradiation Conditioning is Feasible 
and Induces Tumor-Associated Antigen-
Specific T Cell Responses. Biol Blood Marrow 
Transplant. 2016;22(6):1000-1008.
120. Craddock C, Jilani N, Siddique S, Yap C, Khan 
J, Nagra S, Ward J, Ferguson P, Hazlewood 
P, Buka R, Vyas P, Goodyear O, Tholouli 
E, Crawley C, Russell N, Byrne J, Malladi 
R, Snowden J, Dennis M. Tolerability and 
Clinical Activity of Post-Transplantation 
Azacitidine in Patients Allografted for Acute 
Myeloid Leukemia Treated on the RICAZA 
Trial. Biol Blood Marrow Transplant. 
2016;22(2):385-390.
121. Gattinoni L, Klebanoff CA, Restifo NP. Paths 
to stemness: building the ultimate antitumour 
T cell. Nat Rev Cancer. 2012;12(10):671-684.
122. van der Waart AB, van de Weem NM, Maas 
F, Kramer CS, Kester MG, Falkenburg JH, 
Schaap N, Jansen JH, van der Voort R, 
Gattinoni L, Hobo W, Dolstra H. Inhibition 
of Akt signaling promotes the generation of 
superior tumor-reactive T cells for adoptive 
immunotherapy. Blood. 2014;124(23):3490-
3500.
123. Norde WJ, Maas F, Hobo W, Korman A, 
Quigley M, Kester MG, Hebeda K, Falkenburg 
JH, Schaap N, de Witte TM, van der Voort 
R, Dolstra H. PD-1/PD-L1 interactions 
contribute to functional T-cell impairment 
in patients who relapse with cancer after 
allogeneic stem cell transplantation. Cancer 
Res. 2011;71(15):5111-5122.
124. Norde WJ, Overes IM, Maas F, Fredrix H, 
Vos JC, Kester MG, van der Voort R, Jedema 
I, Falkenburg JH, Schattenberg AV, de Witte 
TM, Dolstra H. Myeloid leukemic progenitor 
cells can be specifically targeted by minor 
histocompatibility antigen LRH-1-reactive 
cytotoxic T cells. Blood. 2009;113(10):2312-
8
214
Chapter 8
2323.
125. Boddu P, Kantarjian H, Garcia-Manero G, 
Allison J, Sharma P, Daver N. The emerging 
role of immune checkpoint based approaches 
in AML and MDS. Leuk Lymphoma. 2017:1-13.
126. Allen PB, Gordon LI. PD-1 blockade in 
Hodgkin’s lymphoma: learning new tricks 
from an old teacher. Expert Rev Hematol. 
2016;9(10):939-949.
127. Haverkos BM, Abbott D, Hamadani M, 
Armand P, Flowers ME, Merryman R, 
Kamdar M, Kanate AS, Saad A, Mehta A, 
Ganguly S, Fenske TS, Hari P, Lowsky R, 
Andritsos L, Jagasia M, Bashey A, Brown 
S, Bachanova V, Stephens D, Mineishi S, 
Nakamura R, Chen YB, Blazar BR, Gutman 
J, Devine SM. PD-1 blockade for relapsed 
lymphoma post-allogeneic hematopoietic cell 
transplant: high response rate but frequent 
GVHD. Blood. 2017;130(2):221-228.
128. Saha A, Aoyama K, Taylor PA, Koehn BH, 
Veenstra RG, Panoskaltsis-Mortari A, Munn 
DH, Murphy WJ, Azuma M, Yagita H, Fife 
BT, Sayegh MH, Najafian N, Socie G, Ahmed 
R, Freeman GJ, Sharpe AH, Blazar BR. Host 
programmed death ligand 1 is dominant over 
programmed death ligand 2 expression in 
regulating graft-versus-host disease lethality. 
Blood. 2013;122(17):3062-3073.
129. Teo PY, Yang C, Whilding LM, Parente-
Pereira AC, Maher J, George AJ, Hedrick JL, 
Yang YY, Ghaem-Maghami S. Ovarian cancer 
immunotherapy using PD-L1 siRNA targeted 
delivery from folic acid-functionalized 
polyethylenimine: strategies to enhance T 
cell killing. Adv Healthc Mater. 2015;4(8):1180-
1189.
130. Xu Z, Wang Y, Zhang L, Huang L. 
Nanoparticle-delivered transforming growth 
factor-beta siRNA enhances vaccination 
against advanced melanoma by modifying 
tumor microenvironment. ACS Nano. 
2014;8(4):3636-3645.
131. Pradhan P, Qin H, Leleux JA, Gwak D, 
Sakamaki I, Kwak LW, Roy K. The effect of 
combined IL10 siRNA and CpG ODN as 
pathogen-mimicking microparticles on Th1/
Th2 cytokine balance in dendritic cells and 
protective immunity against B cell lymphoma. 
Biomaterials. 2014;35(21):5491-5504.
132. van Rhenen A, van Dongen GA, Kelder A, 
Rombouts EJ, Feller N, Moshaver B, Stigter-
van Walsum M, Zweegman S, Ossenkoppele 
GJ, Jan Schuurhuis G. The novel AML 
stem cell associated antigen CLL-1 aids in 
discrimination between normal and leukemic 
stem cells. Blood. 2007;110(7):2659-2666.
133. Bakker AB, van den Oudenrijn S, Bakker AQ, 
Feller N, van Meijer M, Bia JA, Jongeneelen 
MA, Visser TJ, Bijl N, Geuijen CA, Marissen 
WE, Radosevic K, Throsby M, Schuurhuis 
GJ, Ossenkoppele GJ, de Kruif J, Goudsmit J, 
Kruisbeek AM. C-type lectin-like molecule-1: 
a novel myeloid cell surface marker associated 
with acute myeloid leukemia. Cancer Res. 
2004;64(22):8443-8450.
134. Baron F, Petersdorf EW, Gooley T, Sandmaier 
BM, Malkki M, Chauncey TR, Maloney 
DG, Storb R. What is the role for donor 
natural killer cells after nonmyeloablative 
conditioning? Biol Blood Marrow Transplant. 
2009;15(5):580-588.
135. Savani BN, Rezvani K, Mielke S, Montero 
A, Kurlander R, Carter CS, Leitman S, Read 
EJ, Childs R, Barrett AJ. Factors associated 
with early molecular remission after T cell-
depleted allogeneic stem cell transplantation 
for chronic myelogenous leukemia. Blood. 
2006;107(4):1688-1695.
136. Savani BN, Mielke S, Adams S, Uribe M, 
Rezvani K, Yong AS, Zeilah J, Kurlander R, 
Srinivasan R, Childs R, Hensel N, Barrett 
AJ. Rapid natural killer cell recovery 
determines outcome after T-cell-depleted 
HLA-identical stem cell transplantation in 
patients with myeloid leukemias but not with 
acute lymphoblastic leukemia. Leukemia. 
2007;21(10):2145-2152.
137. Dunbar EM, Buzzeo MP, Levine JB, Schold JD, 
Meier-Kriesche HU, Reddy V. The relationship 
between circulating natural killer cells after 
reduced intensity conditioning hematopoietic 
stem cell transplantation and relapse-free 
survival and graft-versus-host disease. 
Haematologica. 2008;93(12):1852-1858.
138. Buhlmann L, Buser AS, Cantoni N, Gerull S, 
Tichelli A, Gratwohl A, Stern M. Lymphocyte 
subset recovery and outcome after T-cell 
replete allogeneic hematopoietic SCT. Bone 
Marrow Transplant. 2011;46(10):1357-1362.
215
General discussion and future perspectives
139. Vey N, Bourhis JH, Boissel N, Bordessoule D, 
Prebet T, Charbonnier A, Etienne A, Andre 
P, Romagne F, Benson D, Dombret H, Olive 
D. A phase 1 trial of the anti-inhibitory KIR 
mAb IPH2101 for AML in complete remission. 
Blood. 2012;120(22):4317-4323.
140. Benson DM, Jr., Hofmeister CC, Padmanabhan 
S, Suvannasankha A, Jagannath S, Abonour 
R, Bakan C, Andre P, Efebera Y, Tiollier J, 
Caligiuri MA, Farag SS. A phase 1 trial of the 
anti-KIR antibody IPH2101 in patients with 
relapsed/refractory multiple myeloma. Blood. 
2012;120(22):4324-4333.
141. Kohrt HE, Thielens A, Marabelle A, Sagiv-
Barfi I, Sola C, Chanuc F, Fuseri N, Bonnafous 
C, Czerwinski D, Rajapaksa A, Waller E, 
Ugolini S, Vivier E, Romagne F, Levy R, Blery 
M, Andre P. Anti-KIR antibody enhancement 
of anti-lymphoma activity of natural killer 
cells as monotherapy and in combination with 
anti-CD20 antibodies. Blood. 2014;123(5):678-
686.
142. Cany J H-vEJ, Hobo W, Maas F, Franco 
Fernandez R, Blijlevens NMA, van der Velden 
WJ, Huls G, Jansen JH, Schaap NPM, Dolstra 
H. Decitabine enhances targeting of AML 
cells by CD34+ progenitor-derived NK cells 
in NOD/SCID/IL2Rgnull mice. Blood, under 
revision. 2017.
143. Van den Bergh JM, Van Tendeloo VF, Smits 
EL. Interleukin-15: new kid on the block for 
antitumor combination therapy. Cytokine 
Growth Factor Rev. 2015;26(1):15-24.
144. Rhode PR, Egan JO, Xu W, Hong H, Webb 
GM, Chen X, Liu B, Zhu X, Wen J, You L, Kong 
L, Edwards AC, Han K, Shi S, Alter S, Sacha 
JB, Jeng EK, Cai W, Wong HC. Comparison of 
the Superagonist Complex, ALT-803, to IL15 
as Cancer Immunotherapeutics in Animal 
Models. Cancer Immunol Res. 2016;4(1):49-60.
145. Rosario M, Liu B, Kong L, Collins LI, 
Schneider SE, Chen X, Han K, Jeng EK, Rhode 
PR, Leong JW, Schappe T, Jewell BA, Keppel 
CR, Shah K, Hess B, Romee R, Piwnica-
Worms DR, Cashen AF, Bartlett NL, Wong 
HC, Fehniger TA. The IL-15-Based ALT-803 
Complex Enhances FcgammaRIIIa-Triggered 
NK Cell Responses and In Vivo Clearance 
of B Cell Lymphomas. Clin Cancer Res. 
2016;22(3):596-608.
146. Bailey CP, Budak-Alpdogan T, Sauter CT, 
Panis MM, Buyukgoz C, Jeng EK, Wong 
HC, Flomenberg N, Alpdogan O. New 
interleukin-15 superagonist (IL-15SA) 
significantly enhances graft-versus-tumor 
activity. Oncotarget. 2017;8(27):44366-44378.
147. Dhakal B, Vesole DH, Hari PN. Allogeneic 
stem cell transplantation for multiple 
myeloma: is there a future? Bone Marrow 
Transplant. 2016;51(4):492-500.
148. Zhu D, Corral LG, Fleming YW, Stein 
B. Immunomodulatory drugs Revlimid 
(lenalidomide) and CC-4047 induce apoptosis 
of both hematological and solid tumor cells 
through NK cell activation. Cancer Immunol 
Immunother. 2008;57(12):1849-1859.
149. Lundqvist A, Berg M, Smith A, Childs RW. 
Bortezomib Treatment to Potentiate the 
Anti-tumor Immunity of Ex-vivo Expanded 
Adoptively Infused Autologous Natural Killer 
Cells. J Cancer. 2011;2:383-385.
150. Benson DM, Jr., Cohen AD, Jagannath S, 
Munshi NC, Spitzer G, Hofmeister CC, 
Efebera YA, Andre P, Zerbib R, Caligiuri 
MA. A Phase I Trial of the Anti-KIR Antibody 
IPH2101 and Lenalidomide in Patients with 
Relapsed/Refractory Multiple Myeloma. Clin 
Cancer Res. 2015;21(18):4055-4061.
8

9
Dutch summary / Nederlandse samenvatting
218
Chapter 9
Doelstelling van de thesis
Hoewel de prognose voor patiënten met een hematologische maligniteit in de laatste 
decennia aanzienlijk is toegenomen door verbeterde therapieën, komt in veel patiënten 
de ziekte helaas terug. Deze patiënten reageren onvoldoende of ontwikkelen weerstand 
tegen huidige therapieën. Hierdoor kan residuale ziekte uiteindelijk leiden tot een 
recidief van de maligniteit. Tot op heden is allogene stamceltransplantatie (alloSCT) 
gevolgd door donor lymfocyteninfusies (DLI) de meest effectieve behandeling voor 
veel agressieve hematologische kankersoorten. AlloSCT kan genezend zijn doordat 
krachtige en langdurige antitumor-immuunreacties geïnduceerd worden, die bekend 
staan als de graft-versus-tumor (GVT) reacties. Hierbij zijn donor Natural Killer (NK)-
cellen met een directe cytotoxische werking en cytotoxische CD8+ T-cellen gericht tegen 
minor histocompatibiliteits-antigenen (MiHAs) of tumor-geassocieerde antigenen 
verantwoordelijk voor eliminatie van de resterende kwaadaardige tumorcellen. Daarnaast 
worden er na de initiële antitumor-respons tumor-reactieve geheugen T-cellen gevormd, 
die in staat zijn om levenslange bescherming te geven. Echter, ziekteterugkomst komt 
ook nog vaak voor bij alloSCT patiënten, wat de belangrijkste oorzaak is van falen van 
de behandeling en sterfte.
Er zijn verschillende redenen waarom patiënten een terugval krijgen. Patiënten 
kunnen vroeg na transplantatie recidiveren als de kwaadaardige kloon uitgroeit voordat 
er voldoende immuun-effectorcellen van de donor gevormd zijn om de ziekte te beheersen. 
In dit opzicht speelt de effectiviteit van het conditioneringsregime voor transplantatie een 
belangrijke rol. Zo zijn er minder intensieve conditioneringsbehandelingen ontwikkeld 
om ook oudere en minder fitte patiënten met alloSCT te behandelen. Echter, deze 
mildere voorbehandelingen worden geassocieerd met hogere terugvalpercentages: als 
gevolg van minder effectieve tumorreductie voorafgaande aan de transplantatie wordt 
productieve antitumor-immuniteit belemmerd. Terugval kan ook optreden wanneer 
donor T-cellen en NK-cellen onvoldoende reageren, bijvoorbeeld door minimale/
ongunstige MiHA mismatches tussen patiënt en donor, onvoldoende antigeenpresentatie 
of beperkte NK-celactivatie. Daarnaast kan er terugval plaatsvinden na aanvankelijk 
antitumor immuniteit als er geen langdurig geheugen tegen de kwaadaardige ziekte 
wordt gevormd, het immuunsysteem verzwakt is of als de afweercellen inactief worden 
voor de achtergebleven ziekte. Bovendien kunnen de tumorcellen in sommige gevallen 
verschillende mechanismen gebruiken om een afweerremmende omgeving te vormen 
waardoor ze kunnen ontsnappen aan herkenning en eliminatie door de afweercellen. Naast 
terugval kunnen andere alloSCT-gerelateerde complicaties ontstaan, zoals omgekeerde 
afstotingsziekte tegen gezonde weefsels en opportunistische infecties. Aangezien alloSCT, 
ondanks deze beperkingen, de potentie heeft om patiënten te genezen, worden er grote 
inspanningen verricht om deze behandelingstrategie te verbeteren. Deze inspanningen 
richten zich op het verminderen van de incidentie en ernst van de afstotingsziekte en 
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infecties, waarbij de antitumor-immuniteit gestimuleerd wordt voor langdurige ziektevrije 
overleving.
In dit proefschrift hebben we ons gericht op de preklinische ontwikkeling van 
immuuntherapeutische strategieën die het antitumor-effect specifiek kunnen versterken, 
zonder het risico op afstotingsziekte te verhogen. Eén manier om dit te bewerkstelligen 
is door dendritische cellen (DCs) te gebruiken. DCs zijn professionele antigeen-
presenterende cellen en kunnen krachtige antitumorreacties opwekken door antigenen 
te presenteren aan T-cellen. In dit proefschrift beschrijven we protocollen voor de ex 
vivo ontwikkeling van verschillende DC-populaties uit CD34+ hematopoietische stam- 
en voorlopercellen (HSCs), die gebruikt kunnen worden voor DC-vaccinatie. Daarnaast 
hebben we onderzocht of het CLEC12A eiwit, een opnamereceptor die op het oppervlak 
van DCs voorkomt, een goede kandidaat is voor het gericht afleveren van MiHAs en 
tumor-geassocieerde antigenen in vivo. Verder beschrijven we ook protocollen voor het 
kweken van grote hoeveelheden potente NK-cellen uit CD34+ HSCs voor aanvullende 
therapie.
DC-vaccinatie met ex-vivo beladen HSC-DC-populaties
DC-vaccinatie voor kankerpatiënten is de laatste twee decennia uitgebreid onderzocht, 
vanwege de centrale rol van DCs in het dirigeren van aangeboren en verworven immuniteit. 
Het concept is om met tumorantigeen-beladen DCs tumorspecifieke T-celreacties te 
stimuleren. De tumorspecifieke T-cellen kunnen vervolgens maligne cellen lyseren die 
het overeenkomende antigeen op hun oppervlak presenteren. Vele klinische studies 
zijn uitgevoerd met DCs ontwikkeld uit monocyten (MoDCs) in een breed scala van 
verschillende kankersoorten. Deze studies hebben aangetoond dat DC-vaccinatie haalbaar 
en veilig is en in staat is om in vivo tumor-specifieke immuunreacties te bevorderen. 
Echter, slechts een minderheid van de patiënten ontwikkelt een objectieve klinische 
respons. Dit belemmert de implementatie van DC-vaccinatie in de standaardbehandeling. 
Daarom worden verschillende strategieën onderzocht om deze therapie te verbeteren 
en te optimaliseren. Manieren om de werkzaamheid van MoDCs te verbeteren is door: 
1) liganden voor afweerremmende moleculen op T-cellen te verwijderen of 2) door 
constitutief actieve groeifactoren of activatiemoleculen voor T- en NK-cellen toe te voegen.
Naast het verbeteren van de immunogeniciteit van MoDCs is het zeer interessant 
om natuurlijke DC-populaties voor vaccinatie te gebruiken, zoals plasmacytoide DCs 
(pDCs), BDCA1+ myeloïde DCs (mDCs) en BDCA3+ mDCs. Elk van deze DC-populaties 
heeft een unieke rol in het immuunsysteem met verschillende cytokine secretieprofielen. 
Zo produceren pDCs hoge niveaus van type I interferonen (IFN-α/β), die pleiotrope 
effecten hebben op meerdere celtypen en bijzonder belangrijk zijn voor NK-celfunctie 
en antivirale immuniteit. Anderzijds produceren de mDC-populaties interleukine (IL)-
12 dat, samen met hun hoge expressieniveaus van major histocompatibiliteitscomplex 
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(MHC) en co-stimulatoire moleculen, zorgt voor efficiënte inductie van CD4+ T-helper 
1 (Th1) responsen en activatie van naïeve CD8+ T-cellen. Bovendien blijkt uit studies dat 
cross-talk tussen de verschillende DC-populaties zorgt voor synergie door versterking 
van elkaars afweerstimulerend vermogen. De theorie is dat gelijktijdige vaccinatie met 
meerdere verschillende DC-populaties kan leiden tot bredere en krachtigere afweerreacties 
(vanwege DC cross-talk en het activeren van zowel T-cellen als NK-cellen) en daardoor 
betere therapeutische werkzaamheid dan met de “standaard” MoDC-vaccins. In de 
hoofdstukken 2-4 hebben we daarom de mogelijkheid onderzocht om in het laboratorium 
verschillende DC-populaties uit CD34+ stamcellen te genereren.
In hoofdstuk 2 hebben we een protocol ontwikkeld voor het kweken van myeloide 
DC-populaties uit CD34+ stamcellen afkomstig van navelstrengbloed. CD34+ stamcellen 
werden 11 dagen geëxpandeerd in medium met Flt3L (‘FMS-like tyrosine kinase 3 
ligand’), SCF (‘stem cell factor’), IL-3, IL-6 and TPO (thrombopoietin). Na 11 dagen 
kweek werden de geëxpandeerde cellen verder gekweekt in medium met GM-CSF 
(‘granulocyte-macrophage colony-stimulating factor’) en IL-4 in zowel de aanwezigheid 
als de afwezigheid van ‘transforming growth factor’ (TGF)-β1 om differentiatie tot DCs 
te bewerkstelligen. Aan het einde van de kweek was >60% van de cellen positief voor 
CD11c en HLA-DR, markers die kenmerkend zijn voor monocyten en DCs. Bovendien 
konden DCs met een fenotype vergelijkbaar met interstitiële/dermale DCs en Langerhans-
cellen (LC) geïdentificeerd worden, op basis van respectievelijk CD1a en CD207 (langerin) 
expressie. De populatie langerin-positieve cellen was groter in kweken met TGF-β1, wat 
overeenkomt met bevindingen van anderen. Deze HSC-DCs activeerden efficiënt de 
proliferatie van virale antigeen-specifieke en MiHA-specifieke humane CD8+ T-cellen 
in vitro en in vivo in immunodeficiënte muizen. Echter, in dit kweeksysteem konden 
geen DCs met het fenotype van DC-populaties in bloed, zoals pDCs, BDCA1+ mDCs en 
BDCA3+ mDCs geïdentificeerd worden. In hoofdstuk 3 hebben we daarom alternatieve 
manieren onderzocht om deze populaties uit CD34+ stamcellen te genereren. Hier 
ontdekten we dat remming van de ‘aryl hydrocarbon receptor’ (AhR), met behulp van 
de antagonist StemRegenin 1 (SR1), de in vitro ontwikkeling van pDCs en mDCs uit 
HSCs significant verbeterde. Hiervoor werden CD34+ stamcellen gedurende drie weken 
gekweekt in medium met Flt3L, SCF, TPO en IL-6 in zowel de aanwezigheid als de 
afwezigheid van SR1. In kweken met SR1 konden de verschillende DC-populaties (pDCs, 
BDCA1+ mDCs en BDCA3+ mDCs) worden geïdentificeerd, terwijl de frequenties in de 
kweken zonder SR1 verwaarloosbaar waren. Verder hebben we bevestigd dat de SR1-
geïnduceerde DC differentiatie afhankelijk is van AhR-signalering, door de toevoeging 
van de AhR-agonist VAF347. Dit zorgde voor een dosisafhankelijke blokkade van de door 
SR1 bevorderde DC-ontwikkeling. We hebben verder aangetoond dat de SR1-gegenereerde 
DC-populaties fenotypisch en functioneel vergelijkbaar zijn met hun tegenhangers in 
het perifere bloed. Na stimulatie met ‘Toll-like receptor’ (TLR) liganden produceerden 
de DCs hoge niveaus van populatie-specifieke inflammatoire cytokines, verkregen ze 
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expressie van co-stimulatoire moleculen en maturatiemarkers en waren ze in staat om 
T-cellen te activeren.
In hoofdstuk 4 hebben we dit SR1-gebaseerde kweekprotocol verder doorontwikkeld 
voor een latere klinische toepassing door de juiste kweekomstandigheden vast te stellen. 
Later kunnen deze kweekomstandigheden ook vertaald worden naar ‘good manufacturing 
practice’ (GMP), voor het genereren van voldoende aantallen functionele DC-populaties 
voor vaccinatie. In deze studie hebben we ons gericht op de ontwikkeling van DCs uit 
CD34+ stamcellen afkomstig uit G-CSF-gemobiliseerd perifeer bloed, aangezien dit de 
meest gebruikte stamcelbron is voor transplantatie van patiënten met een hematologische 
maligniteit. Dit biedt de mogelijkheid om DC-populatievaccins te genereren uit een klein 
deel van het transplantaat om vervolgens GVT-immuniteit te stimuleren na alloSCT. 
Het conform GMP-ontwikkelde protocol combineert aspecten uit de twee verschillende 
kweeksystemen die in hoofdstuk 2 en 3 zijn beschreven, met enkele aanvullende 
aanpassingen: in het kort, CD34+ stamcellen werden gedurende 7-13 dagen gekweekt 
met Flt3L, SCF, TPO (afgekort als FST) en SR1, waarna de kweek werd opgesplitst in 
twee verschillende differentiatieprotocollen. Een deel van de geëxpandeerde cellen werd 
gedurende nog een week gekweekt in medium met FST en SR1 (FST kweek), dat met name 
de ontwikkeling van IFN-α-producerende pDCs bevorderde, hoewel ook BDCA1+ mDCs 
en BDCA3+ mDCs werden gevormd. Het andere deel van de geëxpandeerde cellen werd 
voorzien van een myeloïde differentiatie boost door toevoeging van GM-CSF en IL-4 
(genaamd G4 kweek), dat resulteerde in een groot aantal IL-12-producerende BDCA1+ 
mDCs. Voor zover wij weten levert dit kweekprotocol de hoogste aantallen pDCs, BDCA1+ 
mDCs en BDCA3+ mDCs die gelijktijdig kunnen worden gekweekt uit HSCs onder GMP-
conforme condities.
In hoofdstuk 4 hebben we het vermogen van HSC-pDCs en HSC-BDCA1+ mDCs 
onderzocht om ex vivo tumorreactieve T-cel en NK-cel reacties te stimuleren. Hier 
bleken BDCA1+ mDCs superieur in het activeren van naïeve T-cellen en het expanderen 
van MiHA-specifieke CD8+ T-cellen van alloSCT patiënten. Deze T-cellen waren sterk 
geactiveerd, zoals bleek uit efficiënte IFN-γ productie en degranulatie na herstimulatie 
met peptide. Aan de andere kant waren HSC-pDCs superieur in het induceren van IFN-γ 
secretie door ‘effector memory’ T (Tem) cellen en het versterken van NK-celfunctie. Dit 
kan zeer waarschijnlijk worden toegeschreven aan de hoge uitscheiding van IFN-α 
door pDCs. pDC-activatie van NK-cellen resulteerde in verhoogde TRAIL (‘tumor 
necrosis factor-related apoptosis-inducing ligand’) expressie en significant verbeterde 
lysis van tumorcellen. Tezamen tonen deze resultaten aan dat de verschillende HSC-
DCs zorgen voor krachtige activatie van antitumor effectorcellen, en populatie-specifieke 
kenmerken vertonen die overeenkomen met beschrijvingen in de literatuur, d.w.z. dat 
de mDCs beter zijn in het stimuleren van T-celresponsen, terwijl de pDCs superieur 
zijn in het induceren van NK-celresponsen. Deze resultaten geven aan dat een vaccin 
samengesteld uit de verschillende HSC-DC-populaties veelbelovend is voor het opwekken 
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van bredere immuunresponsen door het activeren van immuuneffectorcellen van zowel 
het aangeboren als het verworven immuunsysteem (respectievelijk T-cellen en NK-cellen). 
Dit leidt hopelijk tot verbeterde therapeutische effectiviteit ten opzichte van de MoDC-
gebaseerde vaccinatiestudies.
In vivo targeting van DCs
Een alternatief voor het gebruik van ex vivo gekweekte tumorantigeen-beladen DCs als 
immuuntherapie, is het direct activeren van de verschillende DC-populaties in vivo. 
Het concept van deze strategie is om via antilichamen die gericht zijn tegen specifieke 
oppervlaktereceptoren gelijktijdig tumorantigenen en adjuvans (zoals TLR-liganden) af 
te leveren in de DCs om DC uitrijping te stimuleren en antigeen presentatie en activatie 
van cellulaire afweerreacties te induceren. Hierdoor kan de bewerkelijke, arbeidsintensieve 
en dure kweek en bewerking van DCs vermeden worden. Bovendien is in vivo targeting 
potentieel breder toepasbaar, aangezien niet voor elke individuele patiënt een uniek vaccin 
gemaakt hoeft te worden. Deze strategie is echter nog niet zo ver ontwikkeld als ex vivo 
beladen DC-vaccinatie en slechts enkele klinische studies hebben deze aanpak onderzocht. 
Voor implementatie moeten meerdere parameters verder worden bepaald, waaronder 
een grondige karakterisering van antigeenopnamereceptoren. Deze receptoren moeten 
gerichte en efficiënte afgifte van het antigeen in intracellulaire compartimenten faciliteren 
voor het verwerken en beladen van de antigeenpeptiden in MHC moleculen.
In hoofdstuk 5 hebben we onderzocht of het CLEC12A eiwit, een opnamereceptor, een 
goede kandidaat is voor het gericht afleveren van antigenen in humane DC-populaties. 
In deze studie bevestigden we dat CLEC12A selectief tot expressie komt op myeloïde 
cellen, waaronder monocyten en granulocyten, en de verschillende DC-populaties: 
BDCA1+ mDCs, BDCA3+ mDCs en pDCs. Verder hebben we aangetoond dat in alle DC-
populaties CLEC12A na binding van het CLEC12A-antilichaam efficiënt geïnternaliseerd 
wordt en vervolgens naar intracellulaire compartimenten getransporteerd wordt die 
betrokken zijn bij de verwerking en presentatie van antigenen. Naast het opnemen van 
antigenen kunnen receptoren zoals CLEC12A ook immuunresponsen moduleren via hun 
intracellulaire signaleringsdomeinen. CLEC12A bevat een immunoreceptor tyrosine-
based inhibitory motif (ITIM) in zijn cytoplasmatische deel, wat na triggering de DC 
uitrijping en functionaliteit zou kunnen remmen. Wij hebben echter geen negatieve 
effecten gevonden van CLEC12A antilichaam binding op TLR-geïnduceerde expressie 
van DC uitrijpingsmarkers of productie van cytokines, noch op de capaciteit van de DCs 
om allogene T-celactivatie te induceren. Daarnaast hebben we aangetoond dat CLEC12A-
gemedieerde antigeenopname leidt tot efficiënte antigeenpresentatie aan zowel CD4+ 
als CD8+ T-cellen door de verschillende DC-populaties. We laten zien dat de aflevering 
van ‘keyhole limpet hemocyanin’ (KLH) resulteerde in expansie van en IFN-γ-secretie 
door KLH-specifieke CD4+ T-cellen. Bovendien waren alle primaire DC-populaties, 
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BDCA1+ mDCs, BDCA3+ mDCs en pDCs, in staat om een lang MiHA-peptide, afgeleverd 
via CLEC12A, te presenteren aan CD8+ T-cellen. Dit resulteerde in sterke ex vivo activatie 
van MiHA-specifieke CD8+ T-cellen, afkomstig van alloSCT patiënten. Samen geven deze 
bevindingen aan dat CLEC12A een interessante kandidaat is voor het gericht afleveren 
van antigenen in DCs.
NK-cel therapie
Naast T-cellen spelen alloreactieve NK-cellen een belangrijke rol in de antitumor-reactie. 
NK-celreacties na alloSCT zijn geassocieerd met lagere recidiefcijfers en langdurige 
ziektevrije overleving. Het gunstige effect kan worden toegeschreven aan NK-celactivatie 
door selectieve (stress-geïnduceerde) verhoging van de expressieniveaus van activerende 
NK-liganden en/of de verlaging van MHC klasse I expressie (NK remmende liganden) 
op de tumorcellen. Van belang is dat alloreactieve NK-cellen de eigenschap hebben dat 
ze geen omgekeerde afstotingsziekte veroorzaken, en mogelijk zelfs de inductie en/of de 
ernst van omgekeerde afstotingsreacties kunnen onderdrukken. Deze observaties hebben 
de aandacht van veel onderzoeksgroepen getrokken om toediening van NK-cellen te 
onderzoeken als adjuvante therapie na transplantatie, met als doel eventueel achtergebleven 
ziekte te elimineren zonder omgekeerde afstotingsziekte te induceren. Ook nemen NK-
cellen deel aan de verdediging tegen virale en schimmelinfecties na transplantatie, 
waardoor ze nog aantrekkelijker worden als adjuvante therapie. Ondanks beschrijvingen 
van klinische werkzaamheid van NK-cellen geïsoleerd uit bloed, is het gebruik van dit 
type NK-cellen voor immuuntherapie beperkt om verschillende redenen, waaronder lage 
aantallen circulerende cellen, relatief lage activatiestatus en contaminatie van het product 
met allogene T-cellen die omgekeerde afstotingsziekte kunnen veroorzaken. Om deze 
beperkingen te omzeilen heeft onze groep een nieuw NK-celproduct ontwikkeld. Hierbij 
worden NK-cellen ex vivo gekweekt uit CD34+ stamcellen, afkomstig uit navelstrengbloed, 
aan de hand van een cytokine-gebaseerd kweekprotocol. Via deze benadering kan een 
hoge opbrengst van cytotoxische NK-cellen, zonder contaminatie van T- en B-cellen, 
worden bewerkstelligd. Deze NK-cellen zijn recentelijk onderzocht voor veiligheid, 
toxiciteit en immunologische eigenschappen in een fase I klinische studie in oudere AML-
patiënten. Hoewel het onderzoek niet was ontworpen om eventuele klinische effectiviteit 
te evalueren, werd in sommige patiënten een tijdelijke afname van ziekte waargenomen 
na de cyclophosphamide/fludarabine conditionering en NK-celinfusie. Deze resultaten 
zijn veelbelovend voor verdere ontwikkeling van adoptieve celtherapie met behulp van 
HSC-NK-cellen.
In hoofdstuk 6 onderzochten we de haalbaarheid van het kweken van NK-cellen uit 
andere stamcelbronnen, namelijk G-CSF gemobiliseerd perifeer bloed en beenmerg, om 
dezelfde reden als hierboven beschreven voor de HSC-DCs: het aanbieden van additionele 
celtherapieproducten gegenereerd uit de stamcellen van de transplantatiedonor. 
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Echter, CD34+ stamcellen van volwassenen hebben een lagere capaciteit om zich te 
vermeerderen en te differentiëren tot NK-cellen dan jonge CD34+ stamcellen afkomstig 
uit navelstrengbloed. Dit betekent dat modificaties van ons ex vivo NK-cel kweekprotocol 
nodig waren. Uitgaande van de beschrijvingen in de literatuur en onze eigen ervaring 
met SR1 in het HSC-DC kweeksysteem hebben we onderzocht of behandeling van CD34+ 
stamcellen met SR1 hun expansiesnelheid zou vergroten en NK-cel differentiatie zou 
bevorderen. Inderdaad bleek dat toevoeging van SR1 aan ons cytokine-gebaseerde ex 
vivo NK-cel kweekprotocol leidde tot significant verbeterde vermeerdering van volwassen 
CD34+ stamcellen. Daarnaast induceerde SR1 de expressie van transcriptiefactoren die 
belangrijk zijn voor NK-celdifferentiatie, zoals TOX (‘thymocyte selection-associated 
HMG box factor’), waardoor differentiatie van de SR1-geëxpandeerde HSCs tot NK-
cellen bevorderd werd. De toevoeging van SR1 resulteerde vervolgens in de ontwikkeling 
van hoge aantallen CD56+CD3- NK cellen, met een gemiddelde zuiverheid van 83%, uit 
HSCs van volwassenen. Deze gekweekte NK-cellen hebben hoge expressieniveaus van 
de activerende NKG2D en ‘natural cytotoxicity receptors’ (NCRs) en waren effectief in 
het doden van myeloïde leukemie- en multiple myeloomcellijnen, alsook acute myeloïde 
leukemie (AML) blasten van patiënten. Een interessante bevinding die we gedaan hebben 
is dat de NK-cellen uit de SR1-kweken verbeterde functionele activiteit vertoonden in 
vergelijking met NK-cellen uit de controle kweken zonder SR1: ze vertoonden verhoogde 
expressie van DNAM-1 en TRAIL, produceerden hogere niveaus van IFN-γ en granzyme 
B en hadden betere cytotoxische capaciteit. Bovendien verhoogde SR1 ook de expressie 
van de homingreceptoren CD62L en CXCR3, waardoor de HSC-NK cellen mogelijk beter 
in staat zijn zich te bewegen naar hematologische tumorcellen in lymfoïde organen.
We zijn zeer geïnteresseerd in het onderzoek naar de toepassing van deze SR1-
gegenereerde NK-cellen als adjuvante therapie kort na alloSCT, maar patiënten worden 
dan vaak nog behandeld met de immuunsuppressieve middelen cyclosporine A (CsA) en 
mycophenolic acid (MPA) om alloreactieve T-celreacties te onderdrukken en zo inductie 
van omgekeerde afstotingsziekte te voorkomen. Daarom hebben we in vitro het effect 
van CsA en MPA behandeling op de levensvatbaarheid, proliferatie en functionaliteit 
van de gegenereerde NK-cellen bestudeerd. Therapeutische concentraties van CsA 
hadden geen negatief effect op deze parameters, wat aangeeft dat HSC-NK celtherapie 
parallel aan CsA-behandeling kan plaatsvinden (welke in de meeste gevallen minstens 6 
maanden duurt vanaf transplantatie). In tegenstelling hiermee remde MPA de proliferatie, 
levensvatbaarheid, cytolytisch vermogen en IFN-γ-secretie van de NK-cellen. MPA-
behandeling wordt meestal alleen toegepast in de eerste maand na transplantatie, wat 
aangeeft dat de behandeling met HSC-NK-cellen vanaf de 2e maand na alloSCT mogelijk 
is.
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Conclusie
Concluderend beschrijft dit proefschrift de preklinische ontwikkeling van diverse 
immuuntherapeutische strategieën die mogelijk post-alloSCT zouden kunnen worden 
toegepast als adjuvante therapieën om de werkzaamheid van de alloSCT te verbeteren. 
HSC-DC-populaties die hematopoietisch-geristricteerde MiHAs of tumor-geassocieerde 
antigenen presenteren zouden mogelijk post-alloSCT als vaccin kunnen worden gebruikt 
voor selectieve inductie van GVT-immuniteit. Alternatief kunnen gerichte nanovaccins, 
die MiHAs en/of tumor-geassocieerde antigenen bevatten, direct afgeleverd worden 
in verschillende DC-populaties in vivo via de CLEC12A receptor. Tenslotte zouden 
HSC-NK cellen van toepassing kunnen zijn voor adoptieve toediening vroeg na alloSCT, 
om eventueel residuale ziekte te elimineren en antimicrobiële verdediging/controle te 
bewerkstelligen. Naast de mogelijke therapeutische implicaties van deze strategieën, 
kunnen de DC- en NK-kweekprotocollen die in dit proefschrift zijn beschreven gebruikt 
worden voor ex vivo mechanistische studies naar de ontwikkeling en biologie van DC- en 
NK-cellen. Tezamen hebben de resultaten beschreven in dit proefschrift de weg gebaand 
voor de ontwikkeling van nieuwe, krachtige therapieën die de antitumor-immuniteit 
kunnen versterken en de kwaliteit van leven en ziektevrije overleving van patiënten met 
hematologische maligniteiten kunnen verbeteren.
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EAT-2 Erwing’s sarcoma-associated transcript 2
ECD Electron coupled dye
EEA-1 Early endosome antigen 1
ELISA Enzyme-linked immunosorbent assay
EOMES Eomesodermin
ERα Estrogen receptor α
F
FACS Fluorescence-activated cell sorting
FCM Flow cytometry
FCS Fetal calf serum
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GBGM Glycostem basal growth medium
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factor
GMDP Granulocyte, monocyte and dendritic cell 
progenitor
GMP Granulocyte-macrophage progenitor
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hIgG Human IgG
HLA Human leukocyte antigen
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HS Human serum
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HSPC Hematopoietic stem and progenitor cell
I
IDO Indoleamine 2,3-dioxygenase
IFN Interferon
IL Interleukin
ILC Innate lymphoid cell
IMDM Iscove-modified Dulbecco medium
IP Intraperitoneal(ly)
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KIR Killer immunoglobulin-like receptor
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LAA Leukemia-associated antigen
LAG-3 Lymphocyte-activating gene 3
LAMP-1 Lysosomal-associated membrane protein 1
LC Langerhans cell
LPS Lipopolysaccharide
LUMC Leiden University Medical Center
M
mDC Myeloid dendritic cell
MDP Monocyte-dendritic cell progenitor
MDS Myelodysplastic syndrome
MEP Megakaryocyte-erythrocyte progenitor
MFI Mean fluorescent intensity
MHC Major histocompatibility complex
MICL Myeloid inhibitory C-type lectin-like 
receptor
mIgG Mouse IgG
MiHA Minor histocompatibility antigen
MLR Mixed leukocyte/lymphocyte reaction
MM Multiple myeloma
MoDC Monocyte-derived dendritic cell
MPA Mycophenolic acid
MPP Multi-potent progenitor
MRD Minimal residual disease
N
NCR Natural cytotoxicity receptor
NK cell Natural killer cell
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PB Peripheral blood
PBMC Peripheral blood mononuclear cell
PBL Peripheral blood lymphocyte
PBGD Phorphobilinogen deaminase
PD-1 Programmed death-1
PD-L1 Programmed death-1 ligand 1
PD-L2 Programmed death-1 ligand 2
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PGE2 Prostaglandin E2
PGG2 Prostaglandin G2
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qRT-PCR Quantitative reverse transcription 
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R848 Resiquimod
Radboudumc        Radboud university medical center
RM Repeated measures
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sc Subcutaneous
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SCT Stem cell transplantation
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TNF-α Tumor necrosis factor α
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inducing ligand
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Tcm  Central memory T cell
Tem  Effector memory T cell
Tscm  Stem cell memory T cell
U
UCB Umbilical cord blood
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